---
document_datetime: 2023-09-21 21:46:49
document_pages: 245
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/reblozyl-h-c-4444-ii-0009-epar-assessment-report-variation_en.pdf
document_name: reblozyl-h-c-4444-ii-0009-epar-assessment-report-variation_en.pdf
version: success
processing_time: 339.1618645
conversion_datetime: 2025-12-27 23:37:27.110371
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

26 January 2023 EMA/CHMP/71817/2023 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Reblozyl

International non-proprietary name: luspatercept

Procedure No. EMEA/H/C/004444/II/0009

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                | 7                                                                                                         |
|-------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation                                                                                                  | ..................................................................................................7       |
| 1.2. Steps taken for the assessment of the product                                                                      | ........................................................8                                                 |
| 2. Scientific discussion................................................................................                | 9                                                                                                         |
| 2.1. Introduction                                                                                                       | ........................................................................................................9 |
| 2.1.1. Problem statement                                                                                                | ............................................................................................9             |
| 2.1.2. About the product                                                                                                | ........................................................................................... 11            |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice......                                  | 12                                                                                                        |
| 2.1.4. General comments on compliance with GCP........................................................                  | 13                                                                                                        |
| 2.2. Non-clinical aspects............................................................................................   | 13                                                                                                        |
| 2.2.1. Ecotoxicity/environmental risk assessment.........................................................               | 13                                                                                                        |
| 2.2.1. Discussion on non-clinical aspects .....................................................................         | 13                                                                                                        |
| 2.3. Clinical aspects                                                                                                   | .................................................................................................. 13     |
| 2.3.1. Introduction.................................................................................................... | 13                                                                                                        |
| 2.3.2. Pharmacokinetics                                                                                                 | ............................................................................................ 17           |
| 2.3.3. Pharmacodynamics..........................................................................................       | 34                                                                                                        |
| 2.3.4. PK/PD modelling .............................................................................................    | 37                                                                                                        |
| 2.3.5. Immunogenicity..............................................................................................     | 65                                                                                                        |
| 2.3.6. Discussion on clinical pharmacology...................................................................           | 70                                                                                                        |
| 2.3.7. Conclusions on clinical pharmacology.................................................................            | 74                                                                                                        |
| 2.4. Clinical efficacy                                                                                                  | .................................................................................................. 75     |
| 2.4.1. Dose response study........................................................................................      | 75                                                                                                        |
| 2.4.2. Main study                                                                                                       | ..................................................................................................... 75  |
| 2.4.3. Discussion on clinical efficacy..........................................................................        | 163                                                                                                       |
| 2.4.4. Conclusions on the clinical efficacy ..................................................................          | 172                                                                                                       |
| 2.5. Clinical safety .................................................................................................. | 173                                                                                                       |
| 2.5.1. Discussion on clinical safety............................................................................        | 220                                                                                                       |
| 2.5.2. Conclusions on clinical safety..........................................................................         | 225                                                                                                       |
| 2.5.3. PSUR cycle ...................................................................................................   | 226                                                                                                       |
| 2.6. Risk management plan                                                                                               | ..................................................................................... 226                 |
| 2.7. Update of the Product information......................................................................            | 231                                                                                                       |
| 2.7.1. User consultation ..........................................................................................     | 231                                                                                                       |
| 3. Benefit-Risk Balance...........................................................................                      | 231                                                                                                       |
| 3.1. Therapeutic Context .........................................................................................      | 231                                                                                                       |
| 3.1.1. Disease or condition                                                                                             | ...................................................................................... 231                |
| 3.1.2. Available therapies and unmet medical need.....................................................                  | 232                                                                                                       |
| 3.1.3. Main clinical studies.......................................................................................     | 232                                                                                                       |
| 3.2. Favourable effects............................................................................................     | 233                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects...........................................                  | 234                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................      | 235                                                                                                       |

<div style=\"page-break-after: always\"></div>

3.5. Uncertainties and limitations about unfavourable effects ....................................... 237

Error! Bookmark not defined.

3.6. Uncertainties and limitations about unfavourable effects

3.7. Effects Table  .................................................................................................... 238

3.8. Benefit-risk assessment and discussion  ............................................................... 240

3.8.1. Importance of favourable and unfavourable effects  ............................................ 240

3.8.2. Balance of benefits and risks .......................................................................... 243

3.8.3. Additional considerations on the benefit-risk balance ......................................... 244

3.9. Conclusions  ..................................................................................................... 244

4. Recommendations  ............................................................................... 244

5. EPAR changes ..................................................

Error! Bookmark not defined.

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ActRIIB

human activin receptor type IIB

ADA

antidrug antibody

AE

adverse event

AESI

adverse event of special interest

AHEG

ad hoc expert group

ALT

alanine aminotransferase

ANCOVA

analysis of covariance

AST

aspartate aminotransferase

ATC

Anatomical Therapeutic Chemical

AUC

area under the concentration-time curve

AUCavg24

average AUC from Week 1 to Week 24

AUCavg48

average AUC from Week 1 to Week 48

AUCss

area under the concentration-time curve at steady state

BMD

bone mineral density

BMP

bone morphogenetic protein

BSC

best supportive care

CHMP

Committee for Medicinal Products for Human Use

CI

confidence interval

Cmax

maximum concentration for the starting dose

CMH

Cochran-Mantel-Haenszel

CSR

clinical study report

DBP

diastolic blood pressure

DMC

data monitoring committee

dw

dry weight

DXA

dual-energy x-ray absorptiometry

ECG

electrocardiogram

ECOG

Eastern Cooperative Oncology Group

eCRF

electronic case report form

EMA

European Medicines Agency

EMH

extramedullary hematopoietic

EOI

event of interest

EOS

end of study

EOT

end of treatment

EPO

erythropoietin

ESA

erythropoiesis-stimulating agent

FCBP

female of childbearing potential

FDA US

Food and Drug Administration

<div style=\"page-break-after: always\"></div>

| GCP       | Good Clinical Practice                                                   |
|-----------|--------------------------------------------------------------------------|
| GDF       | growth differentiation factor                                            |
| Hb        | hemoglobin                                                               |
| HbE       | hemoglobin E                                                             |
| HbF       | fetal hemoglobin                                                         |
| HbH       | hemoglobin H                                                             |
| HbS       | hemoglobin S                                                             |
| HBsAg     | hepatitis B virus surface antigen                                        |
| HBV       | hepatitis B virus                                                        |
| HCV       | hepatitis C virus                                                        |
| HIV       | human immunodeficiency virus                                             |
| HRQoL     | health-related QoL                                                       |
| HRU       | healthcare resource utilization                                          |
| HSCT      | hematopoietic stem cell transplantation                                  |
| ICF       | informed consent form                                                    |
| ICH       | International Council for Harmonisation                                  |
| ICT       | iron chelation therapy                                                   |
| ID        | identification                                                           |
| IEC       | Independent Ethics Committee                                             |
| IgG1      | human immunoglobulin G 1                                                 |
| IP        | investigational product                                                  |
| IRB       | Institutional Review Board                                               |
| IRT       | Interactive Response Technology                                          |
| ITT       | intent to treat                                                          |
| LDH       | lactate dehydrogenase                                                    |
| LIC       | liver iron concentration                                                 |
| LS        | least squares                                                            |
| LVEF      | left ventricular ejection fraction                                       |
| MCS       | Mental Component Summary                                                 |
| MedDRA    | Medical Dictionary for Regulatory Activities                             |
| MID       | minimally important difference                                           |
| MRI       | magnetic resonance imaging                                               |
| MUGA      | multigated acquisition scan                                              |
| NCI CTCAE | National Cancer Institute Common Terminology Criteria for Adverse Events |
| nRBC      | nucleated RBC                                                            |
| NTD       | nontransfusion-dependent                                                 |
| OR        | odds ratio                                                               |
| PCS       | Physical Component Summary                                               |
| PK        | pharmacokinetic                                                          |

<div style=\"page-break-after: always\"></div>

| PT      | preferred term                                                  |
|---------|-----------------------------------------------------------------|
| q3w     | every 3 weeks                                                   |
| QoL     | quality of life                                                 |
| QTcF    | QT interval corrected for heart rate using Fridericia's formula |
| RBC     | red blood cell                                                  |
| RD      | responder definition                                            |
| SAE     | serious adverse event                                           |
| SAP     | statistical analysis plan                                       |
| SBP     | systolic blood pressure                                         |
| SC      | subcutaneous                                                    |
| SD      | standard deviation                                              |
| SF-36   | 36-item Short Form Health Survey                                |
| SMQ     | Standardized MedDRA Query                                       |
| SOC     | system organ class                                              |
| t ½     | elimination half-life                                           |
| TD      | transfusion-dependent                                           |
| TEAE    | treatment-emergent adverse event                                |
| TGF- β  | transforming growth factor- β                                   |
| T max   | time to reach C max                                             |
| TranQoL | transfusion-dependent QoL questionnaire                         |
| ULN     | upper limit of normal                                           |
| US      | United States                                                   |
| WBC     | white blood cell                                                |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Bristol-Myers Squibb Pharma EEIG submitted to the European Medicines Agency on 8 October 2021 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

## C.I.6 (Extension of indication)

Extension of indication in β -thalassaemia to include adult patients with nontransfusion dependent β -thalassaemia (NTDT) for Reblozyl; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.5 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information relating to orphan designation

Reblozyl was designated as an orphan medicinal product EU/3/14/1300 on 29.07.2014 in the following condition: treatment of beta (β) -thalassaemia intermedia and major

Reblozyl was designated as an orphan medicinal product EU/3/14/1331 on 22.08.2014 in the following condition: treatment of myelodysplastic syndromes (MDS)

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0037/2021 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP EMEA-001521-PIP01-13-M05 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products at the time of submission.

<div style=\"page-break-after: always\"></div>

## Protocol assistance

The MAH received Protocol Assistance from the CHMP on 25 June 2015 (EMEA/H/SAH/044/1/2015/PA/III)13 October 2016 (MEA/H/SAH/044/1/FU/1/2016/PA/II). The Protocol Assistance pertained to clinical aspects of the dossier.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Daniela Philadelphy

Co-Rapporteur:

Ewa Balkowiec Iskra

| Timetable                                                                     | Actual dates     |
|-------------------------------------------------------------------------------|------------------|
| Submission date                                                               | 8 October 2021   |
| Start of procedure:                                                           | 30 October 2021  |
| CHMP Rapporteur Assessment Report                                             | 21 December 2021 |
| PRAC Rapporteur Assessment Report                                             | 21 December 2021 |
| CHMP Co-Rapporteur Critique                                                   | 30 December 2021 |
| PRAC members comments                                                         | 5 January 2022   |
| Updated PRAC Rapporteur Assessment Report                                     | 6 January 2022   |
| PRAC Outcome                                                                  | 13 January 2022  |
| CHMP members comments                                                         | 17 January 2022  |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report                          | 20 January 2022  |
| Request for supplementary information (RSI)                                   | 27 January 2022  |
| CHMP Rapporteur Assessment Report                                             | 25 May 2022      |
| PRAC Rapporteur Assessment Report                                             | 30 May 2022      |
| PRAC members comments                                                         | 1 June 2022      |
| Updated PRAC Rapporteur Assessment Report                                     | 2 June 2022      |
| PRAC Outcome                                                                  | 10 June 2022     |
| CHMP members comments                                                         | 13 June 2022     |
| Updated CHMP Rapporteur Assessment Report                                     | 16 June 2022     |
| Request for supplementary information (RSI)                                   | 23 June 2022     |
| CHMP Rapporteur Assessment Report                                             | 12 October 2022  |
| Ad hoc expert group meeting to address questions raised by the CHMP (Annex 6) | 20 October 2022  |
| CHMP members comments                                                         | 28 October 2022  |
| Updated CHMP Rapporteur Assessment Report                                     | 4 November 2022  |
| Request for supplementary information (RSI)                                   | 10 November 2022 |
| CHMP Rapporteur Assessment Report                                             | 1 December 2022  |
| PRAC Rapporteur Assessment Report                                             | 1 December 2022  |

<div style=\"page-break-after: always\"></div>

| Timetable                                   | Actual dates     |
|---------------------------------------------|------------------|
| CHMP members comments                       | 5 December 2022  |
| PRAC members comments                       | 5 December 2022  |
| Request for supplementary information (RSI) | 15 December 2022 |
| CHMP Rapporteur Assessment Report           | 11 January 2023  |
| PRAC Rapporteur Assessment Report           | 11 January 2023  |
| CHMP members comments                       | 16 January 2023  |
| PRAC members comments                       | 16 January 2023  |
| Updated CHMP Rapporteur Assessment Report   | 19 January 2023  |
| Updated PRAC Rapporteur Assessment Report   | 19 January 2023  |
| CHMP opinion:                               | 26 January 2023  |

## 2. Scientific discussion

## 2.1. Introduction

Reblozyl (luspatercept) is already authorised for the treatment of adult patients with anemia associated with transfusion-dependent (TD) β -thalassemia (as well as with Myelodysplastic syndrome). This type II variation is aimed at extending the approved β -thalassaemia indication to include adult patients with anemia associated with nontransfusion dependent (NTD) β -thalassemia.

## 2.1.1. Problem statement

## Disease or condition

β -thalassemia comprises a group of inherited disorders characterised by a reduction in the production of β -globin chains of hemoglobin (Hb) and a subsequent imbalance in globin chains (α:non -α ratio). All of the pathophysiologic f eatures of β -thalassemias can be linked to this primary imbalance and accumulation of unpaired α -globin chains within the developing erythrocytes, resulting in ineffective erythropoiesis and peripheral hemolysis that lead to clinical complications including chronic anemia, primary iron overload, and hypercoagulable state (Musallam, 2013a; Taher, 2018a; Sleiman, 2018). Previously, individuals with beta thalassemia were classified as having beta thalassemia major, intermedia, and minor (decreasing severity). Subsequent classification has changed to the terms Transfusion dependent (TD) β -thalassemia or NonTransfusion Dependent (NTD) β -thalassemia (Taher, 2017).

NTD β -thalassemia is characteris ed by mild to moderate disease severity (previously classified as β -thalassemia intermedia or HbE/β -thalassemia) resulting from homozygosity or compound heterozygosity for a mutant β -globin allele. The spectrum and severity of clinical morbidity varies widely in the NTD β -thalassemia group, driven primarily by the underlyi ng ineffective erythropoiesis. NTD β -thalassaemia do not depend on regular transfusion therapy for survival. They sporadically need transfusion therapy, e.g. with significant infection, during surgery or pregnancy or for limited periods of time with growth retardation in children or when the chronic anemia causes clinical morbidity such as splenomegaly, EMH pseudotumours and leg ulcers.

<div style=\"page-break-after: always\"></div>

## State the claimed the therapeutic indication

This type II variation aims at broadening the approved indication in adult transfusiondependent β -thalassaemia to include patients with nontransfusion dependent β -thalassemia. The CHMP had objected to the initially proposed indication ' Reblozyl is indicated for the treatment of adult patients with anaemia associated with β -thalassaemia .'

This would include less severely affected NTD β -Thalassaemia patients than those investigated in the pivotal study (such as patients with minor β -thalassaemia or mild anaemia).

As a consequence, the indication was subsequently proposed by the MAH to read:

Reblozyl is indicated for the treatment of adult patients with anaemia associated with beta- thalassaemia who are:

- transfusion-dependent
- nontransfusion dependent (haemoglobin concentration of ≤ 10 g/dL) (see section 5.1)

As the benefit risk profile of Reblozyl in the claimed indication was considered negative at that stage, the MAH proposed the following restricted indication:

Reblozyl is indicated for the treatment of adult patients with symptomatic anaemia (haemoglobin c oncentration of ≤ 10 g/dL) associated with non -transfusion-dependent beta-thalassaemia (see section 5.1)

This was not supported, as the term 'symptomatic' was not clearly defined and this would introduce additional uncertainties due to methodological limitations of this approach. Further, a reference to section 5.1 was regarded sufficient to provide the relevant information the study/target population (including Hb threshold). The following wording was ultimately suggested, covering both Beta-thalassaemia indications and has been implemented by the MAH:

Reblozyl is indicated in adults for the treatment of anemia associated with transfusion dependent and non-transfusion dependent beta-thalassaemia (see section 5.1) '.

## Epidemiology

About 80 to 90 million peop le (~1.5 % of the global population) are carriers of β -thalassemia with approximately 60,000 symptomatic individuals born annually (Modell, 2007). The annual incidence of symptomatic individuals is estimated at 1 in 100,000 worldwide and 1 in 10,000 in the European Union (EU) (Galanello, 2010). Incidence is highest in the Mediterranean region, the Middle East, North America and South East Asia (particularly India, China, Thailand and Indonesia; this region accounts for approximately 50% of affected births). About 40,000 children are born with TD β -thalassemia each year, while a smaller, illdefined number have NTD β -thalassemia forms (Modell, 2008; Musallam, 2013a; Taher, 2013; Taher, 2021; Weatherall, 2010).

## Biologic features, aetiology and pathogenesis

Pri mary imbalance in globin chain production and accumulation of unpaired α -globin chains within the developing erythrocytes result in ineffective erythropoiesis and peripheral haemolysis leading to chronic anaemia.

<div style=\"page-break-after: always\"></div>

## Clinical presentation, diagnosis

Profound anaemia triggers a number of compensatory mechanisms responsible for the clinical sequelae associated with β -thalassemia such as erythroid marrow expansion, splenomegaly, increased intestinal iron absorption (leading to iron overload), leg ulcers, peripheral haemolysis, hypercoagulable state (Sleiman, 2018), and pulmonary hypertension (Musallam, 2013a; Rivella, 2012). In patients who do not receive any treatment intervention, these complications continue to accumulate with advancing age, leading to an adult population impacted by heavy disease burden and requiring considerable medical attention (Taher, 2010a).

## Management

NTD β -thalassemia patients, unlike TD β -thalassemia patients, do not require regular RBC transfusions for survival. However, NTD β -thalassemia patients still need transfusion therapy intermittently when low Hb levels are anticipated (eg, during surgery, infection, or pregnancy) or even more frequently for limited periods of time (Musallam, 2021a; Cappellini, 2018). Further treatment options include iron chelation therapy (ICT), prophylactic anticoagulant therapy, splenectomy, and (off label) foetal haemoglobin (HbF) induction (such as hydroxyurea) (Taher, 2017).

Currently available treatment options are limited, with iron-chelating agents being the only approved treatment, which only addresses the burden of the iron-related comorbidities. While transfusions are effective for treating chronic anaemia (Hb levels below 10 g/dL), they contribute to the additive effect of underlying iron overloading mechanisms of the disease, and as such, avoidance of lifelong transfusions is an important goal of therapy for these patients, especially since both intrinsic and extrinsic iron has a significant impact on patients' multisystemic comorbidities.

Other impacts to consider are the public health and individual burden for these transfusions, considering this specific therapy would also trigger more intense ICT. Other available treatment options, such as splenectomy and hydroxyurea, have varying degrees of efficacy and are associated with increased risks, respectively.

## 2.1.2. About the product

Luspatercept (ACE-536) is a novel, first in class recombinant fusion protein that binds select transforming growth factor-beta superfamily ligands. By binding to specific endogenous ligands (eg, growth differentiation factor-11, activin B) luspatercept inhibits Smad2/3 signaling, resulting in erythroid maturation through differentiation of late-stage erythroid precursors (normoblasts) in the bone marrow. Smad2/3 signaling is abnormally high in disease models characterised by ineffective erythropoiesis, ie, MDS and β -thalassemia. In mouse models of MDS and β -thalassemia, luspatercept decreased Smad2/3 signaling, reduced erythroid hyperplasia, enhanced erythroid maturation, increased haemoglobin, and increased the number of red blood cells. In mouse models of β -thalassemia, luspatercept also improved the quality of red blood cells, as shown by increased red blood cell (RBC) life span and reduced abnormal red cell morphology and haemolysis.

Reblozyl (luspatercept) was approved by the European Commission on 25 Jun 2020 (EMEA/H/C/004444) in the following indications:

· the treatment of adult patients with transfusion-dependent (TD) anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.

- the treatment of adult patients with TD anemia associated with beta (β) -thalassemia.

<div style=\"page-break-after: always\"></div>

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

Scientific Advice was received from the CHMP on 25 June 2015 on the β -thalassemia clinical development plan, which included an antidrug antibody (ADA) plan, a proposed NTD β -thalassemia pivotal study design and the development plan for an NTDT-PRO tool that would be incorporated into the study (EMEA/H/SAH/044/1/2015/PA/III). Follow-up advice was received on 13 October 2016, specifically on changes to the NTD β -thalassemia pivotal study design, including changing the key secondary endpoint from LIC to the NTDT-PRO T/W domain, and updates to the NTDT-PRO development plan (EMEA/H/SAH/044/1/FU/1/2016/PA/II).

The shift from a more severely affected study population comprising patients with a significant iron overload (not regularly transfused but at the margins of transfusion dependency) towards a broader, more heterogenous population with a high symptomatic burden (probably including most of the severely iron-overloaded patients, but extended to other symptomatic subjects) was found an acceptable approach, but with some caveats to be considered. In the former 'borderline' (nearly transfusion dependent in most instances) population with iron overload, the main benefit could have included easier and more efficient iron overload control, while for the latter 'true independent' population QoL improvement and prevention of other complications might be the main treatment goal. However, by introducing a selection of the study population based on QoL rather than on iron overload as previously planned, it would have been expected that recruitment would also be broader and the sample size to be increased. This was considered important, as with the more heterogeneous population all endpoints would need to contribute to the assessment of the clinical benefit and subgroup analyses would be crucial to justify that the whole population described by the sought indication is getting a benefit also beyond haemoglobin increase (e.g. improved quality of life).

This advice has not been followed and the sample size not been increased. On the contrary, the eligibility criteria were even further widened, i.e., also asymptomatic patients were ultimately eligible to the study, thus further increasing the heterogeneity of the study population.

An additional critical point of discussion in both scientific advice procedures was the development of the new PRO instrument NTDT (at the time including both tiredness/weakness and shortness of breath) within the clinical development programme for Luspatercept. The CHMP welcomed in principle the development of an NTDT-specific questionnaire. However, it was stated that ' Causal conclusions based on study outcome s derived from a setting where still two objectives are to be evaluated (i.e. the treatment outcome on one hand and the validation of the PRO measurement tool on the other hand) will lack reliability. Validation should ideally be performed in a well -known and independent setting. Therefore the suggested approach is not supported. Keeping this in mind it should be considered that a disease specific PRO tool for NTD β -thalassemia developed by Celgene might in the end not be applicable during ACE536 development but only serve for later investigations .' (EMEA/H/SAH/044/1/2015/PA/III). The same concern was reiterated in the follow-up advice (EMEA/H/SAH/044/1/FU/1/2016/PA/II). Several limitations of the tool as proposed at this stage were highlighted (which were not specifically addressed) and the concern was expressed that the PRO instrument would likely have only limited value as a confirmatory parameter, given that the MAH was planning to validate the instrument within their phase 3 study programme. The MAH was also discouraged to use a responder analysis (decrease from baseline ≥ 1 in mean NTDT PRO) as the key secondary outcome, as the latter would, as part of the validation exercise, have to clearly justified as the clinically relevant difference, which seemed difficult at the state of evidence. Although the MAH followed the advice to use the NTDT PRO subsequently as a continuous outcome parameter for the key secondary endpoint, further validation of the PRO in an independent setting was ultimately not performed.

<div style=\"page-break-after: always\"></div>

## 2.1.4. General comments on compliance with GCP

The MAH claimed that all of the studies in the luspatercept β -thalassemia clinical development program were conducted in accordance with Good Clinical Practice. All studies were closely monitored by Sponsor personnel or a contract organisation for compliance to all aspects of the protocol.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

As a protein, luspatercept is exempt from preparation of an Environmental Risk Assessment under the 1 June 2006 ' Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use ' (EMEA/CHMP/S/4447/00). BMS-986346 and the product excipients do not pose a significant risk to the environment.

## 2.2.1. Discussion on non-clinical aspects

The updated data submitted in this application do not lead to a significant increase in environmental exposure further to the use of luspatercept. Considering the above data, luspatercept is not expected to pose a risk to the environment.

## 2.3. Clinical aspects

The luspatercept global clinical developme nt program for NTD β -thalassemia comprises three clinical efficacy studies that include a pivotal Phase 2, randomized, double-blind study in non-transfusion dependent (NTD) β -thalassemia patients (ACE-536-B-THAL-002; BEYOND) and two supportive, sequential Phase 2 open-label, single arm studies (A536-04 and its extension A536-06), which had already been part of the initial β -thalassemia submission and included transfusion dependent (TD) as well as NDT patients. Data from 48 weeks for Study ACE-536-B-THAL-002 is provided. Additionally, a CSR for Study ACE-536-B-THAL-003, an observational study used for the validation of the non-transfusiondependent β -thalassemia patient-reported outcome (NTDT-PRO), is also included in this submission.

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

## Tabular overview of clinical studies

Table 1: Key Design Features of Pivotal Study ACE-536-B-THAL-002 and Supportive Studies A536-04 and A536-06

| Design Feature                          | Study ACE-536-B-THAL-002                                                                                                                                                                                                                                                                                                            | Study A536-04                                                                                                                                                                                                                                          | Study A536-06                                                                                                                                                                                                                                           |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study Start (first subject first visit) | 05 Mar 2018                                                                                                                                                                                                                                                                                                                         | 11 Feb 2013                                                                                                                                                                                                                                            | 20 Oct 2014                                                                                                                                                                                                                                             |
| Status (data cutoff date)               | Ongoing (14 Sep 2020; 15 Mar 2021)                                                                                                                                                                                                                                                                                                  | Completed (11 Nov 2015) a                                                                                                                                                                                                                              | Completed (18 Jun 2020)                                                                                                                                                                                                                                 |
| Study Design                            | Phase 2, randomized 2:1 (luspatercept:placebo), double-blind, placebo- controlled, multicenter                                                                                                                                                                                                                                      | Phase 2, multicenter (8 sites in 2 countries), single-arm, open-label, ascending dose                                                                                                                                                                  | Phase 2 multicenter (8 sites in 2 countries), single-arm, open- label extension                                                                                                                                                                         |
| Primary Comparison(s)                   | Luspatercept vs placebo                                                                                                                                                                                                                                                                                                             | NA                                                                                                                                                                                                                                                     | NA                                                                                                                                                                                                                                                      |
| Subject Population                      | Age ≥ 18 y; documented diagnosis of NTD β - thalassemia or HbE/ β - thalassemia, with or without α -globin mutation and/or duplication; NTD (0 to 5 RBC units in the 24 weeks prior to randomization and not on a regular transfusion program and must be transfusion free for at least ≥ 8 weeks prior to randomization); ECOG ≤ 1 | Age ≥ 18 y; documented diagnosis of β -thalassemia intermedia (dose escalation cohorts) or β -thalassemia major or intermedia (expansion cohort); prior splenectomy or spleen size < 18 cm; anemia (mean Hb < 10.0 g/dL or TD)                         | Subjects who completed participation in Study A536-04                                                                                                                                                                                                   |
| Dose                                    | Starting dose of 1.0 mg/kg SC Q3W; maximum dose of 1.25 mg/kg SC Q3W                                                                                                                                                                                                                                                                | 0.2, 0.4, 0.6, 0.8, 1.0, 1.25, and 1.5 mg/kg SC Q3W for ascending-dose cohorts b (1.5 mg/kg cohort not enrolled per Safety Review Team decision) Expansion cohort: c 0.8 to 1.25 mg/kg; Starting dose determined by the Sponsor and Safety Review Team | Last dose level of Study A536-04 for subjects continuing treatment; Starting dose of 0.8 mg/kg for subjects with a treatment interruption Titration permitted for subsequent cycles based on change in Hb and safety assessment 1.25 mg/kg maximum dose |

<div style=\"page-break-after: always\"></div>

| Duration of Treatment                       | 48 weeks (primary analysis of DB Treatment Period) Up to 15 months in Open-label Phase before roll-over to study ACE536-LTFU- 001 for longer treatment (5 years from Dose 1 in the DBTP (luspatercept/Placebo group) or until study drug discontinuation, whichever occurred later (luspatercept group) Post treatment follow-up for 5 years from first dose or 3 years from the last dose (whichever occurs later), if luspatercept treatment is discontinued in the DBTP; completion of the PTFP (with the option to roll-over to study ACE536- LTFU-001)   | 15 weeks; option to roll-over to study A536-06                                                                                       | Up to 5 years; post treatment follow-up for 3 years after last dose; option to roll-over to study ACE536-LTFU-001   |
|---------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Primary Efficacy Endpoint(s)                | Proportion of subjects who have an increase from baseline ≥1.0 g/dL in mean of hemoglobin values over a continuous 12-week interval from Week 13 to Week 24 of treatment in the absence of transfusions.                                                                                                                                                                                                                                                                                                                                                      | Erythroid response based on Hb increase in NTD subjects or reduction in RBC units transfused compared to pretreatment in TD subjects | None (primary objective was long-term safety and tolerability of luspatercept)                                      |
| Key Secondary Endpoint                      | Mean change from baseline in NTDT- PRO T/W domain score over a continuous 12-week interval from Week 13 to Week 24 Mean change from baseline in mean of hemoglobin values over a continuous 12- week interval from Week 13 to Week 24 in the absence of transfusions Proportion of subjects who have an increase from baseline ≥1.0 g/dL in mean of hemoglobin values over a continuous 12-week interval from Week 37 to Week 48 in the absence of transfusions                                                                                               | None                                                                                                                                 | None                                                                                                                |
| Number of Subjects by Arm Entered/Completed | Luspatercept:96/89 (completed 48 weeks) Placebo: 49/35 (completed 48 weeks)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Luspatercept: 64/56                                                                                                                  | Luspatercept: 51/14                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Design Feature                                           | Study ACE-536-B-THAL-002                                               | Study A536-04                                                                         | Study A536-06                                                                         |
|----------------------------------------------------------|------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| Subject Demographics (Sex, Median Age [range], race [%]) | M 63/F 82 40.0 y (18.0 - 71.0 y) Asian: 30.3% Other: 9.7% White: 60.0% | M 33/F 31 38.5 y (20 - 62 y) Asian: 1.6% Black or African American: 1.6% White: 96.9% | M 29/F 22 37.0 y (22 - 62 y) Asian: 2.0% Black or African American: 2.0% White: 96.1% |

AE = adverse events; DB = double-blind; ECOG = Eastern Cooperative Oncology Group; F = female; Hb = hemoglobin; HbE = hemoglobin E; M = male; NA = not applicable; NTD = nontransfusion-dependent; NTDT-PRO T/W = nontransfusiondependent β -thalassemia-patient reported outcome tiredness and weakness; Q3W = once every 3 weeks; RBC = red blood cell; SC = subcutaneous; TD = transfusion-dependent; y = years

a The last subject last visit was 11 Nov 2015 and the database lock occurred on 30 Jul 2016.

b Enrollment of subsequent cohorts and the expansion cohort was based on Safety Review Team review of Hb response and safety from the prior cohort. Dose reductions were permitted in the dose escalation cohorts; dose reductions and titrations were permitted in the expansion cohort for subjects meeting predefined criteria.

c The expansion cohort was planned for 30 subjects and consisted of 29 subjects, including 10 subjects who were NTD and 19 subjects who were TD.

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacokinetics

Clinical pharmacology data were collected from subjects with NTD β -thalassemia in the pivotal Phase 2 Study ACE-536-B-THAL-002 and 2 supportive Phase 2 studies (Studies A536-04 and A536-06).

The population PK model established previously for subjects with β -thalassemia from Studies A536-04 and ACE-536-B-THAL-001 (Report ACE-536-MPK-001, submitted with the initial MAA) was updated by including subjects with NTD β -thalassemia from Study ACE-536-B-THAL-002 to facilitate the comparison of luspatercept PK between subject s with NTD β -thalassemia and subjects with TD β -thalassemia (Report ACE-536-MPK-006).

Table 2: Summary of Clinical Studies in Subjects with β -thalassemia for Pharmacometrics Analyses

| Study: Title (Data Cut-off Date for Pharmacometrics Analyses)                                                                                                                                                                                                             | Study: Title (Data Cut-off Date for Pharmacometrics Analyses)                                                                                                            | Study: Title (Data Cut-off Date for Pharmacometrics Analyses)                                                                                                                                          | Study: Title (Data Cut-off Date for Pharmacometrics Analyses)                                                                                                            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment                                                                                                                                                                                                                                                                 | Sample Size Efficacy/Safety/PK Target Population                                                                                                                         | Nominal PK/Hb Sampling Schedule                                                                                                                                                                        | Analysis                                                                                                                                                                 |
| A536-04: A Phase 2, open-label, ascending dose study to evaluate the effects of ACE-536 in patients with β -thalassemia (Completed)                                                                                                                                       | A536-04: A Phase 2, open-label, ascending dose study to evaluate the effects of ACE-536 in patients with β -thalassemia (Completed)                                      | A536-04: A Phase 2, open-label, ascending dose study to evaluate the effects of ACE-536 in patients with β -thalassemia (Completed)                                                                    | A536-04: A Phase 2, open-label, ascending dose study to evaluate the effects of ACE-536 in patients with β -thalassemia (Completed)                                      |
| Dose escalation cohorts: 0.2, 0.4, 0.6, 0.8, 1, and 1.25 mg/kg, SC, Q3W. Dose expansion cohort: Starting dose = 0.8 mg/kg, SC, Q3W, with intra-subject dose escalation to 1 and 1.25 mg/kg allowed. Drug product: 25 mg frozen liquid (Process I/II                       | Dose escalation: 35/35/35 Dose expansion: 29/29/29 TD: N = 33 NTD: N = 31                                                                                                | PK sampling schedule: C1D1 (pre-dose), C1D8, C1D11, C1D15, C2D1, C2D8, C4D1, C4D8, C4D15, C5D1, C5D8, C5D15, EOT, and EOS. Hb sampling schedule: Prior to treatment, weekly on treatment, EOT, and EOS | TD + NTD PPK NTD only: E-R (Hb, efficacy, safety)                                                                                                                        |
| A536-06 : An open-label extension study to evaluate the long- term effects of ACE-536 in patients with β -thalassemia previously enrolled in study A536-04 (31 Aug 2017)                                                                                                  | A536-06 : An open-label extension study to evaluate the long- term effects of ACE-536 in patients with β -thalassemia previously enrolled in study A536-04 (31 Aug 2017) | A536-06 : An open-label extension study to evaluate the long- term effects of ACE-536 in patients with β -thalassemia previously enrolled in study A536-04 (31 Aug 2017)                               | A536-06 : An open-label extension study to evaluate the long- term effects of ACE-536 in patients with β -thalassemia previously enrolled in study A536-04 (31 Aug 2017) |
| Subjects without treatment interruption: Starting dose was the same as their last dose in Study A536-04, with intra-subject dose escalation (up to 1.25 mg/kg) allowed. Subjects with treatment interruption: Starting dose = 0.8 mg/kg, SC, Q3W, with intra-subject dose | 51/51/51 TD: N = 27 NTD: N = 24                                                                                                                                          | PK sampling schedule: C1D1 (pre-dose), C1D8, C2D1, C9D1, C9D8, C10D1, C17D1, and C17D8. Additional collections in parallel with ADA sample collections Hb sampling schedule:                           | NTD only E-R (Hb, safety)                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| escalation to 1 and 1.25 mg/kg allowed. Drug product: Switched from 25 mg frozen liquid to 50 mg lyophilized powder (Process II) on a site-by-site                                                                                                                                   |                                                                                                                                                                                                                                                                                      | Prior to treatment, once every 1, 2 or 3 weeks on treatment, EOT, and EOS                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ACE-536-B-THAL-001 : A Phase 3, double-blind, randomized, placebo- controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults who require regular red blood cell transfusions due to beta (β) -thalassemia. (11 May 2018) | ACE-536-B-THAL-001 : A Phase 3, double-blind, randomized, placebo- controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults who require regular red blood cell transfusions due to beta (β) -thalassemia. (11 May 2018) | ACE-536-B-THAL-001 : A Phase 3, double-blind, randomized, placebo- controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults who require regular red blood cell transfusions due to beta (β) -thalassemia. (11 May 2018) | ACE-536-B-THAL-001 : A Phase 3, double-blind, randomized, placebo- controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults who require regular red blood cell transfusions due to beta (β) -thalassemia. (11 May 2018) |
| Starting dose = 1 mg/kg, SC, Q3W, with intra-subject dose escalation to 1.25 mg/kg allowed. Drug product: 25 and 75 mg lyophilized powder (Process III drug substance).                                                                                                              | Luspatercept: 224/223/221 Placebo: 112/109/0 TD                                                                                                                                                                                                                                      | PK sampling schedule: C1D1 (pre-dose), C2D1, C3D1, C4D1, C5D1, C6D1, C6D8, C6D15, C8D1, C10D1, C12D1, C14D1, C16D1; then, once every 6 doses. Hb sampling schedule: Day 1 of each cycle, C6D8, C6D15, EOT, and EOS.                                                                  | PPK                                                                                                                                                                                                                                                                                  |
| ACE-536-B-THAL-002 : A Phase 2, double-blind, randomized, placebo- controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults with non- transfusion dependent be ta (β) - thalassemia. (14 Sept 2020)                     | ACE-536-B-THAL-002 : A Phase 2, double-blind, randomized, placebo- controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults with non- transfusion dependent be ta (β) - thalassemia. (14 Sept 2020)                     | ACE-536-B-THAL-002 : A Phase 2, double-blind, randomized, placebo- controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults with non- transfusion dependent be ta (β) - thalassemia. (14 Sept 2020)                     | ACE-536-B-THAL-002 : A Phase 2, double-blind, randomized, placebo- controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults with non- transfusion dependent be ta (β) - thalassemia. (14 Sept 2020)                     |
| Starting dose = 1 mg/kg, SC, Q3W, with intra-subject dose escalation to 1.25 mg/kg allowed. Drug product: 25 and 75 mg lyophilized powder (Process III drug substance).                                                                                                              | Luspatercept: 96/96/96 Placebo: 49/49/0 NTD                                                                                                                                                                                                                                          | PK sampling schedule: C1D1 (pre-dose), C2D1, C4D1, C6D1, C6D8, C6D15, C8D1, C12D1, C16D1, then, once every 6 doses. Hb sampling schedule: Day 1 of each cycle, C6D8, C6D15, WK 1, WK 13, WK 19, WK 24, WK 37, WK 42, WK 48, and EOS.                                                 | PPK E-R (Hb, efficacy, safety)                                                                                                                                                                                                                                                       |

C = cycle (or dose); D = day; EOS = end of study; EOT = end of treatment; E-R = exposure-response; Hb = hemoglobin; NTD = non-transfusion dependent, defined as baseline red blood cell transfusion burden 0 to 5 units/24 weeks; PD = pharmacodynamic (pharmacodynamics); PK = pharmacokinetic (pharmacokinetics); PPK = population pharmacokinetic (pharmacokinetics); Q3W = once every three weeks; SC = subcutaneous injection; TD = transfusion dependent, defined as baseline red blood cell transfusion burden ≥ 6 un its/24 weeks; WK = week.

<div style=\"page-break-after: always\"></div>

## Methods

## Bioanalytical Methods:

Concentrations of luspatercept in serum were determined using a validated enzyme linked immunosorbent assay. The lower limit of quantitation was 50 ng/mL.

Table 3: Summary Description of Bioanalytical Assays for Luspatercept Concentration

| ValidatedMethod                        | Enzyme Linked Immunosorbent Assay                         |
|----------------------------------------|-----------------------------------------------------------|
| Species and Matrix                     | Human serum                                               |
| Analyte                                | Luspatercept                                              |
| Cross Validated to                     | Not applicable                                            |
| Standard Curve                         |                                                           |
| Lower limit of quantification          | 50 ng/mL                                                  |
| Upper limit of quantification          | 600 ng/mL                                                 |
| Precision (% variation of coefficient) |                                                           |
| Intra Assay                            | ≤8.08 %                                                   |
| Inter Assay                            | ≤12.0 %                                                   |
| Accuracy (% Deviation)                 | Within ± 8%                                               |
| Studies in Which Method Was Used       | A536-04,A536-06,ACE-536-B-THAL-001,and ACE-536-B-THAL-002 |

Source: Report 176680 and addendum 1 (Report 176681).

Updates have been performed in order to meet current guidance requirements and/or qualify new batches of reagents:

Report 176680 addendum 4 (Report 188684): Validation for the Determination of ACE-536 in Human Serum by Quantitative ELISA

A post-validation assessment of the method was performed in order to verify the performance of the assay after an optimisation (blocking buffer and diluent buffer change, curve range narrowed, sample incubation time modified, additional calibration point). All pre-set validation parameters were met and no deviations occurred. The MAH's post-validation assessments confirms that the assay is still in a validated state.

## Population:

In pharmacokinetic (PK) and exposure-response relationship analyses (see PK/PD Modelling section), subjects with NTD β -thalassemia were defined as subjects who had a baseline transfusion burden of 0 to 5 RBC units/24 weeks, and subjects with TD β -thalassemia were defined as subjects who a baseline transfusion burden ≥ 6 RBC units/24 weeks. All subjects with NTD β -thalassemia (N = 127) in the above 3 clinical studies participated in PK assessments.

<div style=\"page-break-after: always\"></div>

Table 4: Number of TD and NTD subjects (Population Pharmacokinetic Analysis)

|                                         | Number (%) of Subjects   | Number (%) of Subjects        | Number (%) of Subjects       | Number (%) of Subjects   |
|-----------------------------------------|--------------------------|-------------------------------|------------------------------|--------------------------|
| Characteristics                         | A536-04 (N = 64)         | ACE-536-B- THAL-001 (N = 221) | ACE-536-B- THAL-002 (N = 96) | Overall (N = 381)        |
| Dependent (≥ 6 RBC units/24 weeks)      | 33 (51.6%)               | 221 (100%)                    | 0 (0%)                       | 254 (66.7%)              |
| Nondependent (0 - 5 RBC units/24 weeks) | 31 (48.4%)               | 0 (0%)                        | 96 (100%)                    | 127 (33.3%)              |

## Software:

Datasets preparation, exploration and visualisation were performed using SAS (Version 9.3), R (version 3.5.1 or greater), and RStudio (Version 3.6 or greater).

The PPK analysis and E-R analysis for the time course of Hb were performed using NONMEM (Version 7.3 or greater), with the firstorder conditional estimation and the INTERACTION option. Perl-Speaks-NONMEM (PsN, Version 4.6.0 or greater) was used during PK and Hb modeling evaluations, and the results were further analyzed by R and RStudio software.

Exposure-response analyses for efficacy and safety were performed using R and RStudio software.

## Population PK model

The population PK model established previously for subjects with TD β -thalassemia from Studies A536-04 and ACE-536-B-THAL-001 (Report ACE-536-MPK-001, submitted with the initial MAA) was updated by including subjects with NTD β -thalassemia from Study ACE-536-B-THAL-002.

## OBJECTIVES:

The objectives of the analysis were to describe the concentration-time profile of luspatercept in subjects with nontransfusion dependent β -thalassemia (NTDT) or transfusion dependent β -thalassemia (TDT) and to assess the effect of selected key covariates on luspatercept pharmacokinetic (PK) parameters.

## METHODOLOGY:

## Analysis Populations:

The population PK (PPK) analysis included subjects with NTDT or TDT in Studies A536-04, ACE-536-BTHAL-001, and ACE-536-B-THAL-002, who received at least one dose of luspatercept and had measurable luspatercept serum concentrations. Studies A536-04 and ACE-536-B-THAL-001 had been included in the previous PPK analysis that characterized luspatercept PK mainly in subjects with TDT, and Study ACE536-B-THAL-002 was included to enable better characterization of luspatercept PK in subjects with NTDT relative to those with TDT. Luspatercept concentration data from Study A536-06 were not included in PPK analysis, because all subjects in this study had already provided sufficient PK samples in Study A536-04.

The PPK analysis dataset included 4636 PK samples from 383 subjects. The included 4636 samples were collected from 5 to 919 days after the first dose.

Categorical and continuous demographic characteristics of subjects included in the PPK analysis are presented in the tables below.

<div style=\"page-break-after: always\"></div>

Table 5: Subjects and Concentration Records Included (Population Pharmacokinetic Analysis)

| Study              | Number (%) of Subjects   | Number (%) of Subjects   | Number (%o) of Hb Records   | Number (%o) of Hb Records   | Number (%o) of Hb Records   |
|--------------------|--------------------------|--------------------------|-----------------------------|-----------------------------|-----------------------------|
|                    | Treated                  | Included                 | Total                       | Excluded                    | Included                    |
| A536-04            | 64                       | 64 (100%)                | 806                         | 79 (10%)                    | 727 (90%)                   |
| ACE-536-B-THAL-001 | 223                      | 221 (99%)                | 3,187                       | 234 (7%)                    | 2.953 (93%)                 |
| ACE-536-B-THAL-002 | 96                       | 96 (100%)                | 1,066                       | 110 (10%)                   | 956 (90%)                   |
| Total              | 383                      | 381 (99%)                | 5,059                       | 423 (8%)                    | 4.636 (92%)                 |

Hb = hemoglobin. Source: Appendix A, Section 6.1.1.

Table 6: Characteristics of Subjects - Categorical Data (Population Pharmacokinetic Analysis)

|                                              | Number (%) of Subjects   | Number (%) of Subjects        | Number (%) of Subjects       | Number (%) of Subjects   |
|----------------------------------------------|--------------------------|-------------------------------|------------------------------|--------------------------|
| Characteristics                              | A536-04 (N = 64)         | ACE-536-B- THAL-001 (N = 221) | ACE-536-B- THAL-002 (N = 96) | Overall (N = 381)        |
| Baseline Characteristics                     |                          |                               |                              |                          |
| Sex                                          |                          |                               |                              |                          |
| Female                                       | 31 (48.4%)               | 131 (59.3%)                   | 56 (58.3%)                   | 218 (57.2%)              |
| Male                                         | 33 (51.6%)               | 90 (40.7%)                    | 40 (41.7%)                   | 163 (42.8%)              |
| Age category                                 |                          |                               |                              |                          |
| ≥ 32 Years                                   | 44 (68.8%)               | 100 (45.2%)                   | 63 (65.6%)                   | 207 (54.3%)              |
| < 32 Years                                   | 20 (31.2%)               | 121 (54.8%)                   | 33 (34.4%)                   | 174 (45.7%)              |
| Race                                         |                          |                               |                              |                          |
| White                                        | 62 (96.9%)               | 119 (53.8%)                   | 59 (61.5%)                   | 240 (63.0%)              |
| Black                                        | 1 (1.6%)                 | 1 (0.5%)                      | 0 (0%)                       | 2 (0.5%)                 |
| Asian                                        | 1 (1.6%)                 | 81 (36.7%)                    | 31 (32.3%)                   | 113 (29.7%)              |
| Other (including uncollected or unreported)  | 0 (0%)                   | 20 (9.0%)                     | 6 (6.2%)                     | 26 (6.8%)                |
| Transfusion dependence                       |                          |                               |                              |                          |
| Dependent (≥ 6 RBC units/24 weeks)           | 33 (51.6%)               | 221 (100%)                    | 0 (0%)                       | 254 (66.7%)              |
| Nondependent (0 - 5 RBC units/24 weeks)      | 31 (48.4%)               | 0 (0%)                        | 96 (100%)                    | 127 (33.3%)              |
| Hepatic impairment categories                |                          |                               |                              |                          |
| Normal (BIL, ALT, AST ≤ ULN)                 | 3 (4.7%)                 | 50 (22.6%)                    | 9 (9.4%)                     | 62 (16.3%)               |
| Mild (BIL > 3x ULN, any ALT or AST)          | 10 (15.6%)               | 68 (30.8%)                    | 11 (11.5%)                   | 89 (23.4%)               |
| Moderate (BIL > 1.5 - 3 ULN, any ALT or AST) | 34 (53.1%)               | 81 (36.7%)                    | 42 (43.8%)                   | 157 (41.2%)              |
| Severe (BIL > 3 x ULN, any ALT or AST)       | 17 (26.6%)               | 22 (10.0%)                    | 34 (35.4%)                   | 73 (19.2%)               |
| Renal impairment categories                  |                          |                               |                              |                          |
| Normal (individual eGFR ≥ 90 mL/min)         | 53 (82.8%)               | 172 (77.8%)                   | 77 (80.2%)                   | 302 (79.3%)              |
| Mild (individual eGFR 60 to < 90 mL/min)     | 10 (15.6%)               | 45 (20.4%)                    | 19 (19.8%)                   | 74 (19.4%)               |

<div style=\"page-break-after: always\"></div>

| Moderate (individual eGFR 30 to < 60 mL/min)   | 1 (1.6%)   | 3 (1.4%)    | 0 (0%)     | 4 (1.0%)    |
|------------------------------------------------|------------|-------------|------------|-------------|
| Missing                                        | 0 (0%)     | 1 (0.5%)    | 0 (0%)     | 1 (0.3%)    |
| Splenectomy                                    |            |             |            |             |
| Yes                                            | 43 (67.2%) | 127 (57.5%) | 34 (35.4%) | 204 (53.5%) |
| No                                             | 21 (32.8%) | 94 (42.5%)  | 62 (64.6%) | 177 (46.5%) |
| β - Thalassemia diagnosis                      |            |             |            |             |
| β - Thalassemia                                | 64 (100%)  | 172 (77.8%) | 63 (65.6%) | 299 (78.5%) |
| β - Thalassemia combined with α - Thalassemia  | 0 (0%)     | 17 (7.7%)   | 5 (5.2%)   | 22 (5.8%)   |
| Hemoglobin E/β - Thalassemia                   | 0 (0%)     | 31 (14.0%)  | 28 (29.2%) | 59 (15.5%)  |
| Missing                                        | 0 (0%)     | 1 (0.5%)    | 0 (0%)     | 1 (0.3%)    |
| β - Thalassemia gene mutation                  |            |             |            |             |
| β0/β0                                          | 0 (0%)     | 67 (30.3%)  | 9 (9.4%)   | 76 (19.9%)  |
| Non- β0/β0                                     | 0 (0%)     | 153 (69.2%) | 87 (90.6%) | 240 (63.0%) |
| Missing                                        | 64 (100%)  | 1 (0.5%)    | 0 (0%)     | 65 (17.1%)  |
| On-Treatment Characteristics                   |            |             |            |             |
| Concurrent use of iron chelation therapy       |            |             |            |             |
| Yes                                            | 43 (67.2%) | 199 (90.0%) | 29 (30.2%) | 271 (71.1%) |
| No                                             | 21 (32.8%) | 0 (0%)      | 67 (69.8%) | 88 (23.1%)  |
| Missing                                        | 0 (0%)     | 22 (10.0%)  | 0 (0%)     | 22 (5.8%)   |
| Antidrug antibodies status                     |            |             |            |             |
| Negative                                       | 60 (93.8%) | 214 (96.8%) | 91 (94.8%) | 365 (95.8%) |
| Pre- existing                                  | 4 (6.2%)   | 2 (0.9%)    | 2 (2.1%)   | 8 (2.1%)    |
| Treatment-emergent                             | 0 (0%)     | 4 (1.8%)    | 3 (3.1%)   | 7 (1.8%)    |
| Missing                                        | 0 (0%)     | 1 (0.5%)    | 0 (0%)     | 1 (0.3%)    |

ALT = alanine transaminase; AST = aspartate transaminase; BIL = total bilirubin; eGFR = estimated glomerular filtration rate; N = number of subjects; RBC = red blood cell; ULN = upper limit of normal.

## Table 7: Baseline Characteristics of Subjects - Continuous Data (Population Pharmacokinetic Analysis)

|                        | A536-04 (N = 64)   | ACE-536-B- THAL-001 (N = 221)   | ACE-536-B- THAL-002 (N = 96)   | Overall (N = 381)   |
|------------------------|--------------------|---------------------------------|--------------------------------|---------------------|
| Age (years)            |                    |                                 |                                |                     |
| Mean (SD)              | 38.1 (10.5)        | 32.1 (10.7)                     | 39.3 (13.2)                    | 34.9 (11.8)         |
| Median (Min, Max)      | 38.5 (20.0, 62.0)  | 29.0 (18.0, 66.0)               | 39.5 (18.0, 71.0)              | 33.0 (18.0, 71.0)   |
| Weight (kg)            |                    |                                 |                                |                     |
| Mean (SD)              | 64.3 (10.3)        | 57.0 (10.2)                     | 61.1 (12.5)                    | 59.3 (11.2)         |
| Median (Min, Max)      | 62.5 (47.5, 97.0)  | 56.0 (34.1, 91.0)               | 59.9 (36.4, 94.5)              | 57.8 (34.1, 97.0)   |
| Erythropoietin (U/L) a |                    |                                 |                                |                     |

<div style=\"page-break-after: always\"></div>

| Mean (SD)                     | 92.6 (96.8)       | 93.8 (113)                    | 159 (272)                    | 110 (168)         |
|-------------------------------|-------------------|-------------------------------|------------------------------|-------------------|
| Median (Min, Max)             | 57.7 (8.80, 499)  | 60.7 (2.40, 972)              | 65.2 (9.61, 1680)            | 60.7 (2.40, 1680) |
| RBCT burden (units/24 weeks)  |                   |                               |                              |                   |
| Mean (SD)                     | 8.74 (9.25)       | 15.0 (3.89)                   | 0.333 (1.08)                 | 10.2 (7.83)       |
| Median (Min, Max)             | 6.00 (0, 34.0)    | 15.0 (6.00, 25.1)             | 0 (0, 8.00) b                | 12.3 (0, 34.0)    |
| Total bilirubin (µmol/L)      |                   |                               |                              |                   |
| Mean (SD)                     | 52.0 (38.4)       | 35.5 (23.2)                   | 59.6 (36.3)                  | 44.3 (31.6)       |
| Median (Min, Max)             | 40.8 (10.6, 246)  | 29.0 (5.00, 195)              | 51.5 (9.00, 180)             | 35.9 (5.00, 246)  |
| Albumin (g/L)                 |                   |                               |                              |                   |
| Mean (SD)                     | 44.9 (4.73)       | 46.0 (3.37)                   | 47.0 (2.91)                  | 46.1 (3.58)       |
| Median (Min, Max)             | 45.3 (30.6, 53.5) | 46.0 (30.0, 56.0)             | 47.0 (41.0, 55.0)            | 46.0 (30.0, 56.0) |
| Alkaline phosphatase (U/L)    |                   |                               |                              |                   |
| Mean (SD)                     | 70.2 (17.7)       | 93.9 (38.5)                   | 64.1 (21.4)                  | 82.4 (34.8)       |
| Median (Min, Max)             | 70.5 (39.0, 121)  | 85.0 (31.0, 262)              | 61.0 (27.0, 141)             | 73.0 (27.0, 262)  |
| Alanine transaminase (U/L)    |                   |                               |                              |                   |
| Mean (SD)                     | 22.6 (14.8)       | 29.8 (25.5)                   | 18.8 (14.2)                  | 25.8 (22.1)       |
| Median (Min, Max)             | 18.5 (6.00, 102)  | 21.0 (6.00, 166)              | 14.0 (6.00, 89.0)            | 18.0 (6.00, 166)  |
| Aspartate transaminase (U/L)  |                   |                               |                              |                   |
| Mean (SD)                     | 26.4 (12.6)       | 29.2 (18.9)                   | 27.1 (15.2)                  | 28.2 (17.1)       |
| Median (Min, Max)             | 22.0 (11.0, 67.0) | 22.0 (10.0, 116)              | 24.0 (10.0, 132)             | 22.0 (10.0, 132)  |
| Lactate dehydrogenase (U/L) c |                   |                               |                              |                   |
| Mean (SD)                     | 397 (234)         | 194 (89.7)                    | 298 (106)                    | 254 (150)         |
| Median (Min, Max)             | 336 (89.0, 1500)  | 170 (75.0, 739)               | 280 (109, 605)               | 210 (75.0, 1500)  |
|                               | A536-04 (N = 64)  | ACE-536-B- THAL-001 (N = 221) | ACE-536-B- THAL-002 (N = 96) | Overall (N = 381) |
| Individual eGFR (mL/min) c    |                   |                               |                              |                   |
| Mean (SD)                     | 125 (37.3)        | 119 (41.0)                    | 122 (35.5)                   | 121 (39.0)        |
| Median (Min, Max)             | 121 (56.5, 224)   | 109 (47.4, 323)               | 120 (66.6, 267)              | 115 (47.4, 323)   |
| eGFR (mL/min/1.73 m²)         |                   |                               |                              |                   |
| Mean (SD)                     | 126 (35.2)        | 130 (43.6)                    | 128 (40.3)                   | 129 (41.4)        |
| Median (Min, Max)             | 117 (59.2, 223)   | 120 (53.7, 314)               | 120 (62.2, 292)              | 120 (53.7, 314)   |

eGFR = estimated glomerular filtration rate; Max = maximum; Min = minimum; N = number of subjects; RBCT = red blood cell transfusion burden; SD = standard deviation.

a Missing value for 8 subjects in Study ACE-536-B-THAL-001 and for 3 subjects in Study ACE-536-B-THAL-002.

b See Section 7.9. CSR ACE-536-MPK-006 for data clarification.

c Missing value for 1 subject in Study ACE-536-B-THAL-001.

<div style=\"page-break-after: always\"></div>

## Analysis:

The luspatercept PPK model was developed in three steps: base, full and final models. A previously developed PPK model was updated with additional 96 subjects with NTDT from Study ACE-536-BTHAL002 and used as a base model for the full model development. The full model was developed by incorporating additional covariates of interest into the base model. The final model was a parsimonious model derived from the full model. The final model was validated using goodness of fit, bootstrap resampling and visual predictive check (VPC).

Empirical Bayesian estimates of individual PK parameters were generated using the final PPK model. Measures of luspatercept serum exposure were computed for each subject including:

- -Maximum concentration after a single dose (Cmax) and at steady state (Cmax,ss).
- -Area under concentration-time curve (AUC) at steady state (AUCss).
- -Average AUC from Week 1 to 15 (AUCavg15), Week 1 to 24 (AUCavg24), and Week 1 to 48 (AUCavg48), which were used as the exposure endpoints for exposure-efficacy analyses during a given evaluation period (see section PK/PD modelling).
- -AUC at the first event (AUCevent), which was used as the exposure endpoint for exposure-safety analyses. (see section PK/PD modelling)
- -Average concentration at steady state (AUCavg.ss), calculated as [AUCss/21 days].

Luspatercept PK parameters were summarised for groups of interest (renal function, race, and transfusion dependence) and for Study ACE-536-B-THAL-002.

## Dataset:

A total of 4,636 luspatercept serum concentration records from 381 subjects, including 96 new subjects with NTDT from Study ACE-536-B-THAL-002, were included in this updated PPK analysis.

## Base model:

The previously developed model, a one-compartment model with first-order absorption and elimination, provided a good fit to the observed data including newly added subjects with NTDT from Study ACE-536B-THAL-002. The base model was stable (condition number of 80.78 was well below 1000), and the parameter estimates were generally consistent with the estimates from the previous model. All retained covariates remained statistically significant with the 95% CI of the covariate effect parameter excluding the null value, but the effect of baseline RBC transfusion burden became smaller compared with the previous model. The goodness-of-fit plots for the base model indicated that the observed concentrations of both subjects with NTDT and subjects with TDT were well described by the model predictions.

The parameter estimates in the base model were generally consistent with the estimates from the previous model.

## Covariate analysis:

The relationships between potential covariates and empirical Bayesian estimates of random effects from the base model for CL/F and V1/F were examined. A positive trend between individual eGFR and random effect of CL/F was observed. High collinearity (Pearson correlation efficient &gt; 0.5) among potential covariates examined was not observed. Effect of ADA was not tested in the covariate analysis as there were less than 10 ADA-positive subjects observed.

Univariate analysis was conducted to select potential new covariates. The following potential new covariates were selected for the full model due to a reduction in BIC in univariate analyses:

<div style=\"page-break-after: always\"></div>

- On CL/F: Age, aspartate aminotransferase (AST), individual eGFR, and total bilirubin
- On V1/F: Age

Addition of alanine aminotransferase (ALT), race, splenectomy, and β -thalassemia gene mutation on CL/F, or addition of albumin, total bilirubin, race, splenectomy, and β -thalassemia gene mutation on V1/F increased BIC compared with the base model in univariate analyses, and thus these factors were not included in the full model.

The full model was derived by simultaneously incorporating all potential covariate-parameter relationships of interest into the model, including the covariates identified for the previous model and potential new covariates selected from univariate analyses.

## Full model:

The full covariate model for CL/F and V1/F were as follows:

<!-- image -->

<!-- image -->

Where CL/Fi is individual CL/F; CLTV is typical value of CL/F for a reference subject; CLWT, CLTRANSBR, CLALB, CLAGE, CLAST, CLIND\\_EGFR, and CLTBIL are typical values of covariate effects on CL/F for baseline body weight, RBC transfusion burden, albumin, age, AST, individual eGFR, and total bilirubin, respectively; V1/Fi is individual V1/F; V1TV is typical value of V1/F for a reference subject; V1WT, V1TRANSBR, and V1AGE, are typical values of covariate effects on V1/F for baseline body weight, RBC transfusion burden and age, respectively; WTi, TRANSBRi, ALBi, AGEi, ASTi, IND\\_EGFRi, and TBILi are individual baseline values for body weight (kg), RBC transfusion burden (units/24 weeks), albumin (g/L), age (years), AST (U/L), individual eGFR (mL/min), and total bilirubin (μmol/L), respectively; ηCL i is the difference between the CL/F estimate based on typical values and individual CL/F estimate; ηV1 i is the difference between the V1/F estimate based on typical values and individual V1/F estimate. The reference subject for the above full covariate models was a subject with body weight of 70 kg, RBC transfusion burden of 14 units/24 weeks, albumin of 46 g/L, age of 32 years, AST of 22 U/L, individual eGFR of 120 mL/min, and total bilirubin of 33 μmol/L at baseline. (ie, at the same reference values used for the previous covariate analysis and previous full model).

In the full model, the effect of body weight, albumin, individual eGFR and total bilirubin on CL/F as well as the effect of body weight and baseline RBC transfusion burden on V1/F were statistically significant. However, only the effect of body weight on CL/F and V1/F may be clinically relevant (exceeding the conventionally accepted limits of 80% to 125% of the reference value). Effects of other significant covariates remained within ± 25% of the reference value.

<div style=\"page-break-after: always\"></div>

Figure 1: Covariate Effects on Luspatercept Pharmacokinetic Parameters (Full Model)

<!-- image -->

AST = aspartate transaminase; CI = confidence interval; CL/F = apparent clearance; Cont. Var = continuous covariate; variable; P05 = 5th percentile, P95 = 95th percentile; V1/F = apparent volume of distribution of the central compartment

The reference subject was the subject with body weight of 57.8 kg, red blood cell transfusion burden of 12.3 units/24 weeks, albumin of 46 g/L, age of 33 years, AST of 22 U/L, individual eGFR of 115 mL/min, and total bilirubin of 35.9 μmol/L at baseline (ie, at median covariate values for the current analysis population).

Continuous covariates effects (95% CI) at the 5 th  /95 th  percentiles of the covariate are represented by the end of horizontal boxes (horizontal red lines). Open/blue area of boxes represent the range of covariate effects from the median to the 5 th  /95 th  percentile of the covariate.

Parameter estimate in the reference subject is considered as 100% (vertical solid line) and dotted vertical lines are at 80% and 125% of this value.

<div style=\"page-break-after: always\"></div>

## Final model:

The final PPK model was derived from the full model by retaining statistically significant covariates, including body weight, albumin, and individual eGFR on CL/F and body weight and baseline RBC transfusion burden on V1/F.

Evaluation of the final PPK model with the goodness-of-fit plots and visual predictive checks demonstrated robust predictive performance. The model was validated to be appropriate for its use in predicting luspatercept exposure for E-R analyses.

The final model adequately described individual luspatercept serum concentration profiles for subjects with either NTDT or TDT.

Table 8: Population Pharmacokinetic Parameters of Luspatercept (Final Model)

| Parameter                             | Estimate                            | RSE (%)                             | 95% CI *                            |
|---------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| Fixed Effects and Covariate Effects   | Fixed Effects and Covariate Effects | Fixed Effects and Covariate Effects | Fixed Effects and Covariate Effects |
| CLTrv (L/day)                         | 0.5248                              | 2.36                                | (0.502, 0.552)                      |
| CLWT                                  | 0.654                               | 12.9                                | (0.503, 0.824)                      |
| CLALB                                 | -0.8613                             | 16.85                               | (-1.14, -0.523)                     |
| CLND_EGFR                             | 0.4071                              | 11.53                               | (0.311, 0.5)                        |
| Vlrv (L)                              | 8.35                                | 2.43                                | (7.958, 8.789)                      |
| Vlwr                                  | 0.7399                              | 11.52                               | (0.581, 0.9)                        |
| VlTRANSBR                             | -0.005899                           | 28.08                               | (-0.009, -0.002)                    |
| Karv (day')                           | 0.4206                              | 6.73                                | (0.372, 0.48)                       |
| Individual Variability                | Individual Variability              | Individual Variability              | Individual Variability              |
| nCL; standard deviation               | 0.3056                              | 9.9                                 | (0.259, 0.375)                      |
| mV1; standard deviation               | 0.2468                              | 14.65                               | (0.163, 0.311)                      |
| mCL; and nV1; correlation             | 0.6363                              | 11.89                               | (0.505, 0.8)                        |
| Residual Variability                  | Residual Variability                | Residual Variability                | Residual Variability                |
| Log-additive error standard deviation | 0.2049                              | 8.96                                | (0.17, 0.242)                       |

CI = confidence interval; CL/F = apparent clearance; CLTV = typical value of CL/F for a reference subject; CLWT = typical value of body weight (kg) effect on CL/F; CLALB = typical value of baseline albumin (g/L) effect on CL/F; CLIND\\_EGFR = typical value of individual estimated glomerular filtration rate (mL/min) effect on CL/F; Ka = first-order rate constant of absorption; KaTV = typical value of Ka for a reference subject; RSE = relative standard error; V1/F = apparent volume of distribution of the central compartment; V1TV = typical value of V1/F for a reference subject; V1WT = typical value of body weight (kg) effect on V1/F; V1TRANSBR = typical value of baseline red blood cell transfusion burden (units/24 weeks) effect on V1/F; ηCLi = difference between the CL/F estimate based on typical values and individual CL/F estimate; ηV1i = difference between the V1/F estimate based on typical values and individual V1/F estimate. a Nonparametric 95% confidence interval obtained from 1000 bootstrap runs with 995 runs minimized successfully.

The reference subject was a subject with body weight of 70 kg, red blood transfusion burden of 14 units/24 weeks, albumin of 46 g/L, and individual eGFR of 120 mL/min at baseline (ie, at the same reference values used for the previous covariate analysis and the previous final model).

Individual variability shrinkage was 3.1% and 25.2% on CL/F and V1/F, respectively. Condition number was 100.

<div style=\"page-break-after: always\"></div>

## Model Evaluation

Population and individual predicted concentrations of luspatercept from the final model suggest good agreement with the observed data for both subjects with NTDT and subjects with TDT.

The final PPK model of luspatercept was also evaluated using VPC with 500 simulations. For each study, the 5th, 50th and 95th percentiles of the observed concentration data at each time point from the previous dose or from the first dose were generally contained within the respective 95% CI of the simulated data. There was a good agreement in the time course and central tendency between distributions of observed and simulated data, with no obvious bias. The VPC also suggested that the final model improved the fits for the observed median and 5 th  percentile concentrations compared with the base model.

Figure 2: Goodness-of- fit Plots for Population Pharmacokinetic Model by Transfusion Dependence (Final Model)

<!-- image -->

NTD = non-transfusion dependent; TD = transfusion dependent.

The black line represents identity or zero horizontal line. The blue line represents locally weighted scatterplot smoothing line. The dash represents residuals at 6 or -6 value. Circles are observed value.

<div style=\"page-break-after: always\"></div>

Figure 3: Visual Predictive Check for the Concentration-Time Profiles of Luspatercept by Study (Final Model, Time after the Previous Dose)

<!-- image -->

Black dots represent observed data, and black dash lines represent observed 5th, 50th, and 95th percentiles. Solid lines represent the 5th (blue), 50th (red), and 95th (blue) percentiles of the simulated data. Shaded areas represent 95% confidence intervals about the 5th (blue), 50th (red), and 95th (blue) percentiles for the corresponding simulated data. Top vertical bars represent binning optimized by partitioning around medoids methodology.

<div style=\"page-break-after: always\"></div>

Figure 4: Visual Predictive Check for the Concentration-Time Profiles of Luspatercept by Study (Final Model, Time after the Frist Dose)

<!-- image -->

Black dots represent observed data, and black dash lines represent observed 5th, 50th, and 95th percentiles. Solid lines represent the 5th (blue), 50th (red), and 95th (blue) percentiles of the simulated data. Shaded areas represent 95% confidence intervals about the 5th (blue), 50th (red), and 95th (blue) percentiles for the corresponding simulated data. Top vertical bars represent binning optimised by partitioning around medoids methodology.

## Results

Luspatercept serum concentration-time profiles for subjects with NTDT or TDT were adequately described by a one-compartment PPK model with the first order absorption and elimination. The typical values of CL/F and V1/F of luspatercept were 0.525 L/day and 8.35 L, respectively. The typical value of elimination half-life of luspatercept was 11 days.

<div style=\"page-break-after: always\"></div>

Summary of empirical Bayesian estimation of individual luspatercept PK parameters showed a 27% to 41% higher mean AUCss in subjects with mild to moderate renal function than in subjects with normal renal function. Mean luspatercept AUCss was similar between races (Asian versus White) or between NTDT and TDT.

Body weight was the most influential covariate for both CL/F and V1/F, while other statistically significant covariates had limited effects (albumin, individual eGFR and total bilirubin on CL/F; baseline RBC transfusion burden on V1/F).

The analysis reconfirmed that age (18 to 71 years), sex, race (White, Asian, and other), splenectomy, β -thalassemia gene mutation (β0/β0 versus non -β0/β0), and liver enzyme levels (up to 3 times of the upper limit of normal range) had no significant effects on luspatercept PK.

Luspatercept PK was similar between subjects with NTDT and those with TDT.

In Study ACE-536-B-THAL-002, luspatercept serum concentrations were at steady state on Day 63, and mean AUCss for the starting dose of 1 mg/kg was 36% or 41% higher in subjects who achieved ≥ 1 g/dL or 1.5 g/dL increase from baseline in mean Hb value during Week 13 to 24 (primary efficacy endpoint) than those who did not.

Table 9: Summary of Individual Pharmacokinetic Parameters by Renal Function Category

<!-- image -->

|                   | Normal function (N =302)   | Mild impairment (N =74)   | Moderate impairment (N = 4)   |
|-------------------|----------------------------|---------------------------|-------------------------------|
| CL/F (L/day)      | 0.486 (36.6)               | 0.366 (30.7)              | 0.278 (33.2)                  |
| V1/F (L)          | 7.52 (24.3)                | 6.94 (24.1)               | 5.98 (14.7)                   |
| t (day)           | 10.7 (24.7)                | 13.2 (24.0)               | 14.9 (22.4)                   |
| Tmax (day)        | 5.25 (3.29 - 6.88)         | 5.69 (4.50-7.46)          | 5.94 (5.33-6.38)              |
| Cmax (μg/mL)      | 5.55 (21.6)                | 6.02 (21.0)               | 6.03 (15.4)                   |
| Cmax,5s (μg/mL)   | 7.97 (28.2)                | 9.61 (24.4)               | 10.3 (28.8)                   |
| Cavg,ss(μg/mL)    | 5.76 (34.6)                | 7.35 (28.7)               | 8.14 (34.2)                   |
| AUCss (day·μg/mL) | 121 (34.6)                 | 154 (28.7)                | 171 (34.2)                    |

AUCss = area under curve at steady state adjusted for the 1 mg/kg dose; Cavg,ss = average concentration at steady state adjusted for the 1 mg/kg dose; Cmax = maximum concentration adjusted for the 1 mg/kg dose; Cmax,ss = maximum concentration from steady state adjusted for the 1 mg/kg dose; CL/F = apparent clearance; CV = coefficient of variation; t½ = elimination half-life; Tmax = time to reach Cmax; V1/F = apparent volume of distribution of the central compartment.

Renal function was classified based on individual estimated glomerular filtration rate (eGFR): normal function = individual eGFR ≥ 90 mL/min; mild renal impairment= individual eGFR 60 to &lt; 90 mL/min; moderate renal impairment = individual eGFR 30 to &lt; 60 mL/min.

Median (minimum - maximum) data are presented for Tmax; geometric mean (geometric CV%) data are presented for other parameters.

<div style=\"page-break-after: always\"></div>

Table 10: Summary of Individual Pharmacokinetic Parameters by Race

|                 | White (N = 240)   | Asian (N =113)   | Black (N =2)      | Other (N = 26)     |
|-----------------|-------------------|------------------|-------------------|--------------------|
| CL/F (L/day)    | 0.461 (40.3)      | 0.445 (32.9)     | 0.419 (17.9)      | 0.477 (35.2)       |
| V1/F (L)        | 7.62 (25.7)       | 6.96 (20.5)      | 6.97 (8.1)        | 7.24 (24.9)        |
| ty (day)        | 11.5 (26.4)       | 10.8 (25.5)      | 11.5 (9.6)        | 10.5 (23.9)        |
| Tmax (day)      | 5.42 (3.29 -7.46) | 5.25 (4.08-6.88) | 5.42 (5.29 -5.54) | 5.19 (4.17 - 5.92) |
| Cmax (μg/mL)    | 5.79 (22.7)       | 5.35 (18.3)      | 6.53 (11.7)       | 5.49 (21.4)        |
| Cmax,s (μg/mL)  | 8.61 (29.4)       | 7.72 (25.7)      | 9.65 (6.7)        | 7.81 (26.8)        |
| Cavgss (μg/mL)  | 6.34 (36.0)       | 5.60 (32.1)      | 7.17 (4.1)        | 5.62 (32.4)        |
| AUC (day·μg/mL) | 133 (36.0)        | 118 (32.1)       | 151 (4.1)         | 118 (32.4)         |

AUCss = area under curve at steady state adjusted for the 1 mg/kg dose; Cavg,ss = average concentration at steady state adjusted for the 1 mg/kg dose; Cmax = maximum concentration adjusted for the 1 mg/kg dose; Cmax,ss = maximum concentration from steady state adjusted for the 1 mg/kg dose; CL/F = apparent clearance; CV = coefficient of variation; t½ = elimination half-life; Tmax = time to reach Cmax; V1/F = apparent volume of distribution of the central compartment.

Median (minimum - maximum) data are presented for Tmax; geometric mean (geometric CV%) data are presented for other parameters.

Table 11: Summary of Individual Pharmacokinetic Parameters by Transfusion Dependency

|                 | Non-transfusion dependent (N = 127)   | Transfusion dependent (N =254)   |
|-----------------|---------------------------------------|----------------------------------|
| CL/F (L/day)    | 0.495 (35.7)                          | 0.440 (38.1)                     |
| V1/F (L)        | 8.17 (21.3)                           | 7.02 (24.3)                      |
| ty: (day)       | 11.4 (24.8)                           | 11.1 (26.6)                      |
| Tmax (day)      | 5.38 (4.33 -6.42)                     | 5.35 (3.29 - 7.46)               |
| Cmax (μg/mL)    | 5.41 (19.1)                           | 5.76 (22.5)                      |
| Cmax,s (μg/mL)  | 8.02 (28.6)                           | 8.42 (28.4)                      |
| Cavg,ss (μg/mL) | 5.91 (35.0)                           | 6.14 (35.1)                      |
| AUC (day·μg/mL) | 124 (35.0)                            | 129 (35.1)                       |

## Summary of Pharmacokinetic Data for Study ACE-536-B-THAL-002

A total of 96 subjects were included in the analysis. Luspatercept concentration data collected from Study ACE-536-B-THAL-002 were combined with the data collected from previous studies (A536-04 and ACE536-B-THAL-001) and analysed using the population PK method.

The mean (SD) of observed luspatercept serum concentrations on a dosing day are displayed below stratified by dose modification category during Week 1 to Week 48:

1. In subjects with no dose modification, the mean concentration values were mostly flat from Day 63 through Day 315.
2. In subjects with at least one dose escalation (without dose reduction/delay), the mean concentration value was lowest after the first dose (Day 21) and it increased with time.

<div style=\"page-break-after: always\"></div>

3. In subjects with least 1 dose reduction and/or delay, the mean concentration values were highest after the first dose (Day 21) and increased later in treatment (Day 231 to Day 315), possibly resulting from dose increases in some subjects during this period.
4. At Day 315 by which time most subjects had completed dose escalation, mean luspatercept serum concentration values were comparable among the 3 dose modification categories.

Figure 5: Mean (SD) Luspatercept Serum Concentrations on A Dosing Day by Dose Modification Category in Week 1 to Week 48 (ACE-536-B-THAL-002)

<!-- image -->

SD=standarddeviation

Numbers at bottom of eachpanel indicate the number of subjects at each time point.

Pharmacokinetic parameters derived from the final PPK model are summarised by responder status. The model-predicted median time to reach Cmax (Tmax) was approximately 5.5 days and the estimated mean t½ in serum was 11.8 days.

The overall individual variability in AUC at steady state (AUCss) for the starting dose of 1 mg/kg was moderate (34.4%). Mean AUCss for the starting dose was 36% higher in subjects who achieved ≥ 1 g/dL increase from baseline in mean Hb value during Week 13 to 24 (primary efficacy endpoint) than those who did not. Compared to the non-responders, a 41% increase in mean AUCss was also observed in subjects who achieved ≥ 1.5 g/dL increase from baseline in mean Hb value during Week 13 to 24.

<div style=\"page-break-after: always\"></div>

Table 12: Summary of Individual Pharmacokinetic Parameters by Responder Status During Week 13 to 24 (ACE-536-B-THAL-002)

|                 | Hb increase ≥ 1 g/dL   | Hb increase ≥ 1 g/dL   | Hb increase ≥ 1.5 g/dL   | Hb increase ≥ 1.5 g/dL   | Total             |
|-----------------|------------------------|------------------------|--------------------------|--------------------------|-------------------|
|                 | Yes (N = 74)           | No (N = 22)            | Yes (N = 50)             | No (N = 46)              | (N =96)           |
| CL/F (L/day)    | 0.432 (33.5)           | 0.558 (26.6)           | 0.406 (28.5)             | 0.523 (34.1)             | 0.458 (33.8)      |
| V1/F (L)        | 7.80 (19.6)            | 7.76 (20.0)            | 7.83 (17.2)              | 7.75 (22.1)              | 7.79 (19.6)       |
| ty (day)        | 12.5 (23.7)            | 9.63 (18.9)            | 13.4 (21.1)              | 10.3 (21.9)              | 11.8 (25.3)       |
| Tmax (day)      | 5.58 (4.33 - 6.42)     | 5.00 (4.50 - 5.71)     | 5.71 (4.33 -6.42)        | 5.17 (4.38 -6.29)        | 5.50 (4.33 -6.42) |
| Cmax (μg/mL)    | 5.68 (16.8)            | 5.13 (15.2)            | 5.93 (13.6)              | 5.17 (17.4)              | 5.55 (16.9)       |
| Cmax,ss (μg/mL) | 8.83 (27.0)            | 6.98 (21.3)            | 9.54 (22.2)              | 7.25 (25.6)              | 8.36 (27.7)       |
| AUC (day·μg/mL) | 140 (33.2)             | 103 (26.4)             | 154 (27.3)               | 109 (31.5)               | 130 (34.4)        |

## Pharmacokinetic interaction studies

No Drug-drug and drug-disease interactions studies have been performed.

## 2.3.3. Pharmacodynamics

## Mechanism of action

Luspatercept (ACE-536) is a novel, first in class recombinant fusion protein that binds select transforming growth factor-beta superfamily ligands. By binding to specific endogenous ligands (e.g. growth differentiation factor-11, activin B) luspatercept inhibits Smad2/3 signaling, resulting in erythroid maturation through differentiation of late-stage erythroid precursors (normoblasts) in the bone marrow. Smad2/3 signaling is abnormally high in disease models characterized by ineffective erythropoiesis, ie, MDS and β -thalassemia.

In mouse models of MDS and β -thalassemia, luspatercept decreased Smad2/3 signaling, reduced erythroid hyperplasia, enhanced erythroid maturation, increased haemoglobin, and increased the number of red blood cells. In mouse models of β -thalassemia, luspatercept also improved the quality of red blood cells, as shown by increased red blood cell (RBC) life span and reduced abnormal red cell morphology and haemolysis.

<div style=\"page-break-after: always\"></div>

Figure 6: Luspatercept Mechanism of Action

<!-- image -->

ActRIIB=activin receptor typeIIB; TGF-β=transforminggrowth factor-beta.

## Primary and secondary pharmacology

Individual exposure measures predicted from the population PK model were used in the exposureresponse analysis to measure effectiveness (erythroid responses) and toxicities. In addition, serum drug concentrations were assessed to assist in the interpretation of the results of ADA tests.

The Hb-time profiles in response to luspatercept dose levels 0.2 to 1.25 mg/kg administered Q3W to subje cts with NTD β -thalassemia were adequately described by an indirect response model with zeroorder rate Hb input into blood (Kin) and first-order rate constant of Hb loss in blood (Kout). The model associated luspatercept serum concentration with its stimulatory effect on Hb input into blood. The typical values of maximum estimable effect (Emax) and the half maximal effective concentration (EC50) of luspatercept were 0.4253 and 7.6 μg/mL, respectively.

This led to a mean 19.1% increase in Hb input into blood at the 1 mg/kg starting dose. Estimates of the system parameters (Kin and Kout) suggested a shorter Hb lifespan (14 days) and fast Hb input rate, consistent with accelerated RBC destruction and compensatory erythroid marrow expansion in subjects with NTD β -thalassemia.

## Haematology mean values over time (ACE-536-B-THAL-002)

At baseline, the serum EPO level in both treatment groups was similar (median: 65.20 and 65.29 IU/L in the luspatercept and placebo treatment groups, respectively). A plot of mean serum EPO values over time was provided.

<div style=\"page-break-after: always\"></div>

Figure 7: Mean and SE for Change in Serum Erythropoietin Over Time

Figure 14.3.4.1.2

in Serum Erythropoietin Over Time by Treatment

SafetyPopulation

<!-- image -->

Mean and SE for Change

6D

At baseline, the median reticulocyte count was 137.30 x 10 9 /L in the luspatercept treatment group and 136.10 x 10 9 /L in the placebo treatment group. A plot of mean reticulocyte values over time was provided. An increase in mean reticulocyte counts from baseline in the luspatercept treatment group reflects increased bone marrow erythropoietic activity which would be consistent with the expected therapeutic effect for this drug.

Figure 8: Mean and SE of Reticulocyte (Blood) Over Time

<!-- image -->

At baseline, the mean (median) nucleated RBCs were lower in the luspatercept treatment group than in the placebo treatment group (16.26 [0.32] versus 25.89 [8.19], respectively). Changes over time in nucleated RBCs indicated decreases of smaller magnitude in the luspatercept treatment group than in the placebo treatment group. No corresponding figure was provided.

Baseline mean (median) values for leukocytes were lower in the luspatercept treatment group (8.86 x 109/L [8.03 x 109/L]) than in the placebo treatment group (10.81 x 109/L [9.07 x 109/L]), and changes over time indicated minimal changes in both treatment groups.

<div style=\"page-break-after: always\"></div>

Figure 9: Mean and SE in Selected Laboratory Values Over Time

Figure 14.3.4.1.1

<!-- image -->

At baseline, the mean (median) platelet count was lower in the luspatercept treatment group than in the placebo treatment group (341.12 [213.00] x 10 9 /L versus 440.37 [470.00] x 10 9 /L, respectively). In the luspatercept treatment group, the platelet count increased at all time points through Dose 29 Day 1. Subsequent time points after Dose 29 Day 1 through Dose 40 Day 1 showed in general minimal fluctuations from baseline in the platelet values. In the placebo treatment group, fluctuations from baseline in the platelet counts compared with the baseline value were generally observed from Dose 2 Day 1 through Dose 29 Day 1. These were generally transient with no clinical consequences.

## 2.3.4. PK/PD modelling

Integrated analyses based on data pooled from subjects with NTD β -thalassemia in Studies A536-04, A536-06 and ACE-536-BTHAL-002 were conducted to evaluate the exposure-response relationship for Hb versus time profiles, efficacy and safety. Exposure-response analyses for efficacy, NTDT-PRO T/W score and safety were also conducted specifically for the pivotal study ACE-536-B-THAL-002.

The objectives of the performed analyses were:

- -To describe the time course of hemoglobin (Hb) response to luspatercept in subjects with NTDT and to determine the effect of selected key covariates on Hb response
- -To evaluate exposure-efficacy relationships for luspatercept in subjects with NTDT and to determine the effect of key covariates on the following efficacy endpoints:
- o Proportion of subjects achieving an increase from baseline ≥ 1.0 g/dL or ≥ 1.5 g/dL in mean Hb values in the absence of transfusions during a given evaluation period (12, 15, or 24 weeks).
- o Duration of mean Hb increase from baseline ≥ 1.0 g/dL or ≥ 1.5 g/dL (Study ACE-536-BTHAL-002 only).
- o Dose level during the first response event in responders (Study ACE-536-BTHAL-002 only).

<div style=\"page-break-after: always\"></div>

- -To evaluate exposure-safety relationships for luspatercept in subjects with NTDT and to determine the effects of key covariates on the following safety endpoints:
- o Proportion of subjects experiencing treatment-emergent adverse events (TEAEs), including serious TEAEs, TEAEs ≥ Grade 3, selected TEAEs ≥ Grade 1 (fatigue-like events, bone pain-like events, dizziness, hypertension, and myalgia).
- o Proportion of subjects experiencing TEAEs leading to dose reduction, dose interruption, or discontinuation (Study ACE-536-B-THAL-002 only).
- o Proportion of subjects experiencing excessive Hb increase leading to dose reduction or dose delay (Study ACE-536-B-THAL-002 only).
- -To assess the relationship between haemoglobin (Hb) change from baseline (ΔHb) and weekly nontransfusion dependent β -thalassemia (NTDT)patient reported outcome (PRO) tiredness and weakness (T/W) score or domain score change from baseline (ΔT/W) in su bjects with NTDT.
- o To explore effects of other factors influencing ΔT/W and/or ΔHb -ΔT/W relationship.

## Methods

## Analysis Populations

The exposure-response analysis for the time course of Hb included subjects with NTDT in Studies A53604, A536-06, and ACE-536-B-THAL-002, who received at least one dose of luspatercept and had both empirical Bayesian estimates of individual luspatercept PK parameters and Hb data.

The exposure-response analysis for safety included subjects from all three studies but the exposureresponse analysis for efficacy included only subjects from studies A536-04 and ACE-536-B-THAL-002. Subjects with treatment interruption ( ≥ 84 ± 7 days) between the last dose in study A536-04 and the first dose in study A536-06 were treated as two separate subjects in the analysis. Placebo subjects with NTDT were excluded from the analysis but included in the graphical data comparisons as appropriate. Only Hb records in the absence of RBC transfusion (&gt; 21 days following a transfusion event) were included in the analysis.

## Software

Please refer to the methods in the PK section above.

## Exposure-response Analysis for the Time Course of Hemoglobin

A sequential approach was used in development a model to describe the Hb versus time profiles under luspatercept therapy. Subject-specific luspatercept serum concentrations at the time of Hb data collection were predicted by empirical Bayesian estimates of individual luspatercept PK parameters from the final PPK model and used as the inputs into the Hb model. The Hb model was developed in three steps: base, full, and final models. The final model was validated using goodness of fit, bootstrap resampling, and VPC.

A total of 3715 Hb records from 143 subjects with NTDT were included in this analysis. An empirical indirect response model best described the time course of Hb in response to luspatercept treatment.

<div style=\"page-break-after: always\"></div>

Table 13: Subjects and Hemoglobin Records Included (Hemoglobin Modeling) Study Number

| Study              | Number(%) of Subjects   | Number(%) of Subjects   | Number (%) of Hb Records   | Number (%) of Hb Records   | Number (%) of Hb Records   |
|--------------------|-------------------------|-------------------------|----------------------------|----------------------------|----------------------------|
|                    | Treated                 | Included                | Total                      | Excluded                   | Included                   |
| ACE-536-B-THAL-002 | 96                      | 96 (100%)               | 2873                       | 40 (1%)                    | 2833 (99%)                 |
| A536-04            | 31                      | 31 (100%)               | 584                        | 13 (2%)                    | 571 (98%)                  |
| A536-06            | 16                      | 16 (100%)               | 336                        | 25 (7%)                    | 311 (93%)                  |
| Total              | 143                     | 143 (100%)              | 3793                       | 78 (2%)                    | 3715 (98%)                 |

Hb = hemoglobin.

Luspatercept was modelled to stimulate the rate of Hb input into blood according to the following equation:

<!-- image -->

where Kin is the zero-order rate of Hb input into blood, Kout is the first-order rate constant of Hb loss from blood, C is the luspatercept concentration in serum, Emax is the maximal stimulatory effect of luspatercept on Kin, EC50 is the luspatercept serum concentration to achieve 50% of the maximum stimulatory effect on Kin, and Hb represents the amount of Hb in blood at a given time.

Figure 10: Diagram of Base Model (Lifespan Indirect Response Model with Saturating Drug Effect)

<!-- image -->

C = luspatercept concentration; CL/F = apparent clearance; CMT = compartment; dHGB/dt = rate equation characterizing change of hemoglobin response over time; EC50 = luspatercept concentration to achieve 50% Emax; Emax = maximum stimulatory effect of drug on hemoglobin input; HGB = hemoglobin; Ka = luspatercept absorption rate constant; Kin = rate of hemoglobin input into blood; Kout = rate constant of hemoglobin loss in blood; SC = subcutaneous; V/F = apparent volume of distribution of central compartment

<div style=\"page-break-after: always\"></div>

Figure 11: Goodness-of-fit Plots for Hemoglobin Response Model (Final Model)

<!-- image -->

The black line represents identity or zero horizontal line. The blue line represents locally weighted scatterplot smoothing line. The dash represents residuals at 6 or -6 value. Circles are observed value.

<div style=\"page-break-after: always\"></div>

Figure 12: Visual Predictive Check for the Hemoglobin-Time Profiles of Luspatercept by Study (Final Model, Time after the First Dose)

<!-- image -->

(blacklines)

Median(lines)95%Cl(areas)

Black dots represent observed data, and black dash lines represent observed 5th, 50th, and 95th percentiles. Solid lines represent the 5th (blue), 50th (red), and 95th (blue) percentiles of the simulated data. Shaded areas represent 95% confidence intervals about the 5th (blue), 50th (red), and 95th (blue) percentiles for the corresponding simulated data. Top vertical bars represent binning optimized by partitioning around medoids methodology.

## Exposure-response Analysis for Efficacy

For E-R analyses of categorical efficacy endpoints, ordinal logistic regression analyses were performed to describe the relationship between luspatercept exposures and the probability of achieving a response after accounting for statistically significant covariate effects.

Development of the model included the following three stages:

- First, a base model was developed to assess the relationship between luspatercept exposure and the probability of achieving an efficacy endpoint. Linear and saturable E-R relationship was explored. The base model was compared with a null model without the E-R relationship. Model discriminatory performance was assessed using BIC criteria.

<div style=\"page-break-after: always\"></div>

- Next, the impact of other covariates in addition to the luspatercept E-R relationship was examined by adding the potential covariates in univariate fashion to the base model. A full model was then estimated including all potential covariates identified based on a reduction in BIC in the univariate search.
- The final model was derived from the full model by dropping statistically insignificant factors (95% CI of odds ratio included the null value). The exposure parameter was retained in the final model regardless of its statistical significance, and its clinical relevance interpreted as appropriate.

Time-averaged AUC (AUCavg15, AUCavg24 or AUCavg48) during an evaluation period was used as the primary exposure measure. For each efficacy endpoint, the exposure measure was selected based on the duration of the evaluation period. The exposure measure was assigned a value of zero for subjects receiving placebo.

Efficacy endpoints included:

- Proportion of subjects achieving an increase from baseline ≥ 1.0 g/dL or ≥ 1.5 g/dL in mean Hb values in the absence of transfusions, during the following evaluation periods:
- o Week 1 to 15 (Study A536-04 and ACE-536-B-THAL-002).
- o Week 13 to 24 and Week 37 to 48 (Study ACE-536-B-THAL-002 only).
- o During any consecutive 24-week interval (Study ACE-536-B-THAL-002 only).
- The longest duration of mean Hb increase from baseline ≥ 1.0 g/dL or ≥ 1.5 g/dL during any consecutive 12-week interval in the absence of transfusion (Study ACE-536-B-THAL-002, responders only)
- Dose level (in mg/kg) during the first response event for ≥ 1 g/dL or ≥ 1.5 g/dL increase from baseline in mean Hb value during any consecutive 12-week interval in the absence of transfusion (Study ACE-536-B-THAL-002, responders only).

The ordinal logistic regression considered three categories of response: 1) No response, 2) ≥ 1.0 g/dL and &lt; 1.5 g/dL Hb increase, or 3) ≥ 1.5 g/dL Hb increase. For the duration of response endpoints (mean Hb increase ≥ 1.0 g/dL or ≥ 1.5 g/dL in any consecutive 12-week interval), E-R relationship were evaluated by Kaplan-Meier analyses stratified by luspatercept exposure quartile, and Cox proportional hazards regression analyses.

The cumulative probability (P) of the outcome (Y) being less than or equal to a specific category (j) as a function of the drug exposure and other covariates was described as follows:

The β1,…., βn characterized the dependence of the Ln(odds) on one or more covariates, X1…, Xn. The coefficients, α, indicated cut points where the latent variable was cut to identify the three categories for each outcome.

Covariate predictors were also evaluated.

The dose level at first response event, defined as an increase from baseline ≥ 1.0 g/dL or ≥ 1.5 g/dL in mean Hb value during any consecutive 12-week interval in the absence of transfusions was also evaluated graphically in responders from study ACE-536-BTHAL-002.

<div style=\"page-break-after: always\"></div>

The following factors were explored as potential covariates of the efficacy endpoints:

- Demographic factors: age, weight, sex, and race (Asian, non-Asian).
- Organ function: renal function category, baseline total bilirubin, and baseline AST.
- Transfusion burden at baseline (continuous, or categorical as 0, ≥ 1 units/12- or 24-weeks).
- Baseline Hb (continuous, or categorical as &lt; 8.5 g/dL, ≥ 8.5 g/dL).
- Splenectomy, β -thalassemia gene mutation (β0/β0 and non -β0/β0).
- Baseline EPO (&lt; 200 U/L, ≥ 200 U/L).
- β -Thalassemia diagnosis ( β -thalassemia, Hb E/ β -thalassemia, β -thalassemia combined with α -thalassemia).

Continuous covariates were not centred in ordinal logistic regression analysis, but they were centred at their respective median values in Cox proportional hazard regression analysis.

The results of the exposure-efficacy analysis were presented graphically by overlaying the observed response rate and its 95% CI within each exposure group with the model-predicted mean probability and its 95% CI (stratified by significant covariates as appropriate). In the reported model parameter tables, the p-values for model parameters were determined based on chi-squared tests versus the reduced model; hence, p-values were not provided for the intercept terms of the ordinal logistic regressions.

The E-R relationships for duration of Hb response ( ≥ 1.0 g/dL and ≥ 1.5 g/dL evaluated separately) were explored by Kaplan-Meier (KM) plots stratified by luspatercept serum exposure quantile groups. Cox proportional hazards regression analysis were conducted to adjust for significant covariates to ascertain if luspatercept exposure was a predictor for duration of response.

The dose level at the first response event ( ≥ 1.0 g/dL and ≥ 1.5 g/dL evaluated separately) were evaluated graphically and summarised numerically. The distribution of luspatercept exposure and other covariates that might impact efficacy and dose escalation were summarized by the highest dose administered in the primary treatment phase of Week 1 to 48.

## Exposure-response Analysis for Safety

The E-R relationships between safety endpoints and luspatercept AUC at the time of the first AE (AUCevent) were explored over two evaluation periods, Weeks 1 to 6 (during which no intra-subject dose escalation was permitted) and Weeks 1 to 48 (during which intra-subject dose escalation was permitted). For the Week 1 to 6 period, logistic regression analyses were conducted, including evaluation of potential covariate predictors. These analyses were repeated for the Week 1 to 48 evaluation periods. Additionally, the influence of luspatercept AUCevent on the time to the first event of the specified safety endpoint during Week 1 to 48 was evaluated by Kaplan-Meier analyses stratified by luspatercept exposure quartile, and Cox proportional hazards regression analyses.

The model development stages were similar to those described for the E-R analysis for efficacy. If a subject had multiple TEAEs of the same type (e.g., serious TEAEs) during the evaluation period, only the earliest event was counted as an event in the logistic regression analysis.

Area under the concentration-time curve at the time of event was used as the primary exposure measure in exposure-safety analysis. The exposure measure was assigned a value of zero for subjects receiving placebo.

<div style=\"page-break-after: always\"></div>

Safety endpoints included:

- Proportion of subjects experiencing the following TEAEs:
- o Serious TEAEs
- o TEAEs ≥ Grade 3
- o Fatigue-like events ≥ Grade 1
- o Bone pain-like events ≥ Grade 1
- o Dizziness ≥ Grade 1
- o Hypertension ≥ Grade 1
- o Myalgia ≥ Grade 1
- o TEAEs leading to dose reduction, dose interruption, or discontinuation (Study ACE-536B-THAL-002 only)
- Proportion of subjects experiencing the following Hb events:
- o Pre-dose Hb increase from baseline ≥ 2.0 g/dL/3 weeks leading to dose reduction (Study ACE-536-B-THAL-002 only)
- o Pre-dose Hb ≥ 11.5 g/dL leading to dose delay (Study ACE-536-B-THAL-002 only)

Preferred terms (MedDRA version 23.0) included 'Asthenia' and 'Fatigue' for fatigue-like events and included 'Bone pain' and 'Arthralgia' for bone pain-like events.

## Model Development

Logistic regression analyses were conducted to develop models describing the relationship between luspatercept serum exposure and the probability of experiencing TEAEs after adjusting for the effect of other significant covariates, if any.

The probability that the event occurs as a function of the drug exposure and other covariates is described as follows:

<!-- image -->

where Pi was the probability of the event in the ith subject and α was the baseline Ln(odds) of the event. The β1,…., βn characterized the dependence of the Ln(odds) on one or more covariates, X1…, Xn.

The following factors were explored as potential covariates to influence the safety endpoints:

- Demographic factors: age, weight, sex, and race (White, Asian, others).
- Organ function: renal function category, baseline total bilirubin, and baseline AST.
- Transfusion burden at baseline (continuous, or as categorical with ranges to be determined).
- Baseline Hb (continuous, or categorical as &lt; 8.5 g/dL and ≥ 8.5 g/dL).
- Splenectomy, β -thalassemia gene mutation (β0/β0 and non -β0/β0).
- Baseline EPO (&lt; 200 U/L, ≥ 200 U/L).
- β -Thalassemia diagnosis ( β -thalassemia, Hb E/ β -thalassemia, β -thalassemia combined with α -thalassemia)

<div style=\"page-break-after: always\"></div>

Continuous covariates were centred at their respective median values in both logistic regression analysis and Cox proportional hazard regression analysis.

The results of the exposure-safety analysis for the binary endpoints were presented graphically by overlaying the observed frequency and its 95% CI within each exposure group with the model-predicted mean probability and its 95% CI (stratified by significant covariates as appropriate).

For the Week 1 to 48 evaluation period, relationships between the time to the first safety event and luspatercept exposures were explored by KM plots stratified by luspatercept serum exposure quartile groups. Cox proportional hazards regression analysis were also conducted. If luspatercept exposure was a predictor of time to the first event for the specified safety endpoint, additional Cox proportional hazards regression analyses were conducted to adjust for significant covariate predictors.

## Analysis of Relationship between Haemoglobin Increase and Tiredness/Weakness Improvements

The T/W domain is part of the NTDT-PRO instrument that was used to assess the severity of anaemiarelated symptoms associated with NTDT. The T/W domain included four items that assessed tiredness with and without physical activity and weakness with and without physical activity using a numerical rating scale ranging from 0 (no) to 10 (extreme). Daily scores of all four items under the NTDT-PRO T/W domain were averaged over 7 days and reported as the weekly T/W domain score.

## Population

Subjects were included who received at least one dose of the study drug (luspatercept or placebo) and had at least one pair of the intervalmatched ΔHb and ΔT/W records in the specified evaluation periods of Study ACE-536-B-THAL-002 were included in the analysis. Individual Hb records and weekly T/W records collected within 3 weeks following a red blood cell (RBC) transfusion event were excluded from the analysis.

## Table 14: Summary of Analysis Datasets

| Description a                                   | Luspatercept    | Placebo           |
|-------------------------------------------------|-----------------|-------------------|
| Number of subjects                              | 95              | 48                |
| Number of paired △Hb-△T/W records               |                 |                   |
| Incremental change analysis                     | 647             | 294               |
| LME modeling                                    | 1172            | 518               |
| Median (Minimum, Maximum) time with paired data |                 |                   |
| Incremental change analysis (week)              | 48 (15, 48)     | 48 (13, 48)       |
| LME modeling (week)                             | 48 (13, 126)    | 33 (12, 114)      |
| Median (Minimum, Maximum) baseline Hb (g/dL)    | 8.3 (5.5, 10.2) | 8.2 (5.8, 10.4)   |
| Median (Minimum, Maximum) baseline score        |                 |                   |
| T/W domain                                      | 4.33 (0, 9.5)   | 4.12 (0.36, 9.54) |
| Tiredness with physical activity                | 5.29 (0, 10.0)  | 5.15 (0.29, 9.86) |
| Weakness with physical activity                 | 5.00 (0, 10.0)  | 5.07 (0.43, 10.0) |

a The value is the same for incremental change analysis and linear mixed-effects modeling unless specified.

Hb = hemoglobin; △Hb = hemoglobin change from baseline; △T/W = tiredness and weakness domain score change from baseline in non-transfusion dependent β-thalassemia-patient reported outcome; LME = linear mixed-effects; T/W = tiredness and weakness in non-transfusion dependent β-thalassemia-patient reported outcome.

<div style=\"page-break-after: always\"></div>

## Incremental Change Analysis (Week 1 to 48):

The average of weekly ΔT/W values during consecutive 6 -week intervals (eg, Weeks 1 to 6, Weeks 7 to 12, Weeks 13 to 18, etc.) was paired with ave rage of ΔHb values during the same 6 -week interval for each subject. The average ΔHb value for each 6 -week interval was rounded to the nearest integer. Mean and standard deviation (SD) of average ΔT/W were calculated for each ΔHb level, stratified by treatment (luspatercept versus placebo) and baseline T/W domain score (&lt; 3 versus ≥ 3) at randomization. The mean ΔT/W for each ΔHb level was graphically examined and compared with that in the absence of Hb change (ie, ΔHb = 0) using two -sided pairwise t-test with the p-value adjusted by Bonferroni correction method. The above analyses were repeated for two individual items under the NTDT-PRO T/W domain: tiredness with physical activity and weakness with physical activity.

## Linear Mixed-Effects Modeling (Double-blind Treatment Period):

Weekly ΔT/W values were paired with corresponding Hb values from the same week during the Double -blind Treatment Period (DBTP). The relationships between ΔHb, ΔT/W, and other contributing factors were assessed using a linear mixed-effects model. Sources of variability were explored systematically, and a formal covariate analysis was performed. At all stages of the model development, model adequacy was assessed based on prior knowledge of luspatercept biology, diagnostic plots, and statistical estimators of goodness of fit. The performance of the final model was also evaluated using visual predictive check.

## Software

Derived analysis datasets were constructed using R® Version 4.0.2. Graphical analysis, model diagnostics, and statistical summaries were performed using R®. Linear mixed-effects modeling and simulation were performed using the nonlinear mixed-effects (nlme) package (Version 3.1-152) in R®. Pair-wise t-test and analysis of covariance were performed using the rstatix package (Version 0.7.0) in R®.

## Analysis

## Base Model

In the absence of strong evidence of a nonlinear relationship, a linear mixedeffects model, with ΔT/W as the dependent variable and ΔHb as the independent variable, was considered a reasonable starting point. Effects of baseline T/W domain score, treatment and time were investigated during base model development.

## Covariate Analysis

According to mechanistic plausibility and clinical interest, the following factors were considered as potential covariates influencing the intercept term and the slope of the ΔHb -ΔT/W relationship:

- Demographics: age, sex, and race (Asian, White, and Other).
- Region (North American and Europe, Middle East, and Asia-Pacific)
- Baseline disease characteristics:
- o β -Thalasse mia diagnosis (β -thalassemia, β -combined with α -thalassemia, and HbE/β -thalassemia)
- o Serum erythropoietin (EPO) level (&lt; 200 and ≥ 200 IU/L)
- o RBC transfusion burden (no transfusion and ≥ 1 RBC unit/24 week)
- o Absence versus presence of splenectomy

<div style=\"page-break-after: always\"></div>

- o Liver iron concentration (&lt; 3, ≥ 3 to ≤ 7, and &gt; 7 mg/g dry weight)
- o Total bilirubin level (as a continuous variable)
- o Renal function (normal and mild impairment)
- Hb level at baseline (as a continuous variable)
- Hb level during treatment (as a continuous variable, varying with time-matched Δ HbΔT/W pairs)
- Selected TEAEs (no event and at least one event, varying with time-matched Δ HbΔT/W pairs):
- o Bone pain and/or arthralgia ≥ Grade 1
- o Asthenia and/or fatigue ≥ Grade 1
- o Other TEAEs ≥ Grade 1 if appropriate

Continuous variables were centered at their median value. Categorical variables were classified either based on the definition in the study protocol or to allow sufficient sample size in each category (eg, EPO, liver iron concentration). The missing values for a categorical variable were treated as a single category of 'missing'.

## Final Model

The final model was derived from the full covariate model by removing statistically insignificant variables (p-value &gt; 0.05 based on likelihood-ratio test).

The final linear mixed-effects model is described by the following equation:

<!-- image -->

where Intercept is the typical value of ΔT/W in the absence of Hb effect for a reference subject; η1 is the random effect (ie, interindividual variability) associated with Intercept; Slope is the typical value of ΔHb slope quantifying the linear associatio n between ΔHb and ΔT/W for a reference subject; cTWDSBL is the centered baseline T/W domain score, calculated as [individual baseline T/W domain score - 4.25]; Coefslp is the coefficient for the effect of cTWDSBL on Slope; η2 is the random effect associate d with Slope (ie, interindividual variability); Coefint is the coefficient for the effect of cTWDSBL on Intercept; CoefBA is the coefficient for the effect of bone pain/arthralgia ≥ Grade 1 on Intercept; BAi is the indicator parameter for bone pain/arthralgia ≥ Grade 1 (0 = no event, 1 = at least one event); CoefTEAE is the coefficient for the effect of nonspecific TEAEs ≥ Grade 1 on Intercept; TEAEi is the indicator parameter for nonspecific TEAEs ≥ Grade 1 (0 = no event, 1 = at least one event); and ε is the residual error (unexplained variability). The reference subject for the final model was a subject with a median baseline T/W domain score of 4.25 (cTWDSBL = 0) who did not experience any TEAE (BAi = 0 and TEAEi = 0) during the week of ΔT/W collection.

<div style=\"page-break-after: always\"></div>

Table 15: Parameter Estimates of the Final Model

| Parameter                                     |   Estimate | 95% CI           | p-value   |
|-----------------------------------------------|------------|------------------|-----------|
| Intercept                                     |     -0.566 | (-0.78, -0.353)  | <0.00001  |
| △Hb slope (dL/g)                              |     -0.223 | (-0.3, -0.146)   | < 0.00001 |
| cTWDSBL coefficient on intercept              |     -0.309 | (-0.406, -0.212) | <0.00001  |
| cTWDSBL coefficient on △Hb slope (dL/g)       |     -0.055 | (-0.089, -0.021) | 0.001692  |
| Bone pain/arthralgia coefficient on intercept |      0.309 | (0.108, 0.509)   | 0.002569  |
| Nonspecific TEAE coefficient on intercept     |      0.099 | (0.007, 0.191)   | 0.03453   |
| Random effect on Intercept (SD)               |      1.184 | (1.039, 1.349)   | NA        |
| Random effect on △Hb slope (dL/g) (SD)        |      0.161 | (0.075, 0.343)   | NA        |
| Correlation of random effects                 |      0.726 | (-0.374, 0.977)  | NA        |
| Residual error (SD)                           |      0.714 | (0.689, 0.74)    | NA        |

CI = confidence interval; Δ Hb = hemoglobin change from baseline; cTWDSBL = centered baseline tiredness/weakness domain score in non-transfusion dependent β -thalassemia-patient reported outcome; NA = not applicable; p-value = lower tail cumulative probability of the t-distribution; SD = standard deviation; TEAE = treatment-emergent adverse event.

## Model Evaluation

At all stages of the model development, assessment of model adequacy was based on prior knowledge of luspatercept biology, diagnostic plots, and statistical estimators of goodness of fit.

For the final model, a plot of the mean and 95% CI of mean for the observed ∆T/W versus deciles or quintiles of observed ΔHb overlaid with the model p redictions (mean and 95% CI) was generated to assess if the model described the observed data adequately.

The observed data were grouped based on deciles of ΔHb for the luspatercept arm and quintiles of ΔHb for the placebo arm to allow a similar number of observations in each ΔHb group across luspatercept and placebo arms (approximately 2:1 observations due to approximately 2:1 enrollment).

The model predictions were generated using a nonparametric bootstrap procedure. Three thousand (3000) new datasets were generated using resampling with replacement.

<div style=\"page-break-after: always\"></div>

Figure 13: Diagnostic Plots for the Final Model

<!-- image -->

Δ T/W = tiredness and weakness domain score change from baseline in nontransfusion dependent β - thalassemia patient reported outcome; IPRED = individual prediction; PRED = population prediction. The black line represents the identity line (top panels and bottom right panel) or zero line (other panels). The green line represents locally weighted scatterplot smoothing line. Δ Hb = hemoglobin change from baseline; TEAEs = treatment-emergent adverse events; The black line represents the zero line. The green line represents locally weighted scatterplot smoothing line. The line in each boxplot represents the mean value. The height of each box corresponds to the interval between the first and the third quartiles. The end of the bar on either side of the box correspond to minimum and maximum values, and the circles are individual data.

The final model was also evaluated by visual predictive check. The model provided a good fit to the observed ΔHb -ΔT/W relationship for both luspatercept and placebo arms, with the observ ed means for most ΔHb groups falling within the 95% CI for model -predicted mean. A ΔHb -dependent reduction in T/W domain score was evident for both observed and predicted data at a baseline T/W domain score ≥ 3 in subjects treated with luspatercept.

<div style=\"page-break-after: always\"></div>

Figure 14: Observed and Model-Predicted Profiles of NTDT-PRO T/W Domain Score Change from Baseline versus Hemoglobin Change Baseline

<!-- image -->

Hb = hemoglobin; NTDT-PRO = nontransfusion dependent β -thalassemia-patient reported outcome; TEAEs = treatment-emergent adverse events; T/W tiredness and weakness in NTDT-PRO. The simulations are weighted by the relative frequency of the categorical covariates (bone pain/arthralgia ≥ Grade 1 and nonspecific TEAEs ≥ Grade 1) for luspatercept and placebo arms in the analysis dataset. The solid blue line and shaded area represent mean and 95% confidence interval of the model-predicted mean NTDT-PRO T/W domain score change from baseline as a function of Hb change from baseline. Red circles and vertical bars represent the observed mean T/W domain score change from baseline bounded by the 95% confidence interval within each Hb group and are plotted at the median Hb change within each Hb group.

## Results

## Exposure-response Analysis for the Time Course of Haemoglobin

Haemoglobin concentration-time data from luspatercept doses of 0.2 to 1.25 mg/kg administered subcutaneously Q3W to subjects with NTDT were best described by an empirical indirect response model with zero-order Hb inputs into blood and first-order Hb loss from blood. The model associated luspatercept serum concentration with its stimulatory effect on Hb input into blood.

Overall, the final model adequately described individual time course of Hb for up to 919 days. Evaluation of the final Hb model with the goodness-of-fit plots and visual predictive checks demonstrated robust predictive performance.

The model is useful for predicting the onset, magnitude, and duration characteristics of Hb response at various luspatercept dosing regimens.

The drug effect parameters (Emax and EC50) were estimated with good precision and pharmacologically plausible. The typical value of luspatercept Emax was 0.4253, which would increase Hb input by a maximum of 42.5%. The IIV on Emax was 38.9% but no covariates were identified for Emax (tested co variates: age, weight, AST, EPO, total bilirubin, sex, race, renal function, β -thalassemia diagnosis, β -thalassemia gene mutation, splenectomy, and baseline RBC transfusion burden). It is possible that the factors affecting Emax had been largely accounted for by using subject-specific PK parameters and baseline Hb values. The typical value of luspatercept EC50 was 7.6 μg/mL, close to the Cmax.ss value (8.36 μg/mL) observed in subjects with NTDT and treated at the 1 mg/kg dose in Study ACE -536-B-

<div style=\"page-break-after: always\"></div>

THAL-002. Covariates could not be assessed for EC50, because the data did not contain sufficient information to allow modeling individual variability for this parameter.

The average luspatercept serum concentration at steady state was estimated to be 6.19 μg/mL for the 1 mg/kg dose and 7.74 μg/mL for the 1.25 mg/kg dose, which are predicted to increase Hb input into blood by 19.1% and 21.4%, respectively. A similar percent increase (18.9%, from 8.2 to 9.75 g/dL) in mean Hb from baseline was observed in the luspatercept arm during Week 13 to 24 when most subjects were treated at 1 to 1.25 mg/kg (Report ACE-536-B-THAL-002, Table 22). It is recognised that the estimated Emax and EC50 values from the final model should not be extrapolated outside the luspatercept dose levels (0.2 to 1.25 mg/kg) used to derive these parameters.

The system parameters (Kout) were also estimated with good precision and physiologically reasonable. The Kout value of 0.07027 from the final model suggested an RBC (thus Hb in RBCs) lifespan of 14 days in subjects with NTDT, which was consistent with the estimated values for patients with thalassemia (Erlandson, 1958; Singer, 2004; Sitarz, 1963), whose RBCs are known to have shorter lifespans (11 to 43 days) than those of normal adults (120 days). The Kin for a subject with a baseline Hb of 8.5 g/dL was estimated to be approximately 0.6 g/dL/day, 5.6 times the theoretical normal rate (0.108 g/dL/day, assuming Hb = 13 g/dL and RBC lifespan = 120 days for a healthy adult), consistent with increased Hb production rate in patients with thalassemia (1.5 to 5.4 times the normal rate) (Erlandson, 1958).

The shorter Hb lifespan and increased Hb input rate are reflective of the accelerated RBC destruction due to peripheral hemolysis/ splenomegaly and compensatory erythroid marrow expansion in subjects with NTDT (Rivella, 2012).

Table 16: Population Pharmacodynamic Parameters of Luspatercept (Final Model)

| Parameter                             | Estimate   | RSE (%)   | 95% CI a       |
|---------------------------------------|------------|-----------|----------------|
| Fixed Effects                         |            |           |                |
| Kout, (1/day)                         | 0.07027    | 7.6       | (0.061, 0.081) |
| Emax                                  | 0.4253     | 15.1      | (0.331, 0.616) |
| EC50 (μg/mL)                          | 7.6        | 13.5      | (4.74, 13.862) |
| Individual Variability                |            |           |                |
| On baseline Hb, standard deviation    | 0.0568     | 10.2      | (0.046, 0.069) |
| On Emax, standard deviation           | 0.3761     | 12.8      | (0.28, 0.475)  |
| On residual error, standard deviation | 0.2916     | 10.8      | (0.229, 0.352) |
| Residual Variability                  |            |           |                |
| Additive error, standard deviation    | 0.4275     | 2.7       | (0.405, 0.452) |

CI = confidence interval; Hb = hemoglobin; EC50 = luspatercept serum concentration to achieve 50% of the maximum stimulatory effect on Hb input rate, Emax = maximum stimulatory effect of drug on Hb input rate; Kout = first-order rate constant of Hb loss in blood; RSE = relative standard error. a Nonparametric 95% confidence interval obtained from 1000 bootstrap runs with 1000 runs minimized successfully. Individual variability shrinkage was 15.8% for baseline Hb, 21.6% for Emax, and 8.3% for additive residual error. Condition number was 97.69.

## CONCLUSIONS: E -R analysis for the time course of Hb (NTDT only)

The time course of Hb in response to luspatercept dose levels 0.2 to 1.25 mg/kg administered Q3W to subjects with NTDT was adequately described by an empirical indirect response model with zero-order Hb input into blood and first order Hb loss from blood. The model associated luspatercept serum concentration with its stimulatory effect on Hb input into blood.

<div style=\"page-break-after: always\"></div>

The typical values of Emax and EC50 of luspatercept were 0.4253 and 7.6 μg/mL, respectively. This led to a mean 19.1% increase in Hb input into blood at the 1 mg/kg starting dose. No significant covariates were identified for luspatercept Emax.

Estimates of the system parameters (Kin and Kout) suggested a shorter Hb lifespan (14 days) and fast Hb input rate, consistent with accelerated RBC destruction and compensatory erythroid marrow expansion in subjects with NTDT.

## Exposure-response Analysis for Efficacy

The relationship between luspatercept serum exposure and Hb-related efficacy endpoints was evaluated for subjects with NTDT (N = 127) over the dose range of 0.2 to 1.25 mg/kg during the first 15 weeks of treatment in an integrated analysis with data pooled from Studies A536-04 and ACE-536-B-THAL-002. The exposure-efficacy relationship was also evaluated specifically for Study ACE-536-B-THAL-002 over the dose range of 0.6 to 1.25 mg/kg during early (Week 13 to 24), late (Week 37 to 48), and any consecutive 12-week or 24-week evaluation periods (N=96). An exposure-dependent increase in Hb response was consistently observed regardless of the analysis population or evaluation period.

The results from ordinal logistic regression and time-to-event analyses demonstrated that the frequency, and magnitude of Hb increase in the absence of transfusion were positively correlated with luspatercept serum exposure in subjects with NTDT. In addition, luspatercept exposure was associated with longer duration of mean Hb increase from baseline ≥ 1 g/dL or ≥ 1.5 g/dL in any consecutive 12-week interval.

The odds of achieving at least 1 g/dL Hb increase from baseline was 43% to 147% higher for every 20unit increase in the time averaged AUC depending on the evaluation period. The risk of losing the Hb response was approximately 22% lower for every 20-unit increase in the time averaged AUC.

The efficacious exposure was reached in most of the subjects in Study ACE-536-B-THAL-002. As such, 54.2% subjects achieved the primary efficacy endpoint ( ≥ 1 g/dL Hb increase from baseline in Week 13 to 24) at the lowest AUCavg24 quartile (64.1 to 98.4 day·μg/mL), and 75% to 96% of subjects achieved the primary efficacy endpoint at higher AUCavg24 quartiles.

The most consistent covariate predictors of the specified Hb response were splenectomy and baseline Hb.

- Subjects with splenectomy were less likely to achieve response, with the odds of achieving at least 1 g/dL Hb increase from baseline being approximately 72% to 78% lower than the odds in subjects without splenectomy.
- Subjects with higher baseline Hb were more likely to achieve response, with the odds of achieving at least 1 g/dL Hb increase from baseline approximately 38% to 67% higher for every 1 g/dL increase in baseline Hb.
- Subjec ts with β0/β0 gene mutation were less likely to achieve at least 1 g/dL Hb increase in any consecutive 24-week interval.
- Other covariates did not significantly influence the Hb-related efficacy endpoints for a given luspatercept exposure level (age, weight, sex, race (Asian versus non-Asian), renal function (mild/moderate impairment versus normal function), baseline AST, baseline total bilirubin, baseline erythropoietin (EPO), β -thalassemia diagnosis, and baseline RBC transfusion burden ( ≥ 1 units/24 weeks versus no transfusion)).

In Study ACE-536-B-THAL-002, assessment of dose escalations suggested that the 1 mg/kg dose was sufficient for 69% (or 67%) of responders to achieve their first Hb ≥ 1 g/dL (or ≥ 1.5 g/dL) event in any 12-week interval, including responders who had the 1 mg/kg dose as the only dose or as the maximum dose during their first response event (approximately 53% (47/88) or 50% (38/76) of responders

<div style=\"page-break-after: always\"></div>

achieved their first response event (increase from baseline in mean Hb ≥ 1 g/dL or ≥ 1.5 g/dL)). Dose escalation to 1.25 mg/kg increased the incidence of first response by at least 9% (or 20%) and was associated with an additional 22% (or 13%) of first responses, including responders who had the 1.25 mg/kg dose as the only dose or as the maximum dose during their first response event. Subjects requiring dose escalations tended to have lower exposures at the starting dose and/or disease characteristics affecting Hb response to luspatercept (e.g., lower baseline Hb and/or presence of splenectomy).

Figure 15: Proportion of Subjects with Specified Hemoglobin Response Levels in Week 1 to 15 by Luspatercept Serum Exposure Quartile (Integrated Analysis)

<!-- image -->

AUCavgi5 = average area under the concentration-time curve from Week 1 to 15.

Table 17: Final Model for the Proportion of ≥ 1 g/dL or ≥ 1.5 g/dL Hemoglobin Increase in Week 1 to 15 (Integrated Analysis)

| Parameter                           |   Estinate |      SE | OR    | 95%CIof0R      | P-value   |
|-------------------------------------|------------|---------|-------|----------------|-----------|
| Luspatercept AUCavgi5 (day·μg/mL)   |     0.0452 | 0.00781 | 1.05  | (1.03, 1.06)   | 9.09e-14  |
| Baseline Splenectomy: Yes           |    -1.34   | 0.435   | 0.261 | (0.109, 0.605) | 0.00172   |
| Baseline Hb (g/dL)                  |     0.513  | 0.172   | 1.67  | (1.2, 2.37)    | 0.00199   |
| no response|≥ 1.0 g/dL & < 1.5 g/dL |     7.94   | 1.8     |       |                |           |
| ≥ 1.0 g/dL &< 1.5 g/dL |≥ 1.5 g/dL  |     9.4    | 1.87    |       |                |           |

<div style=\"page-break-after: always\"></div>

Figure 16: Relationship between Luspatercept Serum Exposure and the Probability of Specified Hemoglobin Response Levels in Week 1 to 15 (Integrated Analysis)

<!-- image -->

AUCavg15 = average area under the concentration-time curve from Week 1 to 15. The solid symbols (vertical error bars) represent the observed proportion (its 95% confidence interval) of subjects individual subjects (y= 0 for no response [open circles]; y= 1 for ≥1.0 g/dL &amp;&lt; 1.5 g/dL [open triangles] or ≥ 1.5 g/dL [open squares] response). The solid lines and shaded regions represent the model prediction and the 95%CI for the prediction.

Figure 17: Proportions of Subjects with ≥ 1 g/dL or ≥ 1.5 g/dL Hemoglobin Increase in Week 1 to 15 as a Function of Luspatercept Serum Exposure (Integrated Analysis)

<!-- image -->

AUCavgls = average area under the concentration-time curve from Week 1 to 15.

Observed proportion (solid circles) and 95% confidence interval (vertical error bars) at each quartile of AUCavgis are presented, along with the predicted ordinal logistic regression fits (slanting lines). The solid circles at zero AUCavgi5 represent the observed placebo data.

<div style=\"page-break-after: always\"></div>

## Exposure-response Analysis for Safety

Table 18: Overview of Results for Exposure-safety Analyses

<!-- image -->

|                                                                              | Week 1 to 6 Logistic Regression                                              | Week 1 to 6 Logistic Regression                                              | Week 1 to 6 Logistic Regression                                              | Week 1 to 48 Logistic Regression                                             | Week 1 to 48 Logistic Regression                                             | Week 1 to 48 Logistic Regression                                             | Week 1 to 48 Cox Regression                                                  | Week 1 to 48 Cox Regression                                                  | Week 1 to 48 Cox Regression                                                  |
|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Endpoint                                                                     | E-R significant?                                                             | E-R significant?                                                             | Significant cOVS                                                             | E-R significant?                                                             | E-R significant?                                                             | Significant cOVS                                                             | E-R significant?                                                             | E-R significant?                                                             | Significant covs b                                                           |
|                                                                              | No covs                                                                      | With cOVS                                                                    | Significant cOVS                                                             | No covs                                                                      | With cOVS                                                                    | Significant cOVS                                                             | No covs                                                                      | With cOVS                                                                    | Significant covs b                                                           |
| Integrated Safety Analysis (Studies ACE-536-B-THAL-002,A536-04, and A536-06) | Integrated Safety Analysis (Studies ACE-536-B-THAL-002,A536-04, and A536-06) | Integrated Safety Analysis (Studies ACE-536-B-THAL-002,A536-04, and A536-06) | Integrated Safety Analysis (Studies ACE-536-B-THAL-002,A536-04, and A536-06) | Integrated Safety Analysis (Studies ACE-536-B-THAL-002,A536-04, and A536-06) | Integrated Safety Analysis (Studies ACE-536-B-THAL-002,A536-04, and A536-06) | Integrated Safety Analysis (Studies ACE-536-B-THAL-002,A536-04, and A536-06) | Integrated Safety Analysis (Studies ACE-536-B-THAL-002,A536-04, and A536-06) | Integrated Safety Analysis (Studies ACE-536-B-THAL-002,A536-04, and A536-06) | Integrated Safety Analysis (Studies ACE-536-B-THAL-002,A536-04, and A536-06) |
| Serious TEAEs                                                                | No                                                                           | N/A                                                                          | None                                                                         | No                                                                           | N/A                                                                          | None                                                                         | No                                                                           | N/A                                                                          |                                                                              |
| TEAEs≥Grade 3                                                                | No                                                                           | No                                                                           | Baseline Hb                                                                  | No                                                                           | N/A                                                                          | None                                                                         | No                                                                           | N/A                                                                          | --                                                                           |
| Asthenia/Fatigue ≥ Grade 1                                                   | No                                                                           | N/A                                                                          | None                                                                         | No                                                                           | N/A                                                                          | None                                                                         | No                                                                           | N/A                                                                          | --                                                                           |
| BonePain/Arthralgia≥Grade1                                                   | Yes                                                                          | Yes                                                                          | Age                                                                          | No                                                                           | N/A                                                                          | None                                                                         | Yesc                                                                         | No                                                                           | Age                                                                          |
| Dizziness ≥ Grade 1                                                          | -.                                                                           |                                                                              |                                                                              | No                                                                           | N/A                                                                          | None                                                                         | No                                                                           | N/A                                                                          |                                                                              |
| Hypertension ≥ Grade 1                                                       | No                                                                           | N/A                                                                          | None                                                                         | Yes                                                                          | Yes                                                                          | Age                                                                          | Yes                                                                          | No                                                                           | Age                                                                          |
| Myalgia ≥ Grade 1                                                            | No                                                                           | N/A                                                                          | None                                                                         | No                                                                           | N/A                                                                          | None                                                                         | No                                                                           | N/A                                                                          | -                                                                            |
| StudyACE-536-B-THAL-002Only                                                  | StudyACE-536-B-THAL-002Only                                                  | StudyACE-536-B-THAL-002Only                                                  | StudyACE-536-B-THAL-002Only                                                  | StudyACE-536-B-THAL-002Only                                                  | StudyACE-536-B-THAL-002Only                                                  | StudyACE-536-B-THAL-002Only                                                  | StudyACE-536-B-THAL-002Only                                                  | StudyACE-536-B-THAL-002Only                                                  | StudyACE-536-B-THAL-002Only                                                  |
| TEAEsleading to dose reduction, dose delay or discontinuation                | No                                                                           | No                                                                           | Asian race                                                                   | No                                                                           | N/A                                                                          | None                                                                         | No                                                                           | N/A                                                                          |                                                                              |
| Dose delay due to pre-dose Hb > 11.5 g/dL                                    |                                                                              |                                                                              |                                                                              | Yes                                                                          | No                                                                           | Baseline Hb, Splenectomy                                                     | Yes                                                                          | Yes                                                                          | Baseline Hb, Splenectomy                                                     |
| Dosereduction due to pre-dose Hb increasefrombaseline> 2g/dL                 | No                                                                           | N/A                                                                          | None                                                                         | No                                                                           | No                                                                           | Baseline Biirubin                                                            | No                                                                           | N/A                                                                          |                                                                              |

covs = covariates; E-R = exposure-response; Hb = hemoglobin; N/A = not applicable, because no covariate effects were added to the model (logistic regression), or covariates were not tested (Cox proportional hazards regression); TEAEs = treatment-emergent adverse events.

a Too few events, covariates not evaluated.

b Covariates were only evaluated in the Cox regression if the E-R relationship was significant.

c In the Kaplan Meier plots stratified by exposure quartile, there was a difference observed among time-to-event curves. The relationship was not statistically significant in the Cox proportional hazards regression.

If 'E-R significant?' is Yes, higher luspatercept exposure was statistically associated with increased frequency of or shorter time to the specified endpoint. The 'No covs' column indicates the relationship in the base model (i.e., without covariates), while the 'With covs' column indicates the relationship in the final model, including statistically significant covariates. The statistically significant covariates in the model are specified in the 'Significant covs' column. All covariates are at baseline.

## Integrated Safety Analysis

Exposure-response relationship for selected TEAEs up to 60 days after the last dose in Week 1 to 48 was explored using the data pooled from Studies A536-04, A536-06, and ACE-536-B-THAL-002 (N = 143, dose range = 0.2 to 1.25 mg/kg).

In the integrated analysis for TEAEs, no positive association was found between luspatercept AUCevent and the probability of experiencing serious TEAEs, TEAEs ≥ Grade 3 or selected TEAEs ≥ Grade 1 (asthenia/fatigue, dizziness, and myalgia).

A statistically significant association with increased luspatercept AUCevent was observed for bone pain/arthralgia ≥ Grade 1 in Week 1 to 6 and hypertension ≥ Grade 1 in Week 1 to 48, during which the TEAE manifested:

- Subjects in the lowest AUCevent quartile group appeared to take a longer time to experience the first event of bone pain/arthralgia (16.7% in Week 1 to 6 versus 44% in Week 1 to 48) than those in the higher AUCevent quartile groups (25% to 50% in Week 1 to 6 and 33.3% to 55.6% in Week 1 to 48). As such, an exposure-dependent increase in bone pain/arthralgia ≥ Grade 1 was only observed in Week 1 to 6, not in Week 1 to 48.

<div style=\"page-break-after: always\"></div>

- On the contrary, few hypertension events occurred in the first 6 weeks, and the event increased over time for the highest AUCevent quartile group. As such, an exposure-dependent increase in hypertension ≥ Grade 1 was only observed in Week 1 to 48, not in Week 1 to 6.

Although the evaluation period influenced the statistical significance of the E-R relationship for these TEAEs, both bone pain/arthralgia and hypertension occurred more frequently in the luspatercept arm than in the placebo arm, and their occurrence is considered treatment-related and thus likely to be dependent on the luspatercept serum exposure level.

Age was the only identified covariate statistically associated with both TEAEs, with older subjects more likely to experience these TEAEs.

## Safety analysis Study ACE536 -BTHAL -002 only

The association of luspatercept serum exposure with the probability of experiencing TEAEs or excessive Hb increases leading to dose modifications or treatment discontinuation was explored in Week 1 to 48 for Study ACE-536-B-THAL-002 where the dose modification rules were implemented consistently across treatment period (N = 96, dose range = 0.6 to 1.25 mg/kg). Due to the limited number of such events in Week 1 to 6, only the results from Week 1 to 48 are considered informative.

No positive association was found between luspatercept AUCevent and the probability of experiencing TEAEs leading to dose reduction, dose delay, or treatment discontinuation or experiencing pre-dose Hb increase &gt; 2 g/dL leading to dose reduction.

Pre-dose Hb &gt; 11.5 g/dL leading to a dose delay was more likely and occurred sooner with increased luspatercept AUCevent. Baseline Hb and splenectomy were risk factors for both the probability of events and the time to first event. After accounting for the effects of baseline Hb and splenectomy, the effect of luspatercept AUCevent became insignificant for the probability of the event but remained significant for the time to first event.

As shown by exposure-efficacy analyses, subjects with a higher baseline Hb or without a splenectomy were more likely to have a greater Hb response at higher luspatercept exposure.

From this perspective, the underlying true cause for Hb &gt; 11.5 g/dL remains the higher levels of drug exposure leading to increased Hb.

<div style=\"page-break-after: always\"></div>

Figure 18: Relationship between Luspatercept Serum Exposure and Probability of Bone Pain or Arthralgia ≥ Grade 1 in Week 1 to 6 (Integrated Analysis)

<!-- image -->

AUC = area under the concentration-time curve; CI = confidence interval; Wk = week. The p-value is two-tailed pvalue corresponding to the z ratio based on a Normal reference distribution.

Table 19: Final Model for the Probability of Bone Pain or Arthralgia ≥ Grade 1 in Week 1 to 6 (Integrated Analysis)

| Parameter                           |   Estimate |      SE | OR    | 95%CIofOR     |   P-value |
|-------------------------------------|------------|---------|-------|---------------|-----------|
| Intercept                           |  -3.266    | 0.7433  |       |               | 1.114e-05 |
| Luspatercept AUCevent ( (day·μg/mL) |   0.008754 | 0.0039  | 1.009 | (1.001,1.017) | 0.02478   |
| Age (years)                         |   0.03701  | 0.01578 | 1.038 | (1.007,1.071) | 0.01901   |

AUCevent = area under the concentration-time curve at the first event; CI = confidence interval; OR = odds ratio; SE = standard error; The p-value is two-tailed p-value corresponding to the z ratio based on a Normal reference distribution.

<div style=\"page-break-after: always\"></div>

Figure 19: Relationship between Luspatercept Serum Exposure and Probability of Bone Pain or Arthralgia ≥ Grade 1 in Week 1 to 48 (Integrated Analysis)

<!-- image -->

AUC = area under the concentration-time curve; CI = confidence interval; Wk = week. The p-value is two-tailed pvalue corresponding to the z ratio based on a Normal reference distribution.

Table 20: Final Cox Model for Time to First Bone Pain or Arthralgia ≥ Grade 1 Event (Integrated Analysis)

| Parameter                          |   Estimate |     SE |     HR | 95% CI of HR   |   P-value |
|------------------------------------|------------|--------|--------|----------------|-----------|
| Luspatercept AUC (day·μg/mL) event |    -0.0001 | 0.0025 | 0.9999 | (0.995, 1.005) |    0.9732 |
| Age (years)                        |     0.0234 | 0.0103 | 1.024  | (1.003, 1.044) |    0.0228 |

AUCevent = area under the concentration-time curve at the first event; CI = confidence interval; HR = hazard ratio; SE = standard error. The p-values for model parameters are the two-sided p-value associated with the hypothesis that the regression term is zero.

<div style=\"page-break-after: always\"></div>

Figure 20: Kaplan-Meier Plot of Proportion of ≥ Grade 1 Bone Pain or Arthralgia events in Week 1 to 48 by Luspatercept Serum Exposure Quartile (Integrated Analysis)

<!-- image -->

Weeks

AUCevent = area under the concentration-time curve at the time of adverse event; KM = Kaplan-Meier; Wk = week. Note: Vertical lines indicate censored subjects.

Hypertension ≥ Grade 1

Figure 21: Relationship between Luspatercept Serum Exposure and Probability of Hypertension ≥ Grade 1 in Week 1 to 6 (Integrated Analysis)

<!-- image -->

AUC = area under the concentration-time curve; CI = confidence interval; N = number of subjects. The p-value is a two-tailed p-value corresponding to the t or z ratio based on a Student t or Normal reference distribution

<div style=\"page-break-after: always\"></div>

Figure 22: Relationship between Luspatercept Serum Exposure and Probability of Hypertension ≥ Grade 1 in Week 1 to 48 (Integrated Analysis)

<!-- image -->

AUC = area under the concentration-time curve; CI = confidence interval; Wk = week. The p-value is two-tailed pvalue corresponding to the z ratio based on a Normal reference distribution.

Table 21: Final Model for the Probability of Hypertension ≥ Grade 1 in Week 1 to 48 (Integrated Analysis)

| Parameter                          |   Estimate |      SE | OR   | 95%CIof OR   | P-value   |
|------------------------------------|------------|---------|------|--------------|-----------|
| Intercept                          |    -6.88   | 1.36    |      |              | <0.0001   |
| Luspatercept AUCevent  (day·μg/mL) |     0.0159 | 0.00678 | 1.02 | (1, 1.03)    | 0.0193    |
| Age (years)                        |     0.0592 | 0.0236  | 1.06 | (1.02, 1.12) | 0.0122    |

AUCevent = area under the concentration-time curve at the first event; CI = confidence interval; OR = odds ratio; SE = standard error. The p-value is two-tailed p-value corresponding to the z ratio based on a Normal reference distribution.

<div style=\"page-break-after: always\"></div>

Figure 23: Kaplan-Meier Plot of Time to First Hypertension ≥ Grade 1 by Luspatercept Serum Exposure Quartile (Integrated Analysis)

<!-- image -->

AUCevent = area under the concentration-time curve at of the first event; Wk = week.

The values in '[ ]' shows the range of AUCevent including both values, and the values in '( ]' shows the range of AUCevent between the two values including the second value. Vertical lines indicate censored subjects.

Exposure -safety Analysis for Study ACE536 -BTHAL -002

Figure 24: Relationship between Luspatercept Serum Exposure and Probability of Predose Hemoglobin &gt; 11.5 g/dL Leading to Dose Delay in Week 1 to 48 (ACE-536-B-THAL-002)

<!-- image -->

AUC = area under the concentration-time curve; CI = confidence interval; Hb = hemoglobin; Wk = week. The p-value is two-tailed p-value corresponding to the z ratio based on a Normal reference distribution.

<div style=\"page-break-after: always\"></div>

Table 22: Final Model for the Probability of Pre-dose Hemoglobin &gt; 11.5 g/dL Leading to Dose Delay in Week 1 to 48 (ACE-536-B-THAL-002)

| Parameter                           |   Estimate |      SE | OR    | 95%CIofOR       | P-value   |
|-------------------------------------|------------|---------|-------|-----------------|-----------|
| Intercept                           |   -19.4    | 4.4     |       |                 | <0.0001   |
| Luspatercept AUCevent ( (day·μg/mL) |     0.0151 | 0.00978 | 1.02  | (0.996, 1.04)   | 0.124     |
| Baseline hemoglobin (g/dL)          |     1.96   | 0.45    | 7.1   | (3.29, 19.8)    | <0.0001   |
| Baseline Splenectomy (Yes)          |    -2.25   | 0.816   | 0.106 | (0.0176, 0.461) | 0.00585   |

AUCevent = area under the concentration-time curve at the first event; CI = confidence interval; OR = odds ratio; SE = standard error. Note: The p-value is two-tailed p-value corresponding to the z ratio based on a Normal reference distribution.

Figure 25: Kaplan-Meier Plot of Time to First Pre-dose Hemoglobin &gt; 11.5 g/dL Event Leading to Dose Delay by Luspatercept Serum Exposure Quartile (ACE-536-B-THAL-002)

<!-- image -->

AUCevent = area under the concentration-time curve at the first event; Hb = hemoglobin; Wk = week. The values in ' [ ] ' shows the range of AUCevent including both values, and the values in ' ( ] ' shows the range of AUCevent between the two values including the second value. Vertical lines indicate censored subjects.

## Exposure-response Relationship for NTDT-PRO T/W Scores

## Incremental Change Analysis (Week 1 to 48)

The association of T/W improvement with Hb unit increases (in 1 g/dL increments) from baseline was quantitated for T/W domain score during Weeks 1 to 48.

In luspatercept-treated subjects with a baseline T/W domain score ≥ 3, increased magnitude of T/W improvements was associated with increased ΔHb, ie, the greater the ΔHb level, the larger the mean reduction in T/W domain score. Similar results were observed for the tiredness with physical activity score and weakness with physical activity score. Almost all mean reductions in the specified T/W scores at 1 to 4 g/dL ΔHb were statistically significant compared with the corresponding score changes at zero ΔHb. The greatest mean reduction in T/W scores (4 to 5 points) occurred at the ΔHb level of 4 g/dL. Overall, a 1 g/dL increase in Hb was associated with approximately 1 point of mean reduction in each specified T/W score.

<div style=\"page-break-after: always\"></div>

In luspatercept-treated subjects with a baseline score &lt; 3, a statistically significant trend towards an improvement in the specified T/W scores with increasing ΔHb (1 to 3 g/dL) was consistently observed. The magnitude of improvement in these T/W scores was smaller, likely due to limited room for further reduction in the score. Indeed, the absolute T/W score decreased to reach near the floor during luspatercept treatment. Noticeably, the improvement in T/W domain score and tiredness with physical activity score at 1 to 3 g/dL ΔHb was statistically significant compared with the corresponding score chang e at zero ΔHb, suggesting the score improvements were associated with Hb increase even in subjects with a baseline T/W score &lt; 3.

In placebotreated subjects, a ΔHb dependent change in the specified T/W scores was not observed regardless of the baseline sc ore. In these subjects, ΔHb fluctuated over a narrow range ( -1 to 1 g/dL), and there were no statistically significant changes in T/W scores when ΔHb increased from 0 to 1 g/dL .

Figure 26: Mean (SD) Change from Baseline in NTDT-PRO T/W Scores (Overall and with Physical Activity) versus Change from Baseline in Hemoglobin (in 1 g/dL Increments)

<!-- image -->

Hb change from baseline (g/dL)

Hb = hemoglobin; NTDT-PRO = nontransfusion dependent β -thalassemia-patient reported outcome; PA = physical activity; SD = standard deviation; T/W = tiredness and weakness in NTDT-PRO.

Note: Hb change from baseline was rounded to the nearest integer.

<div style=\"page-break-after: always\"></div>

Table 23: Summary of Change from Baseline in NTDT-PRO T/W Scores (Overall and with Physical Activity) versus Increase from Baseline in Hemoglobin (in 1 g/dL Increments) in Subjects Treated with Luspatercept

| NTDT-PRO                         | △Hb (g/dL)   | Baseline score < 3   | Baseline score < 3   | Baseline score ≥ 3   | Baseline score ≥ 3   |
|----------------------------------|--------------|----------------------|----------------------|----------------------|----------------------|
|                                  |              | N(m)                 | Mean (SD) Change     | N(E)                 | Mean (SD) Change     |
| Tiredness and weakness domain    | 0            | 8 (31)               | 1.02 (1.33)          | 19 (38)              | -0.26 (1.37)         |
| Tiredness and weakness domain    | 1            | 23 (83)              | 0.18 (1.31) **       | 52 (167)             | -1.05 (1.80)         |
| Tiredness and weakness domain    | 2            | 18 (79)              | 0.23 (0.78) **       | 48 (171)             | -1.73 (1.82) ****    |
| Tiredness and weakness domain    | 3            | 6 (15)               | -0.10 (0.84) **      | 17 (50)              | -2.31 (1.80) ****    |
| Tiredness and weakness domain    | 4            | No data              | No data              | 4 (7)                | -4.48 (2.35) * *兴**  |
| Tiredness with physical activity | 0            | 5 (21)               | 1.52 (1.52)          | 22 (48)              | -0.11 (1.47)         |
| Tiredness with physical activity | 1            | 16 (60)              | 0.40 (1.74) **       | 59 (190)             | -1.13 (2.02) *       |
| Tiredness with physical activity | 2            | 14 (61)              | 0.10 (0.73) ***      | 52 (189)             | -1.72 (2.11) ****    |
| Tiredness with physical activity | 3            | 5 (14)               | -0.42 (0.97) ***     | 18 (51)              | -2.47 (2.18) ****    |
| Tiredness with physical activity | 4            | No data              | No data              | 4 (7)                | -4.78 (2.62) ****    |
| Weakness with physical activity  | 0            | 6 (24)               | 0.79 (1.23)          | 21 (45)              | 0.00 (1.42)          |
| Weakness with physical activity  | 1            | 18 (64)              | 0.17 (1.14)          | 57 (186)             | -1.11 (2.14) *       |
| Weakness with physical activity  | 2            | 16 (68)              | 0.38 (1.16)          | 50 (182)             | -1.89 (2.25) ****    |
| Weakness with physical activity  | 3            | 6 (15)               | -0.04 (0.96)         | 17 (50)              | -2.65 (2.20) ****    |
| Weakness with physical activity  | 4            | No data              | No data              | 4 (7)                | -5.03 (2.83) ****    |

ΔHb = hemoglobin change from baseline rounded to the nearest integer; N (n) = number of subjects (number of observations); NTDT-PRO = nontransfusion dependent β -thalassemia-patient reported outcome; SD = standard deviation; T/W = tiredness and weakness in NTDT-PRO.

* p-value &lt; 0.05, ** p-value &lt; 0.01, *** p-value &lt; 0.001, and **** pvalue &lt; 0.0001 versus ΔHb = 0 based on twosided pairwise t-test with the p-value adjusted by Bonferroni correction method.

Table 24: Summary of Change from Baseline in NTDT-PRO T/W Scores (Overall and with Physical Activity) versus Increase from Baseline in Hemoglobin (in 1 g/dL Increments) in Subjects Treated with Placebo

| NTDT-PRO                         | △Hb (g/dL)   | Baselinescore<3   | Baselinescore<3   | Baselinescore≥3   | Baselinescore≥3   |
|----------------------------------|--------------|-------------------|-------------------|-------------------|-------------------|
|                                  |              | N(E)              | Mean (SD) Change  | N(m)              | Mean (SD) Change  |
| Tiredness and weakness domain    | 0            | 13 (72)           | -0.04 (0.82)      | 34 (148)          | -0.44 (1.41)      |
| Tiredness and weakness domain    | 1            | 5 (9)             | 0.61 (1.25)       | 18 (35)           | -0.60 (1.02)      |
| Tiredness with physical activity | 0            | 9 (45)            | 0.39 (0.81)       | 38 (175)          | -0.55 (1.55)      |
| Tiredness with physical activity | 1            | 4 (6)             | 1.40 (1.94)       | 19 (38)           | -0.45 (1.20)      |
| Weakness with physical activity  | 0            | 9 (45)            | 0.58 (0.87)       | 38 (175)          | -0.45 (1.63)      |
| Weakness with physical activity  | 1            | 4 (6)             | 1.53 (2.23)       | 19 (38)           | -0.44 (1.08)      |

ΔHb = hemoglobin change from baseline rounded to the nearest integer; N (n) = number of subjects (number of observations); NTDT-PRO = nontransfusion dependent β -thalassemia-patient reported outcome; SD = standard deviation; T/W = tiredness and weakness in NTDT-PRO.

Note: p-value &gt; 0.10 for all mean valu es at ΔHb = 1 versus ΔHb = 0 based on two -sided pairwise t-test with the pvalue adjusted by Bonferroni correction method.

<div style=\"page-break-after: always\"></div>

## Linear Mixed-effects Modelling (Double-blind Treatment Period)

In the multivariate analysis using a linear mixed-effects model, Hb change from baseline and baseline T/W domain score were significant predictors (p &lt; 0.0001) of weekly T/W domain score change from baseline, and the T/W domain score improvement due to Hb increase was greater at a higher baseline T/W domain score. The presence of treatment-emergent adverse events (TEAEs) (i.e., bone pain/arthralgia or nonspecific TEAEs ≥ Grade 1), though statistically associated with a small increase in weekly T/W domain score, did not materially interfere with determining T/W improvement by luspatercept therapy.

The following factors were not significantly associated with the weekly NTDT-PRO domain score change from baseline in the multivariate analysis: age, sex, race, geographic region, β -thalassemia diagnosis, baseline EPO, baseline Hb levels, baseline RBC transfusion burden, baseline splenectomy, baseline liver iron concentration, baseline total bilirubin, baseline renal function, and absolute Hb levels during treatment.

Thus, luspatercept treatment, by increasing Hb, was associated with improvement in tiredness and weakness across the NTD β -thalassemia population, especially in more symptomatic subjects.

## 2.3.5. Immunogenicity

Since no subjects were tested positive to TEADA in Studies A536-04/06, the immunogenicity data are summarised for subjects in Study ACE-536-B-THAL-002 only. Additional a comparison between NTD and TD patients was presented.

## Methods

## Bioanalytical Strategy

Antidrug antibodies in serum were analysed using a multi-tiered approach (screening, confirmation, epitope specificity, and neutralising). The methodology and assay performance of the validated methods have been described (MDS B-THAL Module 2 Section 2.7.1). No new analytical methods were developed for the current submission, but the established methods have been updated to meet current guidance requirements and/or qualify new batches of reagents. The assay performance for clinical studies relevant to the current submission were updated.

The following methods have been updated in order to meet current guidance requirements and/or qualify new batches of reagents:

- Report 174275 addendum 4 (Report 187546): Validation for the Detection of Anti-ACE536 Antibodies in Human Serum by an Electrochem iluminescent Assay (ECLA)

A partial validation was performed in order to implement new positive controls  to the assay. A high-, mid-, and low concentration positive control was successfully qualified. No deviations ocurred. The MAH´s partial validation assessments confirms that the assay is still in a validated state.

- Report 176678 addendum 2 (Report 189346): Validation for the Detection of Neutralizing Antibodies to ACE-536 in Human Serum by ELISA

A partial validation was performed in order to implement a positive control antibody (anti-ACE536 chicken polyclonal antibody). The MAH notes data generated from validation experiments are indicative of the positive control antibody used. The positive control most likely is a high affinity antibody and may not be reflective of antibodies that might be present in study subjects. Two

<div style=\"page-break-after: always\"></div>

deviations occurred during the validation, which are related to analyst failures and do not interfere with the validation result. The implementation is acceptable and the data show that the assay is still in a validated state.

- Report 155-1934 (update to 207-1001): Detection of Neutralising Antibodies to ACE-031 in Human Serum by ELISA

A partial validation was performed in order to test matrix selectivity on haemolysed and lipemic individual human serum lots, and target interference of GDF-11. All validation runs met the acceptance criteria. There was no observed interference from GDF-11 to the negative control. All haemolytic and lipemic sample matrixes were successfully implemented. Overall, the assay is fit for use with the indicated matrixes.

## Sampling for Determi ning Antidrug Antibodies in Serum

Blood samples for assessment of ADA in serum were collected from all subjects in Study ACE-536-BTHAL-002 at baseline (prior to the first dose), periodically throughout the treatment period at timepoints where drug levels were expected to be lowest (trough levels), and during the follow-up period (6 months from the last dose) by which time the luspatercept concentration in serum was expected to have minimal interference with ADA assays. The ADA sampling duration was limited to 2 years from the first dose since the presence of ADA was not found to be associated with adverse events in previous studies. Timematched PK samples were collected to facilitate the interpretation of ADA results.

Table 25: Sampling Schedule for Determining Luspatercept Concentration and Antidrug Antibody (Study ACE-536-B-THAL-002)

| Study (Indication)                    | Visits for PK sampling                                                                             | Visits for ADA sampling                                                                                                                                                             |
|---------------------------------------|----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ACE-536-B-THAL-002 (NTDβ-Thalassemia) | On treatment: C1D1 (pre-dose), C2D1,C4D1,C6D1,C6D8,C6D15, C8D1,C12D1,C16D1,thenonce every 6 doses. | On treatment: C1D1 (pre-dose), C2D1, C4D1, C6D1,C8D1,C12D1,C16D1;thenonce every 6 doses. Posttreatment: once every 24 weeks if applicable a. Maximum 2 years of sampling from C1D1. |

ADA = antidiug antibodies; C = cycle (or dose); D = day; PK = pharmacokinetics; NTD = nontransfusiondependent.

Before study unblinding, sampling continued until reaching the maximum sampling duration. After study unblinding, sampling continued only if subjects' last available assessment was positive and had not reached the maximumsamplingduration

## Determination of Antidrug Antibody Status

The ADA status of a subject was determined based on the longitudinal results from the screening/confirmation assay for anti-luspatercept binding antibody and the titer in the confirmed samples as follows:

- -Negative: All samples (baseline and post-baseline) were negative.
- -Positive to TEADA:
- o At least one post-baseline sample was positive if the baseline sample was negative, or
- o At least one post-baseline sample was positive with a titer ≥ 4-fold of the baseline titer if the baseline sample was positive.
- -Positive to pre-existing ADA:
- o Baseline sample was positive and all post-baseline samples were negative, or
- o Both baseline and post-baseline samples were positive, but all positive post-baseline sample had a titer &lt; 4-fold of the baseline titer.

<div style=\"page-break-after: always\"></div>

## Immunogenicity Results (Study ACE-536-B-THAL-002)

## Treatment-Emergent Antidrug Antibodies Against Luspatercept

Treatment-emergent ADA against luspatercept were observed in luspatercept-treated subjects with NTD β -thalassemia at a low incidence: 3 (3.1%) of subjects developed binding antibodies as well as neutralising antibodies. However, not all TEADA appeared to be related to luspatercept treatment, as TEADA were also observed in 3 (6.1%) placebo-treated subjects.

In the luspatercept treatment group, the maximum TEADA titre among subjects ranged from 11.5 to 92.0. All 3 subjects in the luspatercept treatment group with TEADA tested positive within 233 days of the first dose, and 2 subjects had positive samples for more than 2 consecutive visits. No incidence of TEADA resulting from pre-existing ADA boosted to a higher level following luspatercept treatment (i.e. post-baseline ADA titre ≥ 4-fold of baseline titre) was observed in subjects with NTD β -thalassemia.

In the luspatercept treatment group, TEADA binding to the modified ActRIIB ECD on luspatercept was detected in only 1 (1.0%) subject with NTD β -thalassemia.

In the specificity binding assay, only 1 (1.0%) subject treated with luspatercept had TEADA crossreacting with the natural ECD of human ActRIIB. No subjects tested positive in the neutralizing assay for the cross-reactivity.

## Effect of Antidrug Antibody on Luspatercept Pharmacokinetics

Inspection of dose-normalized luspatercept concentration profiles and ADA titer values from luspatercepttreated subjects with NTD β -thalassemia found no obvious effect of TEADA. However, the small number of positive subjects (n=3) did not allow for definitive conclusions.

Figure 27: Dose-Normalized Luspatercept Concentrations at Predose Over Time by Antidrug Antibody Status and Titer Level

<!-- image -->

ADA = antidrug antibody; NAb = neutralizing antibody.

Concentrations were normalized to the level at 1 mg/kg. Data points under the dashed line are concentrations below the lower limit of quantification (50 ng/mL).

Preexisting ADA was only observed prior to the first dose.

<div style=\"page-break-after: always\"></div>

## Effect of Antidrug Antibody on Efficacy

All 3 luspatercept-treated subjects with TEADA were good responders. All of them achieved a ≥ 1.0 g/dL increase from baseline in mean Hb values during Week 13 to 24 and Week 37 to 48. The longest duration with ≥ 1.0 g/dL increase from baseline in mean Hb over a continuous 12-week interval ranged from 319 to 706 days. These results suggested no impact of TEADA on efficacy.

## Effect of Antidrug Antibody on Safety

The TEAE data (as of data cut-off date of 14 Sept 2020) for the 3 subjects with TEADA were searched for preferred terms potentially associated with immunogenicity-like reactions based on Medical Dictionary for Regulatory Activities version 23. None of the 3 subjects with TEADA had immunogenicity-like reactions.

## Preexisting Antidrug Antibodies against Luspatercept

Preexisting ADA against luspatercept (n=2), including neutralizing antibody (n=1), were observed in the luspatercept group but not in the placebo group. The maximum ADA titre in luspatercept-treated subjects (n=2) was 11.5 for pre-existing ADA.

Table 26: Incidence of Pre-existing Antidrug Antibodies in Subjects with NTD β -thalassemia (ACE-536-B-THAL-002)

| AntidrugAntibodies           | Luspatercept (N=96) n (%)   | Placebo (N=49) n (%)   |
|------------------------------|-----------------------------|------------------------|
| ADA against luspatercept     | 2 (2.1)                     | 0 (0.0)                |
| Specificity for ACE-mECD     | 1 (1.0)                     | 0 (0.0)                |
| Specificity for ActRIIB ECD  | 0 (0.0)                     | 0 (0.0)                |
| Neutralizing luspatercept    | 1 (1.0)                     | NA                     |
| Neutralizing ActRIIB-ECD-Fea | 0 (0.0)                     | NA                     |

ActRIIB = activin receptor type IIB; ACE-mECD: modified ECD of human ActRIIB on luspatercept; AetRIIB ECD

= natural ECD of human ActRIIB; ActRIIB-ECD-Fc = a fusion protein joining the natural ECD of human

AetRIIB to Fc portion of human Ig G; ADA = antidrug antibodies; ECD = extracellular domain; N = total number of subjects providing ADA sample; n = number of subjects with preexisting ADA; NA = not available.

a Neutralizing luspatercept and neutralizing AetRIIB-ECD-Fe results were NA for positive placebo samples at the time of the clinical study report.

An impact of pre-existing ADA on PK, efficacy, and safety of luspatercept was not observed. The preexisting ADA was transient, only observed prior to the first dose. Both subjects who tested positive to pre-existing ADA achieved a ≥ 1.0 g/dL increase from baseline in mean Hb values during Week 13 to 24 and Week 37 to 48, and the response was durable (longest duration 507 to 914 days). No immunogenicity like reactions were reported for the two subjects.

## Comparison of Immunogenicity Between Subjects with Non transfusion-dependent and Transfusiondependent β -Thalassemia

There was no obvious difference in the incidence of treatment-emergent antidrug antibodies (TEADA) between subjects with NTD β -thalassemia and those with TD β -thalassemia.

In the luspatercept treatment arms of the pivotal studies, TEADA against luspatercept were observed at a lower incidence: 3 (3.1%) in subjects with NTD β -thalassemia and 4 (1.81%).

<div style=\"page-break-after: always\"></div>

in subjects with TD β -thalassemia. Not all TEADAs appeared to be related to luspatercept treatment, as they were also observed at similar incidences in the placebo arms. However, TEADAs binding to modified or natural ECD of human ActRIIB or neutralising TEADAs were only observed in the luspatercept arm.

To date, there has been no strong evidence for an association of TEADA with changes in luspatercept PK, efficacy and safety profiles in subjects with NTD β -thalassemia or TD β -thalassemia.

Table 27: Incidence of Treatment-Emergent Antidrug Antibodies

|                               | ACE-536-B-THAL-002 (NTD β-thalassemia)   | ACE-536-B-THAL-002 (NTD β-thalassemia)   | ACE-536-B-THAL-001(TD β-thalassemia)   | ACE-536-B-THAL-001(TD β-thalassemia)   |
|-------------------------------|------------------------------------------|------------------------------------------|----------------------------------------|----------------------------------------|
| Antidrug Antibodies           | Luspatercept (N = 96) n (%)              | Placebo (N = 49) n (%)                   | Luspatercept (N = 220) n (%)           | Placebo (N =107) (%) uI                |
| ADA against luspatercept      | 3 (3.1)                                  | 3 (6.1)                                  | 4 (1.81)                               | 2 (1.87)                               |
| Specificity for ACE-mECD      | 1 (1.0)                                  | 0                                        | 1 (0.45)                               | 0 (0)                                  |
| Specificity for ActRIIB ECD   | 1 (1.0)                                  | 0                                        | 1 (0.45)                               | 0 (0)                                  |
| Neutralizing luspatercepta    | 3 (3.1)                                  | NA                                       | 2 (0.90)                               | 0 (0)                                  |
| Neutralizing ActRIIB-ECD-Fc a | 0                                        | NA                                       | 0(0)                                   | 0 (0)                                  |

ActRIIB = activin receptor type IIB; ACE-mECD: modified ECD of human ActRIIB on luspatercept; ActRIIB ECD = natural ECD of human ActRIIB; ActRIIB-ECD-Fc = a fusion protein joining the natural ECD of human ActRIIB to Fc portion of human Ig G; ADA = antidiug antibodies; ECD = extracellular domain; N = total number of subjects providing ADA sample; n = number of subjects with preexisting ADA; NA = not available.

a Neutralizing luspatercept and neutralizing AetRIIB-ECD-Fe results were NA for positive placebo samples at the time of the clinical study report.

## Summary and Conclusions

- The incidence of TEADA was low in subjects with N TD β -thalassemia. Of 96 luspatercept-treated subjects with NTD β -thalassemia, 3 (3.1%) subjects tested positive for TEADA against luspatercept, with neutralizing activity.
- The incidence of TEADA cross-interacting with the natural ECD of human ActRIIB was 1.0%, suggesting a low risk of interaction with endogenous ActRIIB under luspatercept therapy.
- There was no clear trend between dose-normalized trough concentrations and TEADA formation, but the small number of positive subjects did not allow for definitive conclusions.
- There was no apparent loss of efficacy among subjects with TEADA, suggesting a continued benefit from luspatercept therapy.
- Subjects with TEADA did not appear to be at a higher risk for experiencing immunogenicity-like reactions, with no systemic hypersensitivity reactions or any other immunogenicity-like reactions reported for subjects tested ADA positive.
- Pre-existing ADA did not appear to have any effect on PK, efficacy, and safety.
- The low incidence of TEADAs observed in the NTD β -thalassemia population was consistent with that previously reported for the TD β -thalassemia population (1.81%).

<div style=\"page-break-after: always\"></div>

## 2.3.6. Discussion on clinical pharmacology

## Pharmacokinetics

In Pharmacokinetics and exposureresponse relationship analyses, subjects with NTD β -thalassemia were defined as subjects who had a baseline transfusion burden of 0 to 5 RBC units/24 weeks, and subjects with TD β -thalassemia were defined as subjects with a baseline transfusion burden ≥ 6 RBC units/24 weeks. Most NTD subjects had a transfusion burden of 0 at baseline and can be distinguished from TD subjects.

For the characterisation of Pharmacokinetics, the MAH provided a population PK model and a separate representation of PK estimates for the pivotal study ACE-536-B-THAL-002 however these were also based on the popPK model.

The population PK model was established previously for subjects with TD β -thalassemia (submitted with the initial MAA) and was updated by including subjects with NTD β -thalassemia from Study ACE-536-BTHAL-002. However, the population of NTD patients is limited (N=127) and represents only a third of the total population available for the Pharmacology analyses and respective samples only represent about a quarter of all samples. While the overrepresentation of samples from TD patients could potentially influence the results, the developed model seems to describe the data well for both populations. Some minor differences have however been observed. The VPC plots indicate that the 95 th  percentile of the model predictions seems to be wider compared to the observed data. This could also be influenced by the more limited dataset from study ACE-536-B-THAL-002, potentially increasing the variability of the data. Nevertheless, a slight difference between populations can also not be excluded. However, since the general tendency seems to be predicted well, the deviation in the 95 th  percentile is not regarded as a concern but this should be kept in mind when interpreting the data and consecutive analyses.

Only slight differences have been observed between NTD and TD patients (higher CL/F and consequently lower Cmax(SS)) but were not statistically significant.

A 27% to 41% higher mean AUCss in subjects with mild to moderate renal function compared to normal renal function has been observed. No dose adjustments are recommended for these special populations. On the other hand, the MAH also states that the maximum dose should not exceed 1.25 mg/kg every 3 weeks. The MAH refers to the intended general dose adjustments. While it is acknowledged that this might be sufficient in case the dose is lowered when the normal starting dose would not be well tolerated, a potential dose increase in case of insufficient efficacy cannot be excluded. In this case, the expected exposure would exceed the so far observed data, especially for patients with moderate renal impairment. However, only data for four patients with moderate renal impairment are available preventing any conclusions. Consequently, the MAH's arguments are mainly based on patients with mild renal impairment. A starting dose of 1mg/kg seems acceptable for both populations (mild and moderate) given that recommendations for regular monitoring are included in the SmPC. Special focus should be placed on the identified long term risk (please refer to the safety discussion and the respective discussion of the Benefit Risk balance section). Regarding subjects with severe renal impairment no dose recommendations can be made, which is acknowledged by the MAH, consequently these patients should be closely monitored for adverse reactions and dose adjustment should be managed accordingly (see Section 4.4 of the SmPC).

Overall, mean AUCss was 36% or 41% higher in subjects who achieved ≥ 1 g/dL or 1.5 g/dL increase from baseline in mean Hb value during Week 13 to 24 (primary efficacy endpoint) than those who did not (starting dose of 1 mg/kg). This suggests a relation between AUCss and response.

The MAH presented data derived from the analysis of PK data separately for study ACE-536-B-THAL-002 although PK parameters were derived from the final popPK model. The data was grouped into three

<div style=\"page-break-after: always\"></div>

categories (no dose modifications, one dose increase, all others). No distinction between the time points when dose escalations have been made has been presented for the second category and no distinction between modifications was performed at all in the last categories. However, similar concentrations at day 315 were observed for all categories which is reassuring but overall variability is high. Meaningful conclusion are further hampered by the limited number of patients. However, similar observations have been made in TD patients in the initial MAA.

In general non-responder showed a faster clearance (CL, t1/2) and consequently a lower AUCSS was observed. The MAH was asked to discuss a potential target exposure range that could help identifying patients / subgroups that might not reach sufficient response or are more likely in need of higher or lower doses, but the currently available data is too variable to allow a meaningful approach.

## Pharmacodynamics

In order to characterise the Pharmacodynamic effect an analysis of haematology mean values over time was submitted based on the data from study ACE-536-B-THAL-002. Further, the MAH provided several exposure-response models including response parameter including Hb level, efficacy and safety parameter. In addition, the potential association between change in Hb level from baseline and parameters from the patient reported outcomes (tiredness/weakness) was investigated.

## Haematology mean values over time:

The MAH claims that mean serum EPO values over time were generally higher in the luspatercept treatment group than in the placebo treatment group. This cannot entirely be followed, since high variability between the two groups was observed. At some time points, mean serum EPO values were higher in the placebo treatment group. No clear trend can be observed for mean serum EPO levels.

The increase in mean reticulocyte counts from baseline in the luspatercept treatment group is expected owing to luspatercept's mode of action. It is however critically noted that the increase of reticulocyte counts was observed late during the study, when data from the placebo group (but also the luspatercept group) were rather limited due to low patient numbers.

Nucleated RBCs indicate the presence of circulating immature RBC in response to chronic anaemia, which is a common clinical feature of β -thalassaemia. Luspatercept treatment aims at improving erythropoiesis and consequently a decrease of nucleated RBCs would be expected. Unexpectedly however, decreases of nucleated RBCs were of higher magnitude in the placebo treatment group. It is unclear whether the difference of nucleated RBCs at baseline might indicate any possible difference in phenotype, whether this difference could have an impact on the efficacy of luspatercept and how nucleated RBCs correlate with Hb or clinical presentation.

These aspects regarding the more frequent occurrence of EMH masses are discussed in the Clinical Safety section below.

## Exposure -response Analysis for the Time Course of Haemoglobin

The MAH presented an Emax-model describing the time course of Haemoglobin in response to luspatercept treatment. Only Hb data for NTD patients is available due to the frequent RBC transfusions in the TD population influencing the Hb values. Overall, the applied methods are acceptable and the model seems to describe the data well. Only slight trends are observed for overprediction of the 95 th percentile and underprediction of the 50 th  percentile, especially for data from study ACE-536-B-THAL-002. This might be caused by the respective effects on exposure observed in the population PK model for NTD patients potentially caused by the overrepresentation of the TD population. No concerns are raised but this should be kept in mind when interpreting the data and consecutive analyses.

<div style=\"page-break-after: always\"></div>

The developed model seems to adequately describe the time course of Hb in response to luspatercept dose levels 0.2 to 1.25 mg/kg administered Q3W to subjects with NTDT. The MAH also acknowledged that the estimated Emax and EC50 values should not be extrapolated outside the luspatercept dose levels used to derive these parameters.

The MAH states that the model associated luspatercept serum concentration with its stimulatory effect on Hb input into blood, which is agreed. Further, the model suggested a shorter Hb lifespan and fast Hb input rate, consistent with accelerated RBC destruction and compensatory erythroid marrow expansion in subjects with NTDT.

## Exposure -response Analysis for Efficacy

The relationship between luspatercept serum exposure and Hb-related efficacy endpoints (responder with ≥ 1 or 1.5 g/dL Hb increase from baseline) was evaluated for subjects with NTDT applying ordinal logistic regression analyses. Different dose ranges and different evaluation periods were analysed (0.2 to 1.25 mg/kg during the first 15 weeks of treatment; 0.6 to 1.25 mg/kg during early (Week 13 to 24), late (Week 37 to 48) and any consecutive 12-weeks or 24-weeks). In all evaluation periods, the results were similar and showed an exposure-dependent increase in Hb response which was consistent in frequency, magnitude and duration. Splenectomy and baseline Hb have been identified as predictive covariates. Subjects with splenectomy were less likely to achieve response (72% to 78% lower odds to reach at least 1 g/dL Hb increase). Subjects with higher baseline Hb were more likely to achieve response (38% to 67% higher for every 1 g/dL increase in baseline Hb). In addition, subjects with β0/β0 gene mutation were less likely to achieve at least 1 g/dL Hb increase in any consecutive 24-week interval. The MAH provided simulations that indicate that even for a subject with a combination of splenectomy, low baseline Hb and β0/β0 gene mutation the probability of achieving ≥ 1 g/dL mean Hb increas e in the 24-week interval is 23%, which is higher than placebo (6%). While it can be agreed that based on the identified covariates no subgroup exists for which no response can be expected, it seems that an increase in dose would increase the probability of response also for these patients.

The MAH claims that the analysis confirmed the appropriateness of the 1 mg/kg starting dose and suggested that dose escalation to 1.25 mg/kg improved the Hb response. While it is agreed that the analysis indicates an improvement after dose escalation for some patients, it is also observed that subjects requiring dose escalations tended to have lower exposures with the starting dose and/or disease characteristics affecting Hb response to luspatercept. The MAH was asked to discuss whether a higher starting dose might be beneficial in certain subgroups. The MAH referred to the existing titration regimen and that certain safety risks are related to a higher dose. While certain patient subgroups exists that would likely benefit from a higher starting dose, the MAH's more conservative approach is appreciated. Further, since no clinical data with a higher starting dose exist that would elucidate the respective safety profile of a higher starting dose, this issue is currently not further pursued. Nevertheless, the MAH is encouraged to investigate a higher starting dose in the future to improve the benefit of such patients. Respective data might also overall strengthen the presented pharmacology analyses.

## Exposure -response Analysis for Safety

The potential associations of exposure with selected TEAEs up to 60 days after the last dose and with the probability of experiencing TEAEs or excessive Hb increases leading to dose modifications or treatment discontinuation were explored in Week 1 to 48.

In the analysis 16 subjects in study A536-06 were considered as ' new ' subjects due to their having treatment interruption ( ≥ 84 ± 7 days) between the last dose in Study A536-04 and the first dose in Study A536-06. The MAH provided a separate exposure-safety analysis for key TEAEs excluding the 16 'new' subjects in order to show that no significant differences can be found. The analysis is appreciated

<div style=\"page-break-after: always\"></div>

but in contrast to the MAH's claim, difference are observed, e.g. regarding Bone pain/Arthralgia ≥ Grade 1, Week 1-6, but overall the results are in line. A bias can, however, not be excluded even though the MAH claims that 50% of these patients did only receive small doses and did not show a treatment effect in the first study. But neither did they experience any AEs that prevented them to enrol in the second study. This issue is however not further pursued from a pharmacological perspective.

There was no positive association between luspatercept serum exposure and the probability of experiencing serious TEAEs, TEAEs ≥ Grade 3 or selected TEAEs ≥ Grade 1 (asthenia/fatigue, dizziness, and myalgia), and TEAEs leading to dose reduction, dose interruption or treatment discontinuation.

Statistically significant associations with increased luspatercept AUCevent were observed for bone pain/arthralgia ≥ Grade 1 in Week 1 to 6 and hypertension ≥ Grade 1 in Week 1 to 48:

While the effect of bone pain/arthralgia was observed in week 1 - 6, the effect was not as pronounced in the longer observation period up to week 48 although a respective trend is also observed. Bone pain/arthralgia is also more frequently observed in the treatment arm compared to the placebo arm. This TEAE is appropriately reflected in the SmPC.

Only few hypertension events occurred in the first 6 weeks but this increased over time, especially for the highest AUCevent quartile group. In addition, hypertension occurred more frequently in the luspatercept arm than in the placebo arm and is considered treatment-related. The majority of such events occurred during the first year of treatment. Based on the data provided upon request (treatment duration approx. 168 weeks), an increased risk over time after one year of treatment is not apparent but it is apparent that most events required either dose reduction or interruption or additional medication. How this will evolve with long term treatment will be evaluated in the LTFU study in the post marketing (please see Clinical Safety and RMP sections).

Although hypertension is already included in the SmPC as common adverse reaction, the additional burden of an adverse reaction that might require another long term treatment is of concern and is considered accordingly in the benefit -risk assessment. Further, an increased risk with age was also identified as statistically associated with hypertension events, with older subjects being more likely to experience hypertension. The MAH acknowledged the increase of hypertension events after 6 weeks but considers them manageable with dose delay.

Of note, no such effect was observed in the other populations (MDS and TD β -thalassaemia) but the dose range might have been too small to allow detection of a respective exposure-response association.

The MAH claims that based on the above clinical experience, a dose reduction should be considered for patients with hypertension ≥ Grade 3, which is endorsed. Further, dose delay may be considered for lower grade hypertension. Acceptable recommendations for grade 2 events have been suggested.

## Exposure -respo nse Relationship for NTDT -PRO T/W Scores

The MAH presented two analyses to describe the potential association between the haemoglobin change and the change in NTDT-PRO T/W Domain Score: an incremental change analysis and a linear mixedeffects model.

The MAH claims that the model provided a good fit to the observed data, but this is not agreed on. Although the provided VPC-plots are missing an appropriate presentation of percentiles, it can be observed that the model does not fit the data well. The observed data seems to be included in the predicted 95% CI mainly due to the generally high variability, potentially caused by the nature of the used PRO and the limited dataset. Further, the data suggests that a linear model might not be the best model for the underlying data, but no non-linear model has been tested. Overall, the model is not considered appropriate and the respective results should be interpreted with care.

<div style=\"page-break-after: always\"></div>

The MAH claims that the presented analyses show a clear association between change in Hb and improvement in the tiredness/weakness (T/W) score. While it is acknowledged that there seems to be a trend that patients with higher change in Hb also show a more pronounced improvement in T/W scores, conclusions are prevented by the rather limited number of subjects in each category and the overall high variability of the data. Further, the data is not consistent, e.g., it has been observed that patients with no change in Hb seem to improve more while receiving placebo compared to luspatercept. Overall, the analysis is not considered reliable.

## Immun ogenicity

Treatment emergent antibodies were only detected in 3 subjects (3.1%). All three showed neutralising antibodies (all in study ACE-536-B-THAL-002; A536-04/06: 0 patients). The results are in line with the results found in the TD population. There seems to be no clear association of TEADAs with PK, efficacy or safety observations based on this study but the limited dataset prevents final conclusions. Further, in the population PK model, a potential effect of ADA was not tested as there were less than 10 ADA-positive subjects in the complete dataset (4 studies). Nevertheless, as there are stopping rules foreseen for lack of effect in section 4.2 of the SmPC, a possible loss of efficacy due to immunogenicity would not lead to prolonged and unnecessary drug exposure of affected patients.

## 2.3.7. Conclusions on clinical pharmacology

Overall, the PK parameter of NTD patients seem to be similar to TD patients.

The PD effect other than on Hb levels was not further characterised by the MAH, and some aspects concerning haematology mean values over time (nucleated reticulocytes, reticulocytes, EPO levels) cannot be entirely followed in relation to the mode of action. Please refer to the safety section for a discussion in relation with the observed adverse reaction EMH.

The presented exposure-response models for haemoglobin, efficacy and safety endpoints are overall acceptable. Although potentially manageable with dose modifications or additional medication, the occurrence of hypertension events is still considered an uncertainty in this procedure, especially for less severely affected NTDT patients.

The model concerning the PRO T/W is not considered reliable.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

Please see below, section below under the sub-header 'Supportive Studies'.

## 2.4.2. Main study

## Study ACE-536-B-THAL-002

## ACE-536-B-THAL-002: A Phase 2, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults with nontransfusion dependent beta (β) -thalassemia

Approximately 150 subjects diagnosed with NTDT, with a documented diagnosis of β -thalassemia or HbE/β -thalassemia, with or without concomitant α -globin mutation and/or duplication were planned for enrollment.

After signing the ICF, subjects entered the Screening Period for up to 4 weeks (± 3 days) for safety and other assessments (incl. Haemoglobin [Hb]) to determine subject eligibility. If a subject received transfusions during the 24 weeks prior to randomization, 24 weeks of transfusion history (including units or volume transfused and pretransfusion Hb level) was to be recorded in the electronic case report form (eCRF). If a subject received Iron chelation Therapy (ICT) during the 24 weeks prior to randomization, 24 weeks of ICT use history (including types of ICT and doses) was to be recorded in the eCRF.

The duration of study participation for each individual subject was approximately 4 weeks in the Screening Period and at least 48 weeks in the DBTP. The duration of the OLP is a maximum of 15 months, and the duration in the PTFP could be 5 years from the first dose of study drug or 3 years from the last dose of study drug (whichever occurs later) until EOS. The end of treatment for each individual subject was defined as the date of the last study drug dose in the DBTP or OLP. The EOS for each individual subject was defined as occurring after study unblinding (ie, 48 weeks after the last subject received the first dose of study drug) and the OLP or the PTFP were completed, as appropriate, or at EOS, whichever was later.

The study was unblinded after completion of the DBTP for evaluation of the primary and secondary efficacy endpoints. The OLP is ongoing as is the overarching LTFU study, where all luspatercept-treated patients can roll over to. The overall study design is presented in Figure 28.

<div style=\"page-break-after: always\"></div>

Figure 28: overall study design

<!-- image -->

BL = baseline; DBTP = Double-blind Treatment Period; DMC = data monitoring committee; EOS = end of study; Hb = hemoglobin; ICF = informed consent form; IP = investigational product; min = minimum; NTDT-PRO = nontransfusiondependent β -thalassemia patient-reported outcome; OLP = open-label phase; PTFP = Posttreatment Follow-up Period; Q3W = every 3 weeks; SC = subcutaneous.

- a The dose could be titrated up to a maximum of 1.25 mg/kg.
- b The DBTP ended after the last subject enrolled had completed 48 weeks of treatment or discontinued earlier, or when the study was unblinded.
- c The study was unblinded 48 weeks after last subject received the first dose of study drug (ie, IP). At that time, subjects still benefiting from luspatercept treatment as well as subjects who received placebo and who were assessed per protocol up to 48 weeks after the first dose of study drug (even if they discontinued the study drug before completing 48 weeks of treatment) could enter the OLP to receive luspatercept for a maximum of 15 months on the basis of DMC recommendations after unblinded data review, and could continue treatment in the rollover study after EOS up to 5 years after Dose 1 or study drug discontinuation, whichever occurs later.

d Subjects in the DBTP who discontinued luspatercept before study unblinding were to continue the PTFP until EOS, could continue the PTFP in the rollover study for up 5 years after the first dose of study drug or 3 years after the last dose (whichever occurs later), and could complete the PTFP under the rollover study. Subjects in the DBTP who discontinued placebo before study unblinding continued the PTFP until study unblinding and could access the OLP after recommendation by the DMC.

Monitoring was performed by an independent external data monitoring committee (DMC) that reviewed the unblinded safety data regularly during the course of the study in accordance with the guidelines for the pre-planned analyses.

## Methods

## Study participants

Laboratory assessments could be repeated within the screening window or initially screen-failed subjects could be rescreened using a new subject number assigned by the interactive response technology (IRT).

Relevant information about subjects classified as screen failures was to be collected on the appropriate eCRFs and in a screening log.

## Inclusion Criteria

Subjects were required to satisfy the following criteria to be enrolled into the study:

1. Subject was required to be ≥ 18 years of age at the time of signing the ICF.

<div style=\"page-break-after: always\"></div>

2. Subject was required to understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.

3. Subject was willing and able to adhere to the study visit schedule (e.g. not scheduled to receive HSCT) and other protocol requirements.

4. Subject was required to have documented diagnosis of β -thalassemia or HbE/β -thalassemia. Concomitant α -globin mutation and/or duplication were allowed.

5. Subject was required to be NTD, defined as 0 to 5 units of RBCs received during the 24-week period prior to randomization. Note: One unit defined for this entry criterion was approximately 200 to 350 mL of transfused packed RBCs.

6. Subject was required to not be on a regular transfusion program and was required to be RBC transfusion free for at least ≥ 8 weeks prior to randomization.

7. Subject was required to have mean baseline Hb of ≤ 10.0 g/dL, based on a minimum of 2 measurements ≥ 1 week apart within 4 weeks prior to randomization; Hb values within 21 days after transfusion were excluded.

8. Subject was required to have performance status: Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1.

9. A female of childbearing potential (FCBP) for this study was defined as a female who:

(1) had achieved menarche at some point; (2) had not undergone a hysterectomy or bilateral oophorectomy; or (3) had not been naturally postmenopausal (amenorrhea following cancer therapy did not rule out childbearing potential) for at least 24 consecutive months (ie, had menses at any time in the preceding 24 consecutive months). An FCBP participating in the study must: a. Have had 2 negative pregnancy tests as verified by the investigator prior to starting treatment with study drug. She was required to agree to ongoing pregnancy testing during the study and after end of treatment with the study drug. This applied even if the subject practiced true abstinence from heterosexual contact.

b. Either committed to true abstinence from heterosexual contact (which was to be reviewed on a monthly basis and source documented). If an FCBP engaged in sexual activity that may have resulted in a pregnancy, she was required to agree to use, and be able to comply with, effective contraception without interruption, 28 days prior to starting study drug, during treatment with the study drug (including dose interruptions), and for 12 weeks (approximately 5 times the mean t½ of luspatercept based on multipledose PK data) after discontinuation of study drug.

10. A male subject must: a. Have practiced true abstinence (which must have been reviewed on a monthly basis) or agreed to use a condom during sexual contact with a pregnant female or an FCBP** while participating in the study, during dose interruptions, and for at least 12 weeks (approximately 5 times the mean t½ of luspatercept based on multiple-dose PK data) following study drug discontinuation, even if he had undergone a successful vasectomy.

## Exclusion criteria

The presence of any of the following excluded a subject from enrolment:

1. Subject had any significant medical condition, laboratory abnormality, or psychiatric illness that would have prevented the subject from participating in the study.

2. Subject had any condition including the presence of laboratory abnormalities, which placed the subject at unacceptable risk if he/she were to participate in the study.

3. Subject had any condition that may have confounded the ability to interpret data from the study.

<div style=\"page-break-after: always\"></div>

4. Subject had a diagnosis of HbS/β -thalassemia or α -thalassemia (eg, HbH).

5. Subject had active hepatitis C virus (HCV) infection as demonstrated by a positive HCV-RNA test of sufficient sensitivity, or active hepatitis B virus (HBV) infection as demonstrated by the presence of hepatitis B surface antigen (HBsAg) and/or HBV-DNA positive, or known positive human immunodeficiency virus (HIV).

Note: Subjects receiving antiviral therapies were to have 2 negative HCV-RNA tests 3 months apart before ICF signature, ie, 1 test at the end of the antiviral therapy and a second test 3 months following the first test.

6. Subject had deep vein thrombosis or stroke requiring medical intervention for ≤ 24 weeks prior to randomization.

7. Subjects on chronic anticoagulant therapy were excluded unless they had stopped the treatment at least 28 days prior to randomization. Anticoagulant therapies for prophylaxis and for surgery or high-risk procedures as well as low molecular weight heparin for superficial vein thrombosis and chronic aspirin were allowed before and during the study.

8. Subject had received treatment with another investigational drug or device ≤ 28 days prior to randomization.

9. Subject had prior exposure to sotatercept (ACE-011) or luspatercept (ACE-536).

10. Subject had platelet count of &gt; 1000 x 109/L.

11. Subjects on ICT at the time of ICF signature were required to have initiated the treatment with ICT at least 24 weeks before the predicted randomization date. The ICT could be initiated at any time during treatment with the study drug and was to be used according to the label.

12. Subject had hydroxyurea and ESA treatment ≤ 24 weeks prior to randomization and no prior gene therapy.

13. Subject was pregnant or a lactating female.

14. Subject had uncontrolled hypertension. Controlled hypertension for this protocol was considered ≤ Grade 1 according to National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) version 4.0 (current active minor version).

15. Subject had major organ damage, including:

a. Liver disease with alanine aminotransferase (ALT) &gt; 3 x upper limit of normal (ULN) or history/evidence of cirrhosis, as well as presence of liver solid masses/tumor detected by ultrasound at screening.

b. Heart disease, heart failure as classified by the New York Heart Association classification 3 or higher, or significant arrhythmia requiring treatment, or recent myocardial infarction within 6 months of randomization.

c. Severe lung disease, including pulmonary fibrosis or pulmonary hypertension, ie, Grade ≥ 3 NCI CTCAE version 4.0 (current active minor version).

d. Estimated glomerular filtration rate (eGFR) &lt; 60 mL/min/1.73 m2 (per Modification of Diet in Renal Disease formula).

16. Subject had received chronic systemic glucocorticoids ≤ 12 weeks prior to randomization (physiologic replacement therapy for adrenal insufficiency was allowed).

<div style=\"page-break-after: always\"></div>

17. Subject had major surgery ≤ 12 weeks prior to randomization (subjects were required to have completely recovered from any previous surgery prior to randomization).

18. Subject had history of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product (IP; see Investigator's Brochure).

19. Subject had received immunosuppressants ≤ 28 days prior to randomization.

20. Subject had history or current malignancies (solid tumors and hematologic malignancies) unless the subject had been free of the disease (including completion of any active or adjuvant treatment for prior malignancy) for ≥ 5 years. However, subjects with the following history/concurrent conditions were allowed:

- Basal or squamous cell carcinoma of the skin
- Carcinoma in situ of the cervix
- Carcinoma in situ of the breast

- Incidental histologic finding of prostate cancer (T1a or T1b using the tumour, nodes, metastasis clinical staging system)

## Treatments

Luspatercept or placebo was administered as an SC injection to subjects by the study site staff at the study site and administration was documented in the subject's source record. Subcutaneous injections were given in the upper arm, thigh, and/or abdomen. Calculated doses requiring reconstituted volume of &gt; 1.2 mL were to be divided into 2 separate similar volume injections across 2 separate body sites using the same anatomical location but on the opposite sides of the body (left thigh and right thigh). The maximum volume per SC injection was not to exceed 1.2 mL. Rotation of injection sites was possible according to investigator's judgment, and the injections could be given in the following order as needed: (1) right upper arm; (2) left upper arm; (3) right upper thigh; and (4) left upper thigh.

In the DBTP, subjects were assigned to the study drug per 1 of the following regimens:

- Luspatercept starting dose level 1.00 mg/kg SC q3w

- Placebo SC q3w

Rationale for placebo control : Given the lack of approved and/or effective agents to address anemia or ineffective erythropoiesis in β -thalassemia, placebo plus BSC was considered an appropriate comparison treatment. The placebo treatment group was necessary for the assessment of adverse events (AEs), which could be due to potential comorbid complications associated with the disease and/or caused by study drug. A placebo comparator was also required for the assessment of HRQoL and other measures included in the secondary objectives of this study because historical control data would not provide a robust comparison.

## Dose strategy

Dose 1 Day 1 was to be scheduled within 3 days of randomization (and could occur on the same day as randomization). All subjects assigned to receive luspatercept received the starting dose of 1.00 mg/kg SC q3w. Mean increases in Hb not influenced by a transfusion (ie, Hb ≥ 21 days after transfusion) were to be considered when determining dose escalation, dose reduction, dose delay, and study drug discontinuation. Dose levels available for titration are shown in Table 28.

<div style=\"page-break-after: always\"></div>

Table 28: Starting Dose Level With Dose Titrations

| Third Dose Reduction (~25%)   | Second Dose Reduction (~25%)   | First Dose Reduction (~25%)   | Starting Dose Level   | First Dose Increase   |
|-------------------------------|--------------------------------|-------------------------------|-----------------------|-----------------------|
| 0.45 mg/kg                    | 0.60 mg/kg                     | 0.80 mg/kg                    | 1.00 mg/kg            | 1.25 mg/kg            |

## Dose Escalation

Luspatercept dose escalation was permitted up to 1.25 mg/kg during the DBTP and OLP. The dose escalation criteria were defined as follows:

- Dose escalation was permitted if, at a constant dose level, the increase of mean Hb (uninfluenced by transfusions, ie, &gt; 21 days after transfusion) over 2 cycles (6 weeks) was &lt; 1.0 g/dL, compared with the baseline Hb value (mean of 2 values 1 week apart within 4 weeks of randomization).
- Dose escalation was permitted if, at a constant dose level, the increase of mean Hb (uninfluenced by transfusions, ie, &gt; 21 days after transfusion) over 2 cycles (6 weeks) was ≥ 1.0 but &lt; 2.0 g/dL compared with the baseline Hb value (mean of 2 values 1 week apart within 4 weeks of randomization).

The starting dose with dose reductions and escalations are presented in Table 28. Subjects who had dose reductions due to any treatment-related (ie, related to the study drug) Grade ≥ 3 AE, as indicated in Table 29, were not permitted to have dose escalations during the DBTP. However, if requested by the investigator, a dose increase to the next higher dose level was possible with sponsor's permission after safety and efficacy data review.

Placebo for use in the study was sterile normal saline (0.9% sodium chloride for injection) administered as an SC injection. Designated individuals prepared the placebo syringes to match the active syringes. All study staff, except unblinded pharmacists and designated personnel were blinded. The manufacturer's directions for placebo storage and handling were to be followed, as were standard clinical practices for ensuring sterility of the placebo.

In the OLP, subjects previously randomized to receive placebo were to be assigned to receive luspatercept (starting dose level 1.00 mg/kg q3w) and subjects previously randomized to luspatercept were to continue on their last assigned dose.

## Dose Reduction and Dose Delay

Dose reduction and/or dose delay was possible based on the change in mean Hb level (Hb not influenced by a transfusion) and/or based on the experience of AEs. Details of dose modification requirements are provided in Table 29.

If a subject had a dose delay due to Hb increase, Hb measurement was to be performed every week.

If the dose delay was &gt; 15 weeks from the last dose administered, including cases of elective surgery/hospitalization, treatment with the study drug was to be discontinued.

The following assessments were to be performed during the dose delay period:

- All planned Day 1 assessments were to be performed (Table 29) and appropriate samples were to be sent to the central laboratory, regardless of the reason for the dose delay.
- If the dose delay was due to increased Hb (Table 28), heamatology assessments were to be performed on Day 1 of the dose delay by the central and local laboratory and at least weekly thereafter by the local

<div style=\"page-break-after: always\"></div>

laboratory until the subject met either the study drug administration criteria or the study drug discontinuation criteria.

If dose delay was due to AE or laboratory or vital signs abnormality (Table 29), any clinically indicated assessment was to be repeated by the local laboratory at a frequency decided by the investigator until the subject met either the study drug administration criteria or the study drug discontinuation criteria.

- Samples for PK and ADA assessments were to be performed on Day 1 of the dose delay and before the next dose (if applicable).
- At the time of study drug administration after a dose delay, the scheduled dosing visit assessments were to be performed, regardless of the duration of the dose delay.

Table 29: Dose Delay, Dose Reduction, and Study Drug Discontinuation Guidelines

| Event at the Day of Dosing                                                                                                                                                                                                                        | Action                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Any related AE = Grade 2 a                                                                                                                                                                                                                        | Dose was to be delayed b until resolved to < Grade 1 or baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Any related AE Grade ≥ 3a                                                                                                                                                                                                                         | Dose was to be delayed b until resolved to < Grade 1 or baseline, and then dose was to be reduced to the next lower dose level indicated in Table 28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| > 2 dose reductions due to related AEa                                                                                                                                                                                                            | Study drug was to be discontinued c                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| ΔHb ≥ 2.0 g/ compared to the Hb on Day 1 of the previous dose d                                                                                                                                                                                   | Dose was to be reduced to the next lower dose level indicated in Table 28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Hb ≥ 11.5 g/dLd                                                                                                                                                                                                                                   | Dose was to be delayed d until Hb ≤ 11.0 g/dL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Decrease of > 2.0 g/dL Hb from baseline Hb (uninfluenced by transfusion)d or subject became regularly transfused in combination with an unexplained shift from baseline (worsening) of ≥ 2 grades in leukopenia, neutropenia, or thrombocytopenia | Dose was to be delayed d and WBC, neutrophils, and platelets repeated weekly for 2 consecutive weeks If WBC, neutrophils, and platelets resolved to Grade ≤ 1 or baseline, dosing was to be continued at the same dose level If WBC, neutrophils, and platelets were Grade 2 and above baseline, then dose delay was to be continued until resolution to Grade ≤ 1 and subject was evaluated for alternative explanations of cytopenia as per standard clinical practice If shift (worsening) of ≥ 2 grades was maintained for ≥ 14 days, or thrombocytopenia did not improve to Grade < 2 within 14 days, and no alternative explanation was identified, then bone marrow assessment was to be performed: - If hematologic malignancy was confirmed, study drug was to be discontinued c - If hematologic malignancy was not confirmed, then future dosing was to be discussed with the medical monitor |

<div style=\"page-break-after: always\"></div>

| WBC count f ≥ 2 x baseline in the absence of an associated condition (eg, infection or concomitant corticosteroid use)   | Subject could be dosed; WBC count was to be repeated weekly: - If repeat WBC remained ≥ 2 x baseline, the investigator was to assess the cause of increase to exclude malignancy as per standard clinical practice - If hematologic malignancy was confirmed, study drug was to be discontinued c                                                                                                                                                                                                                                                                                                                                                   |
|--------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WBC count f ≥ 3 x baseline                                                                                               | Dose was to be delayed b until WBC count < 3 x baseline, WBC count was to be repeated weekly: - The investigator was to assess the cause of the increase per standard clinical practice to exclude malignancy - If hematologic malignancy was confirmed, study drug was to be discontinued c                                                                                                                                                                                                                                                                                                                                                        |
| Grade ≥ 3 leukopenia, neutropenia, and/or thrombocytopenia g                                                             | Dose was to be delayed d and assessment repeated weekly for 2 consecutive weeks The investigator was to assess the cause of cytopenia per standard clinical practice to exclude hematologic malignancy If WBC, neutrophils, and platelets resolved to Grade ≤ 1, dosing was to be continued at the same dose level If WBC, neutrophils, and platelets Grade ≥ 2 and above baseline were sustained for ≥ 14 days, bone marrow assessment was to be performed If hematologic malignancy was confirmed, study drug was to be discontinued c If hematologic malignancy was not confirmed, then future dosing was to be discussed with a medical monitor |
| Grade 3 leukocytosis h                                                                                                   | Study drug was to be discontinued c                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

ΔHb = Hb change from baseline; AE = adverse event; CTCAE = Common Terminology Criteria for Adverse

Events; DBTP = Double-blind Treatment Period; Hb = hemoglobin; LLN = lower limit of normal; OLP = Open-label Phase; WBC = white blood cell.

a Possibly, probably, or definitely related.

b If dose delay was &gt; 15 consecutive weeks, study drug was to be discontinued.

c Additional study drug discontinuation criteria are in Section 9.3.3.1.

d Based on the predose Hb value not influenced by transfusion (ie, &gt; 21 days after transfusion); Hb was to be rechecked weekly during dose delay.

e Per CTCAE: Grade 1 leukopenia: &lt; LLN to 3000/mm3; Grade 1 neutropenia: &lt; LLN to 1500/mm3; Grade 1 thrombocytopenia: &lt; LLN to 75,000/mm3; Grade 2 leukopenia: &lt; 3000 to 2000/mm3; Grade 2 neutropenia: 1500 to 1000/mm3; Grade 2 thrombocytopenia: &lt; 75,000 to 50,000/mm3.

<div style=\"page-break-after: always\"></div>

## Study Drug Administration Criteria

On dosing days, administration of the study drug at the same dose level could occur if the following criteria were met:

1. Predose Hb, measured on the dosing day (or the day before dosing) by local laboratory, was &lt; 11.5 g/dL. If the predose Hb level was ≥ 11.5 g/dL, study sites were to check if the subject was transfused within 21 days prior to current dose and review the pretransfusion Hb. If this was &lt; 11.5 g/dL, the subject could be dosed, otherwise the dose was to be delayed. If this occurred at Dose 1, the dose was to be delayed until Hb level was &lt; 11.5 g/dL. If this occurred at subsequent doses, the dose was to be delayed until Hb level was ≤ 11.0 g/dL.

2. Increase in Hb level of &lt; 2.0 g/dL compared with the Hb level on Day 1 of previous dose.
3. Absence of treatment-related AE of Grade ≥ 2 severity according to NCI CTCAE criteria on dosing day.
4. Predose white blood cell (WBC) count (corrected by erythroblast count) &lt; 3 x baseline and absence of Grade 3 leukocytosis on dosing day.

5. Leukopenia, neutropenia, and/or thrombocytopenia were Grade &lt; 3 per NCI CTCAE criteria.

6. No decrease of &gt; 2.0 g/dL Hb level from baseline (uninfluenced by transfusion); or subject became regularly transfused in combination with an unexplained shift from baseline (worsening) by ≥ 2 grades in leukopenia, neutropenia, or thrombocytopenia (Table 29).

Best supportive care (BSC) was permitted in both the luspatercept and placebo treatment groups during the DBTP and OLP, including RBC transfusions, ICT, treatments for anemia, antibiotic therapy, antiviral and antifungal therapy, and nutritional support as needed. Treatment with hydroxyurea would lead to treatment discontinuation.

Concurrent therapy with a new prescription medication related to the treatment of anemia during the course of the study required discussion with the sponsor medical monitor or delegate prior to administration, unless the medication needed to begin before the medical monitor could be consulted, as medically indicated. If treatment with hydroxyurea was required during the DBTP, the subject was to be discontinued from treatment with the study drug and entered into the PTFP.

The use of ICT starting from at least 24 weeks prior to Dose 1 Day 1 was to be recorded in the eCRF. Concurrent treatment with ICT was to be used per the product label and investigator practice.

Initiation of anticoagulant therapies and platelet aggregation inhibitors was permitted during the treatment periods only if their use was not due to an AE considered related to the study drug that would lead to dose delay (Table 29). Anticoagulant therapies (for prophylaxis and for surgery or high-risk procedures) and low molecular weight heparin (for superficial vein thrombosis), and chronic and prophylactic aspirin were allowed before and during the study.

## Red blood cell transfusions and transfusion rules

Concurrent treatment for anemia with blood transfusions was allowed, at the discretion of the investigator, for low Hb levels, symptoms associated with anemia (eg, hemodynamic or pulmonary compromise requiring treatment), or comorbidities.

For any RBC transfusions received during the study, information to be collected included Hb values just prior to transfusion, the number of units transfused, and the dates of transfusion. If available, the volume transfused in mL at each transfusion and the hematocrit of the transfused unit were to be collected.

Prohibited medications were any other investigational agents as well as Hydroxyurea, ESAs, and anagrelide during the treatment periods.

<div style=\"page-break-after: always\"></div>

## Objectives

The primary objective is to evaluate the effect of luspatercept versus placebo on anemia, as measured by mean haemoglobin concentration in the absence of transfusions over continuous 12- week intervals, from Week 13 to Week 24 , compared to baseline, as compared to placebo.

The main secondary objectives for efficacy are:

- To evaluate the effect of luspatercept versus placebo on β -thalassemia-related symptoms, as measured by non-transfusiondependent β -thalassemia patient-reported outcome ( NTDT-PRO ) over continuous 12-week intervals (Weeks 13 to 24, Weeks 37 to 48) compared to baseline
- To evaluate the effect of luspatercept versus placebo on functional and health-related quality of life (QoL) as measured by Medical Outcomes Study 36-Item Short Form ( SF-36 ) and Functional Assessment of Chronic Illness Therapy-Fatigue ( FACIT-F ) questionnaires
- To evaluate the long-term effect of luspatercept versus placebo on anemia, as measured by mean haemoglobin concentration in the absence of transfusions over a continuous 12-week interval from Week 37 to Week 48 , compared to baseline
- To evaluate the effect of luspatercept versus placebo on iron overload, as measured by liver iron concentration ( LIC ), iron chelation therapy ( ICT ) daily dose and serum ferritin
- To evaluate the duration of erythroid response
- To evaluate the effect of luspatercept versus placebo on physical activity measured by 6-minute walk ( 6MWT )

## Outcomes/endpoints

Table 30: Study endpoints (primary/secondary efficacy endpoints)

| Endpoint                  | Name                                                                                                                                                                               | Description                                                                                                                                                                                                                                                                                                                              | Timepoint of Measurement   | Timepoint of Measurement   |
|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|----------------------------|
|                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                          | Week 24                    | Week 48                    |
| Primary Efficacy Endpoint | Proportion of subjects who had an increase from baseline ≥ 1.0 g/dL in mean of Hb values over a continuous 12-week interval from Week 13 to Week 24 in the absence of transfusions | Baseline Hb was the average of 2 or more Hb measurements at least 1 week apart within 4 weeks prior to Dose 1 ( before randomisation? ) Central laboratory Hb results were used for determination of the primary and secondary efficacy endpoints that were based on Hb. Because Hb values from samples collected within 21 days after a | x                          |                            |

<div style=\"page-break-after: always\"></div>

|                                 |                                                                                                                                                                                    | transfusion may be influenced by the transfusion, such results were excluded from analyses. Hb was derived as the sum of results over 12 weeks divided by the number of assessments. The mean over 12 weeks was used to derive the mean change from baseline for each subject   |    |    |
|---------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|----|
| Key Secondary Efficacy Endpoint | Mean change from baseline in NTDT-PRO T/W domain score over a vontinuous 12-week interval from Week 13 to Week 24                                                                  | The NTDT-PRO was administered as a daily diary for 24 weeks and after that over the 7 days prior to receiving study drug dose                                                                                                                                                   | x  |    |
| Key Secondary Efficacy Endpoint | Mean change from baseline in mean of Hb values over a continuous 12-week interval from Week 13 to Week 24 in the absence of transfusions                                           | See description above for baseline Hb                                                                                                                                                                                                                                           | x  |    |
| Key Secondary Efficacy Endpoint | Proportion of subjects who had an increase from baseline ≥ 1.0 g/dL in mean of Hb values over a continuous 12-week interval from Week 37 to Week 48 in the absence of transfusions | See description above for baseline Hb                                                                                                                                                                                                                                           |    | x  |
| Secondary Efficacy Endpoint     | Mean change from baseline in mean FACIT-F Fatigue subscale score over a continuous 12-week interval from Week 13 to Week 24                                                        | The FACIT-F Fatigue subscale was administered to subjects every other dose prior to receiving study drug dose                                                                                                                                                                   | x  |    |
| Secondary Efficacy Endpoint     | Mean change from baseline in mean NTDT-PRO SoB domain score over a continuous 12-week interval from Week 13 to Week 24                                                             | See description above for NTDT-PRO                                                                                                                                                                                                                                              | x  |    |
| Secondary Efficacy Endpoint     | Mean change from baseline in mean Hb values over a continuous 12-week interval from Week 37 to Week 48 in the absence of transfusions                                              | See description above for baseline Hb                                                                                                                                                                                                                                           |    | x  |
| Secondary Efficacy Endpoint     | Mean change from baseline in mean FACIT-F Fatigue subscale, mean NTDT-PRO T/W domain,                                                                                              | See descriptions above for FACIT-F Fatigue subscale and NTDT-PRO                                                                                                                                                                                                                |    | x  |

<div style=\"page-break-after: always\"></div>

| and mean NTDT-PRO SoB domain scores over a continuous 12-week interval from Week 37 to Week 48                                                                                                                                                                                                                                                                                                               |                                                                                                                                 |    |    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|----|----|
| Proportion of subjects with an increase from baseline ≥ 3 in mean FACIT-F Fatigue subscale score over a continuous 12-week interval from Week 13 to Week 24                                                                                                                                                                                                                                                  | See description above for FACIT-F Fatigue subscale                                                                              | x  |    |
| Proportion of subjects with an increase from baseline ≥ 3 in mean FACIT-F Fatigue subscale score over a continuous 12-week interval from Week 37 to Week 48                                                                                                                                                                                                                                                  | See description above for FACIT-F Fatigue subscale                                                                              |    | x  |
| Mean change from baseline in the PCS and MCS scores of the SF-36 at Week 24 and Week 48                                                                                                                                                                                                                                                                                                                      | The SF-36 was administered to subjects every other dose prior to receiving study drug dose                                      | x  | x  |
| Proportion of subjects with improvement of iron overload at Week 24 and Week 48, as measured by: - For subjects with baseline (LIC) (by MRI) ≥ 3 mg/g dw: ≥ 20% reduction in LIC or ≥ 33% decrease in ICT daily dose - For subjects with baseline LIC (by MRI) < 3 mg/g dw: no increase in LIC > 1 mg/g dw and not starting treatment with ICT or no increase in ICT daily dose ≥ 33%, if on ICT at baseline | Baseline ICT dose was based on medical history over 24 weeks prior to randomization; ICT drug and dose collected at every visit | x  | x  |
| Mean change from baseline in serum ferritin at Week 24, Week 48, and up to last assessment                                                                                                                                                                                                                                                                                                                   | All values available in the medical history over 24 weeks prior to randomization were entered in the eCRF                       | x  | x  |

<div style=\"page-break-after: always\"></div>

| Mean change from baseline in LIC at Week 24, Week 48, and up to last assessment                                                                                                    | Using LIC at screening, Week 24, Week 48, and in the OLP, as applicable                                                                                                    | x   | x   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|
| Proportion of subjects who were transfusion free over 24 weeks                                                                                                                     | Occurrence of transfusions was assessed at every visit                                                                                                                     | x   |     |
| Proportion of subjects who were transfusion free over 48 weeks                                                                                                                     | See description above                                                                                                                                                      |     | x   |
| Duration of the mean Hb increase from baseline ≥ 1.0 g/dL                                                                                                                          | Time from first to last Hb measurement with increase from baseline ≥ 1.0 g/dL                                                                                              | x   | x   |
| Mean change from baseline in the 6MWT distance at Week 24 and Week 48                                                                                                              | The 6MWT was performed every 4 doses (Dose 1, 5, 9, and so on) and at Week 24 and Week 48 (± 7 days), regardless of dose delay and even if the study drug was discontinued | x   | x   |
| Proportion of subjects who had an increase from baseline ≥ 1.5 g/dL in mean of Hb values over a continuous 12-week interval from Week 13 to Week 24 in the absence of transfusions | See description above for baseline Hb                                                                                                                                      | x   |     |
| Proportion of subjects with a decrease from baseline ≥ RD in mean NTDT-PRO T/W domain score, over Week 13 to Week 24 and Week 37 to Week 48                                        | The NTDT-PRO was administered as a daily diary for 24 weeks and after that over the 7 days prior to receiving study drug dose                                              | x   | x   |

## Rationale for efficacy endpoints

The primary efficacy endpoint was based on Hb levels because correcting anemia and reducing the need for RBC transfusions are unmet needs in the treatment of NTDT. The endpoint was defined as the proportion of subjects who had an increase in Hb from baseline of ≥ 1.0 g/dL over 12 weeks because a mean increase in Hb of ≥ 1.0 g/dL is expected to result in a clinically meaningful reduction in associated symptoms and risks of complications (Taher, 2015b). This degree of response was demonstrated in Study A536-04 to be unlikely to occur by chance: a sustained Hb increase of ≥ 1.0 g/dL over a 12-week period was not observed with subtherapeutic luspatercept dose levels of 0.20 to 0.40 mg/kg, whereas it was achieved at therapeutic dose levels of 0.60 to 1.25 mg/kg. This endpoint is also consistent with current guidelines, which recommend response evaluations after 3 and 6 months of therapy, with response defined as an increase of ≥ 1.0 g/dL at 6 months (Taher, 2013).

<div style=\"page-break-after: always\"></div>

The secondary efficacy endpoints included NTDT-PRO, FACIT-F Fatigue subscale, and Medical Outcomes Study 36-item Short Form Health Survey (SF-36; version 2.0) assessments to allow evaluation of the further clinical relevance of treatment with luspatercept in addressing the fatigue, weakness, shortness of breath (SoB), and other symptoms influencing HRQoL that are associated with chronic anemia in adults with β -thalassemia. Iron overload, use of ICT, and the presence of osteoporosis or osteopenia were also assessed as secondary endpoints because these are additional complications stemming from ineffective erythropoiesis. The 6-minute walk test (6MWT) was also included to provide an objective assessment of functional exercise capacity and thus evaluate whether increased Hb levels were associated with increased walk distances, which were also expected to correlate with improvements in HRQoL (Musallam, 2021b).

## Sample size

Based on the assumption of a targeted primary endpoint response rate of at least 50.0% in the luspatercept treatment group and 10.0% in the placebo treatment group and based on a 2:1 randomization, a total sample size of 150 subjects (100 subjects in the luspatercept treatment group and 50 subjects in the placebo treatment group) was expected to have at least 99% power to detect the difference between the 2 treatment groups with a 2sided α -level of 0.05 with an assumed 10.0% dropout rate.

For NTDT-PRO T/W domain scores, the mean changes from baseline scores at Week 24 were assumed to be 1.2 and 0.5 for the luspatercept and placebo treatment groups, respectively, with a common standard deviation (SD) of 1.2. The statistical power to detect the difference was expected to be 91%.

## Randomisation

Study drug assignment (randomization) occurred at the end of the Screening Period, after all the required screening procedures had been completed and all required data had been submitted to the sponsor or its authorised representative. Upon receiving acknowledgment of subject eligibility from the sponsor or its authorised representative, the subject was assigned the study drug using the IRT.

The IRT was used to ensure an equal weight central randomization based on block randomization method according to stratification factors. The IRT used a randomization algorithm to associate the subject identification number with a randomization number and placed each subject in the next available slot within the appropriate stratum for that subject based on the stratification factors.

Designated research personnel at each study site were assigned password-protected, coded identification numbers to allow them to access the IRT to enrol subjects. For study drug assignment at the start of each dose and in the event of any dose reduction or dose escalation, study site staff were required to contact the IRT to record the new dose level and obtain the new study drug assignment.

The following stratification factors were chosen:

- Baseline Hb level (&lt; 8.5 or ≥ 8.5 g/dL)
- NTDT patient-reported outcome (PRO; NTDT-PRO) Tiredness/Weakness (T/W) domain score (score ≥ 3 or &lt; 3)

<div style=\"page-break-after: always\"></div>

## Rationale:

The baseline Hb category was used as a randomization stratification factor because Hb response is likely to be influenced by the degree of anemia at baseline. Previous Phase 2 studies have shown that response rates (mean Hb increase of ≥ 1.0 g/dL at 12 weeks) among subjects with NTDT treated with luspatercept ≥ 0.8 mg/kg were higher for subjects having a baseline Hb of &lt; 8.5 g/dL compared with subjects having a baseline Hb of ≥ 8.5 g/dL.

The threshold of ≥ 3 on the T/W domain of the NTDT-PRO to define symptomatic subjects was based on Phase 2 study results that demonstrated an association of improvement in symptoms, particularly T/W, with erythroid response . Tiredness and weakness can thus be used as a key secondary endpoint to support the primary efficacy endpoint of increase in Hb and a clinically meaningful benefit with luspatercept treatment. The appropriateness of the 3-point cut-off used in this study to categorise subjects as asymptomatic or symptomatic for randomization stratification is supported by the following data and analyses:

- The determination of this threshold involved estimating a population norm for the T/W domain score and then using this base rate estimate to define symptomatic patients. Because population norms are not available for the NTDT-PRO, population norms for the Functional Assessment of Chronic Illness Therapy -Fatigue (FACIT -F) Fatigue subscale were used . A linear regression analysis of Phase 2 data (Study A53606) showed a correlation of -0.77 between the FACIT-F Fatigue subscale and NTDT-PRO T/W domain score, and the regression equation indicated that the T/W domain score decreased by 0.2 points for every 1 unit increase in the FACIT-F. The base rate estimate for the general population on the FACIT -F Fatigue subscale of 44.2 (on a scale from 0 to 52; Cella, 2002) corresponded with a score on the NTDT -PRO of 2.5 (on a scale from 0 to 10). Based on this analysis, a T/W domain score of ≥ 3 at screening was considered to be indicative of a subject with symptomatic NTDT. In analyses using Phase 2 (Study A536-06) data for the FACIT-F Fatigue subscale and available NTDT-PRO T/W domain scores, subjects who had baseline T/W domain scores of &lt; 3 did not have meaningful decreases in symptom severity (defined as a decrease of ≥ 1 unit on the T/W domain score), regardless of their Hb response, suggesting a low likelihood of observing symptom improvement in subjects with baseline scores of &lt; 3 .

- A confirmation of the threshold was completed using data from the present study (ACE-536-B-THAL002). A receiver operating characteristic analysis using the FACIT-F Fatigue subscale cutoff of 43, which best divides anemic cancer patients and the general population (Cella, 2002) was performed, and an optimal cutoff of 3.04 on the NTDT-PRO T/W domain score was identified based on the cutoff value corresponding to the maximum Youden index. The area under the concentration-time curve (AUC) was 0.83 (95% confidence interval [CI]: 0.80, 0.86), indicating a good discriminant power (Bekkar, 2013). This cutoff yielded 73.0% sensitivity and 76.0% specificity, and 74.0% of subjects were correctly classified.

## Blinding (masking)

When properly mixed, Reblozyl reconstituted solution is a colourless to slightly yellow, clear to slightly opalescent solution which is free of visible foreign particulate matter.

All subjects, study site staff, and sponsor representatives, with the exception of designated individuals (e.g., the pharmacist at the investigational site), were to remain blinded to all study drug assignments until all subjects enrolled in the study had completed 48 weeks of double-blind treatment or had

<div style=\"page-break-after: always\"></div>

discontinued before reaching 48 weeks of double-blind treatment, whichever was the earlier date, or at the time the study was unblinded (per DMC recommendation) and the database was locked.

The designated site individual (eg, the pharmacist) at the study site was to use a syringe (that exactly matched the syringe used for reconstituted luspatercept) and sterile normal saline (0.9% sodium chloride for injection) to prepare a matching placebo. Thus, the designated site individual at the study site was unblinded and gave investigators and study site staff luspatercept and placebo syringes in a blinded manner.

The blind was not to be broken during the course of the study unless, in the opinion of the investigator, unblinding was absolutely necessary to safely treat the subject. If it was medically imperative to know what study drug a subject was receiving, and/or if, in the opinion of the investigator, continuing study drug could negatively affect the outcome of the subject's treatment, study drug was to be temporarily discontinued.

The decision to break the blind in emergency situations remained the responsibility of the investigator and was not to be delayed or refused by the sponsor. However, the investigator had the option to contact the medical monitor prior to breaking the blind to discuss unblinding, mainly in the interest of the subject.

The investigator was to ensure that the code was broken only in accordance with the protocol.

The investigator was to promptly notify the medical monitor of the emergency unblinding and the reason for breaking the blind, which was to be clearly documented by the investigator in the subject's source documentation. Emergency unblinding was to only be performed by the investigator through the IRT.

## Statistical methods

All efficacy evaluations were conducted using the ITT population, except for FACIT-F Fatigue Subscale and SF-36 analyses, which were conducted based on the HRQoL evaluable population. The NTDT-PRO T/W and SoB domain scores were analysed by both ITT and HRQoL evaluable populations. The primary and key secondary efficacy endpoints were also analysed based on the PP population as a sensitivity analysis.

Some continuous variables like Hb and weekly NTDT-PRO T/W and SoB domain scores were derived as the sum of results over 12 weeks divided by the number of assessments. The mean over 12 weeks was used to derive the mean change from baseline for each subject.

The efficacy cut-off date was defined as the minimum date among death date, study discontinuation date, last dose date + 20, and data cut-off date. For the primary and responder-related secondary efficacy endpoints, if at the time of data summary, a subject's efficacy cut-off date was before the end of the 12week interval or a subject had any invalid Hb records (i.e., within 21 days following a transfusion) during the specified 12-week interval, this subject was included in the analysis and his/her responder status was classified in accordance with the definition of erythroid response (i.e., as responder when they had an increase from baseline of ≥ 1.0 g/dL in the mean of Hb va lues over a predefined continuous 12-week interval in the absence of transfusions; otherwise they were classified as non-responder). For other efficacy endpoints, if a subject's efficacy cut-off date was before the end of the 12-week interval, the subject was included in the analyses.

In order to assess the robustness of the findings of the primary and key secondary analyses of Hb response and change from baseline, missing values for binary responder/non-responder values were imputed using the non-responder imputation method and for continuous values, the complete case analysis. The supportive/sensitivity analyses uses for binary Hb outcomes the complete case analysis,

<div style=\"page-break-after: always\"></div>

which excluded all subjects with missing data. A tipping point analysis was also used, in which the missing data from all responder statuses were turned to all non-responder statuses, one-by-one, to find the tipping point value. For continuous values the supportive/sensitivity analysis used postbaseline mean imputation, baseline imputation, or multiple imputation methods.

Regarding missing continuous and categorical assessments for the HRQoL, the complete case analysis was used for the Week 13 to Week 24 analysis. For the key secondary efficacy endpoint (NTDT-PRO T/W domain score at Week 13 to Week 24), the supportive/sensitivity analysis used the postbaseline mean imputation, the baseline imputation, or multiple imputation methods to assess the robustness of the primary result.

To assess the extent of missing data at each assessment visit by treatment group, compliance rates for the NTDT-PRO, FACIT-F, and SF-36 assessments at each scheduled visit were provided. The compliance rate for the NTDT at each visit was defined as the number of subjects with at least half of 6 weekly item scores for that week being non missing (ie, ≥ 3 items) divided by the number of subjects in the ITT population who were still expected to provide a PRO assessment at that time point. Compliance rates for FACIT-F and SF-36 were defined as the number of subjects with at least 80.0% of the 40 items (ie, ≥ 32 items) and at least 50.0% of the 36 items (ie, ≥ 18 items), respectively.

Statistical comparisons were made between the luspatercept and placebo treatment groups. All statistical tests were 2-sided at the significance lev el of α = 0.05, and the corresponding p -values and 2-sided CIs for point estimates were reported, unless specified otherwise.

In general, descriptive statistics were provided and statistical tests were applied if appropriate. For continuous variables, least squares (LS) means with corresponding standard errors (SEs) for each treatment group, along with LS mean of treatment difference (luspatercept versus placebo) with corresponding 95% CI and p-value were presented for analysis of covariance (ANCOVA).

Counts and percentages were used to describe categorical variables, and the treatment comparisons were analysed analogous to the primary endpoints using the Cochran-Mantel-Haenszel (CMH) model stratified by baseline Hb category and baseline NTDT-PRO T/W domain score category (randomization stratification factors). The odds ratio (OR; luspatercept versus placebo) with corresponding 2sided (at 0.05 α -level) 95% CI and p-value were provided. The difference in proportions (luspatercept - placebo) and 95% CI were calculated. A forest plot showing the ORs, 95% CIs, and p-values for the overall result and the results in each subgroup was constructed for the primary and key secondary efficacy endpoints. For all endpoints mentioned in this section, records beyond Week 48 were not used unless otherwise specified. If ANCOVA was used, the statistical assumption was validated first, and logarithmic transformations were applied as needed.

To control the overall Type 1 error rate for the 3 key secondary efficacy endpoints, the testing procedure was implemented strictly in order: the test for key secondary efficacy endpoint 1 was only conducted if there was evidence showing that erythroid response was achieved in the luspatercept treatment group from Week 13 to Week 24 (primary efficacy endpoint). The key secondary efficacy endpoint 2 was to be tested only if the test results for both the primary efficacy endpoint and key secondary efficacy endpoint 1 were significant. The key secondary efficacy endpoint 3 was to be tested only if the test results for the primary efficacy endpoint and the key secondary efficacy endpoints 1 and 2 were all significant.

The ongoing pivotal Phase 2 study (Study ACE-536-B-THAL-002) is using a 14 Sep 2020 data cut- off date for the primary analysis of efficacy and safety data. Updated data from a new cut-off date (15 Mar 2021) were additionally provided. This included the results from additional post-hoc analyses showing longer follow up of red blood cell (RBC) transfusion and serum ferritin data (using a 15 Mar 2021 data cut-off date instead of 14 Sep 2020), as well as the results from the prespecified exploratory endpoint of the non transfusiondependent (NTD) β -thalassemia severity score. Data from subjects initially

<div style=\"page-break-after: always\"></div>

randomized to luspatercept included all data up to the data cut-off date of 15 Mar 2021, whereas data from subjects initially randomized to placebo included data only up to the crossover to luspatercept treatment (ie, only while the subjects were receiving placebo). Therefore, as of the 15 Mar 2021 data cutoff date, the median treatment duration was longer in the luspatercept treatment group compared with the placebo treatment group.

## Generation/Validation of the NTDT-PRO tool

## Choice of PRO

The NTDT-PRO was developed to assess the key symptoms relevant to patients with NTDT. Although generic healthstatus measures had been used with β -thalassemia patients (e.g., Medical Outcomes Study 36-Item Short Form Version 2 [SF-36v2®]), it was determined that the generic health measures were not fit-for-purpose (i.e., the level of validation associated with the existing tools was not sufficient to support their use amongst NTDT patients).

## Content Validity

The Sponsors initially hypothesized a conceptual framework to support the measurement drafting domains and items to be measured based on literature review and expert opinion. Subsequently, conceptual interviews, interview discussions, cognitive interviews and clinical input ensured understanding and completeness of the concepts contained in the items.

## Final NTDT-PRO questionnaire

The resulting item pool was combined to the final version of the NTDT-PRO that comprises a six-item questionnaire tallied to create a T/W score and a Shortness of Breath (SoB) score. The T/W score is an average of responses from four items that assess β -thalassemia related tiredness at rest and upon physical activity and weakness at rest and upon physical activity. To answer the items a 11-point numeric response scale ranging from 0 ('No') to 10 ('Extreme') was provided.

The 6 items are as follows:

- Tiredness (lack of energy) when not doing physical activity (TiredNA)
- Tiredness (lack of energy) when doing physical activity (TiredPA)
- Weakness (lack of strength) when not doing physical activity (WeakNA)
- Weakness (lack of strength) when doing physical activity (WeakPA)
- Shortness of breath (SoB) when not doing physical activity (SobNA)
- Shortness of breath when doing physical activity (SobPA)

It was designed as a daily electronic diary (eDiary) with recall of thalassemia-related symptoms during the past 24 hours to accommodate the high degree of day-to -day variation in NTDT symptoms.

Item scores were summarized as the average over 7day periods. If entries were missing for ≥ 4 days in any week, the average weekly score was declared as missing. Otherwise the mean of the non-missing values was taken. For the subjects with missing average interval scores at Week 13-24 or Week 37-48 during the ACE-536-B-THAL-002 clinical trial, the 4-day rule of weekly NTDT-PRO T/W scores was relaxed to include all available daily scores, including those weeks with only one daily score available. The 4-day rule for deriving weekly item scores, however, was not relaxed for this psychometric analysis.

No item-wise missing data were expected for the eDiary, because of the application logic. Items were grouped according to the following 2 domains, defined a priori:i) tiredness/weakness (T/W; TiredNA, TiredPA, WeakNA, WeakPA) and ii) SoB (SobNA, SobPA).

<div style=\"page-break-after: always\"></div>

For each domain, scores were calculated as the average of the scores of items in the domain. The average of non-missing weekly item scores for each domain will be calculated if ≥ 50% of the items are not missing (i.e., ≥ 2 items for the T/W and ≥ 1 items for the SoB domain) and regarding T/W domain at least one weekly item score for tiredness (i.e., TiredNA or TiredPA) and one weekly item score for weakness (i.e., WeakNA or WeakPA) are not missing; otherwise, the weekly T/W or SoB score will be set to missing.

## Validation of NTDT-PRO

The measurement properties of NTDT-PRO were evaluated in the observational study ACE536 -BTHAL -003 .

This was a multisite, prospective, observational study implemented in β -thalassemia treatment centers from 4 countries (Italy, Greece, Lebanon, and Thailand).

The primary objective of this study was to document the burden of illness (defined as impairment of HRQoL and impact on HRU) in subjects with β -thalassemia who were TD or NTD and receiving SoC. Secondary objectives included the preliminary evaluation of the psychometric properties of the newly developed NTDT-PRO, documentation of the baseline and longitudinal variance in HRQoL across subjects with β -thalassemia who were TD or NTD, and documentation of baseline and longitudinal HRU in subjects with β -thalassemia who were TD or NTD.

In addition, an exploratory objective was to measure physical activity levels in subjects with β -thalassemia who were TD or NTD, recorded using commercial Fitbit devices, and to correlate the physical activities with PROs/HRQoL and timing of transfusions.

The included population of NTDT patients met the key inclusion/ exclusion criteria of the pivotal study ACE-536-B-THAL-002.

Subjects participating in this observational study had the opportunity to be considered for the ongoing Phase 3 (ACE-536-B-THAL-001) or Phase 2 (ACE-536-B-THAL002) β -thalassemia interventional studies being conducted in subjects with β -thalassemia who are TD or NTD, respectively. Additionally, key eligibility criteria for the observational study were similar to criteria for the Phase 3 (ACE-536-B-THAL001) and Phase 2 (ACE-536-B-THAL-002) studies.

Disposition of Subjects: One hundred subjects (n = 50 with TD β -thalassemia [50.0%]; n = 50 with NTD β -thalassemia [50.0%]) were eligible and participated in the study between March 2016 and December 2016. Daily NTDTPRO assessments were performed solely by NTD β -thalassemia patients. Further QoL assessments were performed as follows: SF-36, FACT-An, and the Patient Global Impression of Change (PGI C) scale every 3 weeks. NTDT-PRO was completed every day before bedtime. In addition each patient was provided with a wrist-wearable electronic device (Fitbit) in order to record the subjects continuous activity during both day and night.

The demographic and disease characteristics at baseline were generally reflective of the target subject populations. NTDT patients had a median age of 34 years (range 18, 52), 68% were female, 78% were white, education was balanced with 50% university/college degree and 50% other. The recruitment countries were well balanced with 22.0% of evaluable subjects were from Greece, 30.0% from Italy, 26.0% from Lebanon, and 22.0% from Thailand. The median Hb level was 8.0 g/dL (range 6.0, 10.1), the time of initial diagnosis was 21.5 years (range 0.0, 43.0), 84% had active comorbidities with a median of 2.5 comorbidities (range 1.0, 6.0), 44% had a prior splenectomy, 14% had RBC transfusions within the last 24 weeks, the median of the most recent LIC was 4.0 mg Fe/g dw (range 2.5, 13.00) and 24% received currently an ICT.

<div style=\"page-break-after: always\"></div>

## Assessment of Psychometric Properties of the NTDT-PRO

For the preliminary evaluation of the psychometric properties of the NTDT-PRO several analyses were performed to evaluate Construct Validity (Exploratory Factor Analysis, Convergent and Discriminant Validity, Known-group Validity - Sensitivity, and Predictive Validity) and Reliability (Repeatability/TestRetest Reliability and Internal Consistency).

## Reliability

The repeatability of the NTDT-PRO T/W and SoB domain scores were assessed by comparing NTDT-PRO domain scores in subjects who reported no change on the PGIC over 3-week intervals (Week 1 to 3, 9 to 12, and 21 to 24) via the intraclass correlation coefficient (ICC). The ICC ranged from 0.80 to 1.00 for the T/W domain and from 0.82 to 0.99 for the SoB domain and were therefore above the threshold considered acceptable (0.7).

In order to assess the degree of internal consistency within each NTDT-domain Cronbach's alpha was used. The α coefficients were presented both before (i.e., raw or unstandardized) and after standardization of variances. Standardized α coefficients between 0.70 and 0.90 were regarded as acceptable internal consistency, with α ≥ 0.90 demonstrating redund ancy. For the T/W domain, the overall standardized α was 0.93, indicating that the items were internally consistent, however, results also indicated that some redundancy may be present in the items comprising the T/W domain. For the SoB domain, correlations of the 2 items with the domain score were moderately high, and the overall standardized α was 0.77, indicating good internal consistency among the 2 items.

## Construct validity

Exploratory factor analysis (EFA) was conducted in order to identify the number and nature of latent variables (i.e., factors) that are being measured by the NTDT-PRO instrument. Firstly, the Kaiser-MeyerOlkin (KMO) measure was conducted to assess the suitability of the data for EFA. An index &gt;0.5 considered adequate for EFA, which was met by all NTDT-PRO-items and overall. Secondly, Pearson's and Spearman's correlations were calculated to assess the patterns of inter-item correlations among the NTDT-PRO items. Nearly all items of the NTDT-PRO were acceptable highly correlated with each other (coefficients &gt; .5), with the exception of Item 2 and Item 5, and Item 4 and Item 5 (Spearman coefficients of 0.40 and 0.46, respectively). Correlations between Item 1 and Item 6; and Item 3 and Item 6 were considered high, but slightly lower compared with other items (0.51 and 0.59, respectively). This is somewhat expected as Items 1 to 4 comprise the T/W domain, while Items 5 and 6 comprise the SoB domain. All other interitem correlations were ≥ 0.60.

The principle axis method was used to extract factors with items' squared multiple correlations used as prior estimates of their communality. To choose the number of factors retained, the scree plot was inspected to identify a break in the data, and the percentage of common variance accounted for by a given factor was inspected (i.e. whether that factor accounted for at least approximately 5% of the common variance). The scree plot indicated a break between 2 and 3 factors and since 94% of the variance was explained by the first 2 factors a 2-factor model was selected.

Based on those results, a Varimax (orthogonal) rotation and also a Proxmax (oblique) rotation was applied. Outputs from both rotations were reviewed in order of a resulting 'simple structure' and whether items loading on the same factor sharing some conceptual meaning and when load on different factors measuring different constructs. Indeed, both the Varimax (orthogonal) and Promax (oblique) rotations explained similar proportions of variance and demonstrated similar factor loading patterns. The Promax rotation resulted in the items having slightly higher loadings on one factor and near-zero loadings on the other compared with the Varimax rotation; however, the 2 rotations result in the same interpretation. Items 1, 3, and 5 (those items inquiring about symptoms when not doing physical activity) had relatively

<div style=\"page-break-after: always\"></div>

high loadings on Factor 1, whereas Items 2, 4, and 6 (those items inquiring about symptoms when doing physical activity) had relatively high loadings on Factor 2.

NTDT-PRO domains were compared with the domains of other questionnaires SF-36 [physical component summary (PCS) and mental component summary (MCS)], FACT-An, Hb level, OSS (measured by the NTDT-PRO Item 7) and the Fitbit measurements in order to assess convergent and discriminant validity .

Both Pearson and Spearman correlation coefficients and corresponding p-values were estimated and summarized for assessing the strength of correlation between each NTDT-PRO domain (ie, T/W and SoB) and predefined measures. The hypotheses were that the NTDT-PRO T/W and SoB domains would generally have high correlation with the domains related to physical functioning and fatigue or anemia symptoms (e.g., PF and VT of the SF-36 and PWB and FS of the FACT-An), Hb level, OSS of the NTDTPRO, and outcomes from the Fitbit listed above, and low correlation with domains related to mental health (eg, MH and MCS of the SF-36).

Strong correlations were found between OSS and T/W and SoB domains of the NTDT-PRO during all measurements (baseline, Week 12 and Week 24) as expected. For the domain-domain correlations between NTDT-PRO domain scores and each domain of the SF-36 and of the FACT-Ans, relatively stronger correlations were observed at Weeks 12 and 24 than at baseline. Both T/W and SoB domains were highly correlated across all 3 reported visits with the VT domain of the SF-36 ( ≥ 0.50 in absolute Spearman correlation; with the exception of baseline/enrollment for the SoB domain with a correlation of -0.41), which was consistent with the hypothesis. The PF domain, however, was moderately correlated with the T/W and SoB domains across all 3 reported visits (between 0.30 and 0.50 in absolute Spearman correlation; with the exception of baseline/enrollment for the SoB domain with a correlation of -0.24), inconsistent with the stated hypothesis. Moderate to high correlations were observed with MH and MCS domains of the SF-36 (with the exception of baseline/enrollment correlations, which were generally low), also inconsistent with the stated hypothesis. Regarding FACT-An domain scores T/W domain has relatively moderate to high correlation (absolute value) across all visits while SoB domain showed relatively weaker correlations (but still ≥ 0.50 in most cases) with FS, FS-Exp, and AnS domains. As hypothesized, correlations between the FACT-An FS and the NTDT-PRO domains and between the FACTAn PWB and the NTDT-PRO domains were high at Weeks 12 and 24. Correlations between NTDT-PRO domain scores and each domain of the Fitbit demonstrated relatively little to no correlation across all Fitbit outcomes and all visits, which was not as expected per the hypotheses. Correlations between the NTDT-PRO domains and Hb levels were generally positive, in the opposite direction of what was expected. This may be due to the relatively few Hb levels available alongside the NTDT-PRO, the difference in timing between Hb measurement and NTDT-PRO administration, or the potential fluctuation of Hb levels within subjects.

The sensitivity ( known-group validity ) of the NTDT-PRO was assessed by comparing mean scores (and 95% CIs) of each NTDT-PRO domain per known group. Effect sizes for differences between OSS groups were very large and positive (&gt; 1.0) for both domains of the NTDT-PRO. Effect sizes for the difference between the SF-36 groups (PF, VT, and PCS) ranged from moderate to very large and were consistently negative as expected, indicating adequate known-groups validity. Conversely, effect sizes were small (and sometimes in the opposite direction of what was expected) when classifying groups according to the number of comorbidities at baseline and categories of Fitbit activity (i.e., steps taken, floors climbed, calories burned, and percentage of time active in a week). In addition, when classifying subjects based on Hb level, effect sizes were in the opposite direction of what was expected. This is consistent with the findings of the convergent validity analyses.

<div style=\"page-break-after: always\"></div>

Predictive validity of the NTDT-PRO was assessed by computing mean baseline T/W and SoB domain scores by subjects who experienced predefined HRU outcomes (i.e, any RBC transfusion, ER visits, inpatient hospitalization, outpatient visit, laboratory assessments, or procedures) throughout the study period. Additionally, both Pearson and Spearman correlation coefficients between baseline NTDT-PRO T/W and SoB domain scores and the number of each of the above HRU items over the study period were computed. In general, differences between the groups were relatively small in most cases (&lt; 1.0), and the number of HRU items utilized over follow-up did not demonstrate correlation with either NTDT-PRO domain (ranging from -0.22 to +0.27). Only when analyzing ER visits were the differences between groups larger than 1 (1.52 and 1.38 for the T/W and SoB domains, respectively); however, the differences were in the opposite direction than expected.

In order to determine the MID (Minimally Important Difference) and RD (Responder Definition) for the NTDT-PRO both will be assessed for the T/W and SoB domain scores using anchor-based approaches and distribution-based approaches.

For the anchor-based analysis , PGIC and the OSS were preselected as anchors (i.e. PGIC and change OSS score was classified as 'improved' when 1,2, or 3, and ≤ -1; 'no change' when 4 and &gt; -1 and &lt; 1; and 'worsened' when 5,6, or 7, and ≥ 1, respectively). At Week 12, Week 24, and overall, change from baseline in both the T/W and SoB domain scores showed little to no correlation with the PGIC, indicating that the PGIC may potentially be a weak anchor for the NTDT-PRO. However, at Week 12, Week 24, and overall, change from baseline in both the T/W and SoB domain scores showed moderate to strong correlation with the NTDT-PRO OSS, indicating that the OSS may potentially be a strong anchor for the NTDT-PRO. Subsequently, both within- and between-group mean differences were calculated based on observed scores and a mixed-effect model. For both T/W and SoB domain anchored on PGIC, both withinand between-group effect sizes in improvement were &lt; 0.20 in magnitude (regardless of the estimation method used). Both domains anchored on NTDT-PRO OSS change scores, at Week 24, both within- and between-group effect sizes in improvement were &gt; 0.20 in magnitude (regardless of the estimation method used). Using one estimation model (observed mean change) T/W and SoB domain (regardless of the anchor) showed in both effect sizes in worsened/deterioration &gt; 0.40.

A distribution-based analysis was conducted using the standard error of measurement (SEM) and the SD of the domain score at baseline. Meaningful changes ranged between 0.82 to 0.33 (SD based) and 0.69 (SEM) for the T/W domain and 0.79 to 0.32 (SD) based and 0.64 (SEM) for the SoB.

## Results

## Participant flow

A total of 160 subjects were screened for inclusion in the study and 15 subjects (approximately 9.4% of those screened) failed screening. The most frequently reported (in at least 2 subjects) reasons for screen failures were based on not meeting Inclusion Criterion 7 (mean baseline Hb level of ≤ 10.0 g/dL; 7 of 160 screened subjects) and Inclusion Criterion 3 (ability to adhere to visit schedule and not planned for HSCT; 3 of 160 screened subjects). One screening failure was due to diagnosis of thalassaemia (incl. crit. No 04), presence of laboratory abnormalities (excl. crit. No. 02), diagnosis of HbS/β -thalassemia or α -thalassemia (excl. crit. No. 04), pregnancy/lactating (excl. crit. No. 13), major organ damage (lund disease; excl. crit. No. 15c), history or current malignancies (excl. crit. No. 20).

A total of 145 subjects were randomized to study treatment at 12 sites in 6 countries (Table 31).

<div style=\"page-break-after: always\"></div>

Table 31: Subject disposition (ITT Population)

| Parameter                                         | Luspatercept (N = 96) n (%)   | Placebo (N = 49) n (%)   | Total (N = 145) n (%)   |
|---------------------------------------------------|-------------------------------|--------------------------|-------------------------|
| Subject Randomized                                | 96 (100.0)                    | 49 (100.0)               | 145 (100.0)             |
| Subject Received Treatment                        | 96 (100.0)                    | 49 (100.0)               | 145 (100.0)             |
| Treatment Discontinued during 48 weeks            | 15 (15.6)                     | 31 (63.3)                | 46 (31.7)               |
| Treatment Ongoing (48 weeks; Cut off 14 Sep 2020) | 81 (84.4)                     | 18 (36.7)                | 99 (68.3)               |
| Completed 24 Weeks of Treatment                   | 92 (95.8)                     | 44 (89.8)                | 136 (93.8)              |
| Completed 48 Weeks of Treatment                   | 89 (92.7)                     | 35 (71.4)                | 124 (85.5)              |
| Subject Discontinued Study                        | 4 (4.2)                       | 1 (2.0)                  | 5 (3.4)                 |
| Reason for Study Drug Discontinuation             |                               |                          |                         |
| Withdrawal by Subject                             | 9 (9.4)                       | 10 (20.4)                | 19 (13.1)               |
| Lack of Efficacy                                  | 1 (1.0)                       | 17 (34.7)                | 18 (12.4)               |
| AE                                                | 3 (3.1)                       | 4 (8.2)                  | 7 (4.8)                 |
| Noncompliance with drug                           | 1 (1.0)                       | 0                        | 1 (0.7)                 |
| Other (Covid19-related)                           | 0                             | 0                        | 0                       |
| Other (Non-Covid19- Related)                      | 1 (1.0)                       | 0                        | 1 (0.7)                 |
| Reason for Study Discontinuation                  |                               |                          |                         |
| AE                                                | 1 (1.0)                       | 1 (2.0)                  | 2 (1.4)                 |
| Withdrawal by Subject                             | 2 (2.1)                       | 0                        | 2 (1.4)                 |
| Noncompliance with Study Drug                     | 1 (1.0)                       | 0                        | 1 (0.7)                 |

<div style=\"page-break-after: always\"></div>

As of the second data cutoff date (15 Mar 2021), the median treatment duration was longer in the luspatercept treatment group compared with the placebo treatment group (124.8 versus 61.1 weeks)

Table 32 : Summary of Extent of Exposure (ITT population)

| Category                                    | Luspatercept N=96                           | Placebo N=49                                |
|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Treatment Duration (weeks)                  | Treatment Duration (weeks)                  | Treatment Duration (weeks)                  |
| n                                           | 96                                          | 49                                          |
| Mean (SD)                                   | 115.4 (36.09)                               | 71.9 (41.76)                                |
| Median (min, max)                           | 124.8 (15.0, 158.1)                         | 61.1 (3.0, 138.0)                           |
| Q1, Q3                                      | 97.3, 143.5                                 | 37.1, 112.0                                 |
| Number of Doses Received Per Subject        | Number of Doses Received Per Subject        | Number of Doses Received Per Subject        |
| n                                           | 96                                          | 49                                          |
| Mean (SD)                                   | 33.0 (12.75)                                | 22.5 (13.17)                                |
| Median (min, max)                           | 35.5 (3.0, 53.0)                            | 20.0 (1.0, 46.0)                            |
| Q1, Q3                                      | 23.5, 44.0                                  | 12.0, 33.0                                  |
| Number of Doses Received Per Subject, n (%) | Number of Doses Received Per Subject, n (%) | Number of Doses Received Per Subject, n (%) |
| 1-8                                         | 5 (5.2)                                     | 7 (14.3)                                    |
| 9 -16                                       | 9 (9.4)                                     | 13 (26.5)                                   |
| 17 - 24                                     | 11 (11.5)                                   | 10 (20.4)                                   |
| 25 - 32                                     | 16 (16.7)                                   | 5 (10.2)                                    |
| 33 - 40                                     | 23 (24.0)                                   | 5 (10.2)                                    |
| 41 -48                                      | 26 (27.1)                                   | 9 (18.4)                                    |
| 49 - 56                                     | 6 (6.3)                                     | 0                                           |
| >56                                         | 0                                           | 0                                           |

Source: Climical Information Amendment Table 14.1.14.1.

b Defined as the total mumber of doses the subject received a non-zero dose.

As of the second cut-off date (22-Sep-2021), subject disposition was presented separately for the 'symptomatic' and the ITT population. The majority of symptomatic subjects randomized to luspatercept (83.3%) were continuing to receive treatment as of the updated data cut of 22-Sep-2021 (Table 3), with a median duration of treatment of 145 weeks (data not shown). In addition, 27 of 35 placebo-treated symptomatic subjects (77.1%) crossed over to receive luspatercept treatment after completing the double-blind treatment period, 25 of whom were continuing to receive luspatercept treatment as of the data cut-off date.

<div style=\"page-break-after: always\"></div>

Table 33: Disposition of subjects with symptomatic anaemia (baseline NTDTPRO T/W ≥ 3) and the safety population (study ACE-536-B-THAL-002 (BEYOND))

|                                | Symptomatic Anemia Population   | Symptomatic Anemia Population   | Symptomatic Anemia Population     | ITT Population    | ITT Population   | ITT Population                    |
|--------------------------------|---------------------------------|---------------------------------|-----------------------------------|-------------------|------------------|-----------------------------------|
|                                | Luspatercept N=66               | Placebo N=35                    | Pooled Lusp Indl. Cross-over N=93 | Luspatercept N=96 | Placebo N=49     | Pooled Lusp Indl. 1310-5501 N=134 |
| Completed treatment            | 0                               | 10 (28.6)                       | 0                                 | 1(1.0)            | 18 (36.7)        | 1 (0.7)                           |
| Treatment Ongoing              | 55 (83.3)                       | 0                               | 80 (86.0)                         | 77 (80.2)         |                  | 112 (83.6)                        |
| Discontimed reatment           | 11 (16.7)                       | 25 (71.4)                       | 13 (14.0)                         | 18 (18.8)         | 31 (63.3)        | 21 (15.7)                         |
| Adverse event                  | 2 (3.0)                         | 3 (8.0)                         | 2(2.2)                            | 3 (3.1)           | 4 (8.2)          | 3(2.2)                            |
| Death                          | 0                               | 0                               | 0                                 | 0                 | 0                | 0                                 |
| Lack of efficacy               | 1(1.5)                          | 14 (40.0)                       | 1 (1.1)                           | 1(1.0)            | 17 (34.7)        | 1 (0.7)                           |
| Lost to follow-                | 0                               | 0                               | 0                                 | 0                 | 0                | 0                                 |
| Non-compliance with shudy dnug | 0                               | 0                               | 0                                 | 1(1.0)            | 0                | 1 (0.7)                           |
| Physician decision             | 0                               | 0                               | 0                                 | 0                 | 0                | 0                                 |
| Protocol deviation             | 1(1.5)                          | 0                               | 1(1.1)                            | 1(1.0)            | 0                | 1 (0.7)                           |
| Withdrawal by subject          | 7 (10.6)                        | 8 (22.9)                        | 9 (9.7)                           | 11 (11.5)         | 10 (20.4)        | 14 (10.4)                         |
| Other                          | 0                               | 0                               | 0                                 | 1(1.0)            | 0                | 1 (0.7)                           |
| Completed study                | 0                               | 0                               | 0                                 | 0                 | 0                | 0                                 |
| Study ougoing                  | 60 (90.9)                       | 31 (88.6)                       | 85 (91.4)                         | 87 (90.6)         | 44 (89.8)        | 123 (91.8)                        |
| Discontinued shudy             | 6 (9.1)                         | 4(11.4)                         | 8 (8.6)                           | 9 (9.4)           | 5 (10.2)         | 11 (8.2)                          |
| Adverse event                  | 1(1.5)                          | 1(2.9)                          | 1(1.1)                            | 1(1.0)            | 1 (2.0)          | 1 (0.7)                           |
| Death                          | 0                               |                                 | 0                                 | 0                 | 0                | 0                                 |
| Lost to follow-p               | 1(1.5)                          | 0                               | 1 (1.1)                           | 1(1.0)            | 0                | 1(0.7)                            |
| Nou-compliance with shudy dnug | 0                               | 0                               | 0                                 | 1 (1.0)           | 1 (2.0)          | 1 (0.7)                           |
| Physician decision             | 1(1.5)                          | 0                               | 1 (1.1)                           | 1 (1.0)           | 0                | 1 (0.7)                           |
| Protorol deviation             | 1(1.5)                          | 0                               | 1(1.1)                            | 1 (1.0)           | 0                | 1 (0.7)                           |
| Withdrawal by subject          | 2 (3.0)                         | 3 (8.6)                         | 4(4.3)                            | 3 (3.1)           | 3 (6.1)          | 5(3.7                             |
| Ober                           | 0                               | 0                               | 0                                 | 1(1.0)            | 0                | 1(0.7)                            |

Data cutoff date: 22-Sep-2021

Sowce: EU90 Table 14.1.1e amd RSI Table 14.1.1.lc

Update for Table 33 (Cut-off 21 sept 2021 and cut-off 09 Sep 2022)

|                        | Safety Population         | Safety Population   | Safety Population   | Safety Population              |
|------------------------|---------------------------|---------------------|---------------------|--------------------------------|
| Subject Disposition    | Luspatercept N = 96 n (%) | Luspatercept        | Luspatercept        | Pooled Lusp Incl. Cross - over |
|                        |                           | Placebo N = 49      | Cross-over          | N = 134 n (%)                  |
|                        |                           |                     | N = 38              |                                |
|                        |                           | n (%)               | (%)                 |                                |
|                        |                           |                     | n                   |                                |
| Cut off 21 Sep 2021    |                           |                     |                     |                                |
| Completed treatment    | 1 (1.0)                   | 18 (36.7)           | 0                   | 1 (0.7)                        |
| Treatment Ongoing      | 77 (80.2)                 | 0                   | 35 (92.1)           | 112 (83.6)                     |
| Discontinued treatment | 18 (18.8)                 | 31 (63.3)           | 3 (7.9)             | 21 (15.7)                      |
| Adverse event          | 3 (3.1)                   | 4 (8.2)             | 0                   | 3 (2.2)                        |
| Death                  | 0                         | 0                   | 0                   | 0                              |

<div style=\"page-break-after: always\"></div>

| Lost to follow - up                       | 0                   | 0                 | 0                             | 0                                     |
|-------------------------------------------|---------------------|-------------------|-------------------------------|---------------------------------------|
| Lack of efficacy                          | 1 (1.0)             | 17 (34.7)         | 0                             | 1 (0.7)                               |
| Non- compliance with study drug           | 1 (1.0)             | 0                 | 0                             | 1 (0.7)                               |
| Physician decision                        | 0                   | 0                 | 0                             | 0                                     |
| Pregnancy                                 | 0                   | 0                 | 0                             | 0                                     |
| Protocol deviation                        | 1 (1.0)             | 0                 | 0                             | 1 (0.7)                               |
| Withdrawal by subject                     | 11 (11.5)           | 10 (20.4)         | 3 (7.9)                       | 14 (10.4)                             |
| Other                                     | 1 (1.0)             | 0                 | 0                             | 1 (0.7)                               |
| Completed study                           | 0                   | 0                 | 0                             | 0                                     |
| Study ongoing                             | 87 (90.6)           | 44 (89.8)         | 36 (94.7)                     | 123 (91.8)                            |
| Discontinued study                        | 9 (9.4)             | 5 (10.2)          | 2 (5.3)                       | 11 (8.2)                              |
| Adverse event                             | 1 (1.0)             | 1 (2.0)           | 0                             | 1 (0.7)                               |
| Death                                     | 0                   | 0                 | 0                             | 0                                     |
| Lack of efficacy                          | 0                   | 0                 | 0                             | 0                                     |
| Lost to follow up                         | 1 (1.0)             | 0                 | 0                             | 1 (0.7)                               |
| Non compliance with study drug            | 1 (1.0)             | 1 (2.0)           | 0                             | 1 (0.7)                               |
| Physician Decision                        | 1 (1.0)             | 0                 | 0                             | 1 (0.7)                               |
| Protocol deviation                        | 1 (1.0)             | 0                 | 0                             | 1 (0.7)                               |
| Withdrawal by subject                     | 3 (3.1)             | 3 (6.1)           | 2 (5.3)                       | 5 (3.7)                               |
| Other                                     | 1 (1.0)             | 0                 | 0                             | 1 (0.7)                               |
| Subject Disposition (Cut off 09 Sep 2022) | Safety Population   | Safety Population | Safety Population             | Pooled Lusp Incl. Cross- over N = 134 |
|                                           | Luspatercept N = 96 | Placebo N = 49 (N | Luspatercept Cross-over = 38) |                                       |
| Completed treatment                       | 2 (2.1)             | 18 (36.7)         | 0                             | 2 (1.5)                               |
| Treatment Ongoing                         | 69 (71.9)           | 0                 | 28 (73.7)                     | 97 (72.4)                             |
| Discontinued treatment                    | 25 (26.0)           | 31 (63.3)         | 10 (26.3)                     | 35 (26.1)                             |
| Adverse event                             | 4 (4.2)             | 4 (8.2)           | 1 (2.6)                       | 5 (3.7)                               |
| Death                                     | 1 (1.0)             | 0                 | 0                             | 1 (0.7)                               |
| Lost to follow - up                       | 0                   | 0                 | 0                             | 0                                     |
| Lack of efficacy                          | 1 (1.0)             | 17 (34.7)         | 0                             | 1 (0.7)                               |
| Non- compliance with study drug           | 1 (1.0)             | 0                 | 0                             | 1 (0.7)                               |
| Physician decision                        | 0                   | 0                 | 1 (2.6)                       | 1 (0.7)                               |
| Pregnancy                                 | 0                   | 0                 | 1 (2.6)                       | 1 (0.7)                               |
| Protocol deviation                        | 1 (1.0)             | 0                 | 0                             | 1 (0.7)                               |
| Withdrawal by subject                     | 16 (16.7)           | 10 (20.4)         | 6 (15.8)                      | 22 (16.4)                             |
| Other                                     | 1 (1.0)             | 0                 | 1 (2.6)                       | 2 (1.5)                               |
|                                           | 0                   | 1 (2.0)           | 0                             | 0                                     |

<div style=\"page-break-after: always\"></div>

| Completed study    | 83 (86.5)   | 41 (83.7)   | 35 (92.1)   | 118 (88.1)   |
|--------------------|-------------|-------------|-------------|--------------|
| Study ongoing      | 13 (13.5)   | 7 (14.3)    | 3 (7.9)     | 16 (11.9)    |
| Discontinued study | 1 (1.0)     | 1 (2.0)     | 0           | 1 (0.7)      |
| Adverse event      | 1 (1.0)     | 0           | 0           | 1 (0.7)      |
| Death              | 0           | 0           | 0           | 0            |
| Lack of efficacy   |             |             |             |              |

## Recruitment

- -

- First subject randomised: 05 Mar 2018

- -

- Last subject randomised: 14 Oct 2019

- Last subject completed Week 48 visit: 22 Sep 2020

- Data cut-off date: 14 Sep 2020

- New cut-off date for longer-term efficacy: 15 Mar 2021 (additional post hoc analyses on RBC transfusion data, serum ferritin and the exploratory NTD Beta-thalassaemia severity score)

- Date of report: 28 May 2021

- Date of amended report: 23 Aug 2021 (addition of section 9.8.1.2 to describe the changes in study conduct due to an outage at eResearch Technology Inc.)

## Conduct of the study

## Protocol Amendments

The original protocol (12 May 2017) was amended 2 times. Key changes made to the protocol are listed below.

Protocol Amendment 1 (21 Dec 2018)

- Dose delay for worsening of anemia (Decrease of &gt; 2g/dL Hb from baseline Hb (uninfluenced by transfusion) or subject becomes regularly transfused in combination with an unexplained shift from baseline (worsening) of ≥ 2 grades leukopenia, neutropenia or thrombocytopenia); discontinuation of study drug if hematologic malignancy was confirmed.
- Dose delay for Grade ≥ 3 leukopenia, neutropenia, and/or thrombocytopenia; discontinuation of study drug if hematologic malignancy was confirmed.

Protocol Amendment 2 (12 Jun 2020)

- Baseline Hb was re-defined as the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 instead of before randomisation .
- The addition of the Open Label Study after study unblinding was to allow subjects treated with placebo during the DBTP to cross over to luspatercept treatment and to allow subjects who were still benefiting from treatment with luspatercept to continue this treatment for up to 15 months before moving to the rollover study (ACE536-LTFU-001).
- NTDT-PRO QoL analysis - Section 1.3.2.1 Rationale for Secondary Endpoint and Section 9.6.3.5. (Definition of NTDTPRO Minimum Clinical Important Difference (MCID) and Responder Definition (RD) Thresholds) have been modified to reflect some literature findings as well as the approach that will be implemented to analyze the blinded Quality of Life (QoL) data to determine the MCID. Moreover, Study

<div style=\"page-break-after: always\"></div>

Endpoints has been modified to replace the NTDT-PRO total score with the NTDT-PRO Shortness of Breath (SoB) partial score (as secondary endpoint).

The NTDT-PRO analyses were modified to remove mention of a comparison between Hb levels and NTDTPRO based on literature demonstrating that no linear association was expected between Hb and selfreported fatigue or HRQoL, and that the maximum incremental improvement in HRQoL could be expected at an Hb level of 11.0 to 13.0 g/dL (Shasha, 2004; Crawford, 2002).

- The PGI-S was added to the multiple-anchor approach for the analysis as the preferable anchor point that would directly reflect subjects' perceived severity of symptoms. The PGI-S was already being administered along with the NTDT-PRO but was explicitly added as an assessment in the amended protocol.

- The NTDT-PRO total score was replaced with the NTDT-PRO SoB domain score in the secondary efficacy endpoints because the total score calculation/algorithm had not been fully developed for the instrument.

- To be consistent with the dosing recommendations in the approved product label, the maximum total dose per administration was removed from the study drug administration guidelines.

- Thromboembolic events were added as targeted safety events.

- The 3 key secondary efficacy endpoints and the sequential testing procedure were specified.

- Analysis of the proportion of subjects with an increase from baseline of ≥ 3 in mean FACIT-F score over a continuous 12-week interval from Week 13 to Week 24 and from Week 37 to Week 48 was specified as being for the fatigue subscale only.

- Analysis of change from baseline in the SF-36 at Week 24 and Week 48 was specified as being for the PCS and MCS .

- Analysis of the proportion of subjects with a decrease from baseline ≥ RD in mean NTDT-PRO T/W domain score over Week 13 to Week 24 and from Week 37 to Week 48 was clarified to be a planned endpoint (it had been previously only mentioned in the text).

- The HRQoL evaluable populations were defined and more information was added about HRQoL instruments.

- The planned analyses were clarified with specification that the primary efficacy analysis would occur after all subjects had completed 48 weeks of treatment in the DBTP or discontinued earlier and that updated safety and efficacy analyses would be performed at the end of the OLP.

## Protocol deviations

Treatment compliance by subjects was not measured because all study drug administration was performed by site personnel at the clinical site. All study drug administration data were recorded in the eCRFs, which, along with study drug accountability records and other relevant source documents, were reviewed regularly.

Dosing errors were recorded as important protocol deviations under the category of 'IP issues' and were reported in 5 (5.2%) subjects in the luspatercept treatment group and 1 (2.0%) subject in the placebo treatment group (Table 34). Dose delays for reasons other than the protocol-specified criteria occurred occasionally due to subject circumstances and due to the COVID-19 pandemic.

<div style=\"page-break-after: always\"></div>

Table 34: Summary of Protocol Deviations and Important Protocol Deviations (ITT Population)

| Parameter                                             | Luspatercept (N = 96) n (%)   | Placebo (N = 49) n (%)   | Total (N = 145) n (%)   |
|-------------------------------------------------------|-------------------------------|--------------------------|-------------------------|
| Subjects With at Least 1 Protocol Deviation           | 96 (100.0)                    | 48 (98.0)                | 144 (99.3)              |
| Subjects With at Least 1 Important Protocol Deviation | 6 (6.3)                       | 1 (2.0)                  | 7 (4.8)                 |
| IP Issues                                             | 5 (5.2)                       | 1 (2.0)                  | 6 (4.1)                 |
| Missing Visit or Assessment/Procedure                 | 1 (1.0)                       | 0                        | 1 (0.7)                 |

DBL = database lock; ICF = informed consent form; IP = investigational product; ITT = intent-to treat.

a An important protocol deviation was defined as any departure from the approved protocol that impacted the safety, rights, and/or welfare of the subject; or negatively impacted the quality or completeness of the data; or made the ICF inaccurate.

Note: It was possible for a subject to have more than 1 protocol deviation (including an important protocol deviation). All important protocol deviations were identified based on blinded data reviews of deviation logs throughout the study and were finalized prior to DBL.

## Dose changes

Doses administered including reductions, increases and delays were only summarised in the safety section.

A short summary is given here:

Dose delays: 83.3% in the luspatercept treatment group and 55.1% in the placebo treatment group had their dose delayed at least once during the study.

Between-group imbalance in dose delays was mainly because of Hb ≥ 11.5 g/dL, which was reported for 34 (35.4%) subjects in the luspatercept treatment group compared with 1 (2.0%) subject in the placebo treatment group. The median time to first dose delay due to Hb ≥ 11.5 g/dL was 79.0 days (range: 29.0 to 755.0 days) in the luspatercept treatment group. The time to first dose delay due to Hb ≥ 11.5 g/dL in the placebo-treated subject was 244.0 days.

Dose delays due to treatment-related Grade ≥ 2 TEAEs occurred only in the luspatercept treatment group (7 [7.3%] subjects). The median time to first dose delay due to an AE was 283.0 days in the luspatercept treatment group and 387.0 days in the placebo treatment group.

Dose reduction: Dose reduction from 1.00 mg/kg to 0.80 mg/kg occurred for 19 (19.8%) subjects in the luspatercept treatment group and 1 (2.0%) subject in the placebo treatment group. A second dose reduction from 0.80 mg/kg to 0.60 mg/kg occurred for 3 (3.1%) subjects in the luspatercept treatment group; no such dose reduction occurred in the placebo treatment group. No further dose reductions (0.60 mg/kg to 0.45 mg/kg) were reported.

76 (79.2) and 47 (95.9) of luspatercept and placebo subjects, respectively, had their dose not reduced. 20.8% in the luspatercept treatment group and 4.1% in the placebo treatment group had their study drug dose reduced at least once during the study. These included dose reductions from the starting dose of 1.00 mg/kg and dose reductions back to 1.00 mg/kg after titration to 1.25 mg/kg.

Four subjects (all in the luspatercept treatment group) had their study drug dose reduced twice during the study.

The median time to first dose reduction was 50.0 days (range: 21.0 to 771.0 days) in the luspatercept treatment group and 335.0 days (range: 48.0 to 622.0 days) in the placebo treatment group.

<div style=\"page-break-after: always\"></div>

The most frequently reported (in &gt; 5.0% of subjects) reasons for dose reduction were increase in Hb of &gt; 2.0 g/dL (10.4% vs. 4.1% for luspatercept and placebo, respectively) and treatment-related Grade ≥ 3 TEAEs (8.3% 0% for luspatercept and placebo, respectively).

Table 35 (see CSR, exerpt): Summary of Treatment and Extent of Exposure (Safety Population)

| Dose Received Within 24 Weeks, n (%) Maximum   |           |           |           |
|------------------------------------------------|-----------|-----------|-----------|
| 1.00 mg/kg                                     | 51 (53.1) | 6 (12.2)  | 57 (39.3) |
| 1.25 mg/kg                                     | 45 (46.9) | 43 (87.8) | 88 (60.7) |

## Baseline data

Table 36: Demographics (ITT population)

| Parameter                   | Luspatercept (N=96)   | Placebo (N= 49)   | Total (N =145)    |
|-----------------------------|-----------------------|-------------------|-------------------|
| Age (Years)                 |                       |                   |                   |
| Mean (SD)                   | 39.3 (13.24)          | 41.1 (11.90)      | 39.9 (12.79)      |
| Median (Min, Max)           | 39.5 (18.0, 71.0)     | 41.0 (19.0, 66.0) | 40.0 (18.0, 71.0) |
| Age Category (Years), n (%) |                       |                   |                   |
| ≤32                         | 35 (36.5)             | 12 (24.5)         | 47 (32.4)         |
| >32 to ≤ 50                 | 41 (42.7)             | 26 (53.1)         | 67 (46.2)         |
| >50                         | 20 (20.8)             | 11 (22.4)         | 31 (21.4)         |
| Sex, n (%)                  |                       |                   |                   |
| Male                        | 40 (41.7)             | 23 (46.9)         | 63 (43.4)         |
| Female                      | 56 (58.3)             | 26 (53.1)         | 82 (56.6)         |
| Race, n (%)                 |                       |                   |                   |
| Asian                       | 31 (32.3)             | 13 (26.5)         | 44 (30.3)         |
| White                       | 59 (61.5)             | 28 (57.1)         | 87 (60.0)         |
| Other                       | 6 (6.3)               | 8 (16.3)          | 14 (9.7)          |
| Ethmicity, n (%)            |                       |                   |                   |
| Hispanic or Latino          | 2 (2.1)               | 1 (2.0)           | 3 (2.1)           |
| Not Hispamic or Latino      | 94 (97.9)             | 48 (98.0)         | 142 (97.9)        |
| BMI (kg/m²)b                |                       |                   |                   |
| Mean (SD)                   | 22.1 (3.79)           | 22.3 (4.08)       | 22.2 (3.87)       |
| Median (Min, Max)           | 21.6 (15.2, 36.9)     | 21.5 (16.2, 38.1) | 21.6 (15.2, 38.1) |
| BMI Category (kg/m²), n (%) |                       |                   |                   |
| ≤20                         | 35 (36.5)             | 18 (36.7)         | 53 (36.6)         |
| ≥ 20 to ≤ 25                | 46 (47.9)             | 20 (40.8)         | 66 (45.5)         |
| ≥ 25 to ≤30                 | 12 (12.5)             | 9 (18.4)          | 21 (14.5)         |
| ≥30                         | 3 (3.1)               | 2 (4.1)           | 5 (3.4)           |
| Region, n (%)               |                       |                   |                   |
| North America and Europe    | 60 (62.5)             | 30 (61.2)         | 90 (62.1)         |
| Middle East                 | 9 (9.4)               | 8 (16.3)          | 17 (11.7)         |
| Asia-Pacific                | 27 (28.1)             | 11 (22.4)         | 38 (26.2)         |

<div style=\"page-break-after: always\"></div>

Table 37: Baseline characteristics

| Parameter                                                    | Luspatercept (N=96)   | Placebo (N=49)   | Total (N=145)   |
|--------------------------------------------------------------|-----------------------|------------------|-----------------|
| β-thalassemia Diagnosis, n (%)                               |                       |                  |                 |
| β-thalassemia                                                | 63 (65.6)             | 34 (69.4)        | 97 (66.9)       |
| HbE/β-thalassemia                                            | 28 (29.2)             | 11 (22.4)        | 39 (26.9)       |
| β-thalassemia Combined With a-thalassemia                    | 5 (5.2)               | 4 (8.2)          | 9 (6.2)         |
| β-thalassemia Gene Mutation, n (%)                           |                       |                  |                 |
| [β0/β0, β+/β+, β+/β0] Without α-thalassemia                  | 69 (71.9)             | 33 (67.3)        | 102 (70.3)      |
| [β0/β0, β+/β+, β+/β0] With α-thalassemia                     | 6 (6.3)*              | 4 (8.2)          | 10 (6.9)        |
| [β0/β, β+/β] With o-gene Duplication                         | 21 (21.9)             | 12 (24.5)        | 33 (22.8)       |
| Baseline Hb level (g/dL)                                     |                       |                  |                 |
| 11                                                           | 96                    | 49               | 145             |
| Mean (SD)                                                    | 8.2 (1.22)            | 8.1 (1.30)       | 8.2 (1.24)      |
| Median (Min, Max)                                            | 8.2 (5.3, 10.1)       | 8.1 (5.7, 10.1)  | 8.2 (5.3, 10.1) |
| Subjects With Mean Baseline Hb Levelb Category (g/dL), n (%) |                       |                  |                 |
| 28.5                                                         | 41 (42.7)             | 20 (40.8)        | 61 (42.1)       |
| c8.5                                                         | 55 (57.3)             | 29 (59.2)        | 84 (57.9)       |
| Baseline NTDT-PRO T/W Domain Score                           |                       |                  |                 |
| 11                                                           | 96                    | 49               | 145             |
| Mean (SD)                                                    | 4.1 (2.29)            | 4.0 (2.03)       | 4.0 (2.20)      |
| Median (Min, Max)                                            | 4.3 (0.0, 9.5)        | 4.1 (0.4, 9.5)   | 4.3 (0.0, 9.5)  |
| Baseline NTDT-PRO T/W Domain Score* Category, n (%)          |                       |                  |                 |
| 23                                                           | 66 (68.8)             | 35 (71.4)        | 101 (69.7)      |
| 3                                                            | 30 (31.3)             | 14 (28.6)        | 44 (30.3)       |
| Baseline Transfusion Buuden (Units/24 Weeks)                 |                       |                  |                 |
|                                                              | 96                    | 49               | 145             |
| Mean (SD)                                                    | 0.3 (0.83)            | 0.3 (0.76)       | 0.3 (0.81)      |
| Median (Min, Max)                                            | 0.0 (0.0, 4.0)        | 0.0 (0.0, 4.0)   | 0.0 (0.0,4.0)   |

<div style=\"page-break-after: always\"></div>

Table 38: Baseline Disease characteristics (ITT population, continued)

<!-- image -->

| Parameter                                                    | Luspatercept (N=96)   | Placebo (N=49)   | Total (N=145)   |
|--------------------------------------------------------------|-----------------------|------------------|-----------------|
| Baseline Transfusion Burden (Units/24 Weeks) Category, n (%) |                       |                  |                 |
| =0                                                           | 83 (86.5)             | 42 (85.7)        | 125 (86.2)      |
| >0                                                           | 13 (13.5)             | 7 (14.3)         | 20 (13.8)       |
| Baseline Transfusion Buuden (Units/12 Weeks)                 |                       |                  |                 |
| n                                                            | 96                    | 49               | 145             |
| Mean (SD)                                                    | 0.1 (0.42)            | 0.1 (0.44)       | 0.1 (0.43)      |
| Median (Min, Max)                                            | 0.0 (0.0, 2.0)        | 0.0 (0.0, 2.0)   | 0.0 (0.0, 2.0)  |
| Baseline Transfusion Buuden (Units/12 Weeks) Category, n (%) |                       |                  |                 |
| 0=                                                           | 90 (93.8)             | 45 (91.8)        | 135 (93.1)      |
| >0                                                           | 6 (6.3)               | 4 (8.2)          | 10 (6.9)        |
| Splenectomy, n (%)                                           |                       |                  |                 |
| Yes                                                          | 34 (35.4)             | 26 (53.1)        | 60 (41.4)       |
| No                                                           | 62 (64.6)             | 23 (46.9)        | 85 (58.6)       |
| MRI LIC (mg/g dw)                                            |                       |                  |                 |
| n                                                            | 95                    | 47               | 142             |
| Mean (SD)                                                    | 6.1 (6.15)            | 5.9 (5.82)       | 6.0 (6.02)      |
| Median (Min, Max)                                            | 3.9 (0.8, 39.9)       | 4.1 (0.7, 28.7)  | 4.0 (0.7,39.9)  |
| LIC (mg/g dw) Category, n (%)                                |                       |                  |                 |
| 3                                                            | 35 (36.5)             | 17 (34.7)        | 52 (35.9)       |
| ≥3to g5                                                      | 23 (24.0)             | 13 (26.5)        | 36 (24.8)       |
| >5to ≤7                                                      | 12 (12.5)             | 3 (6.1)          | 15 (10.3)       |
| >7to ≤15                                                     | 14 (14.6)             | 9 (18.4)         | 23 (15.9)       |
| >15                                                          | 11 (11.5)             | 5 (10.2)         | 16 (11.0)       |
| Missing                                                      | 1(1.0)                | 2 (4.1)          | 3 (2.1)         |
| MRI Spleen Volume (cm?)                                      |                       |                  |                 |
| n                                                            | 60                    | 22               | 82              |
| Mean (SD)                                                    | 958.9 (483.71)        | 1113.4 (554.17)  | 1000.4 (504.76) |

<div style=\"page-break-after: always\"></div>

Table 39: Baseline Disease characteristics (ITT population, continued)

| Parameter                                      | Luspatercept (N =96)   | Placebo (N= 49)        | Total (N=145)         |
|------------------------------------------------|------------------------|------------------------|-----------------------|
| Median (Min, Max)                              | 879.9 (276.1, 2419.0)  | 1077.0 (276.5, 2243.0) | 910.5 (276.1, 2419.0) |
| Hip DXA                                        |                        |                        |                       |
| Total Hip BMD (g/cm²), n                       | 92                     | 48                     | 140                   |
| Mean (SD)                                      | 0.9 (0.16)             | 0.9 (0.13)             | 0.9 (0.15)            |
| Median (Min, Max)                              | 0.9 (0.5, 1.3)         | 0.9 (0.6, 1.3)         | 0.9 (0.5, 1.3)        |
| T-score, n                                     | 89                     | 48                     | 137                   |
| Mean (SD)                                      | -0.8 (1.12)            | -1.1 (0.96)            | -0.9 (1.07)           |
| Median (Min, Max)                              | -1.0 (-3.9, 1.9)       | -1.2 (-2.6, 2.4)       | -1.1 (-3.9, 2.4)      |
| Spine DXA                                      |                        |                        |                       |
| Lumbar Spine BMD (g/cm²), n                    | t6                     | 48                     | 142                   |
| Mean (SD)                                      | 1.0 (0.18)             | 0.9 (0.15)             | 1.0 (0.17)            |
| Median (Min, Max)                              | 0.9 (0.5, 1.4)         | 1.0 (0.6, 1.4)         | 0.9 (0.5, 1.4)        |
| T-score, n                                     | 90                     | 48                     | 138                   |
| Mean (SD)                                      | -1.6 (1.31)            | -1.8 (1.17)            | -1.7 (1.27)           |
| Median (Min, Max)                              | -1.7 (-5.5, 1.9)       | -1.8 (-4.2, 1.7)       | -1.7 (-5.5,1.9)       |
| Baseline Senm Femitin (μg/L)                   |                        |                        |                       |
|                                                | 96                     | 49                     | 145                   |
| Mean (SD)                                      | 567.8 (523.16)         | 528.8 (444.92)         | 554.6 (496.88)        |
| Median (Min, Max)                              | 456.5 (30.0,3528.0)    | 360.0 (40.0, 2265.0)   | 441.0 (30.0, 3528.0)  |
| Baseline Serum Femitin (ug/L)# Category, n (%) |                        |                        |                       |
| c 500                                          | 55 (57.3)              | 28 (57.1)              | 83 (57.2)             |
| 500 to 800                                     | 28 (29.2)              | 9 (18.4)               | 37 (25.5)             |
| > 800                                          | 13 (13.5)              | 12 (24.5)              | 25 (17.2)             |
| Baseline ICT, n (%)                            |                        |                        |                       |
| Yes                                            | 28 (29.2)              | 16 (32.7)              | 44 (30.3)             |
| Baseline Serum Femitin ≤ 800 μg/L              | 22 (22.9)              | 12 (24.5)              | 34 (23.4)             |
| Baseline Senum Femitin > 800 μg/L              | 6 (6.3)                | 4 (8.2)                | 10 (6.9)              |
| No                                             | 68 (70.8)              | 33 (67.3)              | 101 (69.7)            |
| Baseline Serum Femitin = 800 μg/L              | 61 (63.5)              | 25 (51.0)              | 86 (59.3)             |
| Baseline Serum Femitin > 800 μg/L              | 7 (7.3)                | 8 (16.3)               | 15 (10.3)             |

<div style=\"page-break-after: always\"></div>

Table 40: Baseline Disease characteristics (ITT population, continued)

<!-- image -->

| Parameter                                         | Luspatercept (N=96)   | Placebo (N=49)       | Total (N=145)      |
|---------------------------------------------------|-----------------------|----------------------|--------------------|
| Hepatitis B and C (Local and Cental Laboratories) |                       |                      |                    |
| HCV Antibody Test, n (%)                          |                       |                      |                    |
| Positive                                          | 4 (4.2)               | 1 (2.0)              | 5 (3.4)            |
| HCV RNA Negative (No RNA Detected)                | 4 (4.2)               | 1 (2.0)              | 5 (3.4)            |
| Negative                                          | 92 (95.8)             | 48 (98.0)            | 140 (96.6)         |
| HBV, HBsAg Results Negative, n (%)                | 96 (100.0)            | 49 (100.0)           | 145 (100.0)        |
| ECOG Performance Status at Screening, n (%)       |                       |                      |                    |
| 0                                                 | 62 (64.6)             | 38 (77.6)            | 100 (69.0)         |
| 1                                                 | 34 (35.4)             | 11 (22.4)            | 45 (31.0)          |
| Baseline 6MWT Category, n (%)                     |                       |                      |                    |
| Women ≤ 450 m                                     | 28 (29.2)             | 17 (34.7)            | 45 (31.0)          |
| Women 450 to 593 m                                | 27 (28.1)             | 8 (16.3)             | 35 (24.1)          |
| Women>593 m                                       | 1 (1.0)               | 1 (2.0)              | 2 (1.4)            |
| Men = 500 m                                       | 26 (27.1)             | 16 (32.7)            | 42 (29.0)          |
| Men 500 to 638 m                                  | 13 (13.5)             | 7 (14.3)             | 20 (13.8)          |
| Men>638 m                                         | 1 (1.0)               | 0                    | 1 (0.7)            |
| Men ≤ 450 m                                       | 51 (53.1)             | 31 (63.3)            | 82 (56.6)          |
| Men > 450 m                                       | 45 (46.9)             | 18 (36.7)            | 63 (43.4)          |
| Baseline 6MWT (m)                                 |                       |                      |                    |
| n                                                 | 96                    | 49                   | 145                |
| Mean (SD)                                         | 447.0 (92.97)         | 435.0 (78.33)        | 442.9 (88.2)       |
| Median (Min, Max)                                 | 447.7 (0.0, 661.0)    | 430.0 (300.0, 600.0) | 443.0 (0.0, 661.0) |
| Baseline FACIT-F Fatigue Subscale                 |                       |                      |                    |
| n                                                 | 96                    | 48                   | 144                |
| Mean (SD)                                         | 36.4 (10.04)          | 36.3 (9.50)          | 36.4 (9.83)        |
| Median (Min, Max)                                 | 39.0 (1.0, 51.0)      | 38.0 (16.0, 50.0)    | 39.0 (1.0, 51.0)   |
| Baseline FACIT-F Fatigue Subscale Category, n (%) |                       |                      |                    |
| 243                                               | 32 (33.3)             | 16 (32.7)            | 48 (33.1)          |
| c43                                               | 64 (66.7)             | 32 (65.3)            | 96 (66.2)          |

<div style=\"page-break-after: always\"></div>

Table 41: Baseline Disease characteristics (ITT population, continued)

| Parameter          | Luspatercept (96= ND)   | Placebo (N=49)    | Total (N =145)    |
|--------------------|-------------------------|-------------------|-------------------|
| Baseline SF-36 PCS |                         |                   |                   |
| n                  | 94                      | 47                | 141               |
| Mean (SD)          | 47.9 (7.13)             | 48.2 (7.22)       | 48.0 (7.14)       |
| Median (Min, Max)  | 48.6 (28.4, 61.6)       | 49.1 (32.9, 63.6) | 48.8 (28.4, 63.6) |
| Baseline SF-36 MCS |                         |                   |                   |
| n                  | 94                      | 47                | 141               |
| Mean (SD)          | 45.9 (9.44)             | 48.8 (8.34)       | 46.9 (9.16)       |
| Median (Min, Max)  | 46.5 (23.3, 60.1)       | 49.2 (26.5, 63.1) | 47.7 (23.3, 63.1) |

below the mean for a healthy 30-year-old adult of the same sex and ethmicity.

6MWT = 6-minute walk test; BMD = bone mineral density, dw = dry weight; DXA = dual-energy X-ray absorptiomety; ECOG =Eastem Cooperative Oncology Group; eCRF = electronic case report fonm; FACIT-F = Fumctional Assessment of Chronic Ilhess Therapy - Fatigue; Hb = hemoglobin; HbE = hemoglobin E: HBsAg = hepatiftis B suuface antigen; HBV = hepatitis B vinus; HCV =hepatitis C vinus; ICT = iron chelation therapy; ITT = intent to treat; LIC =liver iron concentration; Max = maximum; MCS = mental component summary; Min = minimum; MRI = magnetic resonance imaging: NTDT-PRO T/W = nontransfusion-dependent β-thalassemia patient-reported outcome tiredness and weakness; PCS = physical component summary: R2 = relaxation rate corresponding to transverse relaxation time; R2* = effective relaxation rate corresponding to transverse relaxation time; RNA =nibomucleic acid; SD = standard deviation; SF-36 = Medical Outcomes Study 36-item Short Form Health Suuvey; T2* = effective transverse relaxation time; T-score = mumber of SDs above or

- a This included 1 subject for whom HbE/β-thalassemia was a more appropriate clinical diagnosis, while based on the a-gene deletion, this was the more appropriate gene mutation classification.
* Baseline was defined as the average of noumissing NTDI-PRO T/W domain score over 7 days before Dose 1 Day 1.
- b Mean of at least 2 Hb values by the central laboratory duing the 28-day Screening Period.
- d The value of LIC was either the value collected fom the eCRF or the value derived fom T2*, R2*, or R2 parameter depending on which techniques and software were used for MRI LIC acquisition.
- Baseline mean senum femitin was calculated duing the 24 weeks on or prior to Dose 1 Day 1. Baseline ICT was calculated duing the 24 weeks on or prior to Dose 1 Day 1.
- The ECOG Grade: O = fuilly active, able to cary on all predisease perfommance without reshiction; 1 =resticted in physically strenuous activity but ambulatory and able to cary out work of a light or sedentary nature, eg. light housework, office work

Souuces: Table 14.1.7 and Table 14.1.7.3.

Table 42: Cross-tabulation of NTDT-PRO T/W and FACIT-F Fatigue, suscale categories at baseline (study ACE-536-B-THAL-002, ITT population)

| BaselineSymptomScore           | NTDT-PRO T/W ≥3 (symptomatic) N=101 n (%)   | NTDT-PROT/W<3 (asymptomatic) N = 44 n (%)   |
|--------------------------------|---------------------------------------------|---------------------------------------------|
| FACIT-F FS < 43 (symptomatic)  | 81 (80.2)                                   | 15 (34.1)                                   |
| FACIT-F FS ≥ 43 (asymptomatic) | 19 (18.8)                                   | 29 (65.9)                                   |

Abbreviations: FACIT-F FS, Functional Assessment of Chronic Ilness Therapy fatigue subscale; ITT, intent-to-treat; NTDT-PRO T/W, non-transfusion-dependent β-thalassemia patient-reported outcome tiredness and weakness.

Note: One subject in the placebo arm was missing FACIT-F FS score at baseline (refer to ACE-536-B-THAL-002 CSR Table 14.1.7).

Data cutoff date:14-Sep-2020

Source:TableBEE.23C.a.

Prior Iron Chelation Therapies are summarised in Table 43.

<div style=\"page-break-after: always\"></div>

Table 43: Summary of prior iron chelation therapies (ITT population)

| ATC4 Dictionary Level ATC4 Preferred Name                                        | Luspatercept (N=96) n (%)   | Placebo (N=49) n (%)   | Total (N=145) n (%)   |
|----------------------------------------------------------------------------------|-----------------------------|------------------------|-----------------------|
| Subjects Without Prior ICT Over 24 Weeks Before Dose 1                           | 68 (70.8)                   | 33 (67.3)              | 101 (69.7)            |
| Subjects With at Least 1 Prior ICT Before Dose 1                                 | 28 (29.2)                   | 16 (32.7)              | 44 (30.3)             |
| Subjects With at Least 1 Prior ICT That Continued Duing the Study (After Dose 1) | 26 (27.1)                   | 13 (26.5)              | 39 (26.9)             |
| Prior Iron Chelating Agents                                                      | 28 (29.2)                   | 16 (32.7)              | 44 (30.3)             |
| Deferasirox                                                                      | 15 (15.6)                   | 12 (24.5)              | 27 (18.6)             |
| Deferiprone                                                                      | 14 (14.6)                   | 4 (8.2)                | 18 (12.4)             |
| Deferoxamine                                                                     | 0                           | 1 (2.0)                | 1 (0.7)               |

Note: Prior ICTs were defined as the 24-week period prior to Dose 1 Day 1. The ATC4 dictionary level and preferred names were coded using WHODrugDDEB3-202003. Preferred names are presented in descending frequency within the luspatercept treatment group. A subject was counted only once for multiple records within each preferred name.

ATC = Anatomical Therapeutic Chemical; ICT = iron chelation therapy; ITT = intent to treat; WHO = World Health Organization.

The use of concomitant ICT is summarized in Table 44.

Table 44 : Summary of concomitant iron chelation therapies (ITT population)

| ATC4 Preferred Name                      | Luspatercept (N=96) n (%)   | Placebo (N=49) n (%)   | Total (N=145) n (%)   |
|------------------------------------------|-----------------------------|------------------------|-----------------------|
| Subjects With at Least 1 Concomitant ICT | 40 (41.7)                   | 19 (38.8)              | 59 (40.7)             |
| Deferasirox                              | 23 (24.0)                   | 15 (30.6)              | 38 (26.2)             |
| Deferiprone                              | 18 (18.8)                   | 5 (10.2)               | 23 (15.9)             |
| Deferoxamine Mesylate                    | 2 (2.1)                     | 0                      | 2 (1.4)               |
| Deferoxamine                             | 1 (1.0)                     | 1 (2.0)                | 2 (1.4)               |

Note: Concomitant medications were defined as medications that were taken from the date of first dose of study dnug umtil the last dose of shudy dnug. This included any medications that were started before the date of first dose of shudy drug and continued on or after the date of first dose of study dnug. Preferred names were coded using WhoDrugDDEB3-202003.Preferred mames are presented im descending g frequency within the luspatercept treatment group. A subject was coumted only once for multiple records within each preferred name.

AIC = Anatomical Therapeutic Chemical; ICT = iron chelation therapy: ITT = intent to treat; WHO = World Health Organization

Source:Table 14.1.10.2.

## Prior medications

The use of prior medications was generally similar (difference of ≤ 5.0% of subjects) between the treatment groups. Of note, a higher proportion of subjects (difference of &gt; 5.0% of subjects) in the luspatercept treatment group than those in the placebo treatment group used paracetamol (9.4% versus 4.1%, respectively), vitamins not otherwise specified (7.3% versus 0%, respectively), and folic acid and ursodeoxycholic acid (5.2% versus 0% each, respectively). Fewer subjects in the luspatercept treatment group than in the placebo treatment group (difference of &gt; 5.0% of subjects) used acetylsalicylic acid (20.8% versus 30.6%, respectively) and ketoprofen and bisoprolol (1.0% versus 6.1% each, respectively).

Prior medication usage was generally consistent with reported NTDT comorbidities and medical history in the study population.

<div style=\"page-break-after: always\"></div>

Table 45: Prior medication use reported by at least 5.0 % of total subjects (ITT population)

| ATC4PreferredName                         | Luspatercept (N = 96) (%) u   | Placebo (N = 49) n (%)   | Total (N = 145) n (%)   |
|-------------------------------------------|-------------------------------|--------------------------|-------------------------|
| Subjects With at Least 1 Prior Medication | 77 (80.2)                     | 39 (79.6)                | 116 (80.0)              |
| Acetylsalicylic Acid                      | 20 (20.8)                     | 15 (30.6)                | 35 (24.1)               |
| Colecalciferol                            | 18 (18.8)                     | 11 (22.4)                | 29 (20.0)               |
| Calcium Carbonate                         | 15 (15.6)                     | 9 (18.4)                 | 24 (16.6)               |
| Ergocalciferol                            | 11 (11.5)                     | 5 (10.2)                 | 16 (11.0)               |
| Allopurinol                               | 9 (9.4)                       | 5 (10.2)                 | 14 (9.7)                |
| Paracetamol                               | 9 (9.4)                       | 2 (4.1)                  | 11 (7.6)                |
| Levothyroxine Sodium                      | 8 (8.3)                       | 5 (10.2)                 | 13 (9.0)                |

ATC = Anatomical Therapeutic Chemical; ITT = intent to treat; WHO = World Health Organization.

## Other Concomitant Medications

Concomitant medications used by at least 5.0% of total subjects are summarized by preferred name in Table 46.

All subjects (100.0%) received at least 1 concomitant medication. The ATC4 classes from which concomitant medications were most frequently used (in &gt; 20.0% of total subjects) were Anilides (66.2%); Vitamin D and Analogues (55.2%); Propionic Acid Derivatives (37.9%); Influenza Vaccines (30.3%); Platelet Aggregation Inhibitors, excluding Heparin (27.6%); Combinations of Penicillins, including β -lactamase Inhibitors (26.2%); Calcium (24.8%); and Proton Pump Inhibitors (20.0%). By preferred name, the most frequently reported concomitant medications (in &gt; 20.0% of total subjects) were paracetamol (64.1%); colecalciferol (30.3%); acetylsalicylic acid (27.6%); influenza vaccine and amoxicillin sodium/clavulanate potassium (26.2% each); ibuprofen (25.5%); and calcium carbonate (23.4%) (Table 46).

The use of concomitant medications was generally similar (difference of ≤ 10.0% of subjects) between the treatment groups. Of note, a greater proportion of subjects (difference of &gt; 10.0% of subjects) in the luspatercept treatment group than those in the placebo treatment group used paracetamol (71.9% versus 49.0%, respectively), influenza vaccine (30.2% versus 18.4%, respectively), ibuprofen (29.2% versus 18.4%, respectively), and amoxicillin and ketoprofen (16.7% versus 6.1% each, respectively). Some of these differences are related to the difference between the treatment groups in overall duration of treatment, in particular for use of influenza vaccine. Use of concomitant chlorphenamine (20.4% versus 7.3%, respectively) and acetylsalicylic acid (34.7% versus 24.0%, respectively) was more frequent (difference of &gt; 10.0% of subjects) in the placebo treatment group than in the luspatercept treatment group (Table 46). These differences may have been related to a higher incidence of transfusions (with premedication) among subjects in the placebo treatment group.

<div style=\"page-break-after: always\"></div>

Table 46: Concomitant medication use reported by at least 5.0 % of total subjects (ITT population)

<!-- image -->

| ATC4Preferred Name                              | Luspatercept (N= 96) n (96)   | Placebo (N = 49) n (96)   | Total (N =145) n (96)   |
|-------------------------------------------------|-------------------------------|---------------------------|-------------------------|
| Subjects With at Least 1 Concomitant Medication | 96 (100.0)                    | 49 (100.0)                | 145 (100.0)             |
| Paracetamol                                     | 69 (71.9)                     | 24 (49.0)                 | 93 (64.1)               |
| Colecalciferol                                  | 30 (31.3)                     | 14 (28.6)                 | 44 (30.3)               |
| Influenza Vaccine                               | 29 (30.2)                     | 9 (18.4)                  | 38 (26.2)               |
| Iouprofen                                       | 28 (29.2)                     | 9 (18.4)                  | 37 (25.5)               |
| Amoxicillin Sodium; ClavulanatePotassium        | 26 (27.1)                     | 12 (24.5)                 | 38 (26.2)               |
| Acetylsalicylic Acid                            | 23 (24.0)                     | 17 (34.7)                 | 40 (27.6)               |
| Calcium Carbonate                               | 22 (22.9)                     | 12 (24.5)                 | 34 (23.4)               |
| Ergocalciferol                                  | 17 (17.7)                     | 8 (16.3)                  | 25 (17.2)               |
| Amoxicillin                                     | 16 (16.7)                     | 3 (6.1)                   | 19 (13.1)               |
| Ketoprofen                                      | 16 (16.7)                     | 3 (6.1)                   | 19 (13.1)               |
| Allopurinol                                     | 13 (13.5)                     | 6 (12.2)                  | 19 (13.1)               |
| Folic Acid                                      | 13 (13.5)                     | 2 (4.1)                   | 15 (10.3)               |
| Omeprazole                                      | 13 (13.5)                     | 8 (16.3)                  | 21 (14.5)               |
| Loratadine                                      | 11 (11.5)                     | 4 (8.2)                   | 15 (10.3)               |
| Vitamins NOS                                    | 9 (9.4)                       | 1 (2.0)                   | 10 (6.9)                |

<!-- image -->

| ATC4PreferredName    | Luspaterrept (96 = N) n (96)   | Placebo (N = 49) n (96)   | Total (N=145) n (96)   |
|----------------------|--------------------------------|---------------------------|------------------------|
| Diclofenac           | 8 (8.3)                        | 4 (8.2)                   | 12 (8.3)               |
| Domperidone          | 8 (8.3)                        | 4 (8.2)                   | 12 (8.3)               |
| Levothyroxine Sodium | 8 (8.3)                        | 5 (10.2)                  | 13 (9.0)               |
| Vitamin D NOS        | 8 (8.3)                        | 3 (6.1)                   | 11 (7.6)               |
| Chlorpbenamine       | 7 (7.3)                        | 10 (20.4)                 | 17 (11.7)              |
| Naproxen             | 7(7.3)                         | 1 (2.0)                   | 8 (5.5)                |
| Ketoprofen Lysine    | 6 (6.3)                        | 2 (4.1)                   | 8 (5.5)                |
| Sodium Chloride      | 6(6.3)                         | 2 (4.1)                   | 8 (5.5)                |
| Azithromycin         | 5 (5.2)                        | 4 (8.2)                   | 9 (6.2)                |
| Fwrosemide           | 3 (3.1)                        | 5 (10.2)                  | 8 (5.5)                |

ATC = Anatomical Therapeutic Chemical; ITT = intent to treat; NOS =not otherwise specified; WHO = World Health Organization.

Note: Concomitant medications were defined as medications that were taken from the date of first dose of study dnug umtil the last dose of shudy dnug. This included any medications that were started before the date of first dose of study dng and continued on or after the date of first dose of study drug. Preferred names are coded using WhoDrugDDEB3-202003. Preferred names are presented in descending frequency within the luspatercept treatment group. A. subject was counted only ouce for multiple records within each preferred name. Source. Table 14.1.10.1.

This table of the ACE-536-B-THAL-002 CSR was based on the complete study data as of the data cutoff date (14-Sep-2020), and not on 48 weeks of treatment. A revised summary of concomitant medications up to Week 48. Most concomitant medication use during the first 48 weeks was comparable to (within 5% of) the incidence reported in the CSR; exceptions included paracetamol (63.5% [up to Week 48] versus 71.9% [full study]), colecalciferol (25.0% versus 31.3%), amoxicillin sodium-clavulanate potassium (20.8% versus 27.1%), and influenza vaccine (17.7% versus 30.2%).

<div style=\"page-break-after: always\"></div>

Table 47: concomitant medication use reported by at least 5.0 % of total subjects up to week 48 (study ACE-536-B-THAL-002, ITT population)

| ATC4PreferredTerm                               | Luspatercept N=96 n (%)   | Placebo N= 49 n (%)   | Total N =145 (%) u   |
|-------------------------------------------------|---------------------------|-----------------------|----------------------|
| Subjects with at least 1 concomitant medication | 94 (97.9)                 | 49 (100.0)            | 143 (98.6)           |
| Paracetamol                                     | 61 (63.5)                 | 23 (46.9)             | 84 (57.9)            |
| Acetylsalicylic acid                            | 23 (24.0)                 | 16 (32.7)             | 39 (26.9)            |
| Colecalciferol                                  | 24 (25.0)                 | 14 (28.6)             | 38 (26.2)            |
| Ibuprofen                                       | 25 (26.0)                 | 9 (18.4)              | 34 (23.4)            |
| Calcium carbonate                               | 22 (22.9)                 | 12 (24.5)             | 34 (23.4)            |
| Amoxicillin sodium; clavulanate potassium       | 20 (20.8)                 | 10 (20.4)             | 30 (20.7)            |
| Ergocalciferol                                  | 17 (17.7)                 | 8 (16.3)              | 25 (17.2)            |
| Influenza vaccine                               | 17 (17.7)                 | 3 (6.1)               | 20 (13.8)            |
| Allopurinol                                     | 12 (12.5)                 | 6 (12.2)              | 18 (12.4)            |
| Omeprazole                                      | 11 (11.5)                 | 6 (12.2)              | 17 (11.7)            |
| Ketoprofen                                      | 13 (13.5)                 | 3 (6.1)               | 16 (11.0)            |
| Amoxicillin                                     | 12 (12.5)                 | 3 (6.1)               | 15 (10.3)            |
| Loratadine                                      | 10 (10.4)                 | 3 (6.1)               | 13 (9.0)             |

Table 48: concomitant medication use reported by at least 5.0 % of total subjects up to week 48 (study ACE-536-B-THAL-002, ITT population)

| ATC4PreferredTerm    | Luspatercept N=96 n (%)   | Placebo N= 49 n (%)   | Total N =145 n (%)   |
|----------------------|---------------------------|-----------------------|----------------------|
| Vitamins NOS         | 9 (9.4)                   | 1 (2.0)               | 10 (6.9)             |
| Levothyroxine sodium | 8 (8.3)                   | 5 (10.2)              | 13 (9.0)             |
| Domperidone          | 8 (8.3)                   | 4 (8.2)               | 12 (8.3)             |
| Folic acid           | 8 (8.3)                   | 2 (4.1)               | 10 (6.9)             |
| Chlorphenamine       | 6 (6.3)                   | 6 (12.2)              | 12 (8.3)             |
| Diclofenac           | 7 (7.3)                   | 4 (8.2)               | 11 (7.6)             |
| Vitamin D NOS        | 7 (7.3)                   | 2 (4.1)               | 9 (6.2)              |
| Azithromycin         | 5 (5.2)                   | 4 (8.2)               | 9 (6.2)              |

Abbreviations: ITT, intent-to-treat; NOS, not otherwise specified

Data cutoff date: 14-Sep-2020.

Somrco:TohlRFF27A141101

Details of antibiotic therapy for all subjects by treatment arm including reasons for therapy have been provided. Only 2 subjects in the luspatercept arm had concomitant antibiotic use due to splenectomy and one subject in the placebo arm had antibiotic therapy given as prophylaxis for bacterial infection, indicating that prophylactic use was not one of the major reasons for antibiotic therapy. All other antibiotic use was for the treatment of adverse events of infection. As such, it can be concluded that the use of antibiotic treatment did not affect the need for transfusions.

<div style=\"page-break-after: always\"></div>

## Procedures and Surgeries

Prior procedures and surgeries were reported in 27.1% of subjects in the luspatercept treatment group and 36.7% of subjects in the placebo treatment group; only appendicectomy (11 [7.6%] subjects) and tonsillectomy (4 [2.8%] subjects) were reported in &gt; 2 subjects overall.

## Numbers analysed

Table 49: Analysis Populations (Randomized Subjects)

| Analysis Population   |   Luspatercept | Placebo   |   Total |
|-----------------------|----------------|-----------|---------|
| ITTa                  |             96 | 49        |     145 |
| Safety b              |             96 | 49        |     145 |
| PPc                   |             90 | 48        |     138 |
| HRQoL NTDT-PRO        |             95 | 49        |     144 |
| HRQoL FACIT-Fd        |             94 | 47        |     141 |
| HRQoL SF-36d          |             92 | 46        |     138 |
| PKe                   |             96 |           |      96 |

Source: Table 14.1.2.

## Outcomes and estimation

## Hemoglobin parameters

- Primary endpoint

Table 50 : Subjects With a Mean Hemoglobin Increase of at Least 1.0 g/dL From Baseline Over a Continuous 12-week Interval From Week 13 to Week 24; Subjects With Missing Values Classified as Nonresponders (ITT Population)

| Parameter                                | Luspatercept (N = 96)   | Placebo (N = 49)   |
|------------------------------------------|-------------------------|--------------------|
| Number of Responders a , n (%)           | 74 (77.1)               | 0                  |
| Erythroid Response Rate (%) (95% CI) b   | 77.1 (67.4, 85.0)       | 0.0 (0.0, 7.3)     |
| Difference in Proportions (%) (95% CI) c | 77.1 (63.4, 87.0)       | 77.1 (63.4, 87.0)  |

<div style=\"page-break-after: always\"></div>

| Common Risk Difference (%) (95% CI) c   | 77.1 (68.7, 85.5)   |
|-----------------------------------------|---------------------|
| Odds Ratio (95% CI) d                   | INF                 |
| P-valued d                              | < 0.0001            |

CI = confidence interval; CMH = Cochran-Mantel-Haenszel; Hb = hemoglobin; INF = infinity; ITT = intent to treat; NTDT-PRO T/W=non-transfusiondependent β -thalassemia patient-reported outcome tiredness and weakness; RBC = red blood cell.

a Defined as the number of subjects with ≥ 1.0 g/dL Hb increase in the absence of RBC transfusions, compared with baseline, ie, the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1.

b  The 95% CI for response rate (%) was estimated from the Clopper-Pearson exact test.

c  The difference in proportions (luspatercept - placebo) and 95% CI were estimated from the exact unconditional test. The common risk difference (luspatercept - placebo) and 95% CI were estimated from the CMH test stratified by baseline Hb category (&lt; 8.5 versus ≥ 8.5 g/dL) and baseline NTDT -PRO T/W domain score category (≥ 3 versus &lt; 3) defined at randomization as covariates.

d  The odds ratio (luspatercept versus placebo) with 95% CI and p-value were estimated from the CMH test stratified by baseline Hb category (&lt; 8.5 versus ≥ 8.5 g/dL) and baseline NTDT -PRO T/W domain score category (≥ 3 versus &lt; 3) defined at randomization as covariates.

Note: Subjects with missing Hb at the Week 13 to Week 24 interval were classified as non-responders in the analysis. Source: Table 14.2.1.1.

## · Sensitivity analyses (using ITT population)

- -Subjects with missing Hb measurements during the Week 13 to Week 24 interval excluded (PP Population) (1)
- -Subjects with &lt; 3 Hb measurements during the Week 13 to Week 24 interval classified as nonresponders (2)
- -Subjects with &lt; 3 Hb measurements during the Week 13 to Week 24 interval excluded (3)
- -Subjects with transfusion during the Week 13 to Week 24 interval classified as nonresponders (4)
- -COVID-19-impacted subjects excluded (5)
- -A tipping point analysis was also performed using the ITT population, in which the 2 subjects in the placebo treatment group who had missing Hb values during the Week 13 to Week 24 interval were imputed as erythroid responders (erythroid response rate: 4.1% [95% CI: 0.5, 14.0]). In this scenario, the difference in erythroid response rates remained consistent with the main analysis (73.0% [95% CI: 58.9, 83.8]; p &lt; 0.0001)

<div style=\"page-break-after: always\"></div>

| Sensitivity Analyses                                                             |                                                                                 |                                                                                 |                                                                                 |                                                                                 |
|----------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| (1) PP Population (Subjects With Missing Values Classified as Nonresponders) (n) |                                                                                 |                                                                                 |                                                                                 |                                                                                 |
| Total N | Number of responders, n (%)                                            | 90 | 69 (76.7)                                                                  | 48 | 0                                                                          |                                                                                 |                                                                                 |
| Erythroid response Rate (%) [95% CI]                                             | 76.7 [66.6; 84.9]                                                               | 0.0 [0.0; 7.4]                                                                  | 76.7 [62.7; 86.7]                                                               | <.0001                                                                          |
| (2) Subjects With Missing Hb During Week 13 to Week 24 EXCLUDED                  | (2) Subjects With Missing Hb During Week 13 to Week 24 EXCLUDED                 | (2) Subjects With Missing Hb During Week 13 to Week 24 EXCLUDED                 | (2) Subjects With Missing Hb During Week 13 to Week 24 EXCLUDED                 | (2) Subjects With Missing Hb During Week 13 to Week 24 EXCLUDED                 |
| Total N | Number of responders, n (%)                                            | 96 | 74 (77.1)                                                                  | 47 | 0                                                                          |                                                                                 |                                                                                 |
| Erythroid response Rate (%) [95% CI]                                             | 77.1 [67.4; 85.0]                                                               | 0.0 [0.0; 7.5]                                                                  |                                                                                 | <.0001                                                                          |
| (3) Subjects With <3 Hb measurements During Week 13 to Week 24 NONRESPONDER      | (3) Subjects With <3 Hb measurements During Week 13 to Week 24 NONRESPONDER     | (3) Subjects With <3 Hb measurements During Week 13 to Week 24 NONRESPONDER     | (3) Subjects With <3 Hb measurements During Week 13 to Week 24 NONRESPONDER     | (3) Subjects With <3 Hb measurements During Week 13 to Week 24 NONRESPONDER     |
| Total N | Number of responders, n (%)                                            | 96 | 73 (76.0)                                                                  | 49 | 0                                                                          |                                                                                 |                                                                                 |
| Erythroid response Rate (%) [95% CI]                                             | 76.0 [66.3; 84.2]                                                               | 0.0 [0.0; 7.3]                                                                  |                                                                                 | <.0001                                                                          |
| (4) Subjects With < 3 Hb During Week 13 to Week 24 EXCLUDED                      | (4) Subjects With < 3 Hb During Week 13 to Week 24 EXCLUDED                     | (4) Subjects With < 3 Hb During Week 13 to Week 24 EXCLUDED                     | (4) Subjects With < 3 Hb During Week 13 to Week 24 EXCLUDED                     | (4) Subjects With < 3 Hb During Week 13 to Week 24 EXCLUDED                     |
| Total N | Number of responders, n (%)                                            | 93 | 73 (78.5)                                                                  | 45 | 0                                                                          |                                                                                 |                                                                                 |
| Erythroid response Rate (%) [95% CI]                                             | 78.5 [68.8; 86.3]                                                               | 0.0 [0.0; 7.9]                                                                  |                                                                                 | <.0001                                                                          |
| (4) Subjects With Transfusions During Week 13 to Week 24 NONRESPONDER            | (4) Subjects With Transfusions During Week 13 to Week 24 NONRESPONDER           | (4) Subjects With Transfusions During Week 13 to Week 24 NONRESPONDER           | (4) Subjects With Transfusions During Week 13 to Week 24 NONRESPONDER           | (4) Subjects With Transfusions During Week 13 to Week 24 NONRESPONDER           |
| Total N | Number of responders, n (%)                                            | 96 | 71 (74.0)                                                                  | 49 | 0                                                                          |                                                                                 |                                                                                 |
| Erythroid response Rate (%) [95% CI]                                             | 74.0 [64.0; 82.4]                                                               | 0.0 [0.0; 7.3]                                                                  |                                                                                 | <.0001                                                                          |
| (5) Subjects With Missing Hb During Week 13 to Week 24 due to COVID-19 EXCLUDED  | (5) Subjects With Missing Hb During Week 13 to Week 24 due to COVID-19 EXCLUDED | (5) Subjects With Missing Hb During Week 13 to Week 24 due to COVID-19 EXCLUDED | (5) Subjects With Missing Hb During Week 13 to Week 24 due to COVID-19 EXCLUDED | (5) Subjects With Missing Hb During Week 13 to Week 24 due to COVID-19 EXCLUDED |
| Total N | Number of responders, n (%)                                            | 95 | 73 (76.8)                                                                  | 49 | 0                                                                          |                                                                                 |                                                                                 |
| Erythroid response Rate (%) [95% CI]                                             | 76.8 [67.1; 84.9]                                                               | 0.0 [0.0; 7.3]                                                                  |                                                                                 | <.0001                                                                          |

## · Key secondary endpoint 2 Change From Baseline in Mean Hemoglobin Over a Continuous 12-week Interval From Week 13 to Week 24

The LS mean difference for the luspatercept treatment group versus the placebo treatment group was 1.42 (95% CI: 1.16, 1.67) and this treatment difference was nominally significant (nominal p &lt; 0.0001), favoring luspatercept over placebo.

<div style=\"page-break-after: always\"></div>

Table 51: Mean change in Haemglobin (g/dL) from baseline over a continuous 12 week interval from week 13 to week 24 (ITT population)

| Parameter                                               | Luspatercept (N=96)   | Placebo (N=49)    |
|---------------------------------------------------------|-----------------------|-------------------|
| Baseline,'n                                             | 96                    | 49                |
| Mean (SD)                                               | 8.20 (1.216)          | 8.09 (1.305)      |
| Median (Min, Max)                                       | 8.23 (5.3, 10.1)      | 8.13 (5.7, 10.1)  |
| Week 13 to Week 24, n                                   | 96                    | 47                |
| Mean (SD)                                               | 9.75 (1.512)          | 8.25 (1.397)      |
| Median (Min, Max)                                       | 10.17 (5.8, 12.0)     | 8.36 (5.3, 10.7)  |
| Mean Change From Baseline (Week 13 to Week 24), n       | 96                    | 47                |
| Mean (SD)                                               | 1.54 (0.820)          | 0.13 (0.450)      |
| Median (Min, Max)                                       | 1.58 (-0.9, 3.7)      | 0.12 (-1.6, 0.9)  |
| LS Mean (SE)                                            | 1.48 (0.078)          | 0.07 (0.108)      |
| LS Mean of Difference (Luspatercept --Placebo) (95% CI) | 1.42 (1.16, 1.67)     | 1.42 (1.16, 1.67) |
| P-valueb                                                | 0.0001                | 0.0001            |

patient-reported outcome tiredness and weakness; SD = standard deviation; SE = standard error.

b Estimates were based on an ANCOVA model with teatment group and baseline Hb category (= 8.5 versus ≥ 8.5 g/dL) and baseline NIDI-PRO T/W domain score category ( 3 versus ≤ 3) defined at randomization as covaniates.

Baseline was defined as the average of 2 or more Hb measuements at least 1 week apart within 4 weeks before Dose 1 Day 1.

Note: Subjects with missing Hb at the Week 13 to Week 24 interval were excluded in the analysis. Souurce: Table 14.2.3.1.

To enable longitudinal analysis of trends over time using all available Hb data, an MMRM analysis was conducted with intercept and time as the random effect to evaluate the Hb change from baseline at Weeks 12, 24, 36, and 48. The analysis demonstrated that the LS mean changes from baseline in each treatment group and the LS mean differences between the treatment groups at these time points were similar to the change observed for the Week 13 to Week 24 interval and were consistent over time.

<div style=\"page-break-after: always\"></div>

Table 52: MMRM Analysis for Haemoglobin (g/dL) mean change from baseline by week; least squares mean changes from baseline (ITT population)

| Parameter                                     | Luspatercept (N =96)   | Placebo (N = 49)   |
|-----------------------------------------------|------------------------|--------------------|
| Baseline                                      |                        |                    |
| Mean (SD)                                     | 8.20 (1.216)           | 8.09 (1.305)       |
| Median (Min, Max)                             | 8.23 (5.3, 10.1)       | 8.13 (5.7, 10.1)   |
| Change From Baseline to Week 12               |                        |                    |
| LS Mean (SE)                                  | 1.40 (0.067)           | 0.10 (0.094)       |
| Difference (95% CI)b (Luspatercept - Placebo) | 1.30 (1.08, 1.52)      | 1.30 (1.08, 1.52)  |
| P-value                                       | <0.0001                | <0.0001            |
| Change From Baseline to Week 24               |                        |                    |
| LS Mean (SE)b                                 | 1.47 (0.070)           | 0.11 (0.098)       |
| Difference (95% CI)b (Luspatercept - Placebo) | 1.35 (1.12, 1.58)      | 1.35 (1.12, 1.58)  |
| P-valuec                                      | <0.0001                | <0.0001            |
| Change From Baseline to Week 36               |                        |                    |
| LS Mean (SE)b                                 | 1.53 (0.077)           | 0.13 (0.110)       |
| Difference (95% CI)b (Luspatercept - Placebo) | 1.41 (1.15, 1.67)      | 1.41 (1.15, 1.67)  |
| P-valuec                                      | <0.0001                | <0.0001            |
| Change From Baseline to Week 48               |                        |                    |
| LS Mean (SE)b                                 | 1.60 (0.088)           | 0.14 (0.128)       |
| Difference (95% CI) (Luspatercept - Placebo)  | 1.46 (1.16, 1.76)      | 1.46 (1.16, 1.76)  |
| P-valuet                                      | <0.0001                | <0.0001            |

Note: The Hb records collected up to the minimum of (death date, study discontinuation date, last dose date + 20. cutoff date) were used for the analysis.

Source:Table 14.2.6.1.

The following additional sensitivity analyses were provided (LS mean difference and corresponding 95%CI are presented in the following):

- -PP population, subjects with missing Hb values during the Week 13 to Week 24 interval excluded (n=90 vs n=46): 1.44 (95% CI: 1.18, 1.69) (p &lt; 0.0001)
- -ITT population, subjects with missing Hb values during the Week 13 to Week 24 interval imputed by baseline values (n=96 vs. n=49): 1.43 (95% CI: 1.18, 1.67) (p &lt; 0.0001)

<div style=\"page-break-after: always\"></div>

- -ITT population, subjects with missing Hb values during the Week 13 to Week 24 interval imputed by postbaseline mean values (n=96 vs. n=49):  1.42 (95% CI: 1.17, 1.67) (p &lt; 0.0001)
- -ITT population, subjects with missing Hb values during the Week 13 to Week 24 interval imputed by the multiple imputation method (n=96 vs. n=49): 1.42 (95% CI: 1.17, 1.66) (p &lt; 0.0001)
- -ITT population, COVID-19-impacted subjects excluded (n=95 vs. n=47): 1.42 (95% CI: 1.16, 1.67) (p &lt; 0.0001)

## · Key Secondary Efficacy Endpoint 3 -Subjects With a Mean Hemoglobin Increase of at Least 1.0 g/dL From Baseline Over a Continuous 12-week Interval From Week 37 to Week 48

The proportion of erythroid responders (ie, subjects with a mean Hb increase of ≥ 1.0 g/dL from baseline) over a continuous 12-week interval from Week 37 to Week 48 in the absence of transfusions was greater in the luspatercept treatment group than in the placebo treatment group (70.8% versus 2.0%, respectively). The difference in the proportion of erythroid responders between the treatment groups was 68.8% (95% CI: 54.3, 80.4), with results favouring luspatercept over placebo, which was nominally significant (nominal p &lt; 0.0001).

Table 53: Subjects with a mean haemoglobin increase of at least 1.0 g/dL from baseline over a continuous 12 week interval from week 37 to week 48; subjects with missing values classified as non-responders (ITT population)

| Parameter                              | Luspatercept (N= 96)   | Placebo (N=49)     |
|----------------------------------------|------------------------|--------------------|
| Number of Responders', n (%)           | 68 (70.8)              | 1 (2.0)            |
| Erythroid Response Rate (%) (95% CI)   | 70.8 (60.7, 79.7)      | 2.0 (0.1, 10.9)    |
| Difference in Proportions (%) (95% CI) | 68.8 (54.3, 80.4)      | 68.8 (54.3, 80.4)  |
| Common Risk Difference (%) (95% CI)    | 68.6 (58.5, 78.7)      | 68.6 (58.5, 78.7)  |
| Odds Ratio (95% CI)                    | 89.9 (12.9, 628.0)     | 89.9 (12.9, 628.0) |
| P-valued                               | c0.0001                | c0.0001            |

Source: Table 14.2.4.1.

The following additional sensitivity analyses were provided (proportion of erythroid responders for luspatercept and placebo, respectively; difference in the proportion of erythroid responders between luspatercept and Pb):

- PP population, subjects with missing Hb values during the Week 37 to Week 48 interval classified as nonresponders: 70.0% (63 of 90 subjects) vs. 2.1% (1 of 48 subjects); 67.9% (95% CI: 52.9, 80.09)(p &lt; 0.0001)
- ITT population, subjects with missing Hb values during the Week 37 to Week 48 interval excluded: 74.7% (68 of 91 subjects) vs. 2.9% (1 of 34 subjects); 71.8% (95% CI: 55.0, 84.9) (p &lt; 0.0001)

<div style=\"page-break-after: always\"></div>

- ITT population, subjects with &lt; 3 Hb values during the Week 37 to Week 48 interval classified as nonresponders: 69.8% (67 of 96 subjects) vs. 2.0% (1 of 49 subjects); 67.8% (95% CI: 53.1, 80.0) (p &lt; 0.0001)
- ITT population, subjects with &lt; 3 Hb values during the Week 37 to Week 48 interval Excluded: 75.3% (67 of 89 subjects) vs. 3.2% (1 of 31 subjects); 72.1% (95% CI: 54.8, 85.8) (p &lt; 0.0001)
- ITT population, COVID-19-impacted subjects excluded: 72.5% (66 of 91 subjects) vs. 2.1% (1 of 47 subjects); 70.4% (95% CI: 55.9, 82.6) (p &lt; 0.0001)

## · Change From Baseline in Mean Hemoglobin Over a Continuous 12-week Interval From Week 37 to Week 48

The LS mean difference for the luspatercept treatment group versus the placebo treatment group was 1.49 (95% CI: 1.20, 1.79) and this treatment difference was nominally significant (nominal p &lt; 0.0001) favouring the luspatercept treatment group.

Table 54: Mean change in Haemoglobin (g/dL) from baseline over a continuous 12 week interval from week 37 to week 48 (ITT population)

| Parameter                                               | Luspatercept (N=96)   | Placebo (N=49)    |
|---------------------------------------------------------|-----------------------|-------------------|
| Baseline,'n                                             | 96                    | 49                |
| Mean (SD)                                               | 8.20 (1.216)          | 8.09 (1.305)      |
| Median (Min, Max)                                       | 8.23 (5.3, 10.1)      | 8.13 (5.7, 10.1)  |
| Week 37 to Week 48, n                                   | 91                    | 34                |
| Mean (SD)                                               | 9.75 (1.521)          | 7.89 (1.376)      |
| Median (Min, Max)                                       | 10.25 (6.1, 11.9)     | 7.70 (5.4, 10.4)  |
| Mean Change From Baseline (Week 37 to Week 48), n       | 91                    | 34                |
| Mean (SD)                                               | 1.57 (0.812)          | 0.07 (0.503)      |
| Median (Min, Max)                                       | 1.55 (-0.4, 3.6)      | 0.10 (-1.0, 1.2)  |
| LS Mean (SE)                                            | 1.50 (0.083)          | 0.01 (0.130)      |
| LS Mean of Difference (Luspatercept - Placebo) (95% CI) | 1.49 (1.20, 1.79)     | 1.49 (1.20, 1.79) |
| P-valueb                                                | c0.0001               | c0.0001           |

Source:Table 14.2.5.1.

<div style=\"page-break-after: always\"></div>

- Subjects With a Mean Hemoglobin Increase of at Least 1.5 g/dL From Baseline Over a Continuous 12-week Interval From Week 13 to Week 24 and From Week 37 to Week 48

Table 55 : subjects with a mean Haemoglobin increase of at least 1.5g/dL from baseline over a continuous 12 week interval from week 13 to week 24 and week 37 to week 48; subjects with missing values classified as non-responders (ITT population)

| Parameter                               | Luspatercept (N=96)   | Placebo (N=49)    |
|-----------------------------------------|-----------------------|-------------------|
| Week 13 to Week 24                      |                       |                   |
| Number of Responders\"                   | 50 (52.1)             |                   |
| Erythroid Response Rate (%) (95% CI)    | 52.1 (41.6, 62.4)     | 0.0 (0.0, 7.3)    |
| Difference in Proportions (%) (95% CI)  | 52.1 (36.2, 66.2)     | 52.1 (36.2, 66.2) |
| Common Risk Difference (%) (95% CI)     | 52.3 (42.3, 62.3)     | 52.3 (42.3, 62.3) |
| Odds Ratio (95% CD                      | N                     | N                 |
| P-valued                                | c 0.0001              | c 0.0001          |
| Week 37 to 48                           |                       |                   |
| Number of Responders                    | 47 (49.0)             | 0                 |
| Erythroid Response Rate (%) (95% CI)    | 49.0 (38.6, 59.4)     | 0.0 (0.0, 7.3)    |
| Parameter                               | Luspatercept (N=90)   | Placebo (N= 49)   |
| Difference in Proportions (%6) (95% CI) | 49.0 (32.9, 63.4)     | 49.0 (32.9, 63.4) |
| Common Risk Difference (%o) (95% CI)    | 49.1 (39.1, 59.1)     | 49.1 (39.1, 59.1) |
| Odds Ratio (95% C1)                     | INF                   | INF               |
| P-value\"                                | 0.0001                | 0.0001            |

Souwces: Table 14.2.18.1 and Table 14.2.18.2.

## Transfusion use

Few subjects received transfusion therapy prior to study entry, with at least 1 transfusion received by 13 (13.5%) subjects (maximum units transfused: 4) and 7 (14.3%) subjects (maximum units transfused: 4) in the luspatercept and placebo treatment groups, respectively, during the 24 weeks preceding Day 1.

<div style=\"page-break-after: always\"></div>

Table 56: Proportion of subjects who remained transfusion-free

| Endpoint                                                       | Luspatercept (n/N (%)) versus Placebo (n/N (%))   | Treatment Difference (95%CI)   | P-value   |
|----------------------------------------------------------------|---------------------------------------------------|--------------------------------|-----------|
| Proportion of subjects transfusion-free at baseline (12 weeks) | 90/96 (93.8%) versus 45/49 (91.8%)                |                                |           |
| Proportion of subjects transfusion-free at baseline (24 weeks) | 83 /96 ( 86.5% ) versus 42 /49 ( 85.7% )          |                                |           |
| Proportion of subjects who were transfusion free over 24 weeks | 86 /96 ( 89.6% ) versus 33 /49 ( 67.3% )          | 22.2 (5.0, 38.6)               | 0.0013*   |
| Proportion of subjects who were transfusion free over 48 weeks | 79 /96 ( 82.3% ) versus 22 /49 ( 44.9% )          | 37.4 (20.9, 53.0)              | < 0.0001* |

Source: Table 14.2.15.1; Table 14.2.15.2.

The proportion of transfusion-free subjects during the Week 1 to Week 24 interval was nominally significantly greater in the luspatercept treatment group than in the placebo treatment group (89.6% versus 67.3%, respectively; nominal p = 0.0013)

The proportion of transfusion-free subjects during the Week 1 to Week 48 interval was nominally significantly greater in the luspatercept treatment group than in the placebo treatment group (82.3% versus 44.9%, respectively; nominal p &lt; 0.0001)

## Quality of Life

## NTDT PRO T/W

- Key Secondary Efficacy Endpoint 1 Change From Baseline in the NTDTPRO T/W Domain Score to Week 13 to Week 24

The LS mean difference for the luspatercept treatment group versus the placebo treatment group was -0.48 (95% CI: -1.03, 0.08). This treatment difference favoured luspatercept over placebo but was not statistically significant (p = 0.0924).

<div style=\"page-break-after: always\"></div>

Table 57: NTDT-PRO T/W domain change from baseline to week 13 to week 24 (ITT population)

| Parameter                                               | Luspatercept (N = 96)   | Placebo (N = 49)    |
|---------------------------------------------------------|-------------------------|---------------------|
| NTDT-PRO T/W Domain Score at Baseline, n                | 96                      | 49                  |
| Mean (SD)                                               | 4.06 (2.291)            | 4.01 (2.025)        |
| Median (Min, Max)                                       | 4.29 (0.0, 9.5)         | 4.13 (0.4, 9.5)     |
| NTDT-PRO T/W Domain Score at Week 13 to Week 24, n      | 94                      | 48                  |
| Mean (SD)                                               | 3.14 (2.053)            | 3.52 (1.911)        |
| Median (Min, Max)                                       | 3.18 (0.0, 9.0)         | 3.36 (0.5,8.2)      |
| Mean Change From Baseline (Week 13 to Week 24), n       | 94                      | 48                  |
| Mean (SD)                                               | -0.92 (1.862)           | -0.47 (1.356)       |
| Median (Min, Max)                                       | -0.56 (-6.9, 2.1)       | -0.27 (-3.3, 3.7)   |
| LS Mean (SE)                                            | -0.68 (0.176)           | -0.20 (0.240)       |
| LS Mean of Difference (Luspatercept - Placebo) (95% CI) | -0.48 (-1.03, 0.08)     | -0.48 (-1.03, 0.08) |
| P-valueb                                                | 0.0924                  | 0.0924              |

ANCOVA = analysis of covariance; CI = confidence interval; Hb = hemoglobin; ITT = intent to treat; LS = least squares; Max = maximum; Min = minimum; NTDT-PRO T/W = nontransfusion-dependent β-thalassemia patient-reported outcome tiredness and weakness; SD = standard deviation; SE = standard error.

b Estimates were based on an ANCOVA model with baseline Hb category (&lt; 8.5 versus ≥ 8.5 g/dL) and baseline NTDT-PRO T/W domain score category (≥ 3 versus &lt; 3) defined at randomization as covariates.

- a Baseline was defined as the average of nonmissing NTDT-PRO T/W domain scores over 7 days before Dose 1 Day 1.

Note: Subjects with missing NTDT-PRO T/W domain score at the Week 13 to Week 24 interval were excluded in the analysis.

Source: Table 14.2.2.1.

- Sensitivity analyses for this key secondary efficacy endpoint were performed as follows:
- -Per protocol population, subjects who had missing values were excluded (Table 14.2.2.2; data not shown)
- -HRQoL evaluable population, subjects who had missing values were excluded (Table 14.2.2.3; data not shown).
- -ITT population, subjects who had missing values were imputed by their baseline scores (Table 14.2.2.4; data not shown).
- -ITT population, subjects who had missing values were imputed by their postbaseline means (Table 14.2.2.5; data not shown).
- -ITT population, subjects who had missing values were imputed by the multiple imputation method (Table 14.2.2.6; data not shown).
- -ITT population, subjects who had missing values due to COVID-19 were excluded (Table 14.2.2.7).
- -ITT population, ANCOVA model with interaction terms included (Table 14.2.2.8; data not shown).
- -ITT population, subjects with at least 4 nonmissing daily scores per week (Table 14.2.2.9; data not shown).

The results of sensitivity analyses were consistent with those of the main analysis of this key secondary efficacy endpoint.

<div style=\"page-break-after: always\"></div>

| Key Secondary Endpoint (1)                                                                                                                                                                                                                                                                                                                                                            | Luspatercept (ITT, N = 96)                                                                                                                                                                                                                                                                                                                                                            | Placebo (ITT, N = 49)                                                                                                                                                                                                                                                                                                                                                                 | Treatment Difference [95% CI]                                                                                                                                                                                                                                                                                                                                                         | P-Value                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sensitivity Analyses                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                       |
| PP Population                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                       |
| Total N | NTDT-PRO T/W domain score, LS mean change (SE)                                                                                                                                                                                                                                                                                                                              | 88 | -0.68 (0.183)                                                                                                                                                                                                                                                                                                                                                                    | 47 | -0.21 (0.240)                                                                                                                                                                                                                                                                                                                                                                    | -0.47 [-1.04; 0.09]                                                                                                                                                                                                                                                                                                                                                                   | .0993                                                                                                                                                                                                                                                                                                                                                                                 |
| HRQoL evaluable Population                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                       |
| Total N | NTDT-PRO T/W domain score, LS mean change (SE)                                                                                                                                                                                                                                                                                                                              | 94 | -0.68 (0.176)                                                                                                                                                                                                                                                                                                                                                                    | 48 | -0.20 (0.240)                                                                                                                                                                                                                                                                                                                                                                    | -0.48 [-1.03; 0.08]                                                                                                                                                                                                                                                                                                                                                                   | .0924                                                                                                                                                                                                                                                                                                                                                                                 |
| ITT Population, Sensitivity Analyses (1) to (6)                                                                                                                                                                                                                                                                                                                                       | ITT Population, Sensitivity Analyses (1) to (6)                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                       |
| (1) Subjects With Missing Values During Week 13 to Week 24 Were Imputed by Baseline (defined as the average of non-missing NTDT-PRO T/W score over 7 days before Dose 1 Day 1)                                                                                                                                                                                                        | (1) Subjects With Missing Values During Week 13 to Week 24 Were Imputed by Baseline (defined as the average of non-missing NTDT-PRO T/W score over 7 days before Dose 1 Day 1)                                                                                                                                                                                                        | (1) Subjects With Missing Values During Week 13 to Week 24 Were Imputed by Baseline (defined as the average of non-missing NTDT-PRO T/W score over 7 days before Dose 1 Day 1)                                                                                                                                                                                                        | (1) Subjects With Missing Values During Week 13 to Week 24 Were Imputed by Baseline (defined as the average of non-missing NTDT-PRO T/W score over 7 days before Dose 1 Day 1)                                                                                                                                                                                                        | (1) Subjects With Missing Values During Week 13 to Week 24 Were Imputed by Baseline (defined as the average of non-missing NTDT-PRO T/W score over 7 days before Dose 1 Day 1)                                                                                                                                                                                                        |
| Total N | NTDT-PRO T/W domain score, LS mean change (SE)                                                                                                                                                                                                                                                                                                                              | 96 | -0.66 (0.172)                                                                                                                                                                                                                                                                                                                                                                    | 49 | -0.19 (0.236)                                                                                                                                                                                                                                                                                                                                                                    | -0.48 [-1.02; 0.07]                                                                                                                                                                                                                                                                                                                                                                   | .0877                                                                                                                                                                                                                                                                                                                                                                                 |
| (2) Subjects With Missing Values During Week 13 to Week 24 Were Imputed by Postbaseline Means (averages of all non-missing post-baseline 12-week interval values)                                                                                                                                                                                                                     | (2) Subjects With Missing Values During Week 13 to Week 24 Were Imputed by Postbaseline Means (averages of all non-missing post-baseline 12-week interval values)                                                                                                                                                                                                                     | (2) Subjects With Missing Values During Week 13 to Week 24 Were Imputed by Postbaseline Means (averages of all non-missing post-baseline 12-week interval values)                                                                                                                                                                                                                     | (2) Subjects With Missing Values During Week 13 to Week 24 Were Imputed by Postbaseline Means (averages of all non-missing post-baseline 12-week interval values)                                                                                                                                                                                                                     | (2) Subjects With Missing Values During Week 13 to Week 24 Were Imputed by Postbaseline Means (averages of all non-missing post-baseline 12-week interval values)                                                                                                                                                                                                                     |
| Total N | NTDT-PRO T/W domain score, LS mean change (SE)                                                                                                                                                                                                                                                                                                                              | 95 | -0.67 (0.175)                                                                                                                                                                                                                                                                                                                                                                    | 49 | -0.20 (0.237)                                                                                                                                                                                                                                                                                                                                                                    | -0.47 [-1.02; 0.08]                                                                                                                                                                                                                                                                                                                                                                   | .0926                                                                                                                                                                                                                                                                                                                                                                                 |
| (3) Subjects With Missing Values During Week 13 to Week 24 Were Imputed by Multiple Imputation Method (Multiple Imputation assumes all variables are individually and jointly normally distributed and uses the MCMC method to impute all missing values. The number of imputations is 25)                                                                                            | (3) Subjects With Missing Values During Week 13 to Week 24 Were Imputed by Multiple Imputation Method (Multiple Imputation assumes all variables are individually and jointly normally distributed and uses the MCMC method to impute all missing values. The number of imputations is 25)                                                                                            | (3) Subjects With Missing Values During Week 13 to Week 24 Were Imputed by Multiple Imputation Method (Multiple Imputation assumes all variables are individually and jointly normally distributed and uses the MCMC method to impute all missing values. The number of imputations is 25)                                                                                            | (3) Subjects With Missing Values During Week 13 to Week 24 Were Imputed by Multiple Imputation Method (Multiple Imputation assumes all variables are individually and jointly normally distributed and uses the MCMC method to impute all missing values. The number of imputations is 25)                                                                                            | (3) Subjects With Missing Values During Week 13 to Week 24 Were Imputed by Multiple Imputation Method (Multiple Imputation assumes all variables are individually and jointly normally distributed and uses the MCMC method to impute all missing values. The number of imputations is 25)                                                                                            |
| Total N | NTDT-PRO T/W domain score, LS mean change (SE)                                                                                                                                                                                                                                                                                                                              | 96 | -0.69 (0.175)                                                                                                                                                                                                                                                                                                                                                                    | 49 | -0.19 (0.240)                                                                                                                                                                                                                                                                                                                                                                    | -0.50 [-1.04; 0.05]                                                                                                                                                                                                                                                                                                                                                                   | .0775                                                                                                                                                                                                                                                                                                                                                                                 |
| (4) Subjects Impacted by COVID-19 During Week 13 to Week 24 Were Excluded                                                                                                                                                                                                                                                                                                             | (4) Subjects Impacted by COVID-19 During Week 13 to Week 24 Were Excluded                                                                                                                                                                                                                                                                                                             | (4) Subjects Impacted by COVID-19 During Week 13 to Week 24 Were Excluded                                                                                                                                                                                                                                                                                                             | (4) Subjects Impacted by COVID-19 During Week 13 to Week 24 Were Excluded                                                                                                                                                                                                                                                                                                             | (4) Subjects Impacted by COVID-19 During Week 13 to Week 24 Were Excluded                                                                                                                                                                                                                                                                                                             |
| Total N | NTDT-PRO T/W domain score, LS mean change (SE)                                                                                                                                                                                                                                                                                                                              | 93 | -0.67 (0.178)                                                                                                                                                                                                                                                                                                                                                                    | 48 | -0.20 (0.240)                                                                                                                                                                                                                                                                                                                                                                    | -0.47 [-1.03; 0.09]                                                                                                                                                                                                                                                                                                                                                                   | .0996                                                                                                                                                                                                                                                                                                                                                                                 |
| (5) Model With Interaction Term Included                                                                                                                                                                                                                                                                                                                                              | (5) Model With Interaction Term Included                                                                                                                                                                                                                                                                                                                                              | (5) Model With Interaction Term Included                                                                                                                                                                                                                                                                                                                                              | (5) Model With Interaction Term Included                                                                                                                                                                                                                                                                                                                                              | (5) Model With Interaction Term Included                                                                                                                                                                                                                                                                                                                                              |
| Total N | NTDT-PRO T/W domain score, LS mean change (SE)                                                                                                                                                                                                                                                                                                                              | 94 | -0.62 (0.180)                                                                                                                                                                                                                                                                                                                                                                    | 48 | -0.32 (0.253)                                                                                                                                                                                                                                                                                                                                                                    | -0.31 [-0.91; 0.30]                                                                                                                                                                                                                                                                                                                                                                   | .3199 .01731 Interaction                                                                                                                                                                                                                                                                                                                                                              |
| (6) Subjects With At least 4 Non-Missing Daily Score per Week During Week 13 to Week 24 Weekly NTDT-PRO item scores are calculated only when there are at least 4 or more non-missing daily scores for that week. Weekly NTDT-PRO T/W scores are calculated when there are at least 1 non-missing weekly Tiredness item scores and at least 1 non-missing weekly Weakness item scores | (6) Subjects With At least 4 Non-Missing Daily Score per Week During Week 13 to Week 24 Weekly NTDT-PRO item scores are calculated only when there are at least 4 or more non-missing daily scores for that week. Weekly NTDT-PRO T/W scores are calculated when there are at least 1 non-missing weekly Tiredness item scores and at least 1 non-missing weekly Weakness item scores | (6) Subjects With At least 4 Non-Missing Daily Score per Week During Week 13 to Week 24 Weekly NTDT-PRO item scores are calculated only when there are at least 4 or more non-missing daily scores for that week. Weekly NTDT-PRO T/W scores are calculated when there are at least 1 non-missing weekly Tiredness item scores and at least 1 non-missing weekly Weakness item scores | (6) Subjects With At least 4 Non-Missing Daily Score per Week During Week 13 to Week 24 Weekly NTDT-PRO item scores are calculated only when there are at least 4 or more non-missing daily scores for that week. Weekly NTDT-PRO T/W scores are calculated when there are at least 1 non-missing weekly Tiredness item scores and at least 1 non-missing weekly Weakness item scores | (6) Subjects With At least 4 Non-Missing Daily Score per Week During Week 13 to Week 24 Weekly NTDT-PRO item scores are calculated only when there are at least 4 or more non-missing daily scores for that week. Weekly NTDT-PRO T/W scores are calculated when there are at least 1 non-missing weekly Tiredness item scores and at least 1 non-missing weekly Weakness item scores |
| Total N | NTDT-PRO T/W domain score, LS mean change (SE)                                                                                                                                                                                                                                                                                                                              | 93 | -0.69 (0.179)                                                                                                                                                                                                                                                                                                                                                                    | 45 | -0.19 (0.250)                                                                                                                                                                                                                                                                                                                                                                    | -0.50 [-1.08; 0.08]                                                                                                                                                                                                                                                                                                                                                                   | .0879                                                                                                                                                                                                                                                                                                                                                                                 |

## · Change From Baseline in the NTDT-PRO T/W Domain Score to Week 37 to Week 48

The LS mean difference for the luspatercept treatment group versus the placebo treatment group was -0.79 (95% CI: -1.58, 0.00). This treatment difference favoured luspatercept over placebo but was not nominally significant (nominal p = 0.0510).

<div style=\"page-break-after: always\"></div>

- Observed Mean Change From Baseline in the NTDT-PRO T/W Domain Score by Visit Figure 29: observed mean change form basleine in the NTDT-PRO T/W domain score by visit and treatment group (HRQoL evaluable population)

HRQoL = health-related quality of life; NTDT-PRO T/W = nontransfusion-dependent β-thalassemia patient-reported outcome tiredness and weakness domain; SE = standard eiror. Note: The HRQoL evaluable population was defined as subjects with at least half of 6 weekly item scores from the

<!-- image -->

NTDT-PRO T/W for that week (visit) being nonmissing (ie, &gt; 3 weekly items). A \"* indicates a nominal p ≤ 0.05 for the difference in mean change from baseline between the treatment groups at a specific postbaseline assessment visit based on a 2-sample, 2-sided t-test.

Source: Figure 14.1.1.1.7.

- Proportion of Subjects With a Decrease From Baseline ≥ RD (= 1) in the Mean NTDTPRO T/W Domain Score

The RD for the NTDT-PRO T/W domain score was defined as ≥ 1-point decrease (ie, RD = -1) from baseline over the time from Week 13 to Week 24.

The proportion of subjects with a decrease in the NTDT-PRO T/W domain score that was at least as large as the RD over Week 13 to Week 24 was 37.5% and 28.6% in the luspatercept (n=36) and placebo (n=14) treatment groups, respectively (OR = 1.7; 95% CI: 0.8, 3.7; nominal p = 0.1989) (CSR Table 30 for the ITT population, data not shown).

The proportion of subjects with a decrease in the NTDT-PRO T/W domain score that was at least as large as the RD over Week 37 to Week 48 was 31.3% and 18.4% in the luspatercept (30) and placebo (n=9) treatment groups, respectively (OR = 2.1; 95% CI: 0.9, 5.0; nominal p = 0.0733) (CSR Table 30 for the ITT population, data not shown).

- See subgroup anaylses for subjects with a baseline NTDT-PRO T/W domain score of ≥ 3 and &lt;3 as well as baseline Hb level &lt;8.5 and ≥8 -5 g/dL under the header subgroup analyses.

<div style=\"page-break-after: always\"></div>

## NTDT PRO SoB

Week 13-24 (ITT; n= 94 and n=48): The LS mean difference for the luspatercept treatment group versus the placebo treatment group was -0.49 (95% CI: -1.02, 0.04). This treatment difference favoured luspatercept over placebo but was not nominally significant (nominal p = 0.0721).

Week 37-48 (ITT, n= 72 and n= 28 ): The LS mean difference for the luspatercept treatment group versus the placebo treatment group was -1.07 (95% CI: -1.80, -0.33) and this treatment difference was nominally significant (nominal p = 0.0047), favouring luspatercept over placebo.

## FACIT-F

The FACIT-F is a multidimensional, self-reported HRQoL instrument consisting of 27 core items that include the Functional Assessment of Cancer Therapy - General questionnaire (assessing 4 functional domains: Physical, Social/Family, Emotional, and Functional well-being) supplemented by a 13-item measure designed to capture cancer-related fatigue, the Fatigue subscale. Analyses for FACIT-F Fatigue subscale scores were performed for the HRQoL evaluable population unless otherwise indicated. The FACIT-F Fatigue subscale is scored such that higher score reflects less fatigue and better QoL (score range 0-52; with 0 being the worst possible score and 52 being the best possible score indicating no fatigue).

A subject was considered compliant for the FACIT-F at a visit if at least 32 out of the 40 items in the questionnaire were answered. When calculated using the total number of subjects in the ITT population as the denominators, the compliance quotients at baseline were 100.0% and 98.0% in the luspatercept and placebo treatment groups, respectively. The rates remained relatively high ( ≥ 78.1% and ≥ 77.6% in the luspatercept and placebo treatment groups, respectively) during the first 24 weeks but decreased to 75.0% and 65.3% at Week 48, respectively. The analyses were based on the HRQoL Evaluable Population.

Week 13-24 (n=90 and n=43): The LS mean difference for the luspatercept treatment group versus the placebo treatment group was 1.39 (95% CI: -1.06, 3.83). This treatment difference favoured luspatercept over placebo but was not nominally significant (nominal p = 0.2641).

Week 37-48 (n=83 and n=33): The LS mean difference for the luspatercept treatment group versus the placebo treatment group was 2.19 (95% CI: -0.39, 4.78). This treatment difference favoured luspatercept over placebo but was not nominally significant (nominal p = 0.0959).

## SF-36

The SF-36 is a 36-item generic self-administered PRO questionnaire used to assess patient-reported HRQoL outcomes. The SF-36 yields scores for 8 domains of health: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health as well as physical component summary (PCS) and mental component summary (MCS) scores . The SF-36 is scored such that higher scores reflect a better health state. For this study, a 7-day recall period was used.

A subject was considered compliant for the SF-36 at a visit if at least 18 out of the 36 items in the questionnaire were answered. When calculated using the total number of subjects in the ITT population as the denominators, the compliance quotients at baseline were 97.9% and 95.9% in the luspatercept and placebo treatment groups, respectively. The rates remained relatively high ( ≥ 78.1% and ≥ 75.5% in the luspatercept and placebo treatment groups, respectively) during the first 24 weeks, decreasing to 75.0% and 65.3% at Week 48.

<div style=\"page-break-after: always\"></div>

The raw score for each health domain can be transformed into a 0-100 scale score. This scale can be converted to norm-based scores using a T-score transformation, with a mean of 50 and a standard deviation (SD) of 10. This allows one health domain scale to be meaningfully compared with the other scales, and for domain scores to have a direct interpretation in relation to the distribution of scores in the US general population. Higher norm-based T-scores indicate better health/QoL, based on data from a nationally representative sample of US adults.

Table 58 (excerpt): Composition and Interpretation of T-Scores for the Acute Form of the SF36 (Version 2) Component Summary Measures and Health Domain Scales

| Scale/Measure   | Composition   |   Range of Possible T-Scoresa |   Range of Possible T-Scoresa |   MCID |   RD |
|-----------------|---------------|-------------------------------|-------------------------------|--------|------|
| PCS             | All scales    |                         10.8  |                         75.51 |      2 |  3.8 |
| MCS             | All scales    |                          5.62 |                         69.65 |      3 |  4.6 |

MCID = minimum clinically important difference; MCS = Mental Component Summary; PCS = Physical Component Summary; RD = responder definition; SF-36 = Medical Outcomes Study 36-item Short Form Health Survey

a Highest and lowest observed T-scores based on 2009 US general population normative sample.

Based on the HRQoL evaluable population, the mean (SD) change from baseline in the SF-36 PCS at Week 24 was 0.85 (7.149) and -1.18 (5.503) in the luspatercept and placebo treatment groups, respectively. At Week 48, the mean (SD) change from baseline was 1.03 (5.277) and 0.48 (5.367) in the luspatercept and placebo treatment groups, respectively.

The mean (SD) change from baseline in the SF-36 MCS at Week 24 was 0.98 (8.816) in the luspatercept treatment group and -0.76 (6.901) in the placebo treatment group, respectively. At Week 48, the mean (SD) change from baseline was 0.98 (7.882) and -2.53 (6.538) in the luspatercept and placebo treatment groups, respectively.

Table 59: overview of efficacy analyses in terms of SF-36 (HRQoL evaluable population)

| Endpoint                                          | Luspatercept (n/N (%)) versus Placebo (n/N (%))          | Treatment Difference (95%CI)   | P-value   |
|---------------------------------------------------|----------------------------------------------------------|--------------------------------|-----------|
| Mean change from baseline in SF-36 PCS to Week 24 | LS mean change (SE): 1.00 (0.499) versus -0.38 (0.684)f  | 1.39 (-0.19, 2.96)             | 0.0847*   |
| Mean change from baseline in SF-36 PCS to Week 48 | LS mean change (SE): 1.23 (0.571) versus -0.52 (0.822) f | 1.75 (-0.15, 3.65)             | 0.0712*   |
| Mean change from baseline in SF-36 MCS to Week 24 | LS mean change (SE): 0.83 (0.674) Versus -0.71 (0.947)g  | 1.54 (-0.63, 3.72)             | 0.1633*   |
| Mean change from baseline in SF-36 MCS to Week 48 | LS mean change (SE): 0.81 (0.784) Versus -1.89 (1.152)g  | 2.70 (0.04, 5.36)              | 0.0469*   |

<div style=\"page-break-after: always\"></div>

## 6MWT

Subjects were asked to walk as quickly as possible, without running, along a 30-meter corridor for 6 minutes. The average 6MWT distance for healthy adults aged 20 to 50 years is 593 ± 57 m for women and 638 ± 44 m for men (Chetta, 2006). The mean baseline distances were 446.97 m and 434.98 m in the luspatercept and placebo treatment groups, respectively.

At Week 24 (n=87 and n=47 for luspatercept and placebo, respectively), the LS mean (SE) change from baseline in the mean 6MWT distance covered was 7.20 (7.017) m in the luspatercept treatment group and -8.96 (9.297) m in the placebo treatment group. The LS mean difference at Week 24 for the luspatercept treatment group versus the placebo treatment group was 16.15 (95% CI: -5.73, 38.04) . This difference between the treatment groups was not nominally significant (nominal p = 0.1466).

At Week 48 (n=86 and n=41 for luspatercept and placebo, respectively), the LS mean (SE) change from baseline in the mean 6MWT distance covered was 8.82 (5.907) m in the luspatercept treatment group and -3.62 (8.141) m in the placebo treatment group. The LS mean difference at Week 48 for the luspatercept treatment group versus the placebo treatment group was 12.44 (95% CI: -6.72, 31.59) . This difference between the treatment groups was not nominally significant (nominal p = 0.2011).

## Iron parameters

Iron overload (assessed based on LIC determined using magnetic resonance imaging [MRI], daily ICT dose, and serum ferritin measurements).

- Mean change in derived LIC from baseline at Week 24 and Week 48

Treatment with luspatercept did not result in significant reduction in LIC over the 48-week DBTP.

At Week 24, the LS mean (SE) change in derived LIC from baseline was -0.40 (0.137) mg/g dw in the luspatercept treatment group and -0.28 (0.175) mg/g dw in the placebo treatment group. The LS mean difference at Week 24 for the luspatercept treatment group versus the placebo treatment group was -0.12 (95% CI: -0.52, 0.28) . This difference between the treatment groups was not nominally significant (nominal p = 0.5547).

At Week 48, the LS mean (SE) change in derived LIC from baseline was -0.46 (0.265) mg/g dw in the luspatercept treatment group and -1.13 (0.355) mg/g dw in the placebo treatment group. The L S mean difference at Week 48 for the luspatercept treatment group versus the placebo treatment group was 0.66 (95% CI:  -0.15, 1.47) . This difference between the treatment groups was not nominally significant (nominal p = 0.1071).

- Number of LIC/ICT responders (subjects who achieved ≥ 20% reduction in LIC or ≥ 33% decrease in ICT daily dose from baseline) at Week 24 and Week 48

At Week 24, 44.8% and 49.0% of subjects in the luspatercept and placebo treatment groups, respectively, were LIC/ICT responders (nominal p = 0.4787), whereas at Week 48, 34.4% and 49.0% of subjects in the luspatercept and placebo treatment groups, respectively, were LIC/ICT responders (nominal p = 0.0827). Thus, at both Week 24 and Week 48, the proportions of LIC/ICT responders were numerically but not nominally significantly greater in the placebo treatment group than in the luspatercept treatment group . This may possibly be due to a greater proportion of placebo-treated subjects receiving concomitant deferasirox compared with the luspatercept-treated subjects (30.6% versus 24.0%, respectively). Deferasirox is the only approved ICT in NTDT patients and has demonstrated efficacy in decreasing LIC and serum ferritin in this patient population.

<div style=\"page-break-after: always\"></div>

## · Serum Ferritin

At Week 24, the LS mean (SE) change in mean serum ferritin level from baseline was 29.32 (22.949) μg/L in the luspatercept treatment group and 2.18 (32.217) μg/L in the placebo treatment group. The LS mean difference for the luspatercept treatment group versus the placebo treatment group was 27.14 (95% CI: -46.77, 101.06) and this treatment difference was not nominally significant (nominal p = 0.5865).

At Week 48, the LS mean (SE) change in mean serum ferritin level from baseline was 84.98 (23.117) μg/L in the luspatercept treatment group and 71.48 (32.453) μg/L in the placebo treatment group. The LS mean difference for the luspatercept treatment group versus the placebo treatment group was 13.50 (95% CI: -60.96, 87.96) and this treatment difference was not nominally significant (nominal p = 0.3504).

## Co-morbidities

## · Extramedullary hematopoietic mass (EMH) volume

MRI for assessment of extramedullary hemopoietic masses was done at screening only if subjects were already diagnosed with this condition. Because there was no systematic screening for extramedullary hemopoietic masses at baseline, there is a high risk of underdiagnosis at baseline. Only 11 subjects provided baseline data for EMH masses. The mean (median) EMH mass (located in the vertebra region) volume was 30.17 (13.80) cm 3  among 11 subjects in the luspatercept treatment group and 73.41 (4.91) cm 3  among 11 subjects in the placebo treatment group.

The mean EMH volume increased from baseline in the luspatercept group ((30.97 cm 3  [10 subjects]), while it decreased in the placebo group (-30.42 cm 3  [9 subjects]) at week 48. The mean volumes at Week 48 were similar (60.36 cm3 [13 subjects] and 58.81 cm3 [9 subjects] in the luspatercept and placebo treatment groups, respectively).

## · Tricuspid Valve Regurgitation Velocity

Change in TRV serves as an indicator of potential pulmonary hypertension. A TRV of ≤ 2.8 m/sec (indicates a low probability of pulmonary hypertension) was reported at baseline in 77.1% and 75.5% of subjects in the luspatercept and placebo treatment groups, respectively. Postbaseline, 84.4% and 79.6% of subjects in the luspatercept and placebo treatment groups, respectively, had TRV of ≤ 2.8 m/sec. A TRV of &gt; 3.4 m/sec (indicates a high probability of pulmonary hypertension) was reported at baseline for 1 subject in the luspatercept treatment group; no TRV values of &gt; 3.4 m/sec were reported postbaseline in either treatment group. In general, no deterioration was observed in TRV in the 2 treatment groups postbaseline.

## · Spleen volume

Change from baseline in spleen volume (measured by MRI) at Week 24 and Week 48 was assessed as an exploratory efficacy endpoint in the study for subjects without prior splenectomy.

A total of 64.6% and 46.9%) of subjects in the luspatercept and placebo treatment groups, respectively, were not splenectomised at baseline. 60 and 22 subjects for luspatercept and placebo, respectively, provided baseline data. The mean baseline spleen volume was 958.95 cm 3  and 1113.42 cm 3  in the luspatercept and placebo treatment groups, respectively. Decrease in spleen volume was numerically but not nominally significantly greater at Week 24 and Week 48 in the luspatercept treatment group compared with the placebo treatment group. This was expected given the relatively short period of treatment and observation in the DBTP.

<div style=\"page-break-after: always\"></div>

## · Bone Mineral Density

World Health Organization guidance was followed to assess the osteopenic or osteoporotic status of each subject and ensured consistent reporting across study sites. Any T-score reported as &gt; -1.0 and &lt; -2.5 was to be attributed to osteopenia and any T-score reported as ≥ -2.5 was to be assessed as osteoporosis. These 2 diagnoses were mutually exclusive and the worst diagnosis based on T-score was the one to be reported (Cappellini, 2014b; WHO, 2004; WHO, 1994).

T-scores were essentially stable during the 48-week DBTP. At Week 48, the LS mean (SE) change from baseline in total hip T-score was 0.07 (0.039) in the luspatercept treatment group and -0.05 (0.052) in the placebo treatment group. The LS mean difference at Week 48 for the luspatercept treatment group versus the placebo treatment group was 0.12 (95% CI: -0.01, 0.25). In addition, the LS mean (SE) change from baseline in spine T-score was -0.06 (0.421) in the luspatercept treatment group and -0.03 (0.298) in the placebo treatment group. The LS mean difference at Week 48 for the luspatercept treatment group versus the placebo treatment group was -0.02 (95% CI:

-0.17, 0.12). BMD monitoring tends to occur at least every 2 years, so substantial change was not likely to occur during this time.

During the DBTP by Week 48, comorbidity of osteoporosis (not present at baseline) was reported in 3 (3.1%) subjects in the luspatercept treatment group and 1 (2.0%) subject in the placebo treatment group. By Week 48, comorbid osteopenia was reported in 2 luspatercept-treated subjects (1 subject with osteoporosis diagnosed at baseline) and 1 placebo-treated subject.

Concomitant use of denosumab was reported in 4 (4.2%) and 2 (4.1%) subjects in the luspatercept and placebo treatment groups, respectively. Concomitant use of collagen-hydroxyapatite-complex was reported for 2 (2.1%) and 4 (8.2%) subjects in the luspatercept and placebo treatment groups, respectively. Concomitant use of bisphosphonates was reported for 3 (3.1%) and 5 (10.2%) subjects in the luspatercept and placebo treatment groups, respectively.

## Ancillary analyses

## Subgroup analyses

## Hemoglobin

For the primary and second key secondary efficacy endpoint, a treatment effect (significantly and/or numerically greater) in favour of the luspatercept treatment group versus the placebo treatment group was observed in majority of the subgroups examined (figures 30 and 31).

<div style=\"page-break-after: always\"></div>

Figure 30: Forest plt of subjects with a mean haemoglobin increase of at least 1.0 g/dL from baseline to week 13 to week 24 in absence of transfusions by subgroups (ITT population)

<!-- image -->

6MWT = 6-minute walk test; BL = baseline; CI = confidence interval; FACIT-F FS = Functional Assessment of Chronic Illness Therapy - Fatigue, Fatigue subscale; Hb (also HGB) = hemoglobin; INF = infinity; ITT = intent to treat; NTDT-PRO T/W = nontransfusion-dependent β-thalassemia patient-reported outcome tiredness and weakness; Thal = thalassemia.

Note: The Hb records collected up to a minimum of (death date, study discontinuation date, last dose date + 20, cutoff date) were used for the analysis.

<div style=\"page-break-after: always\"></div>

Figure 31: Forest plot of subjects with a mean haemoglobin change from baseline to week 13 to week 24 in absence of transfusions by subgroups (ITT population)

<!-- image -->

6MWT = 6-minute walk test; BL = baseline; CI = confidence interval; Diff = difference; FACIT-F FS = Functional Assessment of Chronic Illness Therapy - Fatigue, Fatigue subscale; Hb (also HGB) = hemoglobin; ITT = intent to treat; LS = least squares; NTDT-PRO T/W = nontransfusion-dependent β-thalassemia patient-reported outcome tiredness and weakness; SE = standard error; Thal = thalassemia.

Note: The Hb records collected up to a minimum of (death date, study discontinuation date, last dose date + 20. cutoff date) were used for the analysis.

Source:Figure 14.2.3.1.1.

<div style=\"page-break-after: always\"></div>

## NTDT PRO T/W

Figure 32: Forest plot of subjects with NTDT-PRO T/W mean change from baseline to week 13 to week 24 by subgroups (ITT population)

<!-- image -->

6MWT = 6-minute wallk test; BL = baseline; CI = confidence interval; Diff = difference; FACIT-F FS = Functional Assessment of Chronic Illness Therapy - Fatigue, Fatigue subscale; HGB = hemoglobin; ITT = intent to treat; LS = least squares; NTDT-PRO T/W = nontransfusion-dependent β-thalassemia patient-reported outcome tiredness and weakness; SE = standard error; Thal = thalassemia. Source: Figure 14.2.2.1.1

<div style=\"page-break-after: always\"></div>

## Dose level

Table 60 : sensitivity analyses of primary and key secondary endpoints by dose level at week 13-24 (study ACE-536-B-THAL-002, ITT population)

|                                                                                                                              | Primary Analysis                                                                                                             | Primary Analysis                                                                                                             | Stable 1.0 mg/kg at Week 13-24                                                                                               | Stable 1.0 mg/kg at Week 13-24                                                                                               | Stable 1.25 mg/kg at Week 13-24                                                                                              | Stable 1.25 mg/kg at Week 13-24                                                                                              | Dose Level Changed at Week 13-24                                                                                             | Dose Level Changed at Week 13-24                                                                                             |
|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|
| Endpoint                                                                                                                     | Luspatercept N=96                                                                                                            | Placebo N=49                                                                                                                 | Luspatercept N=33                                                                                                            | Placebo N=49                                                                                                                 | Luspatercept N=35                                                                                                            | Placebo N=49                                                                                                                 | Luspatercept N=11                                                                                                            | Placebo N=49                                                                                                                 |
| Primary Endpoint: Proportion of subjects with a mean Hb increase from baseline ≥ 1.0 g/dL response at Week 13 to Week 24 (%) | Primary Endpoint: Proportion of subjects with a mean Hb increase from baseline ≥ 1.0 g/dL response at Week 13 to Week 24 (%) | Primary Endpoint: Proportion of subjects with a mean Hb increase from baseline ≥ 1.0 g/dL response at Week 13 to Week 24 (%) | Primary Endpoint: Proportion of subjects with a mean Hb increase from baseline ≥ 1.0 g/dL response at Week 13 to Week 24 (%) | Primary Endpoint: Proportion of subjects with a mean Hb increase from baseline ≥ 1.0 g/dL response at Week 13 to Week 24 (%) | Primary Endpoint: Proportion of subjects with a mean Hb increase from baseline ≥ 1.0 g/dL response at Week 13 to Week 24 (%) | Primary Endpoint: Proportion of subjects with a mean Hb increase from baseline ≥ 1.0 g/dL response at Week 13 to Week 24 (%) | Primary Endpoint: Proportion of subjects with a mean Hb increase from baseline ≥ 1.0 g/dL response at Week 13 to Week 24 (%) | Primary Endpoint: Proportion of subjects with a mean Hb increase from baseline ≥ 1.0 g/dL response at Week 13 to Week 24 (%) |
| Responders, n (%)                                                                                                            | 74 (77.1)                                                                                                                    | 0                                                                                                                            | 32 (97.0)                                                                                                                    | 0                                                                                                                            | 20 (57.1)                                                                                                                    | 0                                                                                                                            | 8 (72.7)                                                                                                                     | 0                                                                                                                            |
| Proportion ofresponders (95% CIa                                                                                             | 77.1 (67.4, 85.0)                                                                                                            | 0.0 (0.0, 7.3)                                                                                                               | 97.0 (84.2, 99.9)                                                                                                            | 0.0 (0.0, 7.3)                                                                                                               | 57.1 (39.4, 73.7)                                                                                                            | 0.0 (0.0, 7.3)                                                                                                               | 72.7 (39.0, 94.0)                                                                                                            | 0.0 (0.0, 7.3)                                                                                                               |
| Difference in proportions (95% CI)                                                                                           | 77.1 (63.4, 87.0)                                                                                                            | 77.1 (63.4, 87.0)                                                                                                            | 97.0 (84.2, 99.9)                                                                                                            | 97.0 (84.2, 99.9)                                                                                                            | 57.1 (37.2, 73.7)                                                                                                            | 57.1 (37.2, 73.7)                                                                                                            | 72.7 (39.0, 94.0)                                                                                                            | 72.7 (39.0, 94.0)                                                                                                            |
| Key Secondary Endpoint: Change from baseline in NTDT-PRO T/W at Week 13 to Week 24                                           | Key Secondary Endpoint: Change from baseline in NTDT-PRO T/W at Week 13 to Week 24                                           | Key Secondary Endpoint: Change from baseline in NTDT-PRO T/W at Week 13 to Week 24                                           | Key Secondary Endpoint: Change from baseline in NTDT-PRO T/W at Week 13 to Week 24                                           | Key Secondary Endpoint: Change from baseline in NTDT-PRO T/W at Week 13 to Week 24                                           | Key Secondary Endpoint: Change from baseline in NTDT-PRO T/W at Week 13 to Week 24                                           | Key Secondary Endpoint: Change from baseline in NTDT-PRO T/W at Week 13 to Week 24                                           | Key Secondary Endpoint: Change from baseline in NTDT-PRO T/W at Week 13 to Week 24                                           | Key Secondary Endpoint: Change from baseline in NTDT-PRO T/W at Week 13 to Week 24                                           |
| LS Mean (SE)°                                                                                                                | -0.68 (0.176)                                                                                                                | -0.20 (0.240)                                                                                                                | -1.33 (0.310)                                                                                                                | -0.28 (0.238)                                                                                                                | -0.10 (0.254)                                                                                                                | -0.25 (0.221)                                                                                                                | -1.07 (0.388)                                                                                                                | -0.32 (0.195)                                                                                                                |
| LS Mean Difference (Lusp- Pbo) (95% CI)                                                                                      | -0.48 (-1.03, 0.08)                                                                                                          | -0.48 (-1.03, 0.08)                                                                                                          | -1.05 (-1.76, -0.35)                                                                                                         | -1.05 (-1.76, -0.35)                                                                                                         | 0.16 (-0.48, 0.80)                                                                                                           | 0.16 (-0.48, 0.80)                                                                                                           | -0.74 (-1.59, 0.11)                                                                                                          | -0.74 (-1.59, 0.11)                                                                                                          |
| Change from baseline in Hb at Week 13 to Week 24 (g/dL)                                                                      | Change from baseline in Hb at Week 13 to Week 24 (g/dL)                                                                      | Change from baseline in Hb at Week 13 to Week 24 (g/dL)                                                                      | Change from baseline in Hb at Week 13 to Week 24 (g/dL)                                                                      | Change from baseline in Hb at Week 13 to Week 24 (g/dL)                                                                      | Change from baseline in Hb at Week 13 to Week 24 (g/dL)                                                                      | Change from baseline in Hb at Week 13 to Week 24 (g/dL)                                                                      | Change from baseline in Hb at Week 13 to Week 24 (g/dL)                                                                      | Change from baseline in Hb at Week 13 to Week 24 (g/dL)                                                                      |
| LS Mean (SE)C                                                                                                                | 1.48 (0.078)                                                                                                                 | 0.07 (0.108)                                                                                                                 | 1.93 (0.107)                                                                                                                 | 0.02 (0.086)                                                                                                                 | 1.10 (0.100)                                                                                                                 | 0.12 (0.087)                                                                                                                 | 1.21 (0.158)                                                                                                                 | 0.11 (0.080)                                                                                                                 |
| LS Mean Difference (Lusp- Pbo) (95% CI)                                                                                      | 1.42 (1.16, 1.67)                                                                                                            | 1.42 (1.16, 1.67)                                                                                                            | 1.90 (1.65, 2.16)                                                                                                            | 1.90 (1.65, 2.16)                                                                                                            | 0.98 (0.73, 1.23)                                                                                                            | 0.98 (0.73, 1.23)                                                                                                            | 1.10 (0.75, 1.45)                                                                                                            | 1.10 (0.75, 1.45)                                                                                                            |

Abbreviations: ANCOVA, analysis of covariance; CI confidence interval; Hb, hemoglobin; ITT, intent-to-treat, LS, least squares; Lusp, luspatercept; NTDT-PRO T/W, nontransfusion-dependent β-thalassemia patient-reported outcome tiredness and weakness; Max, maximum; Min, minimum; Pbo, placebo; SD, standard deviation; SE, standard error.

95% CI for response rate(%) are estimated from Clopper-Pearson exact test.

Difference in Proportions (Luspatercept - Placebo) and 95% CI are estimated from exact unconditional test. Common Risk Difference (Luspatercept - Placebo) and 95% CI are estimated from Cochran Mantel-Haenszel method stratified by baseline Hb category (≥ 8.5 g/dL, &lt; 8.5 g/dL), baseline NTDT-PRO T/W score category (3 versus &lt; 3) defined atrandomization ascovariates.

Estimates are based on an ANCOVA model with baseline hemoglobin category (≥ 8.5 g/dL vs. &lt; 8.5 g/dL) and baseline NTDT-PRO T/W score category (≥ 3 vs. &lt; 3), and the respective additional covariate defined at randomization (if applicable) as covariates.

Luspatercept at 1.25 mg/kg level during Week 13-24 and never changed their dose level. Subjects with Dose Level Changed was defined as subjects who had at least 1 dose modification (increase or decrease) during Week 13-24. Subjects with 0 dose within a given period are considered missing for that period. Placebo group contains all dose levels. Data cutoff date: 14-Sep-2020.

<div style=\"page-break-after: always\"></div>

Table 61: sensitivity analyses of primary and key secondary endpoints by dose level at week 37-48 (study ACE-536-B-THAL-002, ITT population)

|                                                               | Primary Analysis                                              | Primary Analysis                                              | Stable 1.0 mg/kg at Week 37-48                                | Stable 1.0 mg/kg at Week 37-48                                | Stable 1.25 mg/kg at Week 37-48                               | Stable 1.25 mg/kg at Week 37-48                               | Dose Level Changed at Week 37-48                              | Dose Level Changed at Week 37-48                              |
|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Endpoint                                                      | Luspatercept N=96                                             | Placebo N=49                                                  | Luspatercept N=27                                             | Placebo N =49                                                 | Luspatercept N=47                                             | Placebo N=49                                                  | Luspatercept N=2                                              | Placebo N=49                                                  |
| Proportion of responders (Hb >1 g/dL) at Week 37 to Week 48   | Proportion of responders (Hb >1 g/dL) at Week 37 to Week 48   | Proportion of responders (Hb >1 g/dL) at Week 37 to Week 48   | Proportion of responders (Hb >1 g/dL) at Week 37 to Week 48   | Proportion of responders (Hb >1 g/dL) at Week 37 to Week 48   | Proportion of responders (Hb >1 g/dL) at Week 37 to Week 48   | Proportion of responders (Hb >1 g/dL) at Week 37 to Week 48   | Proportion of responders (Hb >1 g/dL) at Week 37 to Week 48   | Proportion of responders (Hb >1 g/dL) at Week 37 to Week 48   |
| Responders, n (%)                                             | 68 (70.8)                                                     | 1 (2.0)                                                       | 25 (92.6)                                                     | 1 (2.0)                                                       | 29 (61.7)                                                     | 1 (2.0)                                                       | 1 (50.0)                                                      | 1 (2.0)                                                       |
| Erythroid response rate (95% CI)a                             | 70.8 (60.7, 79.7)                                             | 2.0 (0.1, 10.9)                                               | 92.6 (75.7, 99.1)                                             | 2.0 (0.1, 10.9)                                               | 61.7 (46.4, 75.5)                                             | 2.0 (0.1, 10.9)                                               | 50.0 (1.3, 98.7)                                              | 2.0 (0.1, 10.9)                                               |
| Difference in proportions (95% CI)                            | 68.8 (54.3, 80.4)                                             | 68.8 (54.3, 80.4)                                             | 90.6 (74.5, 97.8)                                             | 90.6 (74.5, 97.8)                                             | 59.7 (41.6, 73.7)                                             | 59.7 (41.6, 73.7)                                             | 48.0 (-29.8, 96.1)                                            | 48.0 (-29.8, 96.1)                                            |
| Change from baseline in NTDT-PROT/W at Week 37 to Week 48     | Change from baseline in NTDT-PROT/W at Week 37 to Week 48     | Change from baseline in NTDT-PROT/W at Week 37 to Week 48     | Change from baseline in NTDT-PROT/W at Week 37 to Week 48     | Change from baseline in NTDT-PROT/W at Week 37 to Week 48     | Change from baseline in NTDT-PROT/W at Week 37 to Week 48     | Change from baseline in NTDT-PROT/W at Week 37 to Week 48     | Change from baseline in NTDT-PROT/W at Week 37 to Week 48     | Change from baseline in NTDT-PROT/W at Week 37 to Week 48     |
| LS Mean (SE)a                                                 | -0.78 (0.229)                                                 | 0.01 (0.347)                                                  | -1.55 (0.457)                                                 | -0.05 (0.334)                                                 | -0.26 (0.311)                                                 | -0.01 (0.316)                                                 | 0.39 (0.975)                                                  | -0.15 (0.278)                                                 |
| LS Mean Difference (Lusp- Pbo) (95% CI)C                      | -0.79 (-1.58, 0.00)                                           | -0.79 (-1.58, 0.00)                                           | -1.50 (-2.55, -0.44)                                          | -1.50 (-2.55, -0.44)                                          | -0.25 (-1.10, 0.59)                                           | -0.25 (-1.10, 0.59)                                           | 0.55 (-1.54,2.63)                                             | 0.55 (-1.54,2.63)                                             |
| Mean change firom baseline in Hb at Week 37 to Week 48 (g/dL) | Mean change firom baseline in Hb at Week 37 to Week 48 (g/dL) | Mean change firom baseline in Hb at Week 37 to Week 48 (g/dL) | Mean change firom baseline in Hb at Week 37 to Week 48 (g/dL) | Mean change firom baseline in Hb at Week 37 to Week 48 (g/dL) | Mean change firom baseline in Hb at Week 37 to Week 48 (g/dL) | Mean change firom baseline in Hb at Week 37 to Week 48 (g/dL) | Mean change firom baseline in Hb at Week 37 to Week 48 (g/dL) | Mean change firom baseline in Hb at Week 37 to Week 48 (g/dL) |
| LS Mean (SE)a                                                 | 1.50 (0.083)                                                  | 0.01 (0.130)                                                  | 2.01 (0.136)                                                  | -0.05 (0.102)                                                 | 1.25 (0.104)                                                  | 0.05 (0.115)                                                  | 1.00 (0.354)                                                  | 0.04 (0.095)                                                  |
| LS Mean Difference (Lusp- Pbo) (95% CI)                       | 1.49 (1.20, 1.79)                                             | 1.49 (1.20, 1.79)                                             | 2.07 (1.76, 2.38)                                             | 2.07 (1.76, 2.38)                                             | 1.19 (0.90, 1.48)                                             | 1.19 (0.90, 1.48)                                             | 0.96 (0.21, 1.71)                                             | 0.96 (0.21, 1.71)                                             |

Note: Subject with missing hemoglobin at Week 37-48 were classified as non-responders in the analysis. Stable 1.25 mg/kg was defined as subjects taking at least one dose of modification (increase or decrease) during Week 37-48. Subjects with 0 dose within a given period are considered missing for that period. Placebo group contains all dose levels.

Data cutoff date: 14-Sep-2020.

<div style=\"page-break-after: always\"></div>

## Post-hoc analyses

## Subjects Requiring Transfusions Postbaseline

As of the (first) data cut-off date, 15 ( 15.6% ) subjects in the luspatercept treatment group underwent a total of 49 RBC transfusion events postbaseline accounting for 75.33 RBC units and 21 ( 42.9% ) subjects in the placebo treatment group underwent a total of 78 RBC transfusion events postbaseline accounting for 122.03 RBC units. One to 3 packed RBC units were transfused at each transfusion.

The most frequently reported reason for a postbaseline transfusion in the luspatercept treatment group was anaemia. Of note, approximately half the transfusions with reason 'anaemia' were administered while no significant Hb level decreases were observed (ie, &lt; -0.5 g/dL from baseline). Other reasons for postbaseline transfusions were surgery ( 1 luspatercept-treated subject with 1 RBC unit versus 3 placebo-treated subjects with 15 RBC units ), leg ulcer ( 2 luspatercept-treated subjects with 2 RBC units versus 1 placebo-treated subject with 3 RBC units ), infection ( 1 placebo-treated subject with 4 RBC units ), and AE ( 4 luspatercept-treated subjects with 12 RBC units versus 3 placebo-treated subjects with 9 RBC units ). Other reasons for postbaseline transfusion events reported for 7 of the 15 subjects in the luspatercept treatment group were surgery, leg ulcer/forearm fracture, foot ulcer/skin ulcer/anemia, fever, dengue fever, fatigue/dengue hemorrhagic fever, prophylactic measure before travel.

Anemia was again the most frequently reported reason for a postbaseline transfusion event in the placebo treatment group. Other reasons for postbaseline transfusion events were reported for 8 of the 21 subjects in the placebo treatment group were: leg ulcer/skin ulcer, two separate events of traumatic fractures, asthenia/anemia, mitral valve incompetence, infection, surgery, diarrhea/anemia, EMH.

<div style=\"page-break-after: always\"></div>

Figure 33: Swimmer Plot of Responding Period for Responders (Subjects With a Mean Hemoglobin Increase of at Least 1.0 g/dL From Baseline) During Any 12-week Interval Up to the Efficacy Cutoff Date (ITT Population)

<!-- image -->

am

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

## B: Placebo Treatment Group (N= 11)

<!-- image -->

Week

<div style=\"page-break-after: always\"></div>

Figure 34: Swimmer Plot of Responding Period for Nonresponders (Subjects Who Did Not Achieve a Mean Hemoglobin Increase of at Least 1.0 g/dL From Baseline) During Any 12-week Interval Up to the Efficacy Cutoff Date (ITT Population)

## A: Luspatercept Treatment Group (N = S)

<!-- image -->

## B: Placebo Treatment Group (N = 38)

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Assessment of Postbaseline Transfusion Events

In the ITT population, postbaseline transfusion event frequency (defined as the sum of all transfusion events before efficacy cut-off date adjusted for continuous 12-week intervals) was nominally significantly lower among the luspatercept-treated subjects compared with the placebo-treated subjects (mean event frequency: 0.1 versus 0.3, respectively; nominal p = 0.0039) (data not shown). Similar results were noted for analyses over the entire duration of continuous 24-week intervals.

<!-- image -->

Table 62: Analysis of post-baseline transfusion event frequency by 24-week interval and overall ITT population

|                                                     | Luspatercept (N=96)   | Placebo (N=49)    |
|-----------------------------------------------------|-----------------------|-------------------|
| Transfusion Event Frequency at Baseline[a]          |                       |                   |
| N                                                   | 96                    | 49                |
| Mean                                                | 0.2                   | 0.2               |
| SD                                                  | 0.55                  | 0.49              |
| Median                                              | 0                     | 0                 |
| Q1,Q3                                               | 0，0                   | 0，0               |
| Min, Max                                            | 0， 3                  | 0,2               |
| Transfusion Event Frequencyat wEEK 1-24[b]          |                       |                   |
| N                                                   | 92                    | 44                |
| Mean                                                | 0.1                   | 0.4               |
| SD                                                  | 0.62                  | 0.72              |
| Median                                              | 0                     | 0                 |
| Q1,Q3                                               | 0，0                   | 0,0.5             |
| Min, Max                                            | 0,4                   | 0,3               |
| Interval Transfusion Rate (per 24-week) (95&cl) [c] | 0.09(0.04,0.21)       | 0.29 (0.14, 0.64) |
| Relative Risk versus Placebo (95&cl) [c]            | 0.32(0.11, 0.95)      |                   |
| p-value [c]                                         | 0.0394                |                   |

A subject isincludedin an intervalif the subject's efficacycutoff date is on or after the end of the interval.The efficacy cutoff is defined as min(death date，study discontinuation date,last dose date+20，14sEp2020). consecutivedates，theyarecountedas one event;if multipletransfusionshappenonthree consecutive dates，theyarecountedastwoevents. [a]Baseline is defined as the number of transfusion events during the 24-week interval on or prior todose 1 day1. [b]only transfusion events in a full 24-week intervalare counted at Week 1-24 and Week 25-48.Post-baseline per 24-week is defined as the sum ofalltransfusioneventsbeforetheefficacycutoffdateadjustedfora24-weekinterval programpath:/u02/projects/ace\\_536/ace\\_536\\_bthal\\_o02/deliverables/do11\\_csr/programs/tables/final/t\\_chg\\_tf.sas Rundate:03MAY2021 Datasource:adsladefadbase DataExtractiondate:20Nov2020

<div style=\"page-break-after: always\"></div>

Table 63: Analysis of post-baseline transfusion event frequency by 24-week interval and overall ITT population

<!-- image -->

## Reasons for transfusion

Table 64: Number of RBC transfusion events and reasons for transfusion by time interval and by geographic region (Study ACE-536-B-THAL-002, ITT population who received RBC transfusion)

|                                 | Total      | Total     | North America/Europe   | North America/Europe   | MiddleEast   | MiddleEast   | Asia-Pacific   | Asia-Pacific   |
|---------------------------------|------------|-----------|------------------------|------------------------|--------------|--------------|----------------|----------------|
| TinePeriod ReasonforTransfusion | Lusp N=20  | Pbo N=21  | Lusp N=9               | Pbo N=9                | Lusp N=3     | Pbo N=5      | Lusp N=8       | Pbo N=7        |
| Week1to48                       |            |           |                        |                        |              |              |                |                |
| Total RBC transfusion events    | 27         | 35        | 8                      | 14                     | 6            | 2            | 13             | 19             |
| Anemia                          | 18 (66.7)  | 26 (74.3) | 8 (100.0)              | 6 (42.9)               | 2 (33.3)     | 2 (100.0)    | 8 (61.5)       | 18 (94.7)      |
| Surgery                         | 0          | 3 (8.6)   | 0                      | 3 (21.4)               | 0            | 0            | 0              | 0              |
| Othera                          | 9 (33.3)   | 6 (17.1)  | 0                      | 5 (35.7)               | 4 (66.7)     | 0            | 5 (38.5)       | 1 (5.3)        |
| Week 49 to 96                   |            |           |                        |                        |              |              |                |                |
| TotalRBCtransfusion events      | 13         | 26        |                        | 3                      |              | 6            | 10             | 17             |
| Anemia                          | 13 (100.0) | 20 (76.9) | 2 (100.0)              | 0                      | 1 (100.0)    | 4 (66.7)     | 10 (100.0)     | 16 (94.1)      |
| Infection                       | 0          | 2 (7.7)   | 0                      | 0                      | 0            | 2 (33.3)     | 0              | 0              |
| Surgery                         | 0          | 3 (11.5)  | 0                      | 2 (66.7)               | 0            | 0            | 0              | 1 (5.9)        |
| Othera                          | 0          | 1 (3.8)   | 0                      | 1 (33.3)               | 0            | 0            | 0              | 0              |

Abbrevations: ITT, intent-to-treat; Lusp, luspatercept; Pbo, placebo; RBC, red blood cell.

\"\"Other? reasons were predominantly due to adverse events (eg, asthenia, diarrhea, fatigue, fever, fracture, ulcer); 1 subject was given a transfusion as prophylaxis prior to travel.

Data cutoff date: 14-Sep-2020.

Source:Table BEE.15B.14.2.15.15.2.a,Table BEE.15B.14.2.15.15.2.1.a,Table BEE.15B.14.2.15.15.2.2.a,TableBEE.15B.14.2.15.15.2.3.a.

<div style=\"page-break-after: always\"></div>

## Sensitivity analysis for transfusion event frequency over time

## Table 65: Transfusion event frequency over time (study ACE-536-B-THAL-002, ITT population)

|                                                  | All ObservedDataRegardless of D/CWithnoImputation   | All ObservedDataRegardless of D/CWithnoImputation   | All Observed Data with ImputationbyBaselinefor Early D/C Subjectsa   | All Observed Data with ImputationbyBaselinefor Early D/C Subjectsa   |
|--------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| Parameter                                        | Luspatercept N=96                                   | Placebo N=49                                        | Luspatercept N=96                                                    | Placebo N= 49                                                        |
| Transfusion eventfrequency at baseline (24-week) |                                                     |                                                     |                                                                      |                                                                      |
| 1n1                                              | 96                                                  | 49                                                  | 96                                                                   | 49                                                                   |
| Mean (SD)                                        | 0.20 (0.555)                                        | 0.18 (0.486)                                        | 0.20 (0.555)                                                         | 0.18 (0.486)                                                         |
| Median (min, max)                                | 0.00 (0.0, 3.0)                                     | 0.00 (0.0, 2.0)                                     | 0.00 (0.0, 3.0)                                                      | 0.00 (0.0, 2.0)                                                      |
| Transfusion eventfrequencyat Weeks 1 to 24       |                                                     |                                                     |                                                                      |                                                                      |
| n                                                | 96                                                  | 49                                                  | 96                                                                   | 49                                                                   |
| Mean (SD)                                        | 0.18 (0.680)                                        | 0.39 (0.731)                                        | 0.18 (0.680)                                                         | 0.39 (0.731)                                                         |
| Median (min, max)                                | 0.00 (0.0, 4.0)                                     | 0.00 (0.0, 3.0)                                     | 0.00 (0.0, 4.0)                                                      | 0.00 (0.0, 3.0)                                                      |
| Interval transfusion rate (95% CI)               | 0.2 (0.00, 5.99)                                    | 0.4 (0.04, 4.56)                                    | 0.2 (0.00, 5.99)                                                     | 0.4 (0.04, 4.56)                                                     |

<div style=\"page-break-after: always\"></div>

Table 66: Transfusion event frequency over time (study ACE-536-B-THAL-002, ITT population)

|                                                    | All ObservedDataRegardless of D/C With no Imputation   | All ObservedDataRegardless of D/C With no Imputation   | All Observed Data with ImputationbyBaselinefor Early D/C Subjectsa   | All Observed Data with ImputationbyBaselinefor Early D/C Subjectsa   |
|----------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| Parameter                                          | Luspatercept N=96                                      | Placebo N = 49                                         | Luspatercept N=96                                                    | Placebo N=49                                                         |
| Relative risk (luspatercept vs.                    | 0.4 (0.09, 1.97)                                       | 0.4 (0.09, 1.97)                                       | 0.4 (0.09, 1.97)                                                     | 0.4 (0.09, 1.97)                                                     |
| placeb0) (95% CI)c                                 | 0.2671                                                 | 0.2671                                                 | 0.2671                                                               | 0.2671                                                               |
| Transfusion event frequency at Weeks25to48         |                                                        |                                                        |                                                                      |                                                                      |
| N                                                  | 94                                                     | 48                                                     | 96                                                                   | 49                                                                   |
| Mean (SD)                                          | 0.12 (0.546)                                           | 0.35 (0.785)                                           | 0.12 (0.546)                                                         | 0.35 (0.778)                                                         |
| Median (min, max)                                  | 0.00 (0.0, 4.0)                                        | 0.00 (0.0, 4.0)                                        | 0.00 (0.0, 4.0)                                                      | 0.00 (0.0, 4.0)                                                      |
| Interval transfusion rate (95% CI)C                | 0.4 (0.11, 1.10)                                       | 1.5 (0.47, 4.61)                                       | 0.2 (0.06, 0.70)                                                     | 0.7 (0.19,2.39)                                                      |
| Relative risk (luspatercept vs. placebo) (95% CI)c | 0.2 (0.08, 0.71)                                       | 0.2 (0.08, 0.71)                                       | 0.3 (0.11, 0.90)                                                     | 0.3 (0.11, 0.90)                                                     |
| P-valuec                                           | 0.0102                                                 | 0.0102                                                 | 0.0311                                                               | 0.0311                                                               |
| Transfusion event frequency at                     |                                                        |                                                        |                                                                      |                                                                      |
| baseline (48-week)                                 |                                                        |                                                        |                                                                      |                                                                      |
| N                                                  | 96                                                     | 49                                                     | 96                                                                   | 49                                                                   |
| Mean (SD)                                          | 0.21 (0.579)                                           | 0.20 (0.577)                                           | 0.21 (0.579)                                                         | 0.20 (0.577)                                                         |
| Median (min, max)                                  | 0.00 (0.0, 3.0)                                        | 0.00 (0.0, 3.0)                                        | 0.00 (0.0, 3.0)                                                      | 0.00 (0.0, 3.0)                                                      |
| Transfusioneventfrequency at Weeks 1 to 48         |                                                        |                                                        |                                                                      |                                                                      |
| N                                                  | 96                                                     | 49                                                     | 96                                                                   | 49                                                                   |
| Mean (SD)                                          | 0.29 (0.983)                                           | 0.73 (1.381)                                           | 0.30 (0.988)                                                         | 0.74 (1.381)                                                         |
| Median (min, max)                                  | 0.00 (0.0, 6.0)                                        | 0.00 (0.0, 7.0)                                        | 0.00 (0.0, 6.0)                                                      | 0.00 (0.0, 7.0)                                                      |
| Interval transfusion rate (95% CI)C                | 0.4 (0.16, 0.99)                                       | 1.2 (0.45, 3.25)                                       | 0.4 (0.16, 1.00)                                                     | 1.2 (0.45, 3.21)                                                     |
| Relative risk (luspatercept vs. placebo) (95% CI)c | 0.3 (0.14, 0.76)                                       | 0.3 (0.14, 0.76)                                       | 0.3 (0.14, 0.77)                                                     | 0.3 (0.14, 0.77)                                                     |
| P-valuec                                           | 0.0094                                                 | 0.0094                                                 | 0.0102                                                               | 0.0102                                                               |
| Transfusion event frequency at Weeks 49 to96       |                                                        |                                                        |                                                                      |                                                                      |
| N                                                  | 91                                                     | 38                                                     | 96                                                                   | 49                                                                   |
| Mean (SD)                                          | 0.16 (0.703)                                           | 0.74 (1.519)                                           | 0.21 (0.725)                                                         | 0.59 (1.368)                                                         |

<div style=\"page-break-after: always\"></div>

Table 67: Transfusion event frequency over time (study ACE-536-B-THAL-002, ITT population)

|                                                    | All ObservedDataRegardless ofD/CWithnoImputation   | All ObservedDataRegardless ofD/CWithnoImputation   | All Observed Data with InputationbyBaselinefor Early D/C Subjectsa   | All Observed Data with InputationbyBaselinefor Early D/C Subjectsa   |
|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| Parameter                                          | Luspatercept N=96                                  | Placebo N = 49                                     | Luspatercept N=96                                                    | Placebo N= 49                                                        |
| Median (min, max)                                  | 0.00 (0.0, 4.0)                                    | 0.00 (0.0, 7.0)                                    | 0.00 (0.0, 4.0)                                                      | 0.00 (0.0, 7.0)                                                      |
| Interval transfusion rate (95% CI)                 | 0.1 (0.04, 0.45)                                   |                                                    | 0.7 (0.27, 1.63)0.1 (0.04, 0.20)                                     | 0.4 (0.20, 0.67)                                                     |
| Relative risk (luspatercept vs. placebo) (95% CI)c | 0.2 (0.07, 0.65)                                   | 0.2 (0.07, 0.65)                                   | 0.3 (0.1, 0.63)                                                      | 0.3 (0.1, 0.63)                                                      |
| P-valuec                                           | 0.0064                                             | 0.0064                                             | 0.0032                                                               | 0.0032                                                               |

Abbreviations: CI, confidence interval; ITT, intent-to-treat; max, maximum; min, minimum; SD, standard deviation

The missing event frequency during the interval were imputed based on the baseline frequency as the baseline frequency divided by 168 days, then multiplied by the length of unobserved period.

Baseline defined as the number of transfusion events during the 24-week interval on or prior to dose 1 day 1.

P-value and 95% CI are from zero-inflated negative binomial regression with the baseline Hb category (&gt; 8.5 g/dL, &lt; 8.5 g/dL), baseline NTDT-PRO T/W score category (&gt;3 vs. &lt; 3) defined at randomization and baseline transfusion frequency as predictor variables.

Baseline defined as the number of transfusion events during the 48-week interval on or prior to dose 1 day 1.

Note: If for the same subject, multiple transfusions happen on the same date, they are counted as 1 event; if multiple transfusions happen on 2 consecutive dates, they are counted as 1 event; if multiple transfusions happen on 3 consecutive dates, they are counted as 2events.

Data cutoff date:14-Sep-2020.

Source:Table BEE.15C.1.1.a,Table BEE.15C.1.2.a,Table BEE.15C.2.1.a,Table BEE.15C.2.2.a.

## Overall Severity Score (NTDT)

The disease severity scoring system was developed and published by Cappellini et al. to assess disease severity in patients with NTD thalassemia, based on parameters considered to be most pertinent in defining disease severity (Cappellini, 2016). Morbidity in NTD thalassemia is directly linked to the severity of ineffective erythropoiesis and anemia. The novel scoring system was constructed based on clinical parameters thought to be most pertinent by these experts in defining disease severity in NTD thalassemia patients, based on their clinical experience and expertise. In total, 20 parameters were selected to define hematological and iron status, liver status, cardiovascular status, splenomegaly, renal status, pulmonary hypertension, leg ulcers, endocrinopathies, skeletal abnormalities, and extramedullary hematopoiesis. The domain score is tabulated by summing the score for all parameters. The total score is the sum of the domain scores, with a maximum of 52 points for adult patients; the higher the NTD disease severity score, the more severe the disease.

The change from baseline in NTD disease severity score was a prespecified exploratory endpoint analyzed at Week 24 and Week 48 for subjects in the ITT population, but the results were only submitted with the second data cut off.

<div style=\"page-break-after: always\"></div>

Table 68: Mean change in NTD disease severity score from baseline to week 24 to week 48 (ITT population)

<!-- image -->

|                                                          | Luspatercept (N = 96)   | Placebo (N =49)   |
|----------------------------------------------------------|-------------------------|-------------------|
| Baseline\"                                                |                         |                   |
| n                                                        | 86                      | 45                |
| Mean (SD)                                                | 7.77 (2.957)            | 8.60 (2.709)      |
| Median (min, max)                                        | 8.00 (2.0, 15.0)        | 9.00 (3.0,16.0)   |
| Q1,Q3                                                    | 6.00, 10.00             | 7.00, 10.00       |
| Baseline Sevenity Score Category -n (%)                  |                         |                   |
| ≥Mean'                                                   | 47 (49.0)               | 28 (57.1)         |
| <Meanb                                                   | 39 (40.6)               | 17 (34.7)         |
| Week 24                                                  |                         |                   |
| n                                                        | 75                      | 31                |
| Mean (SD)                                                | 6.77 (2.916)            | 8.87 (2.872)      |
| Median (min, max)                                        | 7.00 (1.0, 14.0)        | 9.00 (2.0, 16.0)  |
| Q1, Q3                                                   | 5.00, 9.00              | 8.00, 11.00       |
| Mean Change from Baseline at Week 24*                    |                         |                   |
| n                                                        | 70                      | 27                |
| Mean (SD)                                                | -1.13 (0.977)           | -0.22 (1.086)     |
| Median (min, max)                                        | -1.00 (-3.0, 2.0)       | 0.00 (-2.0, 2.0)  |
| Q1, Q3                                                   | -2.00,-1.00             | -1.00,0.00        |
| LS Mean (SE)*                                            | -1.16 (0.118)           | -0.15 (0.191)     |
| LS Mean ofDifference (Luspatercept - Placebo) (95% CI)   | -1.00 (-1.45, -0.56)    |                   |
| P-value\"                                                 | ≤0.0001                 |                   |
| Week 48                                                  |                         |                   |
| n                                                        | 75                      | 28                |
| Mean (SD)                                                | 6.79 (2.951)            | 9.50 (2.674)      |
| Median (min, max)                                        | 7.00 (1.0, 14.0)        | 10.00 (3.0, 15.0) |
| Q1,Q3                                                    | 4.00, 9.00              | 7.50, 11.00       |
|                                                          | Luspatercept (N = 96)   | Placebo (N = 49)  |
| Mean Change from Baseline at Week 48                     |                         |                   |
| n                                                        | 68                      | 24                |
| Mean (SD)                                                | -1.18 (1.171)           | -0.29 (1.805)     |
| Median (min, max)                                        | -1.00 (-4.0, 2.0)       | 0.00 (-5.0, 4.0)  |
| Q1, Q3                                                   | -2.00,0.00              | -1.00, 1.00       |
| LS Mean (SE)                                             | -1.23 (0.163)           | -0.15 (0.280)     |
| LS Mean of Difference (Luspatercept - Placebo) (95% CI)* | -1.08 (-1.74, -0.43)    |                   |
| P-value\"                                                 | 0.0014                  |                   |

<div style=\"page-break-after: always\"></div>

## Serum Ferritin up to week 96

The change from baseline in serum ferritin at Week 96 was analyzed for subjects in the ITT population and for subjects with or without ICT at baseline and/or postbaseline.

In the ITT population, the mean change (SD) in mean serum ferritin from baseline to Week 96 was +72.53 (256.363) μg/L in the luspatercept treatment group and +211.51 (640.337) μg/L in the placebo treatment group. The between-group difference in LS mean change from baseline in serum ferritin level was -114.03 μg/L (nominal p = 0.5897).

Similar results were observed when the change from baseline in serum ferritin at Week 96 was analyzed for subjects with or without ICT at baseline and/or postbaseline. In this analysis, 4 subgroups were evaluated based on their ICT use at baseline and postbaseline (ie, ICT use at both baseline and postbaseline, no ICT use either at baseline or postbaseline, ICT use at baseline but not postbaseline, and ICT use postbaseline but not at baseline). In each of these analyses, there was an increase in mean and LS mean change in mean serum ferritin from baseline to Week 96 in both the luspatercept and placebo treatment groups, but the increase was always smaller in the luspatercept treatment group, resulting in a between-group difference in LS mean change from baseline in serum ferritin level that favored luspatercept but was not significant.

Graphical displays of the weekly changes in ratings of FACIT-FS, NTDT T/W and SoB, Overall Symptom Severity (OSS) and PGI-C

Figure 35: observed mean change from baseline in NTDT-PRO T/W by visit and treatment group as of 22 Sep 2021 (Study ACE-536-B-THAL-002, ITT population)

<!-- image -->

Abbreviations: ITT, intent-to-treat; NTDT-PRO, non-transfusion-dependent patient reported outcome; SE, standard error; T/W, tiredness and weakness.

Note: The ITT population is defined as all randomized subjects. Asterisk (*) indicates a nominally significant difference in mean change from baseline between treatment arms at a specific postbaseline assessment visit based on a 2-sample 2-sided t-test. Data cutoff date: 22-Sep-2021.

Source: Figure 14.20.1.

<div style=\"page-break-after: always\"></div>

Figure 36: observed mean change from baseline in FACIT-F Fatigue subscale by visit and treatment group as of 22 Sep 2021 (Study ACE-536-B-THAL-002, ITT population)

<!-- image -->

Abbreviations: FACIT-F, Functional Assessment of Chronic Illness Therapy - Fatigue; ITT, intent to treat; SE, standard error. Note: The ITT population is defined as all randomized subjects. Asterisk (*) indicates a nominally significant difference in mean change from baseline between treatment arms at a specific postbaseline assessment visit based on a 2-sample 2-sided t-test. Data cutoff date: 22-Sep-2021.

Source: Figure 14.20.4.

Figure 37: observed mean change from baseline in NTDT- PRO SoB by visit and treatment group as of 22 Sep 2021 (Study ACE-536-B-THAL-002, ITT population)

<!-- image -->

Abbreviations: ITT, intent-to-Treat; NTDT-PRO, non-transfusion-dependent patient reported outcome; SE, standard error; SoB shortness of breath.

Note: The ITT population is defined as all randomized subjects. Asterisk (*) indicates a nominally significant difference in mean change from baseline between treatment arms at a specific postbaseline assessment visit based on a 2-sample 2-sided t-test.

Data cutoff date: 22-Sep-2021.

Source: Figure 14.20.2.

<div style=\"page-break-after: always\"></div>

Figure 38: observed mean change from baseline in PGI-S by visit and treatment group as of 22 Sep 2021 (Study ACE-536-B-THAL-002, ITT population)

<!-- image -->

Abbreviations: ITT, intent-to-Treat; PGI-S, Patient Global Impression of Severity; SE, standard error.

Note: The ITT population is defined as all randomized subjects. Asterisk (*) indicates a nominally significant difference in mean change from baseline between treatment arms at a specific postbaseline assessment visit based on a 2-sample 2-sided t-test. Data cutoff date: 22-Sep-2021.

Source: Figure 14.20.3.

Figure 39: Bar graph proportion of PGI-C by visit and treatment group as of 22 Sep 2021((Study ACE-536-B-THAL-002, ITT population)

<!-- image -->

ITT, intent-to-Treat; PGI-C, Patient Global Impression of Change.

Note: The ITT population is defined as all randomized subjects.

Data cutoff date: 22-Sep-2021.

Source: Figure 14.21.

<div style=\"page-break-after: always\"></div>

## Durability of response and potential for rebound effect

As of 22-Sep-2021 (one year after the data cut-off date for the Type II variation submission), there are 112 subjects remaining on treatment in Study ACE-536-B-THAL-002, including 77 subjects in the luspatercept arm and 35 subjects initially randomized to placebo who entered the Open-label Period (OLP) and began treatment with luspatercept.

## Mean Change from Baseline in Hb by 12 -week Interval

Subjects treated with luspatercept achieved an LS mean increase from baseline (improvement) in Hb of 1.28 g/dL during the Week 1-12 interval which increased in the Week 13-24 interval (1.48 g/dL) and was generally maintained through Week 132-144 among subjects remaining in the study. These improvements reached nominal significance versus placebo at all time intervals up to Week 96 (beyond which inferential statistics were not provided owing to the crossover of placebo subjects into the OLP).

Table 69 : mean change in Haemoglobin from baseline by 12 week interval as of 22 Sep 2021 (ACE-536-B-THAL-002, ITT population)

|              | Luspatercept (N=96)   | Luspatercept (N=96)   | Luspatercept (N=96)           | Placebo (6+=N)   | Placebo (6+=N)   | Placebo (6+=N)                | Treatment Difference (Luspatercept - Placebo)   | Treatment Difference (Luspatercept - Placebo)   |
|--------------|-----------------------|-----------------------|-------------------------------|------------------|------------------|-------------------------------|-------------------------------------------------|-------------------------------------------------|
| Time Period  |                       | Visit Mean            | LS Mean Change From Baseline? |                  | Visit Mfean      | LS Mean Change From Baselinea | LS Mean of Difference (95% CI)a                 | P-valuea                                        |
| Baseline b   | 96                    | 8.20                  | NA                            | 49               | 8.09             | NA                            | NA                                              | NA                                              |
| Week 1-12    | 96                    | 9.50                  | 1.28                          | 48               | 8.22             | 0.09                          | 1.19 (0.97, 1.41)                               | ≤0.0001                                         |
| Week 13-24   | 96                    | 9.75                  | 1.48                          | 47               | 8.25             | 0.07                          | 1.42 (1.16, 1.67)                               | c0.0001                                         |
| Week 25-36   | 91                    | 9.83                  | 1.59                          | 38               | 8.10             | 0.15                          | 1.44 (1.14, 1.74)                               | 0.0001                                          |
| Week 37-48   | 91                    | 9.75                  | 1.50                          | 34               | 7.89             | 0.01                          | 1.50 (1.20, 1.79)                               | ≤0.0001                                         |
| Week 49-60   | 84                    | 9.80                  | 1.54                          | 33               | 8.01             | 0.05                          | 1.49 (1.22, 1.77)                               | ≤0.0001                                         |
| Week 61-72   | 83                    | 9.74                  | 1.48                          | 22               | 7.68             | 0.02                          | 1.46 (1.06, 1.86)                               | ≤0.0001                                         |
| Week 73-84   | 82                    | 9.80                  | 1.45                          | 16               | 7.70             | 0.09                          | 1.36 (0.95, 1.78)                               | ≤0.0001                                         |
| Week 85-96   | 82                    | 9.89                  | 1.60                          | 16               | 7.51             | -0.03                         | 1.63 (1.21, 2.04)                               | 0.0001                                          |
| Week 97-108  | 78                    | 9.72                  | 1.51c                         | 15               | 7.84             | 0.04 []                       | ON                                              | ON                                              |
| Week 109-120 | 80                    | 9.76                  | 1.50c                         | 13               | 7.71             | 0.17 []                       | ON                                              | NC                                              |
| Week 121-132 | 69                    | 9.80                  | 1.58                          | 10               | 7.28             | -0.20 [e]                     | NC                                              | NC                                              |
| Week 133-144 | 60                    | 9.70                  | 1.50c                         | 3                | 7.20             | 0.47 []                       | ON                                              | NC                                              |

Abbreviations: ANCOVA, analysis of covariance; CI, confidence nterval; Hb, hemoglobin; ITT, intent to treat; LS, least squares; NA, not applicable; NC, not caleulated; NTDT-PRO T/W, non-transfusion-dependent β-thalassemia patient-reported outcome tiredness and weakness.

Estimates are based on an ANCOVA model with treatment group and baseline Hb category (≥ 8.5 g/dL, &lt; S.5 g/dL) and baseline NTDT-PRO T/W score category ( 3 vs. ≤ 3) defined at randomization as covariates.

Baseline is defined as the average of 2 or more Hb measurements at least l week apart within 4 weeks before dose 1 day 1.

C Changes from baseline values beyond Week 96 are presented as mean values.

oqaoeld apnpun jou saop dnone pdaorajedsnI 1daaiapedsnl oi 1ano Eunssono ol 1oud o dn passasse aie sjpalqns oqaoeld calon subjects who crossed over to Luspatercept. Subjects with missing Hb at each week interval are excluded in the analysis. Data cutoff date: 22-Sep-2021.

Source:TableBEE.28.14.2.3.1.c.

<div style=\"page-break-after: always\"></div>

Figure 40: Haemoglobin mean change from baseline by subjects treated with Luspatercept 0.20.4 mg/kg compared with subjects treated with Luspatercept 0.6-1.25 mg/kg (ITT population, non-transfusion dependent (NTD)- Study A536-04)

<!-- image -->

Abbreviations: Hgb, hemoglobin; ITT, intent-to-treat.

*As per the study design, subjects could receive 5 cycles of treatment in this study (up to Study Day 85 [± 2 days]) and then were eligible to roll over to the long-term extension study A536-06.

Note: Data shown is for the A536-04 base study only.

Note: Data after Day 85 are from the post-treatment period.

Source: A536-04 CSR Figure 14.2.1.2.

## Efficacy Results in the Symptomatic Patient Population

Increase in Hb

Table 70: Haemoglobin related endpoints in subjects with symptomatic anemia (basline NTDTPRO T/W ≥ 3 and the ITT population (ACE -536-B-THAL-002 (BEYOND))

<!-- image -->

|                                                                                                | Symptomatic Anemia Populationa                                                                 | Symptomatic Anemia Populationa                                                                 | ITT Population                                                                                 | ITT Population                                                                                 |
|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Parameter                                                                                      | Luspatercept N =66                                                                             | Placebo N=35                                                                                   | Luspatercept N=96                                                                              | Placebo N= 49                                                                                  |
| Primary Endpoint: Subjects with mean Hb increase ≥ 1.0 g/dL from Baseline to Weeks 13-24       | Primary Endpoint: Subjects with mean Hb increase ≥ 1.0 g/dL from Baseline to Weeks 13-24       | Primary Endpoint: Subjects with mean Hb increase ≥ 1.0 g/dL from Baseline to Weeks 13-24       | Primary Endpoint: Subjects with mean Hb increase ≥ 1.0 g/dL from Baseline to Weeks 13-24       | Primary Endpoint: Subjects with mean Hb increase ≥ 1.0 g/dL from Baseline to Weeks 13-24       |
| Erythroid Response Rate (%) (95% CI)b                                                          | 78.8 (67.0, 87.9)                                                                              | 0.0 (0.0, 10.0)                                                                                | 77.1 (67.4, 85.0)                                                                              | 0.0 (0.0, 7.3)                                                                                 |
| Difference in Proportion (%) (95% CI)c                                                         | 78.8 (63.1, 89.9)                                                                              | 78.8 (63.1, 89.9)                                                                              | 77.1 (63.4, 87.0)                                                                              | 77.1 (63.4, 87.0)                                                                              |
| P-value e                                                                                      | <0.0001                                                                                        | <0.0001                                                                                        | <0.0001                                                                                        | <0.0001                                                                                        |
| Key Secondary Endpoint: Subjects with mean Hb increase ≥ 1.0 g/dL from Baseline to Weeks 37-48 | Key Secondary Endpoint: Subjects with mean Hb increase ≥ 1.0 g/dL from Baseline to Weeks 37-48 | Key Secondary Endpoint: Subjects with mean Hb increase ≥ 1.0 g/dL from Baseline to Weeks 37-48 | Key Secondary Endpoint: Subjects with mean Hb increase ≥ 1.0 g/dL from Baseline to Weeks 37-48 | Key Secondary Endpoint: Subjects with mean Hb increase ≥ 1.0 g/dL from Baseline to Weeks 37-48 |
| Erythroid Response Rate (%) (95% CI)b                                                          | 72.7 (60.4, 83.0)                                                                              | 0.0 (0.0, 10.0)                                                                                | 70.8 (60.7, 79.7)                                                                              | 2.0 (0.1, 10.9)                                                                                |
| Difference in Proportion (%) (95% CI)c                                                         | 72.7 (55.9, 85.3)                                                                              | 72.7 (55.9, 85.3)                                                                              | 68.8 (54.3, 80.4)                                                                              | 68.8 (54.3, 80.4)                                                                              |
| P-valuee                                                                                       | <0.0001                                                                                        | <0.0001                                                                                        | <0.0001                                                                                        | <0.0001                                                                                        |

<div style=\"page-break-after: always\"></div>

Table 71: Haemgobin related endpoints in subjects with symptomatic anemia (baseline NTDTPRO T/W≥ 3) and the ITT population (study ACE -536-B-THAL-002 (BEYOND))

|                                                                               | Symptomatic Anemia Populationa                                                | Symptomatic Anemia Populationa                                                | ITT Population                                                                | ITT Population                                                                |
|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Parameter                                                                     | Luspatercept N=66                                                             | Placebo N=35                                                                  | Luspatercept N=96                                                             | Placebo N=49                                                                  |
| Subjects with mean Hb increase ≥ 1.5 g/dL from Baseline to Weeks 13-24        | Subjects with mean Hb increase ≥ 1.5 g/dL from Baseline to Weeks 13-24        | Subjects with mean Hb increase ≥ 1.5 g/dL from Baseline to Weeks 13-24        | Subjects with mean Hb increase ≥ 1.5 g/dL from Baseline to Weeks 13-24        | Subjects with mean Hb increase ≥ 1.5 g/dL from Baseline to Weeks 13-24        |
| Erytlhroid Response Rate (%) (95% CI)b                                        | 60.6 (47.8, 72.4)                                                             | 0.0 (0.0, 10.0)                                                               | 52.1 (41.6, 62.4)                                                             | 0.0 (0.0, 7.3)                                                                |
| Difference in Proportion (%) (95% CI)*                                        | 60.6 (42.0, 76.1)                                                             | 60.6 (42.0, 76.1)                                                             | 52.1 (36.2, 66.2)                                                             | 52.1 (36.2, 66.2)                                                             |
| P-value*                                                                      | c0.0001                                                                       | c0.0001                                                                       | c0.0001                                                                       | c0.0001                                                                       |
| Subjects with mean Hb increase ≥ 1.5 g/dL from Baseline to Weeks 37-48        | Subjects with mean Hb increase ≥ 1.5 g/dL from Baseline to Weeks 37-48        | Subjects with mean Hb increase ≥ 1.5 g/dL from Baseline to Weeks 37-48        | Subjects with mean Hb increase ≥ 1.5 g/dL from Baseline to Weeks 37-48        | Subjects with mean Hb increase ≥ 1.5 g/dL from Baseline to Weeks 37-48        |
| Erythroid Response Rate (%) (95% CI)b                                         | 56.1 (43.3, 68.3)                                                             | 0.0 (0.0, 10.0)                                                               | 49.0 (38.6, 59.4)                                                             | 0.0 (0.0, 7.3)                                                                |
| Difference in Proportion (%) (95% CI)*                                        | 56.1 (37.0, 71.8)                                                             | 56.1 (37.0, 71.8)                                                             | 49.0 (32.9, 63.4)                                                             | 49.0 (32.9, 63.4)                                                             |
| P-value*                                                                      | 0.0001                                                                        | 0.0001                                                                        | c0.0001                                                                       | c0.0001                                                                       |
| Key Secondary Endpoint: Mean change in Hb (g/dL) from Baseline to Weeks 13-24 | Key Secondary Endpoint: Mean change in Hb (g/dL) from Baseline to Weeks 13-24 | Key Secondary Endpoint: Mean change in Hb (g/dL) from Baseline to Weeks 13-24 | Key Secondary Endpoint: Mean change in Hb (g/dL) from Baseline to Weeks 13-24 | Key Secondary Endpoint: Mean change in Hb (g/dL) from Baseline to Weeks 13-24 |
| LS mean change fom baseline (SE)d                                             | 1.65 (0.092)                                                                  | 0.19 (0.131)                                                                  | 1.48 (0.078)                                                                  | 0.07 (0.108)                                                                  |
| LSM Dif (usp-pbo) (95% CI)d                                                   | 1.47 (1.15, 1.78)                                                             | 1.47 (1.15, 1.78)                                                             | 1.42 (1.16, 1.67)                                                             | 1.42 (1.16, 1.67)                                                             |
| P-valued                                                                      | ≤0.0001                                                                       | ≤0.0001                                                                       | 0.0001                                                                        | 0.0001                                                                        |
| Mean change in Hb (g/dL) from Baseline to WWeeks 37-48                        | Mean change in Hb (g/dL) from Baseline to WWeeks 37-48                        | Mean change in Hb (g/dL) from Baseline to WWeeks 37-48                        | Mean change in Hb (g/dL) from Baseline to WWeeks 37-48                        | Mean change in Hb (g/dL) from Baseline to WWeeks 37-48                        |
| LS mean change ftom baseline (SE)d                                            | 1.68 (0.094)                                                                  | 0.14 (0.156)                                                                  | 1.50 (0.083)                                                                  | 0.01 (0.130)                                                                  |
| LSMDiff (lusp-pbo) (95% CI)d                                                  | 1.54 (1.17, 1.90)                                                             | 1.54 (1.17, 1.90)                                                             | 1.49 (1.20, 1.79)                                                             | 1.49 (1.20, 1.79)                                                             |
| P-valued                                                                      | =0.0001                                                                       | =0.0001                                                                       | 0.0001                                                                        | 0.0001                                                                        |

Note: Subject with missing Hb duing the time period were classified as non-responders in the amalysis.

Data cutoff date: 14-Sep-2020.

Source: ACE-536-B-THAL-002 CSR Table 14.2.1.1, Table 14.2.1.1.2.1, Table 14.2.3.1, Table 14.2.3.1.2.1, Table 14.2.4.1,Table 14.2.4.1.2.1, Table 14.2.5.1, Table 14.2.5.1.2.1,Table 14.2.18.1 amd Table 14.2.18.2; RSI Table 14.2.18.1.3.a; Table 14.2.18.2.3.a; amd Table BEE.28.14.2.3.1.3.c.

Improvement in Patient -Reported Symptoms

<div style=\"page-break-after: always\"></div>

Table 72: Patient reported outcome endpoints in subjects with symptomatic anemia (NTDTPRO T/W ≥ 3) at baseline and in the ITT population (study ACE-536-B-THAL002 (BEYOND))

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 73: Patient reported outcome endpoints in subjects with symptomatic anemia (NTD PRO T/W≥3) at baseline and in the ITT population (study ACE -536-B-THAL002 (BEYOND))

<!-- image -->

|                                                                       | Synptomatic Anemia Population?                                        | Synptomatic Anemia Population?                                        | ITT Population                                                        | ITT Population                                                        |
|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
|                                                                       | Luspatercept N=66                                                     | Placebo N=35                                                          | Luspatercept N=96                                                     | Placebo N=49                                                          |
| Mean change in NTDT-PRO SoB domain from Baseline² to Weeks 13-24      | Mean change in NTDT-PRO SoB domain from Baseline² to Weeks 13-24      | Mean change in NTDT-PRO SoB domain from Baseline² to Weeks 13-24      | Mean change in NTDT-PRO SoB domain from Baseline² to Weeks 13-24      | Mean change in NTDT-PRO SoB domain from Baseline² to Weeks 13-24      |
| LS mean change from baseline (SE)                                     | -1.01 (0.211)c                                                        | -0.28 (0.293)                                                         | -0.46 (0.168)d                                                        | 0.02 (0.228)d                                                         |
| LSM Diff (lusp-pbo) (95% CD)                                          | -0.72 (-1.44,-0.01)                                                   | -0.72 (-1.44,-0.01)                                                   | -0.49 (-1.02,0.04)d                                                   | -0.49 (-1.02,0.04)d                                                   |
| P-value                                                               | 0.0476c                                                               | 0.0476c                                                               | 0.0721d                                                               | 0.0721d                                                               |
| Mean change in NTDT-PRO SoB domain from Baseline² to Weeks 37-48      | Mean change in NTDT-PRO SoB domain from Baseline² to Weeks 37-48      | Mean change in NTDT-PRO SoB domain from Baseline² to Weeks 37-48      | Mean change in NTDT-PRO SoB domain from Baseline² to Weeks 37-48      | Mean change in NTDT-PRO SoB domain from Baseline² to Weeks 37-48      |
| LS mean change from baseline (SE)                                     | -1.26 (0.264)c                                                        | 0.35 (0.437)c                                                         | -0.59 (0.212)d                                                        | 0.47 (0.320)d                                                         |
| LSM Diff (lusp-pbo) (95% CI)                                          | -1.61 (-2.62, -0.59)                                                  | -1.61 (-2.62, -0.59)                                                  | -1.07 (-1.80, -0.33)d                                                 | -1.07 (-1.80, -0.33)d                                                 |
| P-value                                                               | 0.0025C                                                               | 0.0025C                                                               | pt000                                                                 | pt000                                                                 |
| Mean change in FACII-F Fatigue subscale from Baseline to Weeks 13-24  | Mean change in FACII-F Fatigue subscale from Baseline to Weeks 13-24  | Mean change in FACII-F Fatigue subscale from Baseline to Weeks 13-24  | Mean change in FACII-F Fatigue subscale from Baseline to Weeks 13-24  | Mean change in FACII-F Fatigue subscale from Baseline to Weeks 13-24  |
| LS mean change from baseline (SE)                                     | 3.32 (0.903)                                                          | 1.85 (1.332)c                                                         | 1.64 (0.774)d                                                         | 0.26 (1.066)d                                                         |
| LSM Diff (lusp-pbo) (95% CI)                                          | 1.46 (-1.73, 4.66)                                                    | 1.46 (-1.73, 4.66)                                                    | 1.39 (-1.06, 3.83)d                                                   | 1.39 (-1.06, 3.83)d                                                   |
| P-value                                                               | 0.3649c                                                               | 0.3649c                                                               | 0.2641d                                                               | 0.2641d                                                               |
| Mean change in FACIT-F Fatigue subscale from Baseline' to Weeks 37-48 | Mean change in FACIT-F Fatigue subscale from Baseline' to Weeks 37-48 | Mean change in FACIT-F Fatigue subscale from Baseline' to Weeks 37-48 | Mean change in FACIT-F Fatigue subscale from Baseline' to Weeks 37-48 | Mean change in FACIT-F Fatigue subscale from Baseline' to Weeks 37-48 |
| LS mean change from baseline (SE)                                     | 4.07 (0.957)c                                                         | 1.49 (1.522)                                                          | 2.43 (0.763)d                                                         | 0.24 (1.150)                                                          |
| LSM Diff (lusp-pbo) (95% CI)                                          | 2.57 (-0.99, 6.14)                                                    | 2.57 (-0.99, 6.14)                                                    | 2.19 (-0.39, 4.78)d                                                   | 2.19 (-0.39, 4.78)d                                                   |
| P-value                                                               | 0.1542c                                                               | 0.1542c                                                               | 0.095gd                                                               | 0.095gd                                                               |

Data cutoff date: 14-Sep-2020

<div style=\"page-break-after: always\"></div>

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 74: Summary of Efficacy for trial ACE-536-B-THAL-002

| Title: A Phase 2, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults with   | Title: A Phase 2, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults with                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Title: A Phase 2, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults with                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Title: A Phase 2, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults with                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                 | ClinicalTrials.gov Identifier: NCT03342404; EudraCT number: 2015-003225- 33; Registry Identifier: WHO: U1111-1202-7068                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | ClinicalTrials.gov Identifier: NCT03342404; EudraCT number: 2015-003225- 33; Registry Identifier: WHO: U1111-1202-7068                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | ClinicalTrials.gov Identifier: NCT03342404; EudraCT number: 2015-003225- 33; Registry Identifier: WHO: U1111-1202-7068                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Design                                                                                                                                                                           | Study ACE-536-B-THAL-002 is an ongoing pivotal phase 2 study with a double-blind, randomised (2:1), placebo-controlled, multi-center design to determine the efficacy and safety of luspatercept versus placebo (on top of BSC) in adults with anemia associated with Non Transfusion Dependent (NTD) β - Thalassaemia (either β - thalassemia or HbE/β -thalassemia, with or without conco mitant α -globin mutation and/or duplication). NTD was defined as 0 to 5 units of RBCs received during the 24-week period prior to randomization. Patients were required to have a mean baseline Hb of ≤ 10.0 g/dL, based on a minimum of 2 measurements ≥ 1 week apart within 4 weeks prior to randomization; Hb values within 21 days after transfusion were excluded. They were further required not to be on a regular transfusion program and to be RBC transfusion free for at least ≥ 8 weeks prior to randomization. Patients were randomised stratified baseline Hb category (< 8.5 versus ≥ 8.5 g/dL) and baseline NTDT-PRO T/W domain score category ( ≥ 3 versus < 3). After unblinding, patients were allowed to roll over to the overarching long term study LTFU-001. Duration of main phase: 48 weeks | Study ACE-536-B-THAL-002 is an ongoing pivotal phase 2 study with a double-blind, randomised (2:1), placebo-controlled, multi-center design to determine the efficacy and safety of luspatercept versus placebo (on top of BSC) in adults with anemia associated with Non Transfusion Dependent (NTD) β - Thalassaemia (either β - thalassemia or HbE/β -thalassemia, with or without conco mitant α -globin mutation and/or duplication). NTD was defined as 0 to 5 units of RBCs received during the 24-week period prior to randomization. Patients were required to have a mean baseline Hb of ≤ 10.0 g/dL, based on a minimum of 2 measurements ≥ 1 week apart within 4 weeks prior to randomization; Hb values within 21 days after transfusion were excluded. They were further required not to be on a regular transfusion program and to be RBC transfusion free for at least ≥ 8 weeks prior to randomization. Patients were randomised stratified baseline Hb category (< 8.5 versus ≥ 8.5 g/dL) and baseline NTDT-PRO T/W domain score category ( ≥ 3 versus < 3). After unblinding, patients were allowed to roll over to the overarching long term study LTFU-001. Duration of main phase: 48 weeks | Study ACE-536-B-THAL-002 is an ongoing pivotal phase 2 study with a double-blind, randomised (2:1), placebo-controlled, multi-center design to determine the efficacy and safety of luspatercept versus placebo (on top of BSC) in adults with anemia associated with Non Transfusion Dependent (NTD) β - Thalassaemia (either β - thalassemia or HbE/β -thalassemia, with or without conco mitant α -globin mutation and/or duplication). NTD was defined as 0 to 5 units of RBCs received during the 24-week period prior to randomization. Patients were required to have a mean baseline Hb of ≤ 10.0 g/dL, based on a minimum of 2 measurements ≥ 1 week apart within 4 weeks prior to randomization; Hb values within 21 days after transfusion were excluded. They were further required not to be on a regular transfusion program and to be RBC transfusion free for at least ≥ 8 weeks prior to randomization. Patients were randomised stratified baseline Hb category (< 8.5 versus ≥ 8.5 g/dL) and baseline NTDT-PRO T/W domain score category ( ≥ 3 versus < 3). After unblinding, patients were allowed to roll over to the overarching long term study LTFU-001. Duration of main phase: 48 weeks |
|                                                                                                                                                                                  | Duration of Run-in phase: Duration of Extension phase: Duration of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | PTFU Phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 4 weeks Maximum of 15 weeks 5 years from the first dose of study drug or 3 years from the last dose of study drug (whichever occurs later) until EOS.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Hypothesis                                                                                                                                                                       | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Treatments groups                                                                                                                                                                | Luspatercept + BSC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Luspatercept + BSC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | SC injection (q3w), N=96                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                                                                                                                                                                  | Placebo + BSC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Placebo + BSC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | SC injection (q3w), N=49                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Endpoints and definitions                                                                                                                                                        | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Proportion of subjects who had an increase from baseline ≥ 1.0 g/dL in mean of Hb values (Week 13 - 24) in the absence of transfusions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Hb values from samples collected within 21 days after a transfusion were excluded from analyses. Hb was derived as the sum of results over 12 weeks divided by the number of assessments. The mean over 12 weeks was used to derive the mean change from baseline for each subject                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Key secondary endpoint 1   | Mean change from baseline in NTDT-PRO T/W domain score (Week 13 - 24)                                                                  | The NTDT-PRO was administered as a daily diary for 24 weeks and after that over the 7 days prior to receiving study drug dose   |
|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|
| Key secondary endpoint 2   | Mean change from baseline in mean of Hb values (Week 13 - 24) in the absence of transfusions                                           | See description above for baseline Hb                                                                                           |
| Key secondary endpoint 3   | Proportion of subjects who had an increase from baseline ≥ 1.0 g/dL in mean of Hb values (Week 37 - 48) in the absence of transfusions | See description above for baseline Hb                                                                                           |
| Secondary endpoint         | Mean Hb change (g/dL) from baseline (Week 37- 48)                                                                                      | See description above for baseline Hb                                                                                           |
| Secondary endpoint         | Number of Responders (Hb increase ≥ 1.5g/dL, Week 13-24 and 37-48)                                                                     | See description above for baseline Hb                                                                                           |
| Secondary endpoint         | Mean change from baseline in the NTDT- PRO T/W Domain Score (Week 37- 48)                                                              | See description above for NTDT-PRO                                                                                              |

<div style=\"page-break-after: always\"></div>

|                                            | Secondary endpoint                                                                                                                                   | Mean change from baseline in mean FACIT-F Fatigue subscale score (Week 13- 24 and 37- 48)                                                                                    | The FACIT-F Fatigue subscale was administered to subjects every other dose prior to receiving study drug dose                                        | The FACIT-F Fatigue subscale was administered to subjects every other dose prior to receiving study drug dose                                        |
|--------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                            | Secondary endpoint                                                                                                                                   | Mean change from baseline in SF-36 PCS and MCS (to Week 24 and 48)                                                                                                           | The SF-36 was administered to subjects every other dose prior to receiving study drug dose                                                           | The SF-36 was administered to subjects every other dose prior to receiving study drug dose                                                           |
|                                            | Secondary endpoint                                                                                                                                   | Mean change from baseline in 6MWT distance (at Week 24 and 48)                                                                                                               | The 6MWT was performed every 4 doses and at Week 24 and Week 48, regardless of dose delay and even if the study drug was discontinued                | The 6MWT was performed every 4 doses and at Week 24 and Week 48, regardless of dose delay and even if the study drug was discontinued                |
| Database lock                              | 14 Sep 2020 (but see OC)                                                                                                                             | 14 Sep 2020 (but see OC)                                                                                                                                                     | 14 Sep 2020 (but see OC)                                                                                                                             | 14 Sep 2020 (but see OC)                                                                                                                             |
| Results and Analysis                       | Results and Analysis                                                                                                                                 | Results and Analysis                                                                                                                                                         | Results and Analysis                                                                                                                                 | Results and Analysis                                                                                                                                 |
| Analysis description                       | Primary Analysis                                                                                                                                     | Primary Analysis                                                                                                                                                             | Primary Analysis                                                                                                                                     | Primary Analysis                                                                                                                                     |
| Analysis population and time point         | Intent to treat; 48 weeks of treatment                                                                                                               | Intent to treat; 48 weeks of treatment                                                                                                                                       | Intent to treat; 48 weeks of treatment                                                                                                               | Intent to treat; 48 weeks of treatment                                                                                                               |
| description Effect estimate per comparison | a Defined as                                                                                                                                         | a Defined as                                                                                                                                                                 | a Defined as                                                                                                                                         | a Defined as                                                                                                                                         |
|                                            | RBC transfusions, measurements b The difference from the exact Notes: Subjects as nonresponders Sensitivity measurements with the main Key Secondary | compared with at least 1 week apart in proportions (luspatercept unconditional test. with missing Hb in the analysis. analyses (e.g. subjects or with transfusions analysis. | RBC transfusions, measurements b The difference from the exact Notes: Subjects as nonresponders Sensitivity measurements with the main Key Secondary | RBC transfusions, measurements b The difference from the exact Notes: Subjects as nonresponders Sensitivity measurements with the main Key Secondary |
|                                            |                                                                                                                                                      | 95% CI b                                                                                                                                                                     |                                                                                                                                                      |                                                                                                                                                      |
|                                            | Primary Number of Responders a ITT (N=96 and N=49)                                                                                                   | Primary Number of Responders a ITT (N=96 and N=49)                                                                                                                           | Primary Number of Responders a ITT (N=96 and N=49)                                                                                                   | Primary Number of Responders a ITT (N=96 and N=49)                                                                                                   |
|                                            | endpoint (week 13-24), n (%) (Luspatercept - Pb)                                                                                                     | endpoint (week 13-24), n (%) (Luspatercept - Pb)                                                                                                                             | endpoint (week 13-24), n (%) (Luspatercept - Pb)                                                                                                     | endpoint (week 13-24), n (%) (Luspatercept - Pb)                                                                                                     |
|                                            | Difference in Proportions (%) b 77.1                                                                                                                 | Difference in Proportions (%) b 77.1                                                                                                                                         | Difference in Proportions (%) b 77.1                                                                                                                 | Difference in Proportions (%) b 77.1                                                                                                                 |
|                                            | Pb) b                                                                                                                                                | Pb) b                                                                                                                                                                        | Pb) b                                                                                                                                                | Pb) b                                                                                                                                                |
|                                            | LS mean difference -0.48                                                                                                                             | LS mean difference -0.48                                                                                                                                                     | LS mean difference -0.48                                                                                                                             | LS mean difference -0.48                                                                                                                             |
|                                            | b                                                                                                                                                    | b                                                                                                                                                                            | b                                                                                                                                                    | b                                                                                                                                                    |
|                                            | 95% CI -1.03, 0.08                                                                                                                                   | 95% CI -1.03, 0.08                                                                                                                                                           | 95% CI -1.03, 0.08                                                                                                                                   | 95% CI -1.03, 0.08                                                                                                                                   |
|                                            | P-value 0.0924                                                                                                                                       | P-value 0.0924                                                                                                                                                               | P-value 0.0924                                                                                                                                       | P-value 0.0924                                                                                                                                       |
|                                            | 13-24) (Luspatercept -                                                                                                                               | 13-24) (Luspatercept -                                                                                                                                                       | 13-24) (Luspatercept -                                                                                                                               | 13-24) (Luspatercept -                                                                                                                               |
|                                            | T/W domain score (week                                                                                                                               | T/W domain score (week                                                                                                                                                       | T/W domain score (week                                                                                                                               | T/W domain score (week                                                                                                                               |
|                                            | EP 1                                                                                                                                                 | EP 1                                                                                                                                                                         | EP 1                                                                                                                                                 | EP 1                                                                                                                                                 |
|                                            |                                                                                                                                                      | baseline a in NTDT-PRO                                                                                                                                                       | baseline a in NTDT-PRO                                                                                                                               | baseline a in NTDT-PRO                                                                                                                               |
|                                            |                                                                                                                                                      | Mean change from ITT │ n=94 and n=48*                                                                                                                                        | Mean change from ITT │ n=94 and n=48*                                                                                                                | Mean change from ITT │ n=94 and n=48*                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                      | a Baseline was defined as the average of nonmissing NTDT-PRO T/W domain scores over 7 days before Dose 1 Day 1. b Estimates were based on an ANCOVA model with baseline Hb category (< 8.5 versus ≥ 8.5 g/dL) and baseline NTDT - PRO T/W domain score category (≥ 3 versus < 3) defined at randomization as covariates. Notes: *Subjects with missing NTDT-PRO T/W domain score at the Week 13 to Week 24 interval were excluded in the analysis. Sensitivity analyses, e.g. on the PP, or the ITT, with subjects with at least 4 nonmissing daily scores per week, or subjects who had missing values were imputed by baseline or multiple imputation, or HRQoL evaluable population) show consistent   | a Baseline was defined as the average of nonmissing NTDT-PRO T/W domain scores over 7 days before Dose 1 Day 1. b Estimates were based on an ANCOVA model with baseline Hb category (< 8.5 versus ≥ 8.5 g/dL) and baseline NTDT - PRO T/W domain score category (≥ 3 versus < 3) defined at randomization as covariates. Notes: *Subjects with missing NTDT-PRO T/W domain score at the Week 13 to Week 24 interval were excluded in the analysis. Sensitivity analyses, e.g. on the PP, or the ITT, with subjects with at least 4 nonmissing daily scores per week, or subjects who had missing values were imputed by baseline or multiple imputation, or HRQoL evaluable population) show consistent   | a Baseline was defined as the average of nonmissing NTDT-PRO T/W domain scores over 7 days before Dose 1 Day 1. b Estimates were based on an ANCOVA model with baseline Hb category (< 8.5 versus ≥ 8.5 g/dL) and baseline NTDT - PRO T/W domain score category (≥ 3 versus < 3) defined at randomization as covariates. Notes: *Subjects with missing NTDT-PRO T/W domain score at the Week 13 to Week 24 interval were excluded in the analysis. Sensitivity analyses, e.g. on the PP, or the ITT, with subjects with at least 4 nonmissing daily scores per week, or subjects who had missing values were imputed by baseline or multiple imputation, or HRQoL evaluable population) show consistent   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                      | results with the main Key Secondary EP 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | key secondary endpoint 1 Mean change in Hemoglobin (g/dL) from baseline a (week 13-24) (Luspatercept - Pb)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | analysis. ITT │ n=96 and n=47*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | LS mean difference                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 1.42                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 95% CI b                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.16, 1.67                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      | a Baseline was defined as the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1. b Estimates were based on an ANCOVA model with treatment group and baseline Hb category (< 8.5 versus ≥ 8.5 g/dL) and baseline NTDT-PRO T/W domain score category ( ≥ 3 versus < 3) defined at randomization as covariates. Notes: *Subjects with missing Hb at the Week 13 to Week 24 interval were excluded in this analysis. Sensitivity analyses (e.g. on the PP, or the ITT with subjects with missing Hb values during the Week 13 to Week 24 interval imputed by baseline or multiple imputation) show consistent results with the main key secondary 2 analysis.     | a Baseline was defined as the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1. b Estimates were based on an ANCOVA model with treatment group and baseline Hb category (< 8.5 versus ≥ 8.5 g/dL) and baseline NTDT-PRO T/W domain score category ( ≥ 3 versus < 3) defined at randomization as covariates. Notes: *Subjects with missing Hb at the Week 13 to Week 24 interval were excluded in this analysis. Sensitivity analyses (e.g. on the PP, or the ITT with subjects with missing Hb values during the Week 13 to Week 24 interval imputed by baseline or multiple imputation) show consistent results with the main key secondary 2 analysis.     | a Baseline was defined as the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1. b Estimates were based on an ANCOVA model with treatment group and baseline Hb category (< 8.5 versus ≥ 8.5 g/dL) and baseline NTDT-PRO T/W domain score category ( ≥ 3 versus < 3) defined at randomization as covariates. Notes: *Subjects with missing Hb at the Week 13 to Week 24 interval were excluded in this analysis. Sensitivity analyses (e.g. on the PP, or the ITT with subjects with missing Hb values during the Week 13 to Week 24 interval imputed by baseline or multiple imputation) show consistent results with the main key secondary 2 analysis.     |
|                      | Key Secondary EP 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Number of Responders a (Week 37-48) (Luspatercept - Pb) b                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | ITT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Difference in Proportions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 68.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 95% CI b                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 54.3, 80.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      | Notes: Subjects with missing Hb at the Week 37 to Week 48 interval were classified as nonresponders in the analysis. a Defined as the number of subjects with ≥ 1.0 g/dL Hb increase in the absence of RBC transfusions, compared with baseline, ie, the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1. b The difference in proportions (luspatercept - placebo) and 95% CI were estimated from the exact unconditional test. Sensitivity analyses Inconsistent results were observed across subgroups (e.g. patients with NTDT PRO <3, male patients, patients with Hb baseline levels≥8.5 g/dL,                                                         | Notes: Subjects with missing Hb at the Week 37 to Week 48 interval were classified as nonresponders in the analysis. a Defined as the number of subjects with ≥ 1.0 g/dL Hb increase in the absence of RBC transfusions, compared with baseline, ie, the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1. b The difference in proportions (luspatercept - placebo) and 95% CI were estimated from the exact unconditional test. Sensitivity analyses Inconsistent results were observed across subgroups (e.g. patients with NTDT PRO <3, male patients, patients with Hb baseline levels≥8.5 g/dL,                                                         | Notes: Subjects with missing Hb at the Week 37 to Week 48 interval were classified as nonresponders in the analysis. a Defined as the number of subjects with ≥ 1.0 g/dL Hb increase in the absence of RBC transfusions, compared with baseline, ie, the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1. b The difference in proportions (luspatercept - placebo) and 95% CI were estimated from the exact unconditional test. Sensitivity analyses Inconsistent results were observed across subgroups (e.g. patients with NTDT PRO <3, male patients, patients with Hb baseline levels≥8.5 g/dL,                                                         |
| Analysis description | patients with splenectomy, Secondary endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Middle East).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | patients with splenectomy, Secondary endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                      | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Mean Hb change (g/dL) from baseline q (week 37- 48) (Luspatercept - Pb)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ITT │ n=91 and n=34                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | LS mean difference b                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1.49                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 1.20, 1.79                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      | a Baseline was defined as the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1. b Estimates were based on an ANCOVA model with treatment group and baseline Hb category (< 8.5 versus ≥ 8.5 g/dL) and baseline NTDT -PRO T/W domain score category (≥ 3 versus < 3) defined at randomization as covariates                                                                                                                                                                                                                                                                                                                                                   | a Baseline was defined as the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1. b Estimates were based on an ANCOVA model with treatment group and baseline Hb category (< 8.5 versus ≥ 8.5 g/dL) and baseline NTDT -PRO T/W domain score category (≥ 3 versus < 3) defined at randomization as covariates                                                                                                                                                                                                                                                                                                                                                   | a Baseline was defined as the average of 2 or more Hb measurements at least 1 week apart within 4 weeks before Dose 1 Day 1. b Estimates were based on an ANCOVA model with treatment group and baseline Hb category (< 8.5 versus ≥ 8.5 g/dL) and baseline NTDT -PRO T/W domain score category (≥ 3 versus < 3) defined at randomization as covariates                                                                                                                                                                                                                                                                                                                                                   |
|                      | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Number of Responders (Hb increase ≥ 1.5g/dL in the absence of transfusion, Week 13-24) (Luspatercept - Pb) a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | ITT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Difference in Proportions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 52.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 36.2, 66.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                             | Number of Responders (Hb increase ≥ 1.5g/dL in the absence of transfusion, Week 37-48) (Luspatercept - Pb)                                                                                                                                                                                                                                                                                                                                     | ITT                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | Difference in Proportions a                                                                                                                                                                                                                                                                                                                                                                                                                    | 49.0                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                         | 32.9, 63.4                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                        | <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Notes: Subjects With Missing Values are classified as Nonresponders a The difference in proportions (luspatercept - placebo) and 95% CI were estimated from the exact unconditional test.                                                                                                                                                                                                                                                      | Notes: Subjects With Missing Values are classified as Nonresponders a The difference in proportions (luspatercept - placebo) and 95% CI were estimated from the exact unconditional test.                                                                                                                                                                                                                                                      | Notes: Subjects With Missing Values are classified as Nonresponders a The difference in proportions (luspatercept - placebo) and 95% CI were estimated from the exact unconditional test.                                                                                                                                                                                                                                                      |
| Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                             | Mean change from baseline a in the NTDT- PRO T/W Domain Score (Week 37-48) (Luspatercept - Pb)                                                                                                                                                                                                                                                                                                                                                 | ITT │n=72 and n=28                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | LS mean difference b                                                                                                                                                                                                                                                                                                                                                                                                                           | -0.79                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                         | -1.58, 0.00                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.0510                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| a Baseline is defined as daily average NTDT-PRO T/W score over 7 days before Dose 1 Day 1. b Estimates are based on an ANCOVA model with baseline hemoglobin category (>=8.5 g/dL vs. <8.5 g/dL) and baseline NTDT-PRO T/W score category (>=3 vs. <3) defined at randomization as covariates.                                                                                                                                                 | a Baseline is defined as daily average NTDT-PRO T/W score over 7 days before Dose 1 Day 1. b Estimates are based on an ANCOVA model with baseline hemoglobin category (>=8.5 g/dL vs. <8.5 g/dL) and baseline NTDT-PRO T/W score category (>=3 vs. <3) defined at randomization as covariates.                                                                                                                                                 | a Baseline is defined as daily average NTDT-PRO T/W score over 7 days before Dose 1 Day 1. b Estimates are based on an ANCOVA model with baseline hemoglobin category (>=8.5 g/dL vs. <8.5 g/dL) and baseline NTDT-PRO T/W score category (>=3 vs. <3) defined at randomization as covariates.                                                                                                                                                 |
| Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                             | Mean change from baseline a in mean FACIT- Fatigue subscale score (Week 13-24) (Luspatercept - Pb)                                                                                                                                                                                                                                                                                                                                             | HRQoL evaluable population (N=94 and N=47) │ n=90 and n=43                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | LS mean difference b                                                                                                                                                                                                                                                                                                                                                                                                                           | 1.39                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                         | -1.06, 3.83                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.2641                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                             | Mean change from baseline a in mean FACIT- Fatigue subscale score (Week 37-48) (Luspatercept - Pb)                                                                                                                                                                                                                                                                                                                                             | HRQoL evaluable population (N=94 and N=47) │ n=83 and n=33                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | LS mean difference b                                                                                                                                                                                                                                                                                                                                                                                                                           | 2.19                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                         | -0.39, 4.78                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.0959                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Notes: 'HRQoL Evaluable Population' are subjects with an evaluable FACIT-F questionnaire at baseline and at least one post-baseline. a Baseline is defined as the last FACIT-F FS score on or before Dose 1 Day 1. b Estimates are based on an ANCOVA model with baseline hemoglobin category (>=8.5 g/dL vs. <8.5 g/dL) and baseline NTDT-PRO T/W score category (>=3 vs. <3) defined at randomization and baseline FACIF-F FS as covariates. | Notes: 'HRQoL Evaluable Population' are subjects with an evaluable FACIT-F questionnaire at baseline and at least one post-baseline. a Baseline is defined as the last FACIT-F FS score on or before Dose 1 Day 1. b Estimates are based on an ANCOVA model with baseline hemoglobin category (>=8.5 g/dL vs. <8.5 g/dL) and baseline NTDT-PRO T/W score category (>=3 vs. <3) defined at randomization and baseline FACIF-F FS as covariates. | Notes: 'HRQoL Evaluable Population' are subjects with an evaluable FACIT-F questionnaire at baseline and at least one post-baseline. a Baseline is defined as the last FACIT-F FS score on or before Dose 1 Day 1. b Estimates are based on an ANCOVA model with baseline hemoglobin category (>=8.5 g/dL vs. <8.5 g/dL) and baseline NTDT-PRO T/W score category (>=3 vs. <3) defined at randomization and baseline FACIF-F FS as covariates. |
| Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                             | Mean change from baseline a in SF-36 PCS (to Week 24) (Luspatercept - Pb) b                                                                                                                                                                                                                                                                                                                                                                    | HRQoL evaluable population (N=92 and N=46) │n=76 and n=37                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | LS mean difference                                                                                                                                                                                                                                                                                                                                                                                                                             | 1.39                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                         | -0.19, 2.96                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.0847                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                             | Mean change from baseline a in SF-36 PCS (to Week 48) (Luspatercept - Pb)                                                                                                                                                                                                                                                                                                                                                                      | HRQoL evaluable population (N=92 and N=46) │n=71 and n=30                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | difference b                                                                                                                                                                                                                                                                                                                                                                                                                                   | 1.75                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | LS mean                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                | 95% CI P-value                                                                                                                                                                                                                                                                                                                                                                                                                                 | -0.15, 3.65 0.0712                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Mean change from baseline in SF-36 MCS (to Week 24) (Luspatercept - Pb)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | HRQoL evaluable population (N=92 and N=46) │n=76 and n=37                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | LS mean difference                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.54                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | -0.63, 3.72                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 0.1633                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Mean change from baseline in SF-36 MCS (to Week 48) (Luspatercept - Pb)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | HRQoL evaluable population (N=92 and N=46) │n=71 and n=30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | LS mean difference                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 2.70                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 0.04, 5.36                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 0.0469                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Notes: 'HRQoL Evaluable Population' are subjects with an evaluable SF-36 questionnaire at baseline and at least one post-baseline. A SF-36 is considered evaluable if at least 18 out of the 36 items in SF-36 are answered. a Baseline is defined as the last SF-36 PCS score on or before Dose 1 Day 1. b P-values are calculated based on an MMRM model with treatment, visit, stratification factors, baseline score, baseline score-by-visit interaction, and treatment-by-visit interaction as fixed effects, with intercept and visit as random effects and an unstructured covariance assumption. CI = Confidence Interval. | Notes: 'HRQoL Evaluable Population' are subjects with an evaluable SF-36 questionnaire at baseline and at least one post-baseline. A SF-36 is considered evaluable if at least 18 out of the 36 items in SF-36 are answered. a Baseline is defined as the last SF-36 PCS score on or before Dose 1 Day 1. b P-values are calculated based on an MMRM model with treatment, visit, stratification factors, baseline score, baseline score-by-visit interaction, and treatment-by-visit interaction as fixed effects, with intercept and visit as random effects and an unstructured covariance assumption. CI = Confidence Interval. | Notes: 'HRQoL Evaluable Population' are subjects with an evaluable SF-36 questionnaire at baseline and at least one post-baseline. A SF-36 is considered evaluable if at least 18 out of the 36 items in SF-36 are answered. a Baseline is defined as the last SF-36 PCS score on or before Dose 1 Day 1. b P-values are calculated based on an MMRM model with treatment, visit, stratification factors, baseline score, baseline score-by-visit interaction, and treatment-by-visit interaction as fixed effects, with intercept and visit as random effects and an unstructured covariance assumption. CI = Confidence Interval. |
| Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Mean change from baseline in 6MWT distance (m; at week 24) (Luspatercept - Pb)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ITT │ n=87 and n=47                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | LS mean difference                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 16.15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | -5.73, 38.04                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 0.1466                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Mean change b from baseline a in 6MWT distance (m; at week 48) (Luspatercept - Pb)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | ITT │ n=86 and n=41                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | LS mean difference c                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 12.44                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | -6.72, 31.59                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 0.2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| a Baseline is defined as the last value on or before the first dose of study drug is administered. b Postbaseline is defined as the closest visit at Week 24 or Week 48. c Estimates are based on an ANCOVA model with treatment group, baseline Hb category (>= 8.5 g/dL, < 8.5 g/dL), baseline NTDT-PRO T/W score category (>=3 vs. <3) defined at randomization and baseline 6MWT value as covariates.                                                                                                                                                                                                                           | a Baseline is defined as the last value on or before the first dose of study drug is administered. b Postbaseline is defined as the closest visit at Week 24 or Week 48. c Estimates are based on an ANCOVA model with treatment group, baseline Hb category (>= 8.5 g/dL, < 8.5 g/dL), baseline NTDT-PRO T/W score category (>=3 vs. <3) defined at randomization and baseline 6MWT value as covariates.                                                                                                                                                                                                                           | a Baseline is defined as the last value on or before the first dose of study drug is administered. b Postbaseline is defined as the closest visit at Week 24 or Week 48. c Estimates are based on an ANCOVA model with treatment group, baseline Hb category (>= 8.5 g/dL, < 8.5 g/dL), baseline NTDT-PRO T/W score category (>=3 vs. <3) defined at randomization and baseline 6MWT value as covariates.                                                                                                                                                                                                                           |

## Analysis performed across trials (pooled analyses and meta-analysis)

Two supportive studies (A536-04/06) were conducted. To compare efficacy data to pivotal study ACE536-B-THAL-002, a subset of subjects from studies A536-04/06 that matched key inclusion criteria and approximated the dosing of study ACE-536-B-THAL-002 was defined and used for an integrated summary of efficacy (ISE; see below).

## Supportive studies

A536-04 was a Phase 2, open-label, single-arm, ascending dose study to evaluate efficacy and safety of ACE536 in subjects with β - Thalassemia. A536-06 was an extension study to evaluate long-term effects in patients previously enrolled in study A536-04. Studies A536-04/06 have been also part of the initial submission in TD β -thalassemia patients. At the time of initial submission study A536-04 was completed, and study A536-06 was still ongoing, but is now completed.

The supportive Phase 2 studies (A536-04/06) were conducted in Europe (Italy and Greece) and enrolled both NTD and TD β -thalassemia subjects. To compare efficacy data to pivotal study ACE-536-B-THAL-

<div style=\"page-break-after: always\"></div>

002, a subset of subjects from studies A536-04/06 that matched key inclusion criteria and approximated the dosing of study ACE-536-B-THAL-002 was defined and is referred to as the 'BEYOND-like Population' (n=19), which was used for the integrated summary of efficacy (ISE) data pool.

The primary objective of extension study A536-06 was long-term safety and tolerability of luspatercept. During the initial submission, both TD and NTD β -thalassemia patients (total n=64) were included for the integrated summary of safety (ISS) data pool from studies A536-04/06. For the current submission, ISS data pool comprises NTD β -thalassemia patients only (n=33). Of the 33 NTD β -thalassemia subjects who were enrolled and treated with luspatercept in A536-04, 2 subjects became TD prior to entering A536-06 and were not included in the integrated summary of efficacy (ISE).

## Study A536-04

At the time of initial submission study A536-04 was already completed and discussed in the clinical AR.

## Objectives

The primary objective of this study was to evaluate the proportion o f β -thalassemia subjects who had an erythroid response, defined as: 1) an Hb increase of ≥ 1.5 g/dL from baseline for ≥ 14 days (in the absence of RBC transfusions) in NTD β -thalassemia subjects; [or 2) ≥ 20% reduction in RBC transfusion burden during any rolling 12-week window on treatment compared to pretreatment in TD β -thalassemia subjects.

## Treatments and Doses

Subjects in all cohorts received luspatercept, administered SC, every 3 weeks for up to 5 cycles. The dose level for the first cohort was 0.2 mg/kg and the dose levels for subsequent cohorts followed a modified Fibonacci dose escalation scheme (i.e., maximum dose of 0.4 mg/kg for cohort 2, up to 1.5 mg/kg for cohort 7). Due to efficaciousness of assessed dose levels, the Safety Review Team determined expansion cohort doses ranging from 0.8 to 1.25 mg/kg.

## Recruitment

First subject first visit: 11 Feb 2013. Last subject last visit: 11 Nov 2015. Completed CSR: 29 Aug 2018.

## Sample Size and Statistical Analysis

Each dose escalation cohort consisted of up to 6 subjects. The expansion cohort (target enrolment of 30 subjects) was designed to include a minimum of 12 NTD β -thalassemia subjects and 12 TD β -thalassemia subjects.

All summaries were descriptive. No randomization or formal hypothesis testing was planned.

## Study Subjects

- NTD β -thalassemia subjects (defined as having received &lt; 4 units of RBCs within 8 weeks prior to Cycle 1 Day 1 [C1D1])
- TD β -thalassemia subjects (defined as requiring ≥ 4 units of RBCs every 8 weeks confirmed over 6 months prior to C1D1)

A total of 64 subjects were enrolled in the study; 35 subjects were enrolled in the dose-escalation phase at dose levels of 0.2 to 1.25 mg/kg and 29 subjects were enrolled in the expansion cohort. NTD β -thalassemia subjects (n=33) comprised 51.6% of the total population. Overall, 56 subjects (87.5%) received the planned 5 cycles every 3 weeks of luspatercept. Five (7.8%) subjects discontinued treatment on the advice of the physician. Two (3.1%) subjects did not complete the study due to protocol deviations, and 1 (1.6%) subject withdrew from the study.

<div style=\"page-break-after: always\"></div>

## Efficacy Assessment

NTD β -thalassemia subjects are the primary focus of this submission.

For the primary endpoint , 9 (27.3%) of the 33 NTD β -thalassemia subjects had a Hb increase ≥ 1.5 g/d L sustained for ≥ 14 days, all of whom were treated with luspatercept at dose levels of ≥ 0.8 mg/kg. Overall, 14/33 NTD β -thalassemia subjects (42.4%) had an erythroid response, defined as mean Hb increase ≥ 1.0 g/dL over any rolling 12 -week interval during the study.

Iron Metabolism Parameters: In NTD β -thalassemia subjects with baseline LIC &lt; 3 mg/g DW (dry weight), there was little overall change in mean LIC levels. In NTD β -thalassemia subjects with baseline LIC ≥ 3 mg/g DW, a total of 9/20 (45.0%) subjects had LIC reduction ≥ 1 mg/g DW. No marked changes were observed in serum iron, TIBC, transferrin, soluble transferrin receptor, ferritin, and hepcidin levels.

Erythropoiesis Parameters: Overall, the observed levels of EPO and nucleated RBCs increased from baseline to EOT. The increase was larger for subjects treated with 0.6 to 1.25 mg/kg than for those treated with 0.2 to 0.4 mg/kg. Observed levels of reticulocytes decreased slightly from baseline to EOT in subjects treated with 0.2 to 0.6 mg/kg and increased from baseline in subjects treated with 0.8 to 1.25 mg/kg.

Haemolysis Parameters: Overall, the mean observed levels of haptoglobin, indirect bilirubin, and LDH increased from baseline to EOT.

Bone Metabolism Parameters: The mean observed levels of BSAP and CTX increased from baseline to EOT. No dose-related trends were apparent.

## Exploratory Efficacy Endpoints:

Overall, mean levels of GDF11 and GDF15 increased from baseline to EOT, and levels of GDF8 decreased slightly from baseline to EOT. There were no clinically meaningful patterns in change in spleen size, BMD, EMH mass size, leg ulcer size, and 6MWT distance.

Quality of Life assessments are limited for this study and will be discussed more fully in the extension study (A536-06) that followed this base study. Overall, mean changes from baseline in all components of the FACT-An subscale were small. SF-36 domain T-scores decreased slightly in all components.

## Study A536-06

At the time of initial submission study A536-06 was ongoing and results as of the 31 August 2017 clinical data cut-off date were discussed in the clinical AR, the study is now completed.

## Objectives

The primary objective of this study was to evaluate the long-term safety and tolerability of luspatercept in subjects with β -thalassemia who were previously enrolled in Study A536-04. Efficacy was included as a secondary endpoint to evaluate erythroid response.

## Treatments and Doses

This study evaluated the effects of up to 5 years of luspatercept treatment in s ubjects with β -thalassemia previously enrolled and treated with luspatercept for up to 3 months in Study A536-04. Subjects without treatment interruption (see below) continued dosing with luspatercept at the same dose level administered at their last dose in Study A536-04. All subjects with treatment interruption were initially treated with luspatercept at a starting dose level of 0.8 mg/kg.

<div style=\"page-break-after: always\"></div>

## Recruitment

First subject first visit: 20 Oct 2014. [Last subject last visit: 28 Apr 2020.] Data cut-off: 18 June 2020. Completed CSR: 24 Sep 2020.

## Study Subjects

For 'subjects without treatment interruption' C1D1 of Study A536-06 took place 28 (± 7) days after the last dose administered in Study A536-04. Subjects who completed the EOS visit for Study A536-04 and were ≥ 28 days post EOS visit were considered 'subjects with treatment interruption'. For subjects without treatment interruption, transfusion status (NTD or TD) carried over from base study A536-04. The NTD β -thalassemia subjects with treatment interruption were defined as subjects who required transfusion of &lt; 4 units of RBCs over the 8 weeks prior to C1D1 of Study A53606. For TD β -thalassemia subjects with treatment interruption, transfusion status carried over from base Study A536-04.

A536-06 study enrolment has completed with 51 subjects out of 64 who participated in the base study. For subjects without treatment interruption (n = 26), data from Study A536-04 are included in the combined analysis of Studies A536-04/A536-06. For subjects with treatment interruption (n = 25), only data from Study A536-06 were included in the analysis.

Of total 27 NTD β -thalassemia subjects, 17 (63%) entered after treatment interruption. One participant changed from NTD status in Study A536-04 to TD status in Study A536-06. In the ISS, this subject is categorized as having NTD β -thalassemia.

## Efficacy Assessment

NTD β -thalassemia subjects are the primary focus of this submission.

No primary efficacy endpoint was specified for this study as the primary objective for this study was to evaluate the long-term safety and tolerability of luspatercept.

Erythroid Response: For NTD β -thalassemia subjects (receiving ≥ 0.6 mg/kg luspatercept), 21 (77.8%) had an Hb increase ≥ 1.0 g/dL over any rolling 8 - or 12-week interval, in the absence of RBC transfusion.

Time to and duration of erythroid response had changed in NTD β -thalassemia subjects compared to the data cutoff date from the initial application: the mean (SD) time to erythroid response and duration of erythroid response for NTD subjects was 19.1 (30.96) days and 668.4 (273.82) days, respectively, in the initial application. The updated mean (SD) time to erythroid response and duration of erythroid response for NTD participants is 13.6 (19.28) days and 1147 (637.52) days, respectively.

Iron Metabolism Parameters: At ≥ 18 months, for NTD participants with baseline LIC ≥ 3 mg/g DW, 6 (60.0%) of 10 NTD participants had an LIC reduction of ≥ 1 mg/g DW. The majority of participants with an elevated LIC at baseline were also on stable ICT therapy, possibly confounding interpretation of any LIC-lowering effect of luspatercept in this study.

Mean values for serum ferritin for all participants decreased progressively during the majority of the treatment period.

Erythropoiesis Parameters: Mean EPO levels were minimally changed in NTD participants. The observed mean levels of reticulocytes increased from baseline during the initial cycles in NTD responders, and then gradually returned toward baseline. Overall, in the safety population mean counts of nucleated RBCs increased from baseline during the initial cycles and dropped below baseline towards the end of study.

Haemolysis Parameters: Observed mean levels of total bilirubin and indirect bilirubin increased from baseline in NTD non-responders, whereas they were largely unchanged in NTD responders. Mean LDH levels increased from baseline during the initial cycles, and then decreased toward baseline in NTD nonresponders and gradually decreased further in NTD responders.

<div style=\"page-break-after: always\"></div>

Bone Metabolism Parameters: Mean observed levels of BSAP and CTX were slightly increased from baseline to C4D1 and changes were not thought to be of clinical significance. Mean total hip and lumbar spine BMD by DXA were minimally changed between screening and EOT.

## Exploratory Efficacy Endpoints:

Quality of life questionnaires, including NTDT-PRO, FACT-An, FACIT-Fatigue, and SF-36, were completed. Mean changes from baseline questionnaires, including NTDT-PRO, FACT-An, and SF-36, were small, with transient increases or decreases from baseline for NTD participants. The FACIT-Fatigue questionnaire indicated an improvement from baseline by week 12, which was maintained over time in NTD participants. This improvement was most pronounced in participants who were symptomatic at baseline, indicated by a baseline score &lt; 44. The NTDT-PRO tiredness/weakness domain score and FACIT-Fatigue score were inversely correlated. At week 24, the FACIT-Fatigue score and Hgb change from baseline were correlated in NTD participants.

In NTD participants, compared to baseline, there was an initial improvement in 6MWT distance measured at weeks 16 to 24, followed by continued improvement from baseline at weeks 48 and 72.

There were no clinically meaningful patterns in change in spleen size, EMH mass size, leg ulcer size, and hormone parameters.

## Integrated Summary of Efficacy

To compare efficacy data of supportive studies A536-04/06 to pivotal study ACE-536-B-THAL-002, a subset of subjects that matched key inclusion criteria and approximated the dosing of study ACE-536-BTHAL-002 was defined and is referred to as the 'BEYONDlike Population' (n=19; defined as NTD β -thalassemia subjects receiving 0 to 5 units of RBCs during the 24-week period prior to study enrolment and receiving &gt; 0.8 mg/kg of luspatercept subcutaneously every 3 weeks).

Baseline characteristics were mostly aligned between the luspatercept treatment groups across different studies, except there was a higher proportion of splenectomised subjects and subjects receiving iron chelation therapy in supportive studies A536-04/06 compared to pivotal study ACE-536-B-THAL-002. Most efficacy outcomes showed comparable results between all NTD β -thalassemia subjects in supportive studies A536-04/06 and the 'BEYOND-like Population'. Overall, similar trends were also observed in pivotal study ACE-536-B-THAL-002 and the 'BEYOND-like Population', albeit the effects were generally smaller. For the primary endpoint (mean Hb increase ≥ 1.0 g/dL from Baseline to Week 13 to 24, over a continuous 12 week interval), 57.9% were responders in the 'BEYOND-like Population', whereas 77.1% were responders in ACE-536-B-THAL-002. Comparable differences were observed for most secondary endpoints, except FACIT-F Fatigue Subscore change from baseline to week 13-24, which was 3.17 in the 'BEYOND-like Population' (vs. 1.95 in ACE-536-B-THAL-002). A comparison of NTDT-PRO was not provided since only 5 participants had baseline data in supportive studies A536-04/06.

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The pivotal study ACE-536-B-THAL-002 was a Phase 2, double-blind, randomized, placebo-controlled, multicentre study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults with non-transfusion dependent beta (β) -thalassemia (Hb≤10 g/dL). Patients had a documented diagnosis of β -thalassemia or HbE/β -thalassemia, with or without concomitant α -globin mutation and/or duplication.

<div style=\"page-break-after: always\"></div>

In addition, two supportive phase II studies were submitted; A536-04, an open-label, single-arm, ascending-dose study and its long term extension study A536-06.

The pivotal study consisted of four periods: Screening Period for up to 4 weeks (± 3 days) for safety and baseline determination (incl. Haemoglobin [Hb]; transfusion history was collected for 24 weeks before randomisation, as applicable); a double-blind ( DB) treatment period of 48 weeks; an Open label period ( OLP ) of maximum 15 months. After study drug discontinuation, patients will be followed for 5 years from the first dose of study drug or 3 years from the last dose of study drug (whichever occurs later) until EOS during a Post-treatment follow-up period ( PTFP ).

The initial submission included the 48-week results as well as some additional efficacy data up to a second cut-off date (RBC transfusions, serum ferritin), by which the median treatment duration in the luspatercept group was 124.8 weeks (cut-off 15-March-2021). Placebo-treated patients were allowed to cross-over to open label Luspatercept treatment after the initial double-blind controlled treatment phase. All subjects from ACE-536-B-THAL-002 were allowed to roll-over into the overarching long term follow-up study LTFU-001, which was expected to occur during the second half of 2022. At the second cut-off date, out of 145 initially enrolled subjects, 112 remained on treatment in Study ACE-536-B-THAL-002, including 77 subjects (80%) in the luspatercept arm and 35 subjects (71.4%) initially randomized to placebo who entered the Open-label Period (OLP) and began treatment with luspatercept. As per the most recent cut-off date (09 Sep 2022), 71.9% (n=69) of the initially randomised Luspatercept treated patients continued treatment. Out of the placebo patients that overall crossed over to Luspatercept (n=38/59), 73.7% (n=28) are currently continuing treatment. The main reasons for discontinuing the study was withdrawal by subject without having further information at hand.

Submitting a single pivotal study is accepted, since supportive results come from the already approved TD β -Thalassaemia and MDS population. The small sample size had already been criticised in the scientific advice procedure, as relevant subgroup analyses may not be robustly assessed. This may be viewed as a remaining uncertainty to the interpretability of the study results, though does not preclude the approval after thorough review of the totality of evidence.

The design of the study ACE-536-B-THAL-002, the choice of comparator and choice of the target patient population are largely in line with the EMA  Scientific Advice (EMEA/H/SAH/044/1/2015/PA/III; EMEA/H/SAH/044/1/FU/1/2016/PA/II), with the exception that a broader population was included than had initially been agreed (see below).

In NTDT patients, not requiring regular transfusion therapy for survival, the focus of treatment benefit is set on treating the underlying chronic anaemia, which in NTDT is thought to be mainly due to ineffective erythropoiesis and, to a lesser extent when compared to TD patients, due to haemolysis. Consequently, associated pathological mechanisms (bone expansion, hypersplenism, increased intestinal iron absorption (ultimately iron overload) and hypercoagulable state) as well as downstream manifestations of the disease such as liver disease, bone deformities, osteoporosis, hepatosplenomegaly, extramedullary hematopoietic pseudotumours, thrombotic events, vascular manifestations (such as leg ulcers or pulmonary hypertension) might be expected to be counteracted in the long term due to treatment of the underlying anaemia. Hence, an improvement in hematologic parameters may be assumed to a) result already in the short term in an improvement of anaemia-specific symptoms (among which shortness of breath, tiredness, weakness and fatigue  have  been  particularly  investigated  in  this  study)  and  a  lower  need  of  (sporadic)  transfusions, presumably resulting in an improvement in quality of life and b) also show long-term benefits with regard to co-morbidities associated with ineffective erythropoiesis and chronic anaemia (incl. iron overload).

The MAH uses 'increase in hemoglobin of at least 1 g/dL during 12 weeks' as primary outcome parameter, which directly relates to the postulated mechanism of action of Luspatercept and is considered a parameter of interest. However, it is highlighted that this is not an established surrogate for long term outcome.

<div style=\"page-break-after: always\"></div>

Specifically,  there  is  some  evidence  from  published  literature  data  that  supports  the  clinical  benefit  of increasing Hb levels in NTDT B-Thalassaemia patients (the most relevant are listed below). These were cross-sectional and retrospective studies. In these studies, higher Hb levels at baseline were shown to be associated with a lower risk of co-morbidity development and mortality, while lower Hb levels at baseline are associated with m ore unfavourable outcomes in β -thalassamia patients.

(1) Taher et al, 2015: Hemoglobin level and morbidity in non-transfusion dependent thalssaemia (http://dx.doi.org/10.1016/j.bcmd.2015.05.011)

(2) Musallam et al, 2021: Morbidity-free survival and haemoglobin level in non-transfusion dependent Bthalassemia: a 10 year cohort study (https://doi.org/10.1007/s00277-020-04370-2)

(3) Musallam et al., 2021: Risk of mortality from anemia and iron overload in non transfusion dependent BThalssaemia (https://doi.org/10.1002/ajh.26428)

(4) Musallam et al., 2021: Variations in hemoglobin level and mo rbidity burden in non-transfusiondependent β -thalassemia (DOI: https://doi.org/10.1007/s00277-021-04456-5).

These  results  represent inter-patient  variations linking  Hb  levels  to  co-morbidity  risk.  The  longitudinal variation of Hb levels over time and implications thereof on the development of co-morbidities/mortality risk  yet  remains  to  be  evaluated  by  prospective  studies,  i.e.,  whether  associated  outcomes  apply  to haemoglobin changes over time in the individual patient remains to be elucidated. It also remains unknown what effect size on Hb level (due to treatment) would be needed to result in a certain improvement in long term outcomes such as co-morbidity risk or mortality reduction. The Long term efficacy LFTU study will provide additional efficacy and safety data (please see RMP section).

Several limitations with regard to the available studies need to be kept in mind: As regards the established association between Hb levels and long term co-morbidity risk reduction, confounding effects can ultimately not be ruled out as explanatory factors. The rather small sample size (yet recognising the orphan character of the disease) and retrospective design have important bearings on the interpretability of the results. Furthermore, the results may not be fully applicable to the entire NTD Beta-thalassaemia population due to possible selection bias and cannot be easily translated to the present study population. As an overarching comment to these studies, it is also not known in how far all these patients were reused for analysis across studies, as it seems that the same thalassemia centres and authors have been involved.

Concluding, based on these data, a patient with a Hb level &lt;10 g/dL may be assumed to be at higher risk of  developing  downstream  manifestations  associated  with  the  disease  (liver  disease,  EMH,  diabetes mellitus,  hypothyroidism,  hypoparathyroidism,  osteoporosis,  hypogonadism,  thrombosis,  pulmonary hypertension) and it could be assumed that with higher Hb levels, the morbidity risk might decrease. However, as the increase of at least 1 g/dL in Hb cannot be considered an established/validated surrogate for the prediction of long term outcome, the impact on co-morbidities of Hb increase cannot be quantified for the time being. The study was also not designed to show benefits of Luspatercept treatment in the long term.

From a technical perspective, the statistical analysis of the primary and key secondary efficacy endpoint is considered adequate. Overall, 96 and 49 subjects were randomised to luspatercept and placebo treatment, respectively. A rather large number of subjects completed 24 weeks of treatment (95.8% and 89.9%, respectively), however, a larger number of placebo patients discontinued treatment up to week 48 (i.e., 92.7 and 71.4% of subjects, respectively, completed the study). This imbalance is reflected by the reasons for  discontinuation,  with  more  subjects  in  the  placebo  group  compared  to  the  luspatercept  group (withdrawal by subject: 9.4% vs. 20.4%; lack of efficacy: 1% vs. 34.7%). While this might be related to the fact that very few placebo patients achieved an Hb increase of at least 1 g/dL from baseline at some time point during the study, it also indicates a potential for functional unblinding. This would in particular be of concern with regard to handling of patients in terms of transfusion needs, but also in terms of QoL

<div style=\"page-break-after: always\"></div>

evaluations.  This  potential  for  functional  unblinding  needs  to  be  kept  in  mind  when  interpreting  these outcome parameters. Overall, the weeks 37-48 analyses may be less robust.

The secondary outcome measures planned to support the primary outcome (mean Hb concentration in the absence of transfusion during Weeks 36-48, health related QoL (SF-36, FACIT-F), physical activity (6MWT) and iron parameters (liver iron concentration (LIC) and iron chelation therapy (ICT) daily dose, serum ferritin) are supported as additional important outcome measures.

Development of the new disease-specific PRO tool (NTDT-PRO) is acknowledged and welcomed in principle, though the relevance thereof is questioned at this stage. Results need to be cautiously interpreted, since the new PRO is being validated and simultaneously used to provide key support for the clinical relevance of effects observed in terms of Hb increase from baseline in the pivotal study. This issue had been addressed already in the initial scientific advice (MEA/H/SAH/044/1/2015/PA/III), where it was stated that ' Causal conclusions based on study outcomes derived from a setting where still two objectives are to be evaluated (i.e. the treatment outcome on one hand and the validation of the PRO measurement tool on the other hand) will lack reliability. Validation should ideally be performed in a well -known and independent setting. Therefore the suggested approach is not supported. Keeping this in mind it should be considered that a disease specific PRO tool for NTD β -thalassemia developed by Celgene might in the end not be applicable during ACE536 development but only serve for later investigations. '

Evaluation of bone mineral density, extramedullary hematopoietic (EMH) mass volume, spleen volume, pulmonary hypertension and leg ulcers was covered in the study as exploratory objectives (but only when present in the individual patient) and is supported, as improvement thereof would be considered a relevant treatment target. However, the low patient numbers limit interpretability of the results.

As regards transfusion endpoints, results need to be cautiously interpreted due to remaining uncertainties such as limited information on reasons for infusions (at baseline) or impact of potential functional unblinding on  the  decision  for  need  of  transfusion.  Upon  request  the  MAH  further  explained  how  blinding  was maintained throughout the study. Adequate measures were in place to minimise the risk for inadvertent unblinding. However, given the robust Hb response in luspatercept treated patients compared to lack of Hb response in placebo treated patients and dose changes due to excessive Hb response in the Luspatercept treatment  group  only,  functional  unblinding  is  still  of  concern  and  this  remains  an  uncertainty  in  the interpretation of the transfusion endpoint as well as symptom improvement data.

Additionally, the MAH provided updated analyses for transfusion event rates, transfusion counts, mean change in RBC transfusion units, serum ferritin and derived LIC. While these are overall acceptable, some uncertainties remain regarding number of imputed datapoints.

At baseline, a largely transfusion-free population was included, with approximately 85% of subjects not having received any transfusions during the 24 weeks preceding randomisation. The NTD definition would include patients with 0 to 5 units/24 weeks, as a complement to the TD population (≥6 units/24 weeks), where luspatercept is already approved. It must be critically noted that no transfusion data dating back more  than  24  weeks  were  planned  to  be  retrieved  and  the  baseline  may  hence  be  challenged  to  be representative of the patient's 'real' transfusion burden adequately reflecting their underlying severity of disease.  Comparability  between  groups  can  therefore  also  not  be  confirmed  for  longer  term  historical transfusion data.

The concern on representativeness also applies to the Hb baseline, which was averaged based on at least 2 measurements at least 1 week apart during 4 weeks before randomisation. For inclusion, only patients with a mean baseline Hb ≤10 g/dL were considered, which is endorsed as these patients seem at greatest risk for development of co-morbidities and impaired QoL. In addition, patients had to be transfusion-free in the 8 weeks before randomisation. This may allow to ensure that the Hb baseline level is not acutely

<div style=\"page-break-after: always\"></div>

influenced by a drop in Hb associated with infections, surgeries etc., yet might also have implications to the representativeness of the target population.

There is currently no reason to believe that the results from the study would not be extrapolable to genetic polymorphisms not covered by the study population. Note that an insufficient number of subjects with comorbidities associated with underlying anemia such as pulmonary hypertension, liver and kidney disease and diabetes were included in the study, which is reflected in the SmPC.

The mean baseline haemoglobin level was 8.2 and 8.09 g/dL for Luspatercept and Placebo, respectively. The baseline NTDT-PRO T/W (Tiredness/Weakness) Domain Score was approximately 4.0 (out of 10) and balanced between treatment groups.

Unfortunately, patients were not, as initially planned, ' symptomatic' of their disease (with regard to anemiarelated symptoms as assessed by the newly developed NTDT PRO T/W instrument, using a score of ≥3 out of 10). Obviously, any benefits in terms of symptom improvement may not be evident in the asymptomatic population, which comprised about one third of the overall population. Overall, the population is considered rather heterogeneous, including patients with and without anemia-related symptoms, with and without comorbidities associated with β -thalassaemia (incl. iron overload) and patients presenting with a broad range of haemoglobin values at baseline. The criticism mapped to the small sample size may be reiterated in that respect. Of note, a rather young population was included (mean/median age was approximately 40 years, balanced between treatment groups), which might explain that a relatively low number of patients were affected by β -thalassaemia co-morbidities.

## Supportive studies:

A536-04 was a Phase 2, open-label, single-arm, ascending dose study to evaluate efficacy and safety of ACE536 in subjects with β -thalassemia. The study enrolled both NTD and TD β -thalassemia subjects, who received luspatercept every 3 weeks for up to 5 cycles. To compare efficacy data to pivotal study ACE-536B-THAL-002,  a  subset  of  subjects  from  studies  A536-04/06  that  matched  key  inclusion  criteria  and approximated the dosing of study ACE-536-B-THAL-002 was defined and is referred to as the 'BEYONDlike Population' (n=19), which was used for the integrated summary of efficacy (ISE) data pool.

A536-06 was an extension study to evaluate long-term effects in patients previously enrolled in study A536-04. This study evaluated the effects of up to 5 years of luspatercept treatment and post treatment follow-up for 3 years after last dose. The primary objective of extension study A536-06 was long-term safety and tolerability of luspatercept, which is discussed in the clinical safety section.

## Efficacy data and additional analyses

A consistent effect has been demonstrated on haemoglobin in terms of the primary endpoint (increase of at least 1 g/dL in Hb during weeks 13-24) as well as all secondary endpoints addressing haemoglobin change (a responder analysis using the higher threshold of 1.5 g/dL, continuous evaluation of Hb change from baseline and corresponding week 37-48 analyses). Furthermore, the effect on Hb level was consistent across most subgroups.

The proposed dose titration strategy complicates the interpretation of study results since different dose levels were possible in the trial, the starting dose (1 mg/kg), up-titration (to 1.25 mg/kg) due to lack of response, down-titration (to 0.8, 0.6 or 0.45mg/kg) due to AEs or excessive Hb increase or dose delay in case of exces sive Hb/WBC decrease or if Hb ≥ 11.5 g/dL. When analysed according to dose level, those subjects not requiring any dose increase within 24/48 weeks of treatment overall showed a more pronounced response compared to subjects that needed a dose increase. Nevertheless, the latter group of subjects may still achieve a sufficiently high Hb response, even though the benefit in terms of symptomatic improvement is less evident in these subjects. The stopping rule in section 4.2 of the SmPC

<div style=\"page-break-after: always\"></div>

will ensure that patients that do not show an adequate response in Hb (increase from baseline Hb in the treatment.

absence of transfusions after 9 weeks of treatment (3 doses) at the maximum dose level) will discontinue As mentioned, surrogacy of the selected primary endpoint for the prediction of a long term outcome is not established for this population. The meaningfulness of the observed effect size in terms of Hb increase is therefore difficult to translate into long term clinical benefit, which may be a particularly relevant consideration in a sub-population that does not present anemia-related symptoms, also taking into account the non-negligible safety profile. In order this address this Major Objection raised during the evaluation, the MAH has proposed to update the indication wording as follows: 'Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non-transfusion dependent beta thalassaemia (see section 5.1).' In contrast to TDT patients, NTDT patients per definition do not depend on regular transfusion therapy for survival, but only sporadically need transfusion therapy, e.g. in case of concomitant infection or surgery, for the treatment of a clinical morbidity associated with disease such as EMH, leg ulcer etc. or for the treatment of acute anaemia- related symptoms. Some patients are significantly iron overloaded, which is attributed to the underlying ineffective erythropoiesis in this patient population (with subsequent increased intestinal absorption and, to a lower extent, from the sporadic transfusional iron accumulated over time). The magnitude of iron overload hence varies with clinical phenotype/disease severity and increases with age and cumulative transfusion therapy. However, in comparison with the TD population, transfusion therapy seems to only modestly contribute to the iron overload. Nevertheless, iron overload is also associated with morbidity in NTDT patients (Musallam KM, Cappellini MD, et al. Serum ferritin level and morbidity risk in transfusion -independen t patients with β -thalassemia intermedia: the ORIENT study . Haematologica. 2014;99(11):e218-e221). The MAH claimed in the 2016 scientific advice procedure that the main treatment aim was to treat the symptomatic effects of anaemia commonly experienced in this population, potential beneficial effects on other complications of the disease would be also anticipated due to luspatercept's mechanism of action. For this, they identified a population that would be symptomatic in terms of tiredness/weakness (or more generally fatigue). The CHMP had agreed with both improvement of QoL and prevention of co-morbidities being relevant treatment targets in a symptomatic population, but that patients with iron overload would be another subgroup of key interest, for whom control of iron overload would be a relevant benefit, all of which would need to be weighed against the risks associated with luspatercept treatment. Outcome parameters of interest in this patient group to help with interpretability of the meaningfulness of the primary endpoint would be measures of iron overload such as LIC or serum ferritin as well as the use of iron chelator therapy. The MAH claims that the study duration was too short to be able to show any benefits in the long term and that haemoglobin increase can be viewed a clinical benefit per se . Therefore, additional efficacy data will be provided as part of the long term extension LFTU study (please see RMP). Approximately 37.0% of the study population were having a clinically significant iron overload at baseline (&gt; 800 μg/L Serum Ferritin or LIC &gt; 5 Fe/g dw), while roughly 30% of subjects received ICT at baseline as well as around 40% during the study. Results in terms of iron parameters however do not indicate a significant effect of luspatercept compared to placebo. For LIC at week 48 and LIC/ICT responders at week 24 and 48, even a larger effect in the placebo group is evident, which the MAH possibly attributes to a greater proportion of placebo-treated subjects receiving concomitant deferasirox compared with the luspatercept-treated subjects (30.6% versus 24.0%, respectively). Overall, the MAH claims that changes in iron parameters attributable to the study drug were unlikely to be apparent by Week 48 and were influenced by baseline status and ICT usage. Results may also have been affected by an imbalance in splenectomy status (35.4% versus 53.1%

<div style=\"page-break-after: always\"></div>

for luspatercept- and placebo-treated patients, respectively). Taken together, no relevant effect of luspatercept on iron overload can be observed.

A new NTDT PRO T/W instrument has been developed to evaluate the most relevant symptoms affecting QoL in the NT DT β -Thalassaemia population, determined to be tiredness/weakness (T/W) and shortness of breath (SoB) or fatigue as a more general concept. A ' symptomatic' score of at least 3 out of 10 on the T/W domain of the NTDT-PRO has been defined. One issue that arises based on the eligibility criteria is that the MAH had initially planned to only include patients with a 'symptomatic' score in the NTDT PRO T/W at baseline (Scientific advice 2016). This score has been related to the fatigue domain of the FACIT PRO (Fatigue subscale), for which the MAH claimed that the average FACIT-F score for all 13 items in the general population is 44.2 on a 0-52 scale (higher scores indicating less fatigue and better functioning (Cella et al., 2002) (2016 SA)). In an NTDT population that shows a relevant symptomatic burden compared to the general population, improvement of those symptoms (T/W or fatigue) would logically reflect a relevant benefit, as measured with the NTDT PRO T/W outcome tool (taken drawbacks with regard to its validity aside) or the FACIT-F instrument (fatigue subscale).

Roughly 70% of patients presented a 'symptomatic' score on the T/W domain of the NTDT-PRO at baseline, while roughly 66% of subjects had a score &lt; 43 in the FACIT- Fatigue subscale score. This implies that a rather significant proportion of subjects were included in this study that could per se not show relevant changes in these symptoms, yet would still be treated with Luspatercept with the aim to prevent or reduce downstream manifestations of the disease in the long term.

The study seems to have been sufficiently powered for the key secondary endpoint ' Mean change from baseline in NTDT -PRO T/W domain score over a continuous 12 -week interval from Week 13 to Week 24' . This endpoint has been assessed in the overall population. However, no statistically significant effect has been demonstrated (LS mean difference for luspatercept versus placebo -0.48 (95%CI: -1.03, 0.08)). Results in terms of NTDT PRO T/W and SoB are undermined by the fact that phase 3 data were used to confirm the validity/reliability of the PRO, limiting its interpretability as a confirmatory parameter. Further support is however derived from other secondary endpoints such as SF-36, FACIT-F or the 6MWT, where at least no detrimental effect for the overall population comparing luspatercept and placebo groups have been observed (looking at point estimates), though the results are also not reassuring in terms of clinical relevance of the observed mean changes compared to placebo.

When analysed according to baseline symptomatic score, among subjects with a baseline NTDT-PRO T/W domain score of ≥ 3 ('symptomatic'), the LS mean difference for luspatercept versus placebo was -0.73 (95% CI: -1.48, 0.03).

Among subjects with a baseline NTDT-PRO T/W domain score of &lt; 3 ('asymptomatic'), the level of symptoms was not improved compared to placebo patients (LS mean difference 0.11 (95% CI: -0.48, 0.70)).

Similarly discrepant subgroup results are observed, when subjects are analysed according to Hb baseline level, with patients with Hb level ≥8.5g/dL showing not notable benefit (LS mean difference: -0.13 (95% CI: -1.05, 0.80).

It is further of note that among male subjects, no notable benefit was observed compared to female subjects (LS mean difference: -0.03 (95%CI: -0.81, 0.87) vs. -0.84 (95%CI: -1.58, -0.10)). In contrast, results in terms of Hb increase were similar comparing both subgroups.

Also when looking at subjects with compared to without splenectomy, inconsistent QoL results are observed: LS mean difference for patients with splenectomy: -0.11 (95%CI: -0.77, 0.56) compared to subjects without splenectomy: -0.71 (-1.59, 0.18).

These subgroup results need to be cautiously interpreted due to smaller number of patients included.

<div style=\"page-break-after: always\"></div>

The small mean increase of around 0.7 points (out of 10) compared to placebo as observed in the 'symptomatic' population is difficult to interpret, bearing in mind a) the limitations/weaknesses mentioned with regard to the validation exercise, and b) that it is difficult to understand what a score averaged over 12 weeks means to the individual patient also with regard to a day-to-day variation. As noted, this is further complicated by inconsistent results observed across several subgroups (male subjects, subjects with Hb level ≥ 8.5g/dL and subjects with splenectomy). This the reason why the restriction to symptomatic patients in the indication, as proposed by the MAH during the evaluation was not considered acceptable.

Results for the FACIT-F evaluation are in line with the results observed for the NTDT PRO T/W. However, as for the NTDT PRO T/W, it is unclear how the observed small mean improvement of 1.4 points (out of 52) compared to placebo (during weeks 13-24) ought to be interpreted in terms of its meaningfulness. The MAH highlights the pronounced symptom improvement at weeks 37-48 in the different evaluations (NTDT SoB, T/W, FACIT Fs). However, results of weeks 37-48 need to be cautiously interpreted due to the high number of missing subjects in the analysis. In addition, all non-objective endpoint evaluations need cautious interpretation as the blinding could most likely not be upheld in this study, given the consistent improvement in terms of Hb in luspatercept patients, while none of the placebo patients showed a Hb response.

Since there is little support from secondary endpoint results that would reflect a benefit of the observed Hb response, an expert group had been asked during the procedure on the relevance of the observed Hb increase. Based on this, it was concluded that the observed Hb response should be viewed as a relevant benefit to the patient per se - although it must be weighed with the safety profile associated with Luspatercept treatment.

## Supportive studies:

Efficacy results of supportive studies A536-04/06 need to be cautiously interpreted due to differences in design specifics (e.g. lack of control, different endpoints, low patient numbers, different geographical regions). Results from supportive study A536-04 overall support the doses used in phase III and also the efficacy conclusions, although most endpoint outcomes indicated smaller effects (i.e. a lower number of responders compared to luspatercept-treated patients in pivotal study ACE-536-B-THAL-002).

Of 33 NTD β -thalassemia subjects treated with luspatercept in study A536-04, 2 subjects became TD prior to entering study A536-06. Upon request, a detailed description of those subjects was provided. It was concluded that the transition from NTD to TD is unlikely to be linked to luspatercept treatment.

<div style=\"page-break-after: always\"></div>

## Additional expert consultation

An ad hoc expert group meeting was convened on 20 th  October 2022 and were asked to respond to the following efficacy questions as agreed by CHMP:

## 1. Do the submitted efficacy results establish clinical benefit for the target population with NTD beta-thalassemia applied for? Please elaborate why (not).

Yes. The expert group agreed unanimously that the improvement of Hb levels associated with luspatercept is expected to represent a clinical benefit for the target population with unmet medical need. This effect is expected to result in improvements in morbidity or mortality, which are difficult to observe given the long timelines needed.

There are limited therapeutic options in this population, including iron chelation, splenectomy, and transfusion strategies, which are however limited due to the high risk of alloimmunization. Additional safe and effective treatment options are needed in this population, who will develop a number of complications involving many organs and systems, including iron overload, hypercoagulability, cardiomyopathy and osteoporosis.

T he difference in proportion of patients with ≥ 1 g/dL Hb increase associated with luspatercept v. placebo in the pivotal study ACE-536-B-THAL-002 was large (difference from baseline during weeks 13-24; 77.1%; 95%CI: 63.4-87.0). During a fixed 12-week interval (Week 13-24), a mean change in Hb of 1.42 g/dL (95%CI: 1.16-1.67) compared to placebo was observed, which continued also in the Week 37-48 period. The effect on Hb level was consistent across most subgroups.

There is a pharmacological rationale to expect an association with long-term benefits, as shown for instance with the effect of exogenous Hb (Mussalam et al., 2013; Bana, 2012; Chen et al. 2020). The effect reported in terms of health-related quality of life was promising although the validity of the tool and anecdotal reports have been questioned. External uncontrolled data from small studies with hydroxyurea are limited but also support the pharmacological rationale.

The observation of ameliorations on complications takes decades of follow-up, which does not seem justified given the unmet medical need. Currently, there is no other endpoint that is known to better predict long-term outcome.

An approval on the basis of improvement in Hb levels seems justified given the manageable toxicity (see below).

Overall, a clinical benefit is plausible but given the remaining uncertainties it is important that uncertainties about long-term effects are part of the clinical decisions.

## 2. Does the expert group consider the safety profile as observed in the clinical study and mainly known from other indications acceptable for the NTD thalassemia patient population?

- o More specifically, how does the expert group see the risk for EMH masses, traumatic fractures, hypertension, worsening of liver and kidney parameters in the context of the overall less severely affected patient population of NTDT compared to TDT?

The expert group agreed that overall the safety profile was acceptable although it will be important to collect long-term safety data post-approval to address remaining uncertainties. In particular:

- The risk of fractures in NTDT patients associated with luspatercept was considered acceptable. However, the relationship between timing of luspatercept treatment and fractures should be further analysed based on available data and further data, as necessary, adjusting for age and gender (e.g., stratification).

<div style=\"page-break-after: always\"></div>

- The risk of EMH was considered acceptable. The expert group agreed that there should be recommendations about screening patients by imaging before entering into treatment, and follow-up, and that treatment options should be re-discussed in the event of an increase in known EMH, the appearance of new masses or of symptoms related to EMH.
- The risk hypertension was considered acceptable. The identification of risk factors should be further explored on the basis of available data and further data, as necessary, adjusting for age and gender.
- The risk for liver and kidney disease was considered acceptable. It should be recommended to maintain the follow-up on iron-overload and blood tests according to standard local best  practice. See for example, https://www.thalassemia.org/wp-content/uploads/2021/06/TIF-2021Guidelines-for-Mgmt-of-TDT.pdf and applicable national recommendations on clinical management of long term organ damage in hemoglobinopathies, thalassemia included. (See for example, https://www.site-italia.org/protocolli.php?166780619258.)
- Other risks that will need surveillance are the risk of thrombosis and the risk of development of malignancies.
- o Are additional data needed to further characterize the safety profile of luspatercept in NTDT patients?

Yes, overall profile is acceptable but there is a need to assess long-term safety, and further explore risk factors, especially for pathological fractures and hypertension, as well as to try to develop optimal management strategies.

## 3. Given the heterogeneity of the NTDT patient population, does the expert group consider the study population representative of the NTDT patient population applied for?

Yes. In terms of generalisability, the study appears to have included a relevant patient population.

Concerning the precise definition of the target population the expert group debated the evidence, and pros and cons for different rules and thresholds. Strict rules based on clear-cut thresholds in Hb levels are difficult due to the non-binary nature of the endpoint. There is a need for clinical judgment since many aspects of clinical decisions require separate considerations for each patient until more long-term efficacy and safety data are available. However, for practical purposes, the expert group considered that the current proposal of a threshold of Hb ≤10 g/dL and presence of symptomatic anaemia, appears sensible.

## 4. Do the experts believe that, in case Reblozyl would be approved for treatment of adults patients with anaemia associated with NTD beta-thalassaemia, further long-term efficacy and/or safety data should be generated?

Yes - see above.

## 2.4.4. Conclusions on the clinical efficacy

A consistent increase in Hb levels was demonstrated, although other endpoints (e.g. on iron overload, other co-morbidities or QoL) did not provide compelling evidence on additional clinical benefits. The key secondary endpoint employed NTDT PRO, which is not validated and also failed to show a statistically significant difference between luspatercept and placebo. Several other secondary outcome measures such as health-related QoL and functional exercise capacity showed trends favouring luspatercept over placebo, the observed differences between treatment-groups being however of questionable clinical relevance. Furthermore, no effect was seen in endpoints investigating the impact on co-morbidities associated with β -thalassemia (e.g. no effect on iron overload related parameters or splenomegaly and a

<div style=\"page-break-after: always\"></div>

potentially detrimental effect in terms of EMH masses). This could partly be due to patients being asymptomatic or being well adapted to their anemia and may also be partly due to a too short study duration where no long term effect can be observed. Overall, it could not be quantified in this study how the observed Hb increase will translate into long term benefit. Additional efficacy data will come from the long term efficacy LFTU study (please see RMP). However, the observed robust effect on Hb increase is considered a clinical benefit per se .

## 2.5. Clinical safety

## Introduction

The safety profile of luspatercept in the existing indications is summarised as follows:

- Myelodysplastic syndromes: The most frequently reported adverse drug reactions in patients receiving Reblozyl (at least 15% of patients) were fatigue, diarrhoea, asthenia, nausea, dizziness, back pain and headache. The most commonly reported Grade 3 or higher adverse drug reactions (at least 2% of patients) included syncope/presyncope, fatigue, hypertension and asthenia. The most commonly reported serious adverse drug reactions (at least 2% of patients) were urinary tract infection, back pain and syncope. Treatment discontinuation due to an AE occurred in 2.0% of patients treated with luspatercept and was due to fatigue and headache.
- Transfusion dependent β -thalassaemia: The most frequently reported adverse drug reactions in patients receiving Reblozyl (at least 15% of patients) were headache, bone pain and arthralgia. The most commonly reported Grade 3 or higher adverse drug reaction was hyperuricaemia. The most serious adverse reactions reported included thromboembolic events of deep vein thrombosis, ischaemic stroke portal vein thrombosis and pulmonary embolism. Treatment discontinuation due to an AE occurred in 2.6% of patients treated with and was due to arthralgia, back pain, bone pain and headache.

The MAH submitted this type II variation to obtain an extension of indication to include the treatment of adult subjects with nontransfusion dependent (NTD) β -thalassemia.

Data from three clinical studies are presented to support the registration of luspatercept for the proposed new indication:

- ACE-536-B-THAL-002 : A pivotal Phase 2, double-blind, randomized, placebo-controlled, multicentre study to determine the efficacy and safety of luspatercept in adults with NTD β -thalassemia (BEYOND study).
- A536-04 : A supportive Phase 2, open-label, ascending dose study to evaluate the effects of luspatercept in subjects with β -thalassemia.
- A536-06 : A supportive open-label extension study to evaluate the long-term effects of luspatercept in patients with β -thalassemia previously enrolled in study A536-04.

Safety data from these three clinical studies are pooled for the integrated safety analysis (ISS). The safety data are presented as follows: Supportive studies A536-04/06 (NTD cohort), pivotal study ACE536-B-THAL-002 and pooled analysis of ACE-536-B-THAL-002 and the NTD cohort from studies A53604/06.

## Limitations of Pooling Data Sets

There are multiple limitations regarding the pooling strategy of the integrated data: the supportive studies were single-arm open-label studies without comparator; there were differences in the doses

<div style=\"page-break-after: always\"></div>

received, and the extent of exposure was shorter in the placebo treatment group compared with the luspatercept treatment group in the pivotal Study ACE-536- B-THAL-002, and the luspatercept exposure was shorter in Study ACE-536-B-THAL-002 compared with supportive studies.

For these reasons, the company proposes to compare TEAE rates and review the exposure-adjusted incidence rates (EAIRs) of AEs.

The EAIR per 100 subject-years was defined as 100 times the number of subjects with the specific event divided by the total exposure time (in years) among subjects included in the analysis. Subjects with multiple occurrences of the specific event in the specific analysis period were counted only once in the numerator. The exposure time for a subject without the specific event was the treatment duration, whereas the exposure time for a subject with the specific event was the treatment duration up to the start date (inclusive) of the first occurrence of the specific event. The total exposure time in years was calculated by dividing the sum of exposure time in days over all subjects included in the analysis by 365.25. The EAIR per 100 subject-years was interpreted as the expected number of subjects with at least 1 occurrence of the specific event per 100 subject-years of exposure to the IP.

## Patient exposure

As of 24 Dec 2020, approx. 940 subjects have been exposed to luspatercept clinical studies, including 357 subjects with MDS, 476 subjects with β -thalassemia, 83 subjects with MPN-associated MF, and 24 healthy, postmenopausal females. The overall exposure from all sources globally is estimated to be 7,826 patients as of 24 Dec 2020.

Safety cut-off dates for ongoing and completed studies are provided in the following table:

Table 75: Safety data cut-off for ongoing and completed studies

| Study              |   Study Phase | Data Cutoff Date (study status)   |
|--------------------|---------------|-----------------------------------|
| ACE-536-B-THAL-002 |             2 | 14 Sep 2020 (ongoing)             |
| A536-04            |             2 | 11 Nov 2015²(completed)           |
| A536-06            |             2 | 18 Jun 2020 (completed)           |

The NTD β -thalassemia data pool includes 129 subjects who had received at least 1 dose of luspatercept and contains all subjects treated with luspatercept from the two supportive phase 2 studies (A536-04 &amp; A53606, n=33), and from the pivotal β -thalassemia phase 2 study (ACE-536-B-THAL-002, n=96). Only the pivotal phase 2 study was placebo-controlled and included 49 subjects.

Updated data from the pivotal Phase 2 ACE-536-B-THAL-002 study were submitted after request for SAEs and AESIs with a cut-off date of 22 Sep 2021. 38 subjects who originally received placebo during the double-blind treatment period crossed over to receive luspatercept in the open-label phase.

As of the 14 Sept 2020 initial data cut-off date, the 129 subjects had a mean treatment exposure of 105.1 weeks and received thereby a mean of 31.7 doses. The average length of cycles between the doses was 24.9 days. The mean treatment exposure in each category is summarised in the table below.

<div style=\"page-break-after: always\"></div>

Table 76: Treatment exposure (NTD- beat Thalassemia safety population)

|                                              | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002             | Pivotal Study ACE-536-B-THAL-002             | NTD β-thalassemia Data Pool\"                 |
|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
| Category                                     | Luspatercept N=33                            | Luspatercept N=96                            | Placebo N= 49                                | Pooled Luspatercept N = 129                  |
| Total Subject-yearsb                         | 86.98                                        | 172.91                                       | 61.96                                        | 259.89                                       |
| Treatment Duration (weeks)                   | Treatment Duration (weeks)                   | Treatment Duration (weeks)                   | Treatment Duration (weeks)                   | Treatment Duration (weeks)                   |
| n                                            | 33                                           | 96                                           | 49                                           | 129                                          |
| Mean (SD)                                    | 137.5 (100.62)                               | 94.0 (29.76)                                 | 66.0 (35.02)                                 | 105.1 (59.60)                                |
| Median (min, max)                            | 135.7 (5.7, 279.3)                           | 99.7 (15.0, 132.1)                           | 61.1 (3.0, 121.9)                            | 101.7 (5.7, 279.3)                           |
| Number of Doses Received                     | Number of Doses Received                     | Number of Doses Received                     | Number of Doses Received                     | Number of Doses Received                     |
| n                                            | 33                                           | 96                                           | 49                                           | 129                                          |
| Mean (SD)                                    | 44.5 (33.03)                                 | 27.3 (10.63)                                 | 20.7 (11.16)                                 | 31.7 (20.33)                                 |
| Median (min, max)                            | 41.0 (2.0,92.0)                              | 28.5 (3.0, 44.0)                             | 20.0 (1.0, 41.0)                             | 29.0 (2.0, 92.0)                             |
| Average Length of Cycle Between Doses (days) | Average Length of Cycle Between Doses (days) | Average Length of Cycle Between Doses (days) | Average Length of Cycle Between Doses (days) | Average Length of Cycle Between Doses (days) |
| n                                            | 33                                           | 96                                           | 49                                           | 129                                          |
| Mean (SD)                                    | 21.7 (2.23)                                  | 26.0 (9.74)                                  | 22.3 (1.94)                                  | 24.9 (8.67)                                  |
| Median (min, max)                            | 21.3 (18.3, 32.8)                            | 22.4 (20.3, 77.0)                            | 21.7 (20.4, 28.8)                            | 21.8 (18.3, 77.0)                            |

IP = investigational product;max =maximum; min = minimum; NTD = nontransfusion dependent; SD )= standard deviation.

aIncludessubjectsfromStudyACE-536-B-THAL-002andtheNTDcohortfromStudiesA536-04/06

Note: Treatment duration was defined as (Treatment end date - Date of first dose of IP + 1)/ 7. Treatment end date was defined

ra pun a u sans fe pr srea u uep n go uns a se pup sea seaefns s q

as minimum [(the last dose date + 20), death date, study discontinuation date, study cut-off date].

Source:NTDISSTable14.3.1.1

Extent of exposure of the pivotal Phase 2 ACE-536-B-THAL-002 study:

Table 77: Extent of exposure as of the initial 14 Sep 2020 and updated 22 Sep 2021 data cutoff dates

|                                              | Pivotal Phase 2 (ACE-536-B-THAL-002)               | Pivotal Phase 2 (ACE-536-B-THAL-002)               | Pivotal Phase 2 (ACE-536-B-THAL-002)         | Pivotal Phase 2 (ACE-536-B-THAL-002)          | Pivotal Phase 2 (ACE-536-B-THAL-002)                                      | Pivotal Phase 2 (ACE-536-B-THAL-002)                                    |
|----------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------|-----------------------------------------------|---------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Category                                     | Initial 14-Sep-2020 Cutoff Luspatercept N=96 n (%) | Updated 22-Sep-2021 Cutoff Luspatercept N=96 n (%) | Initial 14-Sep-2020 Cutoff Placebo N=49 n(%) | Updated 22-Sep-2021 Cutoff Placebo N=49 n (%) | Updated 22-Sep-2021 Cutoff Luspatercept Cross-overFrom Placebo N=38 n (%) | Updated 22-Sep-2021 Cutoff Luspatercept IncludingCross-over N=134 n (%) |
| Total subject-yearsa                         | 172.91                                             | 252.17                                             | 61.96                                        | 67.50                                         | 21.56                                                                     | 273.73                                                                  |
| TreatmentDuration(weeks)                     |                                                    |                                                    |                                              |                                               |                                                                           |                                                                         |
| Mean (SD)                                    | 94.0 (29.76)                                       | 137.1 (43.04)                                      | 66.0 (35.02)                                 | 71.9 (41.76)                                  | 29.6 (8.74)                                                               | 106.6 (60.9)                                                            |
| Median (min, max)                            | 99.7 (15.0, 132.1)                                 | 150.1 (15.0, 185.4)                                | 61.1 (3.0, 121.9)                            | 61.1 (3.0, 138.0)                             | 33.1 (3.0, 38.1)                                                          | 126.6 (3.0, 185.4)                                                      |
| NumberofDosesReceived                        |                                                    |                                                    |                                              |                                               |                                                                           |                                                                         |
| Mean (SD)                                    | 27.3 (10.63)                                       | 38.9 (15.07)                                       | 20.7 (11.16)                                 | 22.5 (13.17)                                  | 8.7 (3.27)                                                                | 30.3 (18.75)                                                            |
| Median (min, max)                            | 28.5 (3.0, 44.0)                                   | 42.0 (3.0, 61.0)                                   | 20.0 (1.0, 41.0)                             | 20.0 (1.0, 46.0)                              | 9.5 (1.0, 13.0)                                                           | 33.0 (1.0, 61.0)                                                        |
| Average Length of Cycle Between Doses (days) | Average Length of Cycle Between Doses (days)       |                                                    |                                              |                                               |                                                                           |                                                                         |
| Mean (SD)                                    | 26.0 (9.74)                                        | 26.7 (11.01)                                       | 22.3 (1.94)                                  | 22.4 (1.89)                                   | 25.3 (6.61)                                                               | 26.3 (9.96)                                                             |
| Median (min, max)                            | 22.4 (20.3, 77.0)                                  | 22.7 (20.2, 88.9)                                  | 21.7 (20.4, 28.8)                            | 21.7 (20.9, 28.7)                             | 22.8 (19.8, 51.0)                                                         | 22.7 (19.8, 88.9)                                                       |

Sources: Initial: refer to Tab1e 14.3.1.1 in the NTD ISS.* Updated: Table 14.3.1.1c.

<div style=\"page-break-after: always\"></div>

Table 78: summary of luspatercept treatment duration at therapeutic doses for betathalassemia (NTD beta-thalassemia safety population- subjects treated at therapeutic dose level)

<!-- image -->

|                                                       | Supportive Studies A536-04/06 (NTD Cohort)            | Pivotal Study ACE-536-B-THAL-002                      | Pivotal Study ACE-536-B-THAL-002                      | NTD β-thalassemia Data Pool?                          |
|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                                       | Luspatercept N=32                                     | Luspatercept N=96                                     | Placebo N=49                                          | Pooled Luspatercept N=128                             |
| Treatmentduration(weeks)                              | Treatmentduration(weeks)                              | Treatmentduration(weeks)                              | Treatmentduration(weeks)                              | Treatmentduration(weeks)                              |
| Mean (SD)                                             | 136.5 (99.04)                                         | 94.0 (29.76)                                          | 66.0 (35.02)                                          | 104.6 (58.30)                                         |
| Median (min, max)                                     | 136.6 (3.3, 272.1)                                    | 99.7 (15.0, 132.1)                                    | 61.1 (3.0, 121.9)                                     | 102.4 (3.3, 272.1)                                    |
| Number (%) of subjects who received luspatercept for: | Number (%) of subjects who received luspatercept for: | Number (%) of subjects who received luspatercept for: | Number (%) of subjects who received luspatercept for: | Number (%) of subjects who received luspatercept for: |
| ≤ 24 weeks                                            | 7 (21.9)                                              | 4 (4.2)                                               | 5 (10.2)                                              | 11 (8.6)                                              |
| ≥24 weeks                                             | 25 (78.1)                                             | 92 (95.8)                                             | 44 (89.8)                                             | 117 (91.4)                                            |
| ≥48 weeks                                             | 22 (68.8)                                             | 89 (92.7)                                             | 35 (71.4)                                             | 111 (86.7)                                            |
| ≥72 weeks                                             | 20 (62.5)                                             | 75 (78.1)                                             | 20 (40.8)                                             | 95 (74.2)                                             |

Data cutoffdate:14-Sep-2020.

Source:Table14.3.1.3a

## Baseline Demographic Characteristics &amp; Baseline Disease Characteristics

The demographic characteristics and baseline disease characteristics of subjects from the NTD β -thalassemia Data Pool were summarized in Tables above.

<div style=\"page-break-after: always\"></div>

Table 79: baseline demographic characteristics (NTD beta-thalassemia safety population)

<!-- image -->

|                              | Supportive Studies A536-04/06 (NID Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Pool   |
|------------------------------|----------------------------------------------|------------------------------------|------------------------------------|-------------------------------|
| Characteristics              | Luspatercept N=33                            | Luspatercept N=96                  | Placebo N=49                       | Pooled Luspatercept N=129     |
| Age (years)                  |                                              |                                    |                                    |                               |
| n                            | 33                                           | 96                                 | 49                                 | 129                           |
| Mean (SD)                    | 39.4 (11.48)                                 | 39.3 (13.24)                       | 41.1 (11.90)                       | 39.3 (12.77)                  |
| Median (min, max)            | 40.0 (20.0, 62.0)                            | 39.5 (18.0, 71.0)                  | 41.0 (19.0, 66.0)                  | 40.0 (18.0, 71.0)             |
| Age Group, n (%)             |                                              |                                    |                                    |                               |
| ≤32 years                    | 10 (30.3)                                    | 35 (36.5)                          | 12 (24.5)                          | 45 (34.9)                     |
| >32 years                    | 23 (69.7)                                    | 61 (63.5)                          | 37 (75.5)                          | 84 (65.1)                     |
| Gender, n (%)                |                                              |                                    |                                    |                               |
| Male                         | 20 (60.6)                                    | 40 (41.7)                          | 23 (46.9)                          | 60 (46.5)                     |
| Female                       | 13 (39.4)                                    | 56 (58.3)                          | 26 (53.1)                          | 69 (53.5)                     |
| Ethnicity, n (%)             |                                              |                                    |                                    |                               |
| Hispanic or Latino           | 0                                            | 2 (2.1)                            | 1 (2.0)                            | 2 (1.6)                       |
| Not Hispanic or Latino       | 33 (100.0)                                   | 94 (97.9)                          | 48 (98.0)                          | 127 (98.4)                    |
| Race, n (%)                  |                                              |                                    |                                    |                               |
| White                        | 32 (97.0)                                    | 59 (61.5)                          | 28 (57.1)                          | 91 (70.5)                     |
| Asian                        | 1 (3.0)                                      | 31 (32.3)                          | 13 (26.5)                          | 32 (24.8)                     |
| Other                        | 0                                            | 6 (6.3)                            | 8 (16.3)                           | 6 (4.7)                       |
| Weight (kg)                  |                                              |                                    |                                    |                               |
| n                            | 33                                           | 96                                 | 49                                 | 129                           |
| Mean (SD)                    | 67.1 (10.07)                                 | 61.1 (12.54)                       | 61.6 (13.45)                       | 62.6 (12.21)                  |
| Median (min, max)            | 67.0 (49.5,97.0)                             | 59.9 (36.4, 94.5)                  | 62.0 (37.0, 102.0)                 | 62.0 (36.4,97.0)              |
| Body Mass Index (kg/m?)      |                                              |                                    |                                    |                               |
| n                            | 33                                           | 96                                 | 49                                 | 129                           |
| Mean (SD)                    | 23.3 (3.57)                                  | 22.1 (3.79)                        | 22.3 (4.08)                        | 22.4 (3.76)                   |
| Median (min, max)            | 22.8 (17.8, 31.8)                            | 21.6 (15.2,36.9)                   | 21.5 (16.2, 38.1)                  | 22.0 (15.2,36.9)              |
| Region, n (%)                |                                              |                                    |                                    |                               |
| North America and Euurope    | 33 (100.0)                                   | 60 (62.5)                          | 30 (61.2)                          | 93 (72.1)                     |
| Asia-Pacific                 | 0                                            | 27 (28.1)                          | 11 (22.4)                          | 27 (20.9)                     |
| Middle East and North Affica | 0                                            | 9 (9.4)                            | 8 (16.3)                           | 9 (7.0)                       |

max = maximum; min = minimum; NID = nontransfiusion dependent; SD = standard deviation

* Includes subjects fom Study ACE-536-B-THAL-002 and the NTD cohort fom Studies A536-04/06.

Source: NTD ISS Table 14.1.2

<div style=\"page-break-after: always\"></div>

Table 80: Baseline characteristics (NTD-beta thalassemia safety population)

|                                | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassenia Data Pool?   |
|--------------------------------|----------------------------------------------|------------------------------------|------------------------------------|--------------------------------|
| Characteristics                | Luspatercept N=33                            | Luspatercept N=96                  | Placebo N=49                       | Pooled Luspatercept N=129      |
| ECOG Performance Status, n (%) |                                              |                                    |                                    |                                |
| 0                              | 0                                            | 62 (64.6)                          | 38 (77.6)                          | 62 (48.1)                      |
| 1                              | 0                                            | 34 (35.4)                          | 11 (22.4)                          | 34 (26.4)                      |
| 2                              | 0                                            | 0                                  | 0                                  | 0                              |
| Missing                        | 33 (100.0)b                                  | 0                                  | 0                                  | 33 (25.6)b                     |
| Baseline Hemoglobin (g/dL)     |                                              |                                    |                                    |                                |
| n                              | 33                                           | 96                                 | 49                                 | 129                            |
| Mean (SD)                      | 8.4 (0.95)                                   | 8.2 (1.28)                         | 8.2 (1.35)                         | 8.3 (1.21)                     |
| Median (min, max)              | 8.6 (6.3, 9.9)                               | 8.4 (5.5, 10.3)                    | 8.2 (5.8, 10.4)                    | 8.4 (5.5, 10.3)                |
| Splenectomy, n (%)             |                                              |                                    |                                    |                                |
| Yes                            | 22 (66.7)                                    | 34 (35.4)                          | 26 (53.1)                          | 56 (43.4)                      |
| No                             | 11 (33.3)                                    | 62 (64.6)                          | 23 (46.9)                          | 73 (56.6)                      |
| Liver Iron Content (mg/g)c     |                                              |                                    |                                    |                                |
| n                              | 33                                           | 95                                 | 47                                 | 128                            |
| Mean (SD)                      | 5.4 (3.79)                                   | 6.1 (6.15)                         | 5.9 (5.82)                         | 5.9 (5.63)                     |
| Median (min, max)              | 4.9 (0.9, 15.1)                              | 3.9 (0.8, 39.9)                    | 4.1 (0.7, 28.7)                    | 4.2 (0.8, 39.9)                |

Source: NTD ISS Table 14.1.2

° Liver iron content units are mg iron / gram dry weight.

## o Medical history

<div style=\"page-break-after: always\"></div>

Table 81 : Medical history terms reported by ≥ 5 % subjects in the pooled luspatercept treatment group (NTD beta-Thalassemia safety population)

| Category Preferred Term     | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Pool       |
|-----------------------------|----------------------------------------------|------------------------------------|------------------------------------|-----------------------------------|
| Category Preferred Term     | Luspatercept N=33 (%) u                      | Luspatercept N=96 n (%)            | Placebo N=49 n (%)                 | Pooled Luspatercept N = 129 n (%) |
| Subjects with at least 1 PT | 33 (100.0)                                   | 96 (100.0)                         | 49 (100.0)                         | 129 (100.0)                       |
| Splenomegaly                | 11 (33.3)                                    | 66 (68.8)                          | 28 (57.1)                          | 77 (59.7)                         |
| Iron overload               | 1 (3.0)                                      | 63 (65.6)                          | 32 (65.3)                          | 64 (49.6)                         |
| Cholecystectomy             | 16 (48.5)                                    | 47 (49.0)                          | 26 (53.1)                          | 63 (48.8)                         |
| Osteopenia                  | 16 (48.5)                                    | 44 (45.8)                          | 30 (61.2)                          | 60 (46.5)                         |
| Cholelithiasis              | 3 (9.1)                                      | 52 (54.2)                          | 24 (49.0)                          | 55 (42.6)                         |
| Splenectomy                 | 21 (63.6)                                    | 34 (35.4)                          | 26 (53.1)                          | 55 (42.6)                         |
| Hepatomegaly                | 8 (24.2)                                     | 26 (27.1)                          | 10 (20.4)                          | 34 (26.4)                         |
| Osteoporosis                | 6 (18.2)                                     | 24 (25.0)                          | 19 (38.8)                          | 30 (23.3)                         |
| Thrombocytosis              | 8 (24.2)                                     | 12 (12.5)                          | 11 (22.4)                          | 20 (15.5)                         |
| Hyperbilirubinaemia         | 0                                            | 19 (19.8)                          | 10 (20.4)                          | 19 (14.7)                         |
| Vitamin D deficiency        | 2 (6.1)                                      | 17 (17.7)                          | 10 (20.4)                          | 19 (14.7)                         |
| Extramedullary haemopoiesis | 3 (9.1)                                      | 14 (14.6)                          | 13 (26.5)                          | 17 (13.2)                         |
| Hyperuricaemia              | 5 (15.2)                                     | 9 (9.4)                            | 6 (12.2)                           | 14 (10.9)                         |
| Hypothyroidism              | 2 (6.1)                                      | 12 (12.5)                          | 8 (16.3)                           | 14 (10.9)                         |
| Asthenia                    | 1 (3.0)                                      | 12 (12.5)                          | 5 (10.2)                           | 13 (10.1)                         |
| Menopause                   | 2 (6.1)                                      | 10 (10.4)                          | 6 (12.2)                           | 12 (9.3)                          |
| Skin ulcer                  | 5 (15.2)                                     | 7 (7.3)                            | 2 (4.1)                            | 12 (9.3)                          |
| Cholecystitis               | 0                                            | 11 (11.5)                          | 5 (10.2)                           | 11 (8.5)                          |
| Gilbert's syndrome          | 3 (9.1)                                      | 6 (6.3)                            | 2 (4.1)                            | 9 (7.0)                           |
| Haemochromatosis            | 6 (18.2)                                     | 3 (3.1)                            | 1 (2.0)                            | 9 (7.0)                           |
| Drug hypersensitivityb      | 2 (6.1)                                      | 5 (5.2)                            | 0                                  | 7 (5.4)                           |
| Hypertension                | 2 (6.1)                                      | 5 (5.2)                            | 3 (6.1)                            | 7 (5.4)                           |
| Bone pain                   | 1 (3.0)                                      | 7 (7.3)                            | 3 (6.1)                            | 8 (6.2)                           |

MedDRA = Medical Dictionary for Regulatory Activities; NSAIDs = nonsteroidal antinflammatory drugs; NTD = nontransfusion dependent; PT = preferred term.

b In Study ACE-536-B-THAL-002, these were acetylsalicylic acid; amoxicillin; NSAIDS, specifically diclofenac; penicillin; prednisone; and surgam. For the 2 subjects in Studies A536-4/06, the specific drug name was not specified (ACE 536-B-THAL-002 Listing 16.2.4.3.1 and A536-04 CSR Listing 16.2.4.4).

Note: A subject with multiple events was counted only once within each PT. MedDRA version 23.0 was used for coding. Comorbidities are included in medical history in Study ACE-536-B-THAL-002. Table is sorted by descending frequency of PTs reported for ≥ 5% of subjects in the Pooled Luspatercept column. Source:NTDISSTable14.1.3

<div style=\"page-break-after: always\"></div>

## o Concomitant medication and procedures

## NTD β -thalassemia Data Pool (ACE-536-B-THAL-002 and A536-04/06 NTD Cohort)

Concomitant medications were used by all subjects in the NTD β -thalassemia Data Pool. The proportion of subjects receiving concomitant medications was generally consistent between the pooled luspatercept treatment group and the placebo treatment group in Study ACE-536-B-THAL-002.

The most frequently reported classes of concomitant medications in the pooled luspatercept treatment group and the placebo treatment group in Study ACE-536-B-THAL002 (≥ 50% of subjects in either group) were antianemic preparations (86.8% and 85.7%, respectively); analgesics (77.5% and 55.1%); vitamins (67.4% and 57.1%); antibacterials for systemic use (57.4% and 51.0%); antiinflammatory and antirheumatic products (57.4% and 34.7%); and 'all other therapeutic products' (51.9% and 46.9%), which included mostly iron chelators.

## Adverse events

Adverse events were analysed in terms of TEAEs, which was defined as any new AE or AE that worsened in severity on or after the first dose of IP until 63 days after the last dose of IP, as well as any SAE made known to the investigator at any time thereafter that was suspected to be related to the IP. If a subject experienced multiple TEAEs under the same SOC or PT, then the subject was counted only once for that SOC or PT. All AEs were coded using MedDRA version 23.0. The severity/intensity of TEAEs was graded 1 to 5 according to NCI CTCAE version 4.0.

- Overall Adverse Event Experience

Table 7: Overview of TEAEs (NTD β-thalasseimia Safety Population)

|                                              | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Pool\"              |
|----------------------------------------------|----------------------------------------------|------------------------------------|------------------------------------|-------------------------------------------|
| Subjects with at least 1:                    | Luspatercept N=33 n(%) [EAIR']               | Luspatercept N=96 n (%) [EAIR']    | Placebo N=49 n (%) [EAIR]          | Pooled Luspatercept N = 129 n (%) [EAIR'] |
| TEAE                                         | 33 (100.0) [1611.4]                          | 96 (100.0) [1533.2]                | 48 (98.0) [720.9]                  | 129 (100.0) [1552.5]                      |
| SAE                                          | 2 (6.1) [2.4]                                | 11 (11.5) [6.8]                    | 12 (24.5) [22.3]                   | 13 (10.1) [5.3]                           |
| TEAEleadingtodeath (CTCAE Grade 5)           | 1 (3.0) [1.2]                                | [0]o                               | [0]o                               | 1 (0.8) [0.4]                             |
| CTCAEGrade3or 4                              | 9 (27.3) [14.2]                              | 27 (28.1) [19.7]                   | 12 (24.5) [22.2]                   | 36 (27.9) [18]                            |
| TEAE leading to dose interruption            | 7 (21.2) [10.1]                              | 23 (24.0) [15.2]                   | 9 (18.4) [16.3]                    | 30 (23.3) [13.6]                          |
| TEAEleadingtodosereduction                   | 5 (15.2) [6.2]                               | 10 (10.4) [6.4]                    | 0[0]                               | 15 (11.6) [6.4]                           |
| TEAE leading to permanent IP discontinuation | 3 (9.1) [3.5]                                | 3 (3.1) [1.7]                      | 4 (8.2) [6.5]                      | 6 (4.7) [2.3]                             |

One luspatercept-treated subject from the supportive studies had Grade 5 (fatal) TEAE during the study. The AE leading to death (cardiac arrest) was not considered related to luspatercept. No subject had a Grade 5 TEAE in Study ACE-536-B-THAL-002 by the updated data cut-off date (22 Sep 2021).

<div style=\"page-break-after: always\"></div>

## Treatment-emergent Adverse Events

## Table 82: Treatmentemergent adverse vents reported for ≥ 10 % of subjects in any treatment group (NTD- beta thalassemia safety population)

|                                                      | Supportive Stulies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemiaData Poola            |
|------------------------------------------------------|----------------------------------------------|------------------------------------|------------------------------------|----------------------------------------|
| System Organ Class Preferred Term                    | Luspatercept N=33 n (%) [EAIR]               | Luspatercept N=96 n (%) [EAIR]     | Placebo N= 49 n (%) [EAIR]         | Pooled Luspatercept N=129 n(%) [EAIR'] |
| Subjects with at least 1 TEAE                        | 33 (100.0) [1611.4]                          | 96 (100.0) [1533.2]                | 48 (98.0) [720.9]                  | 129 (100.0) [1552.5]                   |
| Musculoskeletal and connective tissue disorders      | 29 (87.9) [197.1]                            | 76 (79.2) [145]                    | 28 (57.1) [92.8]                   | 105 (81.4) [156.4]                     |
| Bone pain                                            | 16 (48.5)                                    | 35 (36.5)                          | 3 (6.1)                            | 51 (39.5)                              |
| Arthralgia                                           | 13 (39.4)                                    | 28 (29.2)                          | 7 (14.3)                           | 41 (31.8)                              |
| Back pain                                            | 9 (27.3)                                     | 27 (28.1)                          | 5 (10.2)                           | 36 (27.9)                              |
| Pain in extremity                                    | 9 (27.3)                                     | 16 (16.7)                          | 5 (10.2)                           | 25 (19.4)                              |
| Myalgia                                              | 10 (30.3)                                    | 11 (11.5)                          | 5 (10.2)                           | 21 (16.3)                              |
| Musculoskeletal pain                                 | 11 (33.3)                                    | 6 (6.3)                            | 3 (6.1)                            | 17 (13.2)                              |
| Neck pain                                            | 4 (12.1)                                     | 7 (7.3)                            | 2 (4.1)                            | 11 (8.5)                               |
| Musculoskeletal chest pain                           | 4 (12.1)                                     | 4 (4.2)                            | 1 (2.0)                            | 8 (6.2)                                |
| Muscle spasms                                        | 4 (12.1)                                     | 1 (1.0)                            | 1 (2.0)                            | 5 (3.9)                                |
| Infections and infestations                          | 26 (78.8) [186.7]                            | 71 (74.0) [90.6]                   | 33 (67.3) [110]                    | 97 (75.2) [105.1]                      |
| Pharyngitis                                          | 8 (24.2)                                     | 19 (19.8)                          | 7 (14.3)                           | 27 (20.9)                              |
| Upper respiratory tract infection                    | 4 (12.1)                                     | 20 (20.8)                          | 11 (22.4)                          | 24 (18.6)                              |
| Influenza                                            | 8 (24.2)                                     | 12 (12.5)                          | 5 (10.2)                           | 20 (15.5)                              |
| Gastroenteritis                                      | 6 (18.2)                                     | 10 (10.4)                          | 3 (6.1)                            | 16 (12.4)                              |
| Rhinitis                                             | 7 (21.2)                                     | 8 (8.3)                            | 5 (10.2)                           | 15 (11.6)                              |
| Nasopharyngitis                                      | 9 (27.3)                                     | 5 (5.2)                            | 0                                  | 14 (10.9)                              |
| Tonsillitis                                          | 1 (3.0)                                      | 2 (2.1)                            | 6 (12.2)                           | 3 (2.3)                                |
| General disorders and administration site conditions | 23 (69.7) [133.8]                            | 53 (55.2) [52.6]                   | 22 (44.9) [53.2]                   | 76 (58.9) [64.5]                       |
| Pyrexia                                              | 22 (66.7)                                    | 14 (14.6)                          | 9 (18.4)                           | 36 (27.9)                              |
| Asthenia                                             | 13 (39.4)                                    | 13 (13.5)                          | 5 (10.2)                           | 26 (20.2)                              |
| Influenza like illness                               | 3 (9.1)                                      | 16 (16.7)                          | 3 (6.1)                            | 19 (14.7)                              |
| Fatigue                                              | 1 (3.0)                                      | 16 (16.7)                          | 10 (20.4)                          | 17 (13.2)                              |
| Oedema peripheral                                    | 6 (18.2)                                     | 3 (3.1)                            | 2 (4.1)                            | 9 (7.0)                                |
| Injection site pain                                  | 5 (15.2)                                     | 1 (1.0)                            | 0                                  | 6 (4.7)                                |
| Gastrointestinal disorders                           | 23 (69.7) [85.6]                             | 47 (49.0) [41.9]                   | 22 (44.9) [60.7]                   | 70 (54.3) [50.3]                       |
| Diarrhoea                                            | 16 (48.5)                                    | 16 (16.7)                          | 6 (12.2)                           | 32 (24.8)                              |
| Toothache                                            | 6 (18.2)                                     | 12 (12.5)                          | 1 (2.0)                            | 18 (14.0)                              |

<div style=\"page-break-after: always\"></div>

| Nausea                                          | 5 (15.2)          | 10 (10.4)        | 6 (12.2)         | 15 (11.6)        |
|-------------------------------------------------|-------------------|------------------|------------------|------------------|
| Abdominal pain                                  | 5 (15.2)          | 9 (9.4)          | 5 (10.2)         | 14 (10.9)        |
| Abdominal pain upper                            | 5 (15.2)          | 9 (9.4)          | 3 (6.1)          | 14 (10.9)        |
| Vomiting                                        | 6 (18.2)          | 5 (5.2)          | 0                | 11 (8.5)         |
| Nervoussystemdisorders                          | 26 (78.8) [104.3] | 44 (45.8) [40.1] | 16 (32.7) [36.6] | 70 (54.3) [52]   |
| Headache                                        | 22 (66.7)         | 29 (30.2)        | 10 (20.4)        | 51 (39.5)        |
| Dizziness                                       | 6 (18.2)          | 8 (8.3)          | 4 (8.2)          | 14 (10.9)        |
| Sciatica                                        | 4 (12.1)          | 4 (4.2)          | 0                | 8 (6.2)          |
| Respiratory, thoracic and mediastinal disorders | 20 (60.6) [52.2]  | 40 (41.7) [32.8] | 15 (30.6) [31.7] | 60 (46.5) [37.4] |
| Oropharyngeal pain                              | 13 (39.4)         | 19 (19.8)        | 6 (12.2)         | 32 (24.8)        |
| Cough                                           | 11 (33.3)         | 17 (17.7)        | 1 (2.0)          | 28 (21.7)        |
| Epistaxis                                       | 4 (12.1)          | 9 (9.4)          | 1 (2.0)          | 13 (10.1)        |
| Vasculardisorders                               | 10 (30.3) [15.5]  | 37 (38.5) [31.6] | 10 (20.4) [18.5] | 47 (36.4) [25.9] |
| Hypertension                                    | 5 (15.2)          | 19 (19.8)        | 1 (2.0)          | 24 (18.6)        |
| Prehypertension                                 | 0                 | 22 (22.9)        | 7 (14.3)         | 22 (17.1)        |
| Skin and subcutaneous tissue disorders          | 20 (60.6) [57.1]  | 26 (27.1) [18.4] | 5 (10.2) [8.4]   | 46 (35.7) [26.1] |
| Pruritus                                        | 5 (15.2)          | 2 (2.1)          | 0                | 7 (5.4)          |
| Injury, poisoning and procedural complications  | 13 (39.4) [24.6]  | 26 (27.1) [18]   | 7 (14.3) [12.1]  | 39 (30.2) [19.8] |
| Post-traumatic pain                             | 4 (12.1)          | 4 (4.2)          | 2 (4.1)          | 8 (6.2)          |
| Reproductivesystemandbreast disorders           | 9 (27.3) [13.4]   | 24 (25.0) [16]   | 6 (12.2) [10.2]  | 33 (25.6) [15.2] |
| Menstruation irregular                          | 1 (3.0)           | 12 (12.5)        | 3 (6.1)          | 13 (10.1)        |
| Metabolismandnutritiondisorders                 | 7 (21.2) [10.7]   | 23 (24.0) [15.7] | 13 (26.5) [26.4] | 30 (23.3) [14.2] |
| Iron overload                                   | 0                 | 10 (10.4)        | 5 (10.2)         | 10 (7.8)         |
| Blood and lymphatic system disorders            | 9 (27.3) [12.8]   | 14 (14.6) [8.7]  | 7 (14.3) [12.4]  | 23 (17.8) [6:6]  |
| Extramedullaryhaemopoiesis                      | 4 (12.1)          | 6 (6.3)          | 1 (2.0)          | 10 (7.8)         |
| Psychiatricdisorders                            | 4 (12.1) [5.2]    | 17 (17.7) [11.1] | 2 (4.1) [3.2]    | 21 (16.3) [9.1]  |
| Insomnia                                        | 1 (3.0)           | 11 (11.5)        | 1 (2.0)          | 12 (9.3)         |
| Cardiac disorders                               | 8 (24.2) [12.1]   | 11 (11.5) [6.8]  | 9 (18.4) [17.2]  | 19 (14.7) [8.3]  |
| Palpitations                                    | 5 (15.2)          | 6 (6.3)          | 6 (12.2)         | 11 (8.5)         |
| Earandlabyrinthdisorders                        | 4 (12.1) [5.2]    | 12 (12.5) [7.7]  | 7 (14.3) [12.7]  | 16 (12.4) [6.9]  |
| Ear pain                                        | 4 (12.1)          | 2 (2.1)          | 4 (8.2)          | 6 (4.7)          |

Source:NTDISSTable14.3.1.3

<div style=\"page-break-after: always\"></div>

## o Analysis of Adverse Events by Relationship to Study Drug

Table 14.3.1.4 Treatment-Related Treatment-Emergent Adverse Event by SoC and PT Non-transfusion Dependent Beta-Thal Safety Population

|                                                      | A536-04/06                           | Pivota1 ACE-536-B-THAL-002           | Pivota1 ACE-536-B-THAL-002      | NTD B-THAL Pooled                     |
|------------------------------------------------------|--------------------------------------|--------------------------------------|---------------------------------|---------------------------------------|
| System Organ Class Preferred Term                    | Luspatercept （N=33） n（8） EAIR/100 PY | Luspatercept (N=96) n（%） EAIR/100 PY | Placebo (N=49) n（%） EAIR/100 PY | Luspatercept (N=129) n（8） EAIR/100 PY |
| Subjects with atleast one specified event            | 27(81.8) 155.5                       | 73(76.0) 149.9                       | 18(36.7) 51.8                   | 100(77.5) 151.4                       |
| Musculoskeletal and connective tissue disorders      | 19(57.6)                             | 61(63.5)                             | 6 (18.4)                        | 80(62.0)                              |
| Bone pain                                            | 51.2 9(27.3)                         | 85.2 35(36.5)                        | 19.6 1（ 2.0)                    | 73.6 44(34.1)                         |
| Arthralgia                                           | 14.6 5(15.2)                         | 30.8 18 (18.8)                       | 1.7 3（ 6.1)                     | 25.1 23(17.8)                         |
| Back pain                                            | 7 2(6.1)                             | 12.2 19(19.8)                        | 5.1 2（ 4.1)                     | 10.5 21 (16.3)                        |
| Myalgia                                              | 2.4 5(15.2)                          | 13.3 9(9.4)                          | 3.4 2（ 4.1)                     | 9.3 14 (10.9)                         |
| Musculoskeletal pain                                 | 6.6 5(15.2)                          | 5.7 2（ 2.1)                          | 3.4 。（ 0.0)                     | 6 7（ 5.4)                             |
| Pain in extremity                                    | 6.9 1（ 3.0)                          | 1.2 4（ 4.2)                          | 1（ 2.0)                         | 2.9 5（ 3.9)                           |
| Coccydynia                                           | 1.2 。（ 0.0)                          | 2.4 2（ 2.1)                          | 1.7 。（ 0.0)                     | 2 2（ 1.6)                             |
| Muscle spasms                                        | 。 2（ 6.1)                            | 1.2 。（ 0.0)                          | 0 1（ 2.0)                       | 0.8 2（ 1.6)                           |
| Musculoskeletal chest pain                           | 2.5 2（ 6.1)                          | 0 0（ 0.0)                            | 1.7 0（ 0.0)                     | 0.8 2（ 1.6)                           |
| Neck pain                                            | 2.5 1（ 3.0)                          | 0 1（ 1.0)                            | 0 （ 2.0)                        | 0.8 2（ 1.6)                           |
| Pain in jaw                                          | 1.2 1（ 3.0)                          | 0.6 1（ 1.0)                          | 1 .7 。（ 0.0)                    | 0.8 2（ 1.6)                           |
| Spinal pain                                          | 1.2 1（ 3.0)                          | 0.6 1（ 1.0)                          | 0 0.0)                          | 0.8 2（ 1.6)                           |
| Bone infarction                                      | 1.2 1（ 3.0)                          | 0.6 。（ 0.0)                          | 0 0（ 0.0)                       | 0.8 1（ 0.8)                           |
|                                                      | 1.2                                  | 0                                    | 0 。（ 0.0)                       | 0.4 1（ 0.8)                           |
| Limb discomfort                                      | 1（ 3.0) 1.2                          | 。（ 0.0) 0                            | 0                               | 0.4                                   |
| Lupus-like syndrome                                  | 0（ 0.0) 0                            | 1.0)                                 | 0（ 0.0) 0                       | 1（ 0.8) 0.4                           |
| Muscle contracture                                   | 1（ 3.0) 1.2                          | 0.6 。（ 0.0) 0                        | 。（ 0.0) 0                       | 1（ 0.8) 0.4                           |
| Muscular weakness Temporomandibular joint syndrome   | 。（ 0.0) 0 1（ 3.0)                    | 1( 1.0) 0.6                          | 3（ 6.1) 5.4 。（ 0.0)             | 1（ 0.8) 0.4 1（ 0.8)                   |
| Vertebral column mass                                | 1.2                                  | 。（ 0.0) 0                            | 0                               | 0.4 1（ 0.8)                           |
|                                                      | 1(3.0) 1.2                           | 。（ 0.0) 0                            | 。（ 0.0) 0                       | 0.4                                   |
| General disorders and administration site conditions | 11(33.3) 19.6                        | 22 (22.9) 16.3 1 (1.0)               | 5(10.2) 9.3 0（ 0.0)             | 33 (25.6) 17.3 6(4.7)                 |
| Injection site pain                                  | 5(15.2) 7.1 ）。 0.0)                  | 0.6 5（ 5.2) 3.1                      | 0 2（ 4.1)                       | 2.5 5（ 3.9)                           |
| Fatigue                                              |                                      |                                      | 3.4                             | 2                                     |
| Injection site erythema                              | 0（ 0.0)                              | 5（ 5.2)                              | 。（ 0.0)                         | 5( 3.9)                               |
| Asthenia                                             | 0 3（ 9.1)                            | 3 1（ 1.0)                            | 0 。（ 0.0)                       | 2 4（ 3.1)                             |
| Influenza like illness                               | 3.8 。（ 0.0)                          | 0.6 4（ 4.2)                          | 0 1（ 2.0) 1.7                   | 1.6 4（ 3.1) 1.6                       |
| Chills                                               | 0 2（ 6.1) 2.4                        | 2.4 1 (1.0) 0.6                      | 1（ 2.0)                         | 3（ 2.3)                               |
| Face oedema                                          | 。（ 0.0)                              | 3（ 3.1)                              | 1.7 。（ 0.0)                     | 1.2 3（ 2.3)                           |
| Pyrexia                                              | 0 3（ 9.1)                            | 1.8 。（ 0.0) 0                        | 0 1( 2.0) 1.7                   | 1.2 3（ 2.3) 1.2                       |
| Injection site swelling                              | 3.8 1（ 3.0)                          | 1（ 1.0) 0.6                          | 。（ 0.0) 0 0（ 0.0)               | 2（ 1.6) 0.4                           |
| Administration site pain                             | 1.2 0（ 0.0) 0                        | 1（ 1.0) 0.6                          | 0 。（ 0.0)                       | 0.8 1（ 0.8)                           |
| Feeling hot                                          | 0（ 0.0)                              | 1( 1.0) 0.6                          | 0                               | 0.8) 0.4                              |
| Injection site haematoma                             | 0 0（ 0.0) 0                          | 1（ 1.0) 0.6                          | 。（ 0.0) 0                       | 0.4 0.8)                              |
| Injection site inflammation                          | 0（ 0.0)                              | 1（ 1.0)                              | 0（ 0.0)                         | 1（ 0.8)                               |
| Injection site oedema                                | 0 0（ 0.0) 0                          | 0.6 1（ 1.0) 0.6                      | 0 。（ 0.0) 0                     | 0.4 1（ 0.8) 0.4                       |
| Injection site pruritus                              | 0（ 0.0) 0 0（ 0.0)                    | 1（ 1.0) 0.6                          | 。（ 0.0) 0 。（ 0.0)               | 1（ 0.8) 0.4 1（ 0.8)                   |
| Injection site rash Malaise                          | 0 1（ 3.0) 1.2 0（ 0.0)                | 1（ 1.0) 0.6 0（ 0.0) 0                | 0 。（ 0.0) 0 0（ 0.0)             | 0.4 1（ 0.8) 0.4                       |
| Oedema peripheral                                    | 0（ 0.0) 0 0（ 0.0)                    | 0 0（ 0.0) 0                          | 1.7 1（ 2.0) 1.6                 | 1（ 0.8)                               |
| Peripheral swelling                                  | 0                                    | 1( 1.0) 0.6 0（ 0.0)                  | 0                               | 0.4 。（ 0.0)                           |
| Non-cardiac chest pain                               |                                      |                                      | 2.0)                            | 0                                     |
|                                                      | 0                                    |                                      |                                 | 0（ 0.0) 0                             |
|                                                      |                                      |                                      | 4（ 8.2)                         |                                       |
| Nervous system disorders                             | 13(39.4) 22.9                        | 15 ( 15.6) 10.1 10(10.4)             | 7.3 4（ 8.2)                     | 28(21.7) 13.6                         |
|                                                      | 11 ( 33.3) 18 2（ 6.1)                | 6.5 1（ 1.0)                          | 7.3 。（ 0.0)                     | 21 (16.3) 9.7 3(2.3)                  |
| Headache Paraesthesia Dizziness                      | 2.4 0（ 0.0) 0 0（ 0.0)                | 0.6 2( 2.1) 1.2 1（ 1.0)              | 0 1( 2.0) 1.7 0（ 0.0)           | 1.2 2（ 1.6) 0.8 1（ 0.8)               |
| Migraine                                             | 0                                    | 0.6                                  | 0                               | 0.4                                   |
| Migraine with aura                                   | 1( 3.0) 1.2                          | 0（ 0                                 | 0（ 0.0) 0                       | 1（ 0.8) 0.4                           |
| Presyncope                                           | 0（ 0.0)                              | 0.0)                                 | 0（                              | 1( 0.8)                               |
|                                                      |                                      | 1（ 1.0)                              | 0                               | 0.4                                   |
|                                                      | 0                                    | 0.6                                  | 0.0)                            |                                       |

<div style=\"page-break-after: always\"></div>

| Sciatica                                        | 1（ 3.0) 1.2       | 0.0) 0              | 0 0.0) 0           | 1 0.8) 0.4          |
|-------------------------------------------------|-------------------|---------------------|--------------------|---------------------|
| Spinal cord compression                         | 0（ 0.0) 0         | 1( 1.0) 0.6         | 0（ 0.0) 0          | 1( 0.8) 0.4         |
| Vascular disorders                              | 4(12.1)           | 24 (25.0)           | 5 (10.2) 8.6       | 28 ( 21.7) 13.1     |
| Hypertension                                    | 5 .1 2 6.1)       | 17.9 13 ( 13.5)     | 0（ 0.0)            | 15(11.6)            |
| Prehypertension                                 | 2.5 0（ 0.0)       | 8.5 15 ( 15.6)      | 0 5(10.2)          | 6.4 15  ( 11.6)     |
| Flushing                                        | 0 0（ 0.0) 0       | 10.2 2(2.1)         | 8.6 0（ 0.0) 0      | 6.4 2(1.6) 0.8      |
| Spider vein                                     | 0（ 0.0) 0         | 1.2 1（ 1.0) 0.6     | 0（ 0.0) 0          | 1（ 0.8) 0.4         |
| Systolic hypertension                           | 1 ( 3.0) 1.2      | 。（ 0.0) 0           | 0（ 0.0)            | 1（ 0.8) 0.4         |
| Thrombophlebitis superficial                    | 1（ 3.0) 1.2       | 0（ 0.0) 0           | 0（ 0.0)            | 1( 0.8) 0.4         |
| Thrombosis                                      | 1（ 3.0) 1.2       | 。（ 0.0) 0           | 0 0（ 0.0) 0        | 1(0.8) 0.4          |
| Gastrointestinal disorders                      | 3（ 9.1)           | 10 (10.4)           | 6.1)               | 13 (10.1)           |
| Nausea                                          | 3.6 0（ 0.0)       | 6.4 4（ 4.2)         | 5.4 3( 6.1)        | 5.5 4( 3.1)         |
|                                                 | 0 1( 3.0)         | 2.4 2.1)            | 5.4                | 1.6                 |
| Diarrhoea                                       | 1.2               | 2（ 1.2              | 0（ 0.0) 0          | 3( 2.3) 1.2         |
| Toothache                                       | 1（ 3.0)           | 1（ 1.0)             | 0（ 0.0)            | 2（ 1.6)             |
| Abdominal pain                                  | 1.2 0（ 0.0)       | 0.6 1（ 1.0)         | 0 0（ 0.0)          | 0.8 1（ 0.8)         |
|                                                 | 0 1（ 3.0)         | 0.6 0（ 0.0)         | 0 2.0)             | 0.4 1（ 0.8)         |
| Dry mouth                                       | 1.2               | 0                   | 1 ( 1.7            | 0.4 1（ 0.8)         |
| Oral pain Paraesthesia oral                     | 0（ 0.0) 0 0（ 0.0) | 1（ 1.0) 0.6 1（ 1.0) | 0（ 0.0) 0 0 （ 0.0) | 0.4 1（ 0.8)         |
|                                                 | 3（                |                     | 0（                 | 9( 7.0)             |
| Skin and subcutaneous tissue disorders          | 9 .1) 3.8         | 6（ 6.3) 3.7         | 0.0) 0             | 3.7                 |
| Erythema                                        | 2.4 0（ 0.0)       | 0 1( 1.0)           | 0 0（ 0.0)          | 0.8 1（ 0.8)         |
| Hyperhidrosis                                   | 0 0（ 0.0)         | 0.6 1（ 1.0)         | 0 0（ 0.0)          | 0.4 1（ 0.8) 0.4     |
| Palmar erythema                                 | 0 1（ 3.0) 1.2     | 0.6 。（ 0.0) 0       | 0 0（ 0.0) 0        | 1（ 0.8) 0.4         |
|                                                 | 0.0) 0            | 0.6                 | 0                  | 0.4 1（ 0.8)         |
| Rash macular                                    | 0（ 0.0)           | 1（ 1.0)             | 0（ 0.0)            | 0.4                 |
| Rash papular                                    | 0 0（ 0.0)         | 0.6 1 (1.0)         | 0 。（ 0.0)          | 1（ 0.8) 0.4         |
| Telangiectasia                                  | 0 0（ 0.0) 0       | 0.6 1（ 1.0) 0.6     | 0 0（ 0.0) 0        | 1( 0.8) 0.4         |
| Blood and lymphatic system disorders            | 9.1) 3.7          | 2（ 2.1) 1.2         | ）。 0.0) 0          | 5( 3.9) 2           |
| Extramedullary haemopoiesis                     | 3 （ 9.1) 3.6 1(   | 1( 1.0) 0.6         | ）。 0.0) 0          | 4( 3.1) 1.6         |
| Erythroblastosis                                | 3.0)              | 。（ 0.0)             | ）。 0.0)            | 1( 0.8)             |
|                                                 | 1.2               | 0                   | 0 0（ 0.0)          | 0.4                 |
| Haemolytic anaemia                              | 0（ 0.0) 0         | 1( 1.0) 0.6         | 0                  | 1（ 0.8) 0.4         |
| Insomnia                                        | 0 0（ 0.0) 0       | 2.4 2（ 2.1) 1.2     | 0 。（ 0.0) 0        | 1.6 2（ 1.6) 0.8     |
| Irritability                                    | 0（ 0.0) 0         | 2（ 2.1) 1.2         | 0（ 0.0) 0          | 2( 1.6) 0.8         |
| Anxiety                                         | ）。 0.0) 0         | 1（ 1. 0) 0.6        | ）。 0.0) 0          | 1（ 0.8) 0.4         |
| Cardiac disorders                               | 0（ 0.0) 0         | 3（ 3.1) 1.8         | 1( 2.0)            | 3（ 2.3)             |
| Palpitations                                    | 0 （ 0.0)          | 2（ 2.1)             | 1.7 （ 2.0)         | 1.2 2（ 1.6)         |
| Tachycardia                                     | 0 0（ 0.0) 0       | 1.2 1( 1.0) 0.6     | 1.7 0（ 0.0) 0      | 0.8 1（ 0.8) 0.4     |
| Investigations                                  | 3( 9.1)           | 0（ 0.0)             | 0（ 0.0)            | 3（ 2.3)             |
| Blood pressure increased                        | 3.7 2（ 6.1) 2.5   | 0 0（ 0.0)           | 0 0（ 0.0) 0        | 1.2 2( 1.6) 0.8     |
| Blood lactate dehydrogenase increased           | 1( 3.0) 1.2       | 0 0（ 0.0) 0         | 0（ 0.0) 0          | 1（ 0.8) 0.4 1( 0.8) |
|                                                 | 1（ 3.0) 1.2       | 0（ 0.0) 0           | 0（ 0.0) 0          | 0.4                 |
| Intraocular pressure increased                  |                   |                     |                    |                     |
| Reproductive system and breast disorders        | 2（ 6.1)           | 0.0)                | 0（ 0.0)            | 2（ 1.6) 0.8         |
| Hypomenorrhoea                                  | 2.5 1（ 3.0)       | 0 。（ 0.0)           | 0 。（ 0.0)          | 1（ 0.8)             |
| Priapism                                        | 1.2 1( 3.0) 1.2   | 0 0.0) 0            | 0 0（ 0.0) 0        | 0.4 1（ 0.8) 0.4     |
| Respiratory, thoracic and mediastinal disorders | 0（ 0.0) 0         | 2( 2.1) 1.2         | 4 .1) 3.5          | 2(1.6) 0.8          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

TEAE=Treatment-emergent adverseevents.Treatment-emergent adverse eventsinclude adverseevents that started on or after the date of first dose and up to 63 days after the date of last dose of investigational product (IP), as well as any serious adverse event suspected to be related to the IP. for that SoC and PT level. EAIR/1o0 PY: Exposure adjusted incidence rate (EAIR) per 100 person-years is 100 times the number of subjects with the specific TEAE divided by the total exposure time （in years)to the event.Exposure time is the overall treatment exposure for subjects without the event and the time up tothefirsteventstartdateforsubjectswiththeevent. MedDRAVersion23.0isusedforcoding. Programpath:/u02/projects/ace\\_536/ace\\_536\\_bthal\\_sbla\\_iss/deliverables/d001\\_iss\\_2021/programs/tables/final/t\\_ae.sas Data source: adae adsl Run date: 16JUL2021

## Analysis of Grade 3 or 4 Adverse Events

The most frequent TEAEs of Grade 3 or 4 in the pooled luspatercept treatment group were traumatic fracture and hypertension (3.1% each) and AST increased, bone pain and menstruation irregular (2.3% each). Of these events, only traumatic fracture and AST increased were reported in the placebo treatment group (2.0%). All 4 subjects with Grade 3 or 4 traumatic fracture had Grade 3 events; 3 of the 4 subjects in the pooled luspatercept treatment group and the 1 subject in the placebo treatment group in Study ACE-536-B-THAL-002 had osteopenia or osteoporosis reported at baseline. All 4 subjects with Grade 3 or 4 hypertension in the luspatercept treatment group had Grade 3 events; and 2 of these subjects had prehypertension or hypertension reported at baseline. All 3 subjects with Grade 3 or 4 menstruation irregular had Grade 3 events and all were females ≥ 44 years of age.

<div style=\"page-break-after: always\"></div>

Table 83: Grade 3 or 4 TEAEs Reported for ≥ 2% of Subjects in the Pooled Luspatercept Treatment Group (NTD β -thalassemia Safety Population)

| SystemOrganClass                                | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Pool     |
|-------------------------------------------------|----------------------------------------------|------------------------------------|------------------------------------|---------------------------------|
| PreferredlTerm                                  | Luspatercept N=33 n (%)                      | Luspatercept N=96 n (%)            | Placebo N = 49 n (%)               | Pooled Luspatercept N=129 n (%) |
| Subjects with at 1east 1 Grade 3 or 4 TEAE      | 9 (27.3) [14.2b]                             | 27 (28.1) [19.7]                   | 12 (24.5) [22.2]                   | 36 (27.9) [18]                  |
| Musculoskeletal and connective tissue disorders | 2 (6.1)                                      | 7 (7.3)                            | 0                                  | 9 (7.0)                         |
| Bone pain                                       | 0                                            | 3 (3.1)                            | 0                                  | 3 (2.3)                         |
| Injury, poisoning and procedural complications  | 1 (3.0)                                      | 4 (4.2)                            | 1 (2.0)                            | 5 (3.9)                         |
| Traumaticfracture                               | 0                                            | 4 (4.2)                            | 1 (2.0)                            | 4 (3.1)                         |
| Investigations                                  | 1 (3.0)                                      | 4 (4.2)                            | 1 (2.0)                            | 5 (3.9)                         |
| Aspartate aminotransferase increased            | 0                                            | 3 (3.1)                            | 1 (2.0)                            | 3 (2.3)                         |
| Reproductive system and breast disorders        | 1 (3.0)                                      | 4 (4.2)                            | 1 (2.0)                            | 5 (3.9)                         |
| Menstruationirregular                           | 0                                            | 3 (3.1)                            | 0                                  | 3 (2.3)                         |
| Vascular disorders                              | 1 (3.0)                                      | 3 (3.1)                            | 1 (2.0)                            | 4 (3.1)                         |
| Hypertension                                    | 1 (3.0)                                      | 3 (3.1)                            | 0                                  | 4 (3.1)                         |

²Includes subjects from Study ACE-536-B-THAL-002 and the NTD cohort from Studies A536-04/06.

EAIR = exposure-adjusted incidence rate; IP = investigational product; MedDRA = Medical Dictionary for RegulatoryActivities;NCI-CTCAE=National Cancer Institute-CommonTerminology Criteria forAdverse Events;NTD=nontransfusion dependent;PT=preferred term;SAE=serious adverse event;SOC= system organ class;TEAE=treatment-emergent adverse event.

b Exposure-adjusted incidence rates per 100 subject-years. EAIR per 100 subject-years is 100 times the number of subjectswith the specificTEAE divided by the total exposure time(in years)to the event.Exposure time is the overall treatment exposure for subjects without the event and the time up to the first event start date for subjects with the event.

Source:NTDISSTable 14.3.1.7

Note: Treatment-emergent adverse events include adverse events that started on or after the date of first dose and up to 63 days after the date of the last dose of IP, as well as any SAE suspected to be related to the IP. If a subject experienced multipleeventsunder the sameSOCand PT,then thesubject was counted only onceforthatSOC and PT 1evel. MedDRA version 23.0 was used for coding. NCI-CTCAE version 4.0 was used for grading severity. Table is sortedby descending frequency of SOCs and then by descending frequency of PTs with eachSOCfor ≥2%of subjectsin thePooled Luspatercept column.

## Serious adverse event/deaths/other significant events

## · Deaths

No deaths were reported in the pivotal study ACE-536-B-THAL-002 as of the updated cut-off of 22 Sept 2021.

In the NTD β -thalassemia Data Pool, 1 (0.8%) subject from the pooled luspatercept treatment group (Studies A536-04/06; NTD Cohort) died.

- The subject was a 59-yearold, white male with an initial diagnosis of β -thalassemia approximately 1 year prior to study entry.

The subject had relevant and ongoing medical history of arrhythmia (supraventricular and ventricular extrasystoles, and ventricular bigeminy), splenectomy, cholecystectomy, transient ischemic attack, paroxysmal supraventricular tachycardia, atrioventricular nodal re-entrant tachycardia, osteoporosis, appendectomy, and hypertension.

The subject enrolled into Study A536-04 on 02 Apr 2014, at a dose level of 1 mg/kg. The subject's last dose in Study A536-04 was on 25 Jun 2014, Study Day 85. The subject enrolled into Study A536-06 as a dose interrupted subject on 05 Nov 2014, Study Day 218, and started study treatment on 27 Nov 2014, Study Day 240, with a dose of 0.8 mg/kg. The dose of luspatercept was increased to 1 mg/kg on 08 Jan 2015, Study Day 282, and to 1.25 mg/kg on 30 Jun 2015, Study Day 455, because the hemoglobin increase from baseline was &lt; 1.5 g/dL

<div style=\"page-break-after: always\"></div>

throughout the previous 2 cycles at a single dose. The last dose was received on 30 Mar 2016, Study Day 729. Total treatment duration for this subject in Study A536-06 was 494 days with a total of 23 doses received.

On 03 Mar 2015, Study Day 336, the subject had a loop recorder implantation operation. On 30 Dec 2015, Study Day 638, electrocardiogram results showed sinus rhythm and counter clockwise rotation. On 16 Feb 2016, Study Day 686, echocardiography results showed slightly enlarged left ventricle, mild hypertrophy of septal and parietal wall, mitral valve fibrosclerosis, and hypomobility of posterior leaflet; left atrium size was noted to be at upper normal limit and diastolic function was normal. On 03 Apr 2016, Study Day 733, the subject experienced the SAE of cardiac arrest (verbatim: asystole). The subject was found lifeless in their garden and attempts at resuscitation were unsuccessful. The outcome of the event was fatal. The death occurred 5 days after the last dose of study treatment. The reported cause of sudden death was unknown, as the first reading of the loop recorder only revealed asystole, preventing a clear diagnosis. Post mortem analysis of cardiac rhythm, which was registered by the previously implanted loop recorder highlighted a sudden transition from sinus rhythm to asystole. The investigator reported that an autopsy was not performed.

In the opinion of the investigator, the event of cardiac arrest was not related to the study treatment. The investigator stated that to their knowledge there is no known mechanism of action of the study drug that can cause a sudden death. Moreover, in relation to the previous central nervous system and arrhythmic problems the subject experienced, the investigator stated that the death would have also occurred if the subject was not taking the study drug.

## · Other Serious Adverse Events

## Table 84: Serious adverse events (NTD beta-Thalassemia safety population)

| System Organ Class Preferred Term              | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Pool\"    |
|------------------------------------------------|----------------------------------------------|------------------------------------|------------------------------------|---------------------------------|
|                                                | Luspatercept N=33 n (%)                      | Luspatercept N=96 n (%)            | Placebo N =49 n (%)                | Pooled Luspatercept N=129 n (%) |
| Subjects with at least 1 SAE                   | 2 (6.1) [2.4]                                | 11 (11.5) [6.8]                    | 12 (24.5) [22.3b]                  | 13 (10.1) [5.3]                 |
| Injury, poisoning and procedural complications | 0                                            | 5 (5.2)                            | 1 (2.0)                            | 5 (3.9)                         |
| Traumaticfracture                              | 0                                            | 5 (5.2)                            | 1 (2.0)                            | 5 (3.9)                         |
| Pulmonary contusion                            | 0                                            | 1 (1.0)                            | 0                                  | 1 (0.8)                         |
| Blood and lymphatic system disorders           | 1 (3.0)                                      | 1 (1.0)                            | 1 (2.0)                            | 2 (1.6)                         |
| Bone mairowfailure                             | 1 (3.0)                                      | 0                                  | 0                                  | 1 (0.8)                         |
| Splenomegaly                                   | 0                                            | 1 (1.0)                            | 0                                  | 1 (0.8)                         |
| Extramedullary haemopoiesis                    | 0                                            | 0                                  | 1 (2.0)                            | 0                               |

<div style=\"page-break-after: always\"></div>

| Infections and infestations                                         | 0       | 2 (2.1)   | 6 (12.2)   | 2 (1.6)   |
|---------------------------------------------------------------------|---------|-----------|------------|-----------|
| Dengue haemorrhagic fever                                           | 0       | 1 (1.0)   | 0          | 1 (0.8)   |
| Pilonidal cyst                                                      | 0       | 1 (1.0)   | 0          | 1 (0.8)   |
| Abscess limb                                                        | 0       | 0         | 1 (2.0)    | 0         |
| Gastroenteritis                                                     | 0       | 0         | 1 (2.0)    | 0         |
| Influenza                                                           | 0       | 0         | 1 (2.0)    | 0         |
| Pharyngitis                                                         | 0       | 0         | 1 (2.0)    | 0         |
| Pyelonephritis acute                                                | 0       | 0         | 1 (2.0)    | 0         |
| Tonsillitis                                                         | 0       | 0         | 1 (2.0)    | 0         |
| Viral upper respiratory tract infection                             | 0       | 0         | 2 (4.1)    | 0         |
| Metabolism and nutrition disorders                                  | 0       | 2 (2.1)   | 0          | 2 (1.6)   |
| Diabetes mellitus                                                   | 0       | 1 (1.0)   | 0          | 1 (0.8)   |
| Hyperglycaemia                                                      | 0       | 1 (1.0)   | 0          | 1 (0.8)   |
| Respiratory, thoracic and mediastinal disorders                     | 0       | 2 (2.1)   | 1 (2.0)    | 2 (1.6)   |
| Pleural effusion                                                    | 0       | 1 (1.0)   | 0          | 1 (0.8)   |
| Pulmonary arterial hypertension                                     | 0       | 1 (1.0)   | 0          | 1 (0.8)   |
| Haemoptysis                                                         | 0       | 0         | 1 (2.0)    | 0         |
| Cardiac disorders                                                   | 1 (3.0) | 0         | 0          | 1 (0.8)   |
| Cardiac arrest                                                      | 1 (3.0) | 0         | 0          | 1 (0.8)   |
| Nervous system disorders                                            | 0       | 1 (1.0)   | 0          | 1 (0.8)   |
| Spinal cord compression                                             | 0       | 1 (1.0)   | 0          | 1 (0.8)   |
| Reproductive system and breast disorders                            | 1 (3.0) | 0         | 1 (2.0)    | 1 (0.8)   |
| Priapism                                                            | 1 (3.0) | 0         | 0          | 1 (0.8)   |
| Ovarian cyst ruptured                                               | 0       | 0         | 1 (2.0)    | 0         |
| Hepatobiliary disorders                                             | 0       | 0         | 1 (2.0)    | 0         |
| Biliary colic                                                       | 0       | 0         | 1 (2.0)    | 0         |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0       | 0         | 2 (4.1)    | 0         |
| Diffuse large B-cell lymphoma                                       | 0       | 0         | 1 (2.0)    | 0         |
| Hepatocellular carcinoma                                            | 0       | 0         | 1 (2.0)    | 0         |
| Renal and urinary disorders                                         | 0       | 0         | 1 (2.0)    | 0         |
| Renal colic                                                         | 0       | 0         | 1 (2.0)    | 0         |

EAIR = exposure-adjusted incidence rate; IP = investigational product; MedDRA =Medical Dictionary for Regulatory Activities; NTD = nontransfusion dependent; PT = preferred term; SAE = serious adverse event; SOC=system organ class;TEAE=treatment-emergent adverse event.

b Exposure-adjusted incidence rates per 100 subject-years. EAIR per 100 subject-years is 100 times the number of subjects with the specific TEAE divided by the total exposure time (in years) to the event. Exposure time is the overall treatment exposureforsubjects without the event and the time upto thefirst event start date for subjects with the event.

Note: Treatment-emergent adverse events include adverse events that started on or after the date of first dose and up to63days afterthedate ofthelast dose ofIP,aswell as anySAEsuspected toberelated totheIP.Ifasubject experienced multiple events under the same SOC and PT, then the subject was counted only once for that SOC and PT level. MedDRA version 23.0 was used for coding. Table is sorted by descending frequency of SOCs and then by descending frequency of PTs within each SOC based on thePooled Luspatercept column.

Source:NTDISSTable14.3.1.5

<div style=\"page-break-after: always\"></div>

## Pivotal Phase 2 ACE-536-B-THAL-002 study

As of the updated data cut-off date of 22 Sep 2021, the percentage of subjects with SAEs was 26.5% (EAIR 23 per 100 subject-years) in the placebo treatment arm vs 16.7% (EAIR 6.9 per 100 subjectyears) in the luspatercept treatment arm, and 13.4% (EAIR 7.2 per 100 subject-years) including the cross-over subjects. Only a few SAEs have been additionally reported: New cases reported in the luspatercept treatment group included haemothorax, prostatic obstruction, cholangitis, cholelithiasis, haemoglobin decreased and skin ulcer each occurring in one patient. Pneumonia related to COVID-19 and pleural effusion occurred in 2 (2.1%) subjects.

## · Analysis of adverse effects dose-response information

Subjects wit h NTD β -thalassemia received luspatercept over a dose range from 0.2 to 1.25 mg/kg in the Supportive Studies A536-04/06 (NTD Cohort) and 1.0 mg and 1.25 mg/kg in the Pivotal Study ACE-536B-THAL-002 (Note: for this study, doses lower than 1 mg/kg [i.e., 0.6, 0.8 mg/kg] were possible if subjects needed to reduce their dose).

A total of 129 luspatercept treated subjects with NTD β -thalassemia were included in the dose response analyses for the following safety measurements: Any TEAE Grade ≥ 3, SAEs, asthenia Grade ≥ 1, bone pain Grade ≥ 1, bone pain like events Grade ≥ 1, dizziness Grade ≥ 1, hypertension Grade ≥ 1, myalgia Grade ≥ 1, TEAEs leading to dose reduction, TEAEs leading to dose interruption, and TEAEs leading to permanent treatment discontinuation. Subjects were grouped under their actual dose level of luspatercept. For subjects who experienced a specified event more than once with different grades of severity, the actual dose level was the last actual dose level on or prior to the start date of the event with the highest grade. If there were multiple events with the same highest grade, the actual dose level was the last actual dose on or prior to the start date of the first event among them. For subjects with no specified event, the actual dose level was the last actual dose level of the study treatment.

To minimise having small sample sizes for comparisons, the actual dose levels were grouped for low dose levels (0.2 to 0.4 mg/kg and 0.6 to 0.8 mg/kg).

Table 85: Frequency of treatment emergent adverse event by actual dose level in luspatercept -treated subjects (NTD beta-thalassemia safety population)

|                                                      | Pooled Luspatercept     | Pooled Luspatercept     | Pooled Luspatercept   | Pooled Luspatercept   |
|------------------------------------------------------|-------------------------|-------------------------|-----------------------|-----------------------|
| Specified TEAEs                                      | 0.2 - 0.4 mg/kg n/M (%) | 0.6 - 0.8 mg/kg n/M (%) | 1.0 mg/kg n/M (%)     | 1.25 mg/kg n/M (%)    |
| TEAEsGrade≥3                                         | 1/2 (50.0)              | 6/19 (31.6)             | 13/46 (28.3)          | 17/62 (27.4)          |
| SAEs                                                 | 1/2 (50.0)              | 2/21 (9.5)              | 3/42 (7.1)            | 7/64 (10.9)           |
| TEAEsleadingtodosereduction                          | 0/1 (0)                 | 1/16 (6.3)              | 10/47 (21.3)          | 4/65 (6.2)            |
| TEAEsleading todose interruption                     | 1/2 (50.0)              | 4/20 (20.0)             | 11/38 (28.9)          | 14/69 (20.3)          |
| TEAEs leading to permanent treatment discontinuation | 0/1 (0)                 | 2/21 (9.5)              | 2/42 (4.8)            | 2/65 (3.1)            |
| Asthenia                                             | 0/1 (0)                 | 8/22 (36.4)             | 9/42 (21.4)           | 9/64 (14.1)           |
| Bone pain                                            | 0/1 (0)                 | 11/19 (57.9)            | 35/61 (57.4)          | 5/48 (10.4)           |
| Bone pain like events                                | 1/2 (50.0)              | 17/20 (85.0)            | 58/70 (82.9)          | 15/37 (40.5)          |
| Dizziness                                            | 0/1 (0)                 | 0/20 (0)                | 6/45 (13.3)           | 8/63 (12.7)           |
| Hypertension                                         | 0/1 (0)                 | 3/19 (15.8)             | 15/45 (33.3)          | 6/64 (9.4)            |
| Myalgia                                              | 2/3 (66.7)              | 5/21 (23.8)             | 7/43 (16.3)           | 7/62 (11.3)           |

<div style=\"page-break-after: always\"></div>

## Analysis of Adverse Events of Special Interest

Based on the nonclinical and clinical experience with luspatercept, the pharmacology of luspatercept, and comorbidities of β -thalassemia, the following types of events were summarised separately:

Adverse events of special interest/Events of Interest: Malignancy disorders, premalignant disorders, EMH masses, thromboembolic events, kidney injury, hypertension, and musculoskeletal disorder-bone pain like events.

These events were selected based on nonclinical or clinical findings from Phase 2 and/or Phase 3 clinical studies of luspatercept in β -thalassemia and other indications:

- Based on findings from a juvenile toxicity study, malignancy and premalignant disorders were considered as adverse events of interest:
- -The PTs used to evaluate the malignancy EOI category were based on narrow scope of sub-Standardized MedDRA Queries (SMQs) for malignancy related conditions; malignancy related therapeutic and diagnostic procedures; haematological malignant tumours; nonhaematological malignant tumours; haematological tumours of unspecified malignancy; nonhematological tumours of unspecified malignancy; and tumour markers. The PTs of human chorionic gonadotropin positive, human chorionic gonadotropin increased, leukostasis syndrome, tumour lysis syndrome, gammopathy and monoclonal gammopathy were excluded, as these conditions do not qualify as malignant tumors.
- -The PTs used to evaluate the premalignant disorder EOI category were all based on the narrow scope of sub-SMQs for blood premalignant disorders; gastrointestinal premalignant disorders; premalignant disorders, general conditions and other site-specific disorders; reproductive premalignant disorders; and skin premalignant disorders.
- The EMH masses EOI category was selected based on the numerical imbalance observed in subjects treated with luspatercept in Study ACE-536-B-THAL-002 and the clinical relevance as a disease-related comorbidity. The PTs used to evaluate this EOI category were cutaneous extramedullary hemopoiesis and extramedullary hemopoiesis.
- The thromboembolic EOI category was selected based on the findings observed in the Phase 3 Study ACE-536-B-THAL-001 and thromboembolic event is currently listed as an adverse drug reaction for subjects with TD β -thalassemia (Reblozyl USPI, Reblozyl SmPC). The PTs used to evaluate this EOI category were based on the narrow scope of sub-SMQs for embolic and thrombotic events, arterial; embolic and thrombotic events, venous; and embolic and thrombotic events, vessel type unspecified and mixed arterial and venous; as well as the MedDRA broad scope of SMQ thrombophlebitis. The PTs of device occlusion, device related thrombosis, thrombosis in device, and transient ischemic attack were excluded.
- The kidney injury EOI category was selected based on nonclinical data. The PTs used to evaluate this EOI category were based on the broad scope of SMQ acute renal failure. In addition, albumin/creatinine ratio (ACR) data for Study ACE-536-B-THAL-002 and Studies A536-04/06 were analysed for the potential of nephron damage. The ACR data are presented separately for Study ACE-536-B-THAL-002 and Studies A536-04/06 due to the different visit schedules between these studies.
- The hypertension EOI category was selected based on the findings observed in the Phase 3 pivotal Studies ACE-536-MDS-001 and ACE-536-B-THAL-001; hypertension is currently listed as an adverse drug reaction for subjects with TD β -thalassemia (Reblozyl USPI, Reblozyl SmPC). The PTs used to evaluate this EOI category were based on the narrow scope of SMQ hypertension.

<div style=\"page-break-after: always\"></div>

Treatment-emergent hypertension (based on the narrow scope of SMQ hypertension) was also summarized by subjects' history of hypertension (Yes/No).

- The musculoskeletal disorder-bone pain EOI category was selected based on the findings in the Phase 3 pivotal Study ACE-536-B-THAL-001. The musculoskeletal disorder-bone pain EOIs includes a collection of PTs that are indicative of a bone pain-like event: back pain, bone pain, musculoskeletal pain, neck pain, pain in extremity, pain in jaw, and spinal pain.

Analyses of individual AESI categories are presented in the subsequent sections.

Table 86 : Summary pf adverse events of interest (NTD- beta thalassemia safety population)

|                                       | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Pool*            |
|---------------------------------------|----------------------------------------------|------------------------------------|------------------------------------|-----------------------------------------|
| Subjects with ≥ 1:                    | Luspatercept N=33 n (%) [EAIR]               | Luspatercept N=96 n (%) [EAIR']    | Placebo N = 49 n (%) [EAIR']       | Pooled Luspatercept N=129 n (%) [EAIR'] |
| Malignancy EO1                        | [0]o                                         | [0]o                               | 2 (4.1) [3.2]                      | [0]o                                    |
| PremalignantdisorderEOI               | [0]o                                         | 1 (1.0) [0.6]                      | 1 (2.0) [1.6]                      | 1 (0.8) [0.4]                           |
| EMH masses EOI                        | 4 (12.1) [5]                                 | 6 (6.3) [3.5]                      | 1 (2.0) [1.7]                      | 10 (7.8) [4]                            |
| ThromboembolicEOI                     | 2 (6.1) [2.4]                                | 0[0]                               | [0]o                               | 2 (1.6) [0.8]                           |
| Kidney injury EO1                     | 3 (9.1) [3.8]                                | 2 (2.1) [1.2]                      | []o                                | 5 (3.9) [2]                             |
| Hypertension EOI                      | 6 (18.2) [8.2]                               | 34 (35.4) [28.3]                   | 8 (16.3) [14.6]                    | 40 (31.0) [20.7]                        |
| Musculoskeletaldisorder-bone pain EOI | 26 (78.8) [118.5]                            | 65 (67.7) [95.2]                   | 15 (30.6) [32.8]                   | 91 (70.5) [100.9]                       |

Source:NTDISSTable14.3.1.19

## Pivotal Phase 2 ACE-536-B-THAL-002 study

Table 88 provides an overview of the AESI categories with the percentages and EAIRs for the initital cutoff date 14 Sep 2020 and the updated analysis with the cut-off 22 Sep 2021.

<div style=\"page-break-after: always\"></div>

Table 87: treatment emergent adverse events of interest by category as of the initial 14 Sep 2020 and updated 22 Sep 2021 data cut-off dates

|                                  | PivotalPhase2 (ACE-536-B-THAL-002)                         | PivotalPhase2 (ACE-536-B-THAL-002)                         | PivotalPhase2 (ACE-536-B-THAL-002)                   | PivotalPhase2 (ACE-536-B-THAL-002)                  | PivotalPhase2 (ACE-536-B-THAL-002)                                               | PivotalPhase2 (ACE-536-B-THAL-002)                                            |
|----------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------|-----------------------------------------------------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| EOI category Subjects with≥1:    | Initial 14-Sep-2020 Cutoff Luspatercept N=96 n (%) [EAIR]\" | Updated 22-Sep-2021 Cutoff Luspatercept N=96 n (%) [EAIR]a | Initial 14-Sep-2020Cutoff Placebo N=49 n (%) [EAIR]a | Updated 22-Sep-2021Cutoff Placebo N=49 n (%) [EAIR] | Updated 22-Sep-2021 Cutoff Luspatercept Cross-overFrom Placebo N=38 n(%) [EAIR]* | Updated 22-Sep-2021Cutoff Luspatercept IncludingCross-over N=134 n(%) [EAIR]a |
| Maligmaney EOI                   | [0] 0                                                      | [0] 0                                                      | 2 (4.1) [3.2]                                        | 2 (4.1) [3]                                         | [0] 0                                                                            | [0] 0                                                                         |
| Premalignant disorder EOI        | 1 (1.0) [0.6]                                              | 1 (1.0) [0.4]                                              | 1 (2.0) [1.6]                                        | 1 (2.0) [1.5]                                       | 0 [0]                                                                            | 1 (0.7) [0.4]                                                                 |
| EMH masses EOI                   | 6 (6.3) [3.5]                                              | 6 (6.3) [2.5]                                              | 1 (2.0) [1.7]                                        | 1 (2.0) [1.5]                                       | 1 (2.6) [4.7]                                                                    | 7 (5.2) [2.6]                                                                 |
| ThromboembolicEOI                | [0] 0                                                      | [0] 0                                                      | [0] 0                                                | [0] 0                                               | 1 (2.6) [4.7]                                                                    | 1 (0.7) [0.4]                                                                 |
| Kidney injuy EOI                 | 2 (2.1) [1.2]                                              | 6 (6.3) [2.5]                                              | 0 [0]                                                | 0 [0]                                               | 3 (7.9) [14.9]                                                                   | 9 (6.7) [3.4]                                                                 |
| Hypertension EOI                 | 34 (35.4) [28.3]                                           | 35 (36.5) [20.9]                                           | 8 (16.3) [14.6]                                      | 8 (16.3) [13.3]                                     | 4 (10.5) [20.8]                                                                  | 39 (29.1) [20.9]                                                              |
| Musculoskeletaldisorder-bonepain | 65 (67.7) [95.2]                                           | 72 (75.0) [81.8]                                           | 15 (30.6) [32.8]                                     | 16 (32.7) [32.6]                                    | 18 (47.4) [138.9]                                                                | 90 (67.2) [89.1]                                                              |

Sources: Initial: refer to Table 14.3.1.19 in the NTD ISS. Updated: Table 14.3.1.19c.

## Malignancy AESI

Table 89: Malignancy events of interest (NTD-beta thalassemia safety population)

| E01 Category                | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia DataPool              |
|-----------------------------|----------------------------------------------|------------------------------------|------------------------------------|-----------------------------------------|
| Preferred Term              | Luspatercept N=33 n(%) [EAIR]                | Luspatercept N=96 n(%) [EAIR]      | Placebo N = 49 n (%) [EAIR]        | Pooled Luspatercept N = 129 n(%) [EAIR] |
| Malignancy EOr              | [0]o                                         | [0]o                               | 2 (4.1) [3.2]                      | [0]o                                    |
| DiffuselargeB-cell lymphoma | [0]o                                         | [0]o                               | 1 (2.0) [1.6]                      | [0]o                                    |
| Hepatocellularcarcinoma     | [0]o                                         | 0[0]                               | 1 (2.0) [1.6]                      | [0]o                                    |

²IncludessubjectsfromStudyACE-536-B-THAL-002 and theNTDcohortfrom StudiesA536-04/06.

Exposure-adjusted incidence rate in events per 100 subject-years. EAIR per 100 subject-years is 100 times the subjectswiththeevent.

Note: Treatment-emergent adverse events include adverse events that started on or after the date of first dose and up to 63days after the dateofthelast dose of IP,aswell as anySAEsuspected tobe related to theIP.Ifa subject EOI and PT level. MedDRA version 23.0 was used for coding. Preferred terms are presented in descending order of subject proportion in the Pooled Luspatercept column.

c The PTs used to evaluate this EOI category were based on the narrow scope of SMQ for malignancy related conditions; malignancyrelated therapeutic and diagnostic procedures;hematological malignant tumors; nonhematologicalmalignanttumors;hematologicaltumorsofunspecifiedmalignancy,nonhematologicaltumors of unspecified malignancy, and tumor markers. The PTs of human chorionic gonadotropin positive, human chorionic gonadotropin increased, leukostasis syndrome, tumor lysis syndrome,gammopathy,and monoclonal gammopathy were excluded, as these conditions do not qualify as malignant tumors.

Source:NTDISSTable14.3.1.19

<div style=\"page-break-after: always\"></div>

## Premalignant Disorder AESI

Table 90: Premalignant disorder events of interest (NTD beta-thalassemia safety population)

| EOI Category              | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Pool            |
|---------------------------|----------------------------------------------|------------------------------------|------------------------------------|----------------------------------------|
| PreferredTerm             | Luspatercept N=33 n(%) [EAIR]                | Luspatercept N=96 n (%) [EAIR]     | Placebo N = 49 n(%) [EAIR']        | Pooled Luspatercept N =129 n(%) [EAIR] |
| Premalignant disorderEOrc | [0]o                                         | 1 (1.0) [0.6]                      | 1 (2.0) [1.6]                      | 1 (0.8) [0.4]                          |
| Colon adenoma             | [0]o                                         | 1 (1.0) [0.6]                      | [0]o                               | 1 (0.8) [0.4]                          |
| Anal polyp                | [0]o                                         | [0]o                               | 1 (2.0) [1.6]                      | [0]o                                   |

Source:NTDISSTable14.3.1.19

## Extramedullary Hematopoiesis Masses AESI

Table 91: Extramedullary haematopoiesis masses events of interest by preferred term (NTDbeta Thalassemia safety population)

|                                        | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Poola            |
|----------------------------------------|----------------------------------------------|------------------------------------|------------------------------------|-----------------------------------------|
| EO1Category Preferred Term             | Luspatercept N=33 n(%) [EAIR]                | Luspatercept N=96 n(%) [EAIR]      | Placebo N = 49 n (%) [EAIR]        | Pooled Luspatercept N =129 n (%) [EAIR] |
| Extramedullaryhematopoiesis masses EOr | 4 (12.1) [5]                                 | 6 (6.3) [3.5]                      | 1 (2.0) [1.7]                      | 10 (7.8) [4]                            |
| Extramedullaryhaemopoiesis             | 4 (12.1) [5]                                 | 6 (6.3) [3.5]                      | 1 (2.0) [1.7]                      | 10 (7.8) [4]                            |

Source:NTDISSTable14.3.1.19

All events from the pivotal study ACE-536-B-THAL-002, except one were Grade 1 or 2 in severity, nonserious in nature, ongoing as of the data cut-off date, considered by the investigator to be not related to the study drug, and did not result in study drug discontinuation. 2.0% (EAIR 1.6 per 100 subject-years) in the placebo treatment group experienced a Grade 3 EMH.

<div style=\"page-break-after: always\"></div>

One subject in the luspatercept treatment group with an ongoing history of EMH masses prior to the start of luspatercept treatment experienced a Grade 4 SAE of spinal cord compression as a result of a preexisting paravertebral EMH mass. Prior to study entry, the subject had been on treatment with hydroxyurea for control of the underlying EMH masses approximately 8 months prior to the start of luspatercept treatment. The subject received the last dose of IP 6 days prior (Study Day 107) to the onset of the serious spinal cord compression. The SAE resulted in IP discontinuation. Following discontinuation of luspatercept treatment, the subject's Grade 2 extramedullary hemopoiesis mass was diagnosed.

In addition to the 6 subjects in the luspatercept treatment group with EMH masses EOIs, 1 subject in the luspatercept treatment group experienced a TEAE of chest wall mass, which was reported as worsening of an existing chest wall extramedullary mass. Of these 7 subjects in the luspatercept treatment group, 3 subjects had an increase in existing EMH mass size, 6 subjects reported a newly diagnosed EMH mass (includes the 3 subjects with existing EMH mass at baseline as previously described), and 1 subject had an EMH mass on Study Day 1 during a screening magnetic resonance imaging (MRI) for extramedullary hemopoiesis prior to treatment (ACE-536-B-THAL-002 CSR Listing 16.2.6.3).

One subject in the luspatercept treatment group also experienced an SAE of the PT spinal cord compression (verbatim term: extramedullary hemopoiesis masses expansion into spinal canal causing compression).

One subject in the luspatercept treatment group and no subjects in the placebo treatment group had extramedullary hemopoiesis as a reported PT that led to IP discontinuation. No subjects had extramedullary hemopoiesis that led to dose reduction, and 1 subject in the placebo treatment group had extramedullary hemopoiesis that led to dose interruption.

Screening and post-treatment MRI results for EMH masses were not performed in Studies A536-04/06 (NTD Cohort). The proportion of subjects with EMH masses EOIs was higher in subjects in the luspatercept treatment group in Study A536-04/06 than subjects in the luspatercept treatment group in Study ACE-536-B-THAL-002 (12.1% versus 6.3%), of which all were the PT of extramedullary hemopoiesis. No Grade 3 or higher extramedullary hemopoiesis masses were reported. Among subjects with treatment-emergent extramedullary hemopoiesis as a reported PT, none were considered SAEs or led to IP discontinuation. Two subjects had extramedullary hemopoiesis masses that led to dose reduction.

The proportion of subjects with EMH masses EOIs was higher in the pooled luspatercept treatment group than in the placebo treatment group in Study ACE-536-B-THAL-002 (7.8% vs 2.0%). When adjusted for exposure, the EAIR was 4 per 100 subject-years in the pooled luspatercept treatment group and 1.7 per 100 subject-years in the placebo treatment group in Study ACE-536-B-THAL-002.

The proportion of extramedullary hematopoiesis masses EOIs occurred in ≤ 2 subjects between the different treatment cycles (NTD ISS Table 14.3.1.20).

As of the 22 Sep 2021 updated data cut-off date, one additional luspatercept subject, after crossing over from placebo, had EMH masses reported (see Annex 2, Response to Q32). As of the 24 Dec 2021 updated data cut-off date (where EMH masses were analysed in response to a FDA Information Request), a total of 9 (6.7%) subjects with EMH masses treated with luspatercept were reported in the pivotal ACE-536-BTHAL-002 study.

<div style=\"page-break-after: always\"></div>

Table 92 :Summary of EMH prevalence in luspatercept beta-thalassemia clinical studies

|                                    |                         |                                  |                                  |                                |                                | DetailsforSubjectswithEMIHEvents   | DetailsforSubjectswithEMIHEvents   | DetailsforSubjectswithEMIHEvents   | DetailsforSubjectswithEMIHEvents   |
|------------------------------------|-------------------------|----------------------------------|----------------------------------|--------------------------------|--------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                                    |                         | SubjectswithEMHat Baseline (MHx) | SubjectswithEMHat Baseline (MHx) | SubjectswitheventPost Baseline | SubjectswitheventPost Baseline | MHxEMH                             | MHxEMH                             | EventOccured                       | EventOccured                       |
|                                    | Exposed to Luspatercept | Number                           | Prevalence (%)                   | Number                         | % of Exposed                   | Yes                                | No                                 | In Parent Study                    | In LTFU                            |
| ACE-536-B-THAL-0013                | 315 (223+92)            | 22 (14+8)                        | 7.0%                             | 10                             | 3.2%                           | 4                                  | 6                                  | 5                                  | 5                                  |
| ACE-536-B-THAL-002                 | 134 (96+38)             | 24 (14+10)                       | 17.9%                            | gb                             | 6.7%                           | 4                                  | 5                                  | 9                                  | 0                                  |
| A536-04/06a                        | 9                       | 9                                | 14.1%                            | 7                              | 10.9%                          | 3                                  | 4                                  | 6                                  | 1                                  |
| A536-04/06NTD                      | 31                      | 3                                | 9.7%                             | 5                              | 16.1%                          | 2                                  | 3                                  | 5                                  |                                    |
| A536-04/06TD                       | 33                      | 6                                | 18.2%                            | 2                              | 6.1%                           | 1                                  | 1                                  | 1                                  | 1                                  |
| Totalsubjectsexposedtoluspatercept | 513                     |                                  |                                  | 26                             | 5.1%                           | 11                                 | 15                                 |                                    |                                    |

LTFU = long-term follow up; MHx = medical history.

Takes into account exposure and events in parent study and long-term follow-up study ACE-536-LTFU-001 (randomized to luspatercept + crossed over to luspatercept).

Excludes 1 subject who developed EMH while on placebo in the ACE-536-B-THAL-002 study.

## Thromboembolic AESI

Table 93: Thromboembolic EOIs (NTD Beta-Thalassemia safety population)

| EOI Category Preferred Term   | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Pool\"            |
|-------------------------------|----------------------------------------------|------------------------------------|------------------------------------|-----------------------------------------|
|                               | Luspatercept N=33 n(%) [EAIR]                | Luspatercept N=96 n(%) [EAIR]      | Placebo N = 49 n (%) [EAIR]        | Pooled Luspatercept N =129 n (%) [EAIR] |
| ThromboembolicEorc            | 2 (6.1) [2.4]                                | [0]o                               | [0]o                               | 2 (1.6) [0.8]                           |
| Thrombosis                    | 1 (3.0) [1.2]                                | [0]o                               | []o                                | 1 (0.8) [0.4]                           |
| Thrombophlebitissuperficial   | 1 (3.0) [1.2]                                | [0]o                               | [0]o                               | 1 (0.8) [0.4]                           |
| Bone infarction               | 1 (3.0) [1.2]                                | [0]o                               | [0]o                               | 1 (0.8) [0.4]                           |

Source:NTDISSTable14.3.1.19

One subject experienced one arterial event: Grade 3 bone infarction and 1 subject experienced 3 venous events (Grade 1 thrombosis, Grade 1 thrombophlebitis superficial, and Grade 2 thrombophlebitis superficial). All events were nonserious, possibly/probably related to IP, and resolved. Both subjects were splenectomised and had additional relevant risk factors. The subject with bone infarction was taking concomitant bisphosphonate and the subject with thrombophlebitis superficial had a history of thrombophlebitis superficial. Both subjects were already receiving acetylsalicylic acid and haemoglobin at time of event onset tended to be low (highest value 10.4 g/dL).

<div style=\"page-break-after: always\"></div>

Among the subjects with thromboembolic EOIs, none was classified as serious, led to dose reduction or led to IP discontinuation. One subject each had a thromboembolic EOI of bone infarction and thrombophlebitis superficial that led to dose interruption. Time to onset ranged between 27 to 353 days. There was no subject with elevated haemoglobin, and values ranged from 9.6 to 10.4 g/dL around the time of event.

As of the 22 Sep 2021 updated data cut-off date, one additional luspatercept subject, after crossing over from placebo, had thromboembolic EOIs reported.

## Kidney Injury AESI

Glomerulonephritis was observed in rat and monkey, and therefore kidney function and injury were evaluated in the clinical program.

This section also summarises the following laboratory analyses:

1. Reported kidney injury (i.e. decreased glomerular filtration rate [GFR]- and proteinuria-type AEs)
2. Median ACR over time by cycle for subjects with ACR baseline Grade = 0 (ACR &lt; 30 mg/g) and the worst postbaseline Grade = 1 (30 mg/g ≤ ACR &lt; 1000 mg/g) receiving luspatercept in Studies A53604/06 (NTD Cohort) as well as a comparison over time of the median ACR for subjects receiving luspatercept versus placebo in Study ACE-536-B-THAL-002.
3. Shifts from baseline to worst postbaseline NCI-CTCAE grade for ACR ratio and from baseline to EOT or last on treatment postbaseline NCI-CTCAE grade for ACR ratio.
4. The clinical course for subjects who at some point during treatment with luspatercept or placebo had ≥ 50% reduction in kidney function (ie, eGFR) compared with baseline.

Table 94: Kidney injury events of interest (NTD-beta Thalassemia safety population)

| PreferredTerm                     | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Pool              |
|-----------------------------------|----------------------------------------------|------------------------------------|------------------------------------|------------------------------------------|
| E01Category                       | Luspatercept N=33 n (%) [EAIR]               | Luspatercept N=96 n (%) [EAIR]     | Placebo N=49 n (%) [EAIR']         | Pooled Luspatercept N =129 n (%) [EAIR\"] |
| Kidney injury EOrc                | 3 (9.1) [3.8]                                | 2 (2.1) [1.2]                      | []o                                | 5 (3.9) [2]                              |
| Proteinuria                       | 3 (9.1) [3.8]                                | 0[0]                               | [0]o                               | 3 (2.3) [1.2]                            |
| Anuria                            | [0]o                                         | 1 (1.0) [0.6]                      | [0]o                               | 1 (0.8) [0.4]                            |
| Blood creatinineincreased         | 1 (3.0) [1.2]                                | [0]o                               | [0]o                               | 1 (0.8)[0.4]                             |
| Blood urea increased              | 1 (3.0) [1.2]                                | [0]o                               | [0]o                               | 1 (0.8) [0.4]                            |
| Glomerularfiltrationratedecreased | [0]o                                         | 1 (1.0) [0.6]                      | [0]o                               | 1 (0.8) [0.4]                            |

Source:NTDISSTable14.3.1.19

<div style=\"page-break-after: always\"></div>

A total of 5 subjects (3.9%; EAIR 2 per 100 subject-years) had a kidney injury EOI in the pooled luspatercept treatment group compared with 0 subjects in the placebo treatment group of Study ACE536-B-THAL-002. The most frequently reported event in luspatercept-treated subjects was proteinuria (2.3%; EAIR 1.2 per 100 subject-years). Anuria, blood creatinine increased, blood urea increased, and GFR decreased were reported in 1 subject each (0.8%; EAIR 0.4 per 100 subject-years). No acute kidney injury TEAEs (i.e. renal failure, acute kidney injury, and renal impairment) were reported.

The events of GFR decreased, anuria, blood creatinine increased, and blood urea increased resolved and were not suspected/unlikely related to IP. Of the 5 reported events of proteinuria in 3 subjects, all 5 events were unlikely related to IP and 3 events were ongoing as of the data cut-off date.

The proportion of kidney injury EOIs was highest within the first 4 cycles of treatment and between treatment cycles 21 and 24.

As of the 22 Sep 2021 updated data cut-off date, in the luspatercept treatment group, kidney injury EOIs were reported for 6 subjects (6.3%, EAIR 2.5 per 100 subject-years) excluding the crossover subjects and 9 subjects (6.7%, EAIR 3.4 per 100 subject-years) including the cross-over subjects. Albuminuria and proteinuria were the only newly reported PTs in this category during the updated period.

In the NTD β -thalassemia Data Pool, there were 3 (2.3%) subjects in the pooled luspatercept treatment group who experienced an eGFR ≥ 50% reduction in kidney function at s ome point during the study, compared with baseline, versus 1 subject in the placebo treatment group in Study ACE-536-B-THAL-002. This threshold was selected because it roughly correlates with CTCAE Grade ≥ 2 for acute renal failure events. Of the 3 subject s in the NTD β -thalassemia Data Pool, 2 subjects were in Studies A536-04/06 (NTD Cohort) and 1 subject was in the luspatercept treatment group in Study ACE-536-B-THAL-002. For all 3 subjects, ≥ 50% decreases from baseline in eGFR were transient and resolve d. One of the 3 subjects (Study A536-04/06 [NTD Cohort]) experienced a TEAE of blood creatinine increased and blood urea increased. Both events were not considered related and there was no change to IP. The subject recovered from both events.

## Urinary Albumin/Creatinine Ratio

In addition, albumin/creatinine ratio (ACR) data were analyzed for the potential of nephron damage.

ACR over time are shown by treatment group for subjects with ACR baseline Grade = 0 (ACR &lt; 30 mg/g) and the worst postbaseline Grade = 1 (30 mg/g ≤ ACR &lt; 1000 mg/g) in study ACE -536-B-THAL-002 and for luspatercept-treated subjects in studies A536-04/06 (NTD Cohort).

Grade 1 proteinuria includes microalbuminuria (30 mg/g &lt; ACR ≤ 300 mg/g) and macroalbuminuria (300 mg/g &lt; ACR &lt; 1000 mg/g). In general, ACRs in the luspatercept treatment were associated with small increases from baseline with no clinically meaningful differences compared with the placebo treatment group. There was no sustained, clinically meaningful elevation from baseline in median ACR values over time associated with luspatercept treatment.

<div style=\"page-break-after: always\"></div>

Figure 41: Study ACE-536-B-THAL-002: Albumin/Creatinine ratio over time (NTD betaThalassemia safety population)

<!-- image -->

Figure 42: Studies A536-04-06 (NTD cohort): albumin /creatine ratio over time (NTD beatthalassemia safety population)

<!-- image -->

ACR=albumin/creatinine ratio;C=cycle;EOS=end of study;EOT=end of treatment;IP=investigational product; SD = standard deviation.

Notes: Only includes subjects with ACR baseline Grade 0 (ACR&lt; 30 mg/g) and worst postbaseline Grade 1 (30 mg/g≤ ACR &lt; 1000). Grade 1 proteinuria includes microalbuminuria (30 mg/g&lt; ACR ≤ 300 mg/g) and macroalbuminuria (300 mg/g &lt; ACR &lt; 1000 mg/g). Baseline is the last value measured before the first IP dose. Lineconnectson the median.

Source:NTDISSFigure14.3.4.1.2

Shifts from baseline to the worst post-baseline NCI-CTCAE grade for ACR ratio are presented in the table below.

<div style=\"page-break-after: always\"></div>

Table 95: Shift table for urinary albumin/creatinine ratio (mg/g) from baseline to worst postbaseline NCI-CTCAE grade (NTD beta-Thalassemia safety population)

| Treatment                                                  |     |                | Worst Postbaseline Gradea   | Worst Postbaseline Gradea   | Worst Postbaseline Gradea   | Worst Postbaseline Gradea   | Worst Postbaseline Gradea   | Worst Postbaseline Gradea   |
|------------------------------------------------------------|-----|----------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Group                                                      | m b | Baseline Grade | Grade 0 n (%)               | Grade 1 n (%)               | Grade 2 n (%)               | Grade 3 n (%)               | Grade 4 n (%)               | Total n (%)                 |
| Luspatercept - Pivotal Study ACE-536-B- THAL-002           | 95  | Grade 0        | 30 (31.6)                   | 34 (35.8)                   | 1 (1.1)                     | 0                           | 0                           | 65 (68.4)                   |
| Luspatercept - Pivotal Study ACE-536-B- THAL-002           | 95  | Grade 1        | 1 (1.1)                     | 23 (24.2)                   | 6 (6.3)                     | 0                           | 0                           | 30 (31.6)                   |
| Luspatercept - Pivotal Study ACE-536-B- THAL-002           | 95  | Grade 2        | 0                           | 0                           | 0                           | 0                           | 0                           | 0                           |
| Luspatercept - Pivotal Study ACE-536-B- THAL-002           | 95  | Grade 3        | 0                           | 0                           | 0                           | 0                           | 0                           | 0                           |
| Luspatercept - Pivotal Study ACE-536-B- THAL-002           | 95  | Grade 4        | 0                           | 0                           | 0                           | 0                           | 0                           | 0                           |
| Luspatercept - Pivotal Study ACE-536-B- THAL-002           | 95  | Total          | 31 (32.6)                   | 57 (60.0)                   | 7 (7.4)                     | 0                           | 0                           | 95 (100.0)                  |
| Placebo - Pivotal Study ACE-536-B- THAL-002                | 48  | Grade 0        | 24 (50.0)                   | 8 (16.7)                    | 0                           | 0                           | 0                           | 32 (66.7)                   |
| Placebo - Pivotal Study ACE-536-B- THAL-002                | 48  | Grade 1        | 3 (6.3)                     | 12 (25.0)                   | 1 (2.1)                     | 0                           | 0                           | 16 (33.3)                   |
| Placebo - Pivotal Study ACE-536-B- THAL-002                | 48  | Grade 2        | 0                           | 0                           | 0                           | 0                           | 0                           | 0                           |
| Placebo - Pivotal Study ACE-536-B- THAL-002                | 48  | Grade 3        | 0                           | 0                           | 0                           | 0                           | 0                           | 0                           |
| Placebo - Pivotal Study ACE-536-B- THAL-002                | 48  | Grade 4        | 0                           | 0                           | 0                           | 0                           | 0                           | 0                           |
| Placebo - Pivotal Study ACE-536-B- THAL-002                | 48  | Total          | 27 (56.3)                   | 20 (41.7)                   | 1 (2.1)                     | 0                           | 0                           | 48 (100.0)                  |
| Luspatercept -- Supportive Studies A536-04/06 (NTD Cohort) | 31  | Grade 0        | 9 (29.0)                    | 14 (45.2)                   | 1 (3.2)                     | 0                           | 0                           | 24 (77.4)                   |
| Luspatercept -- Supportive Studies A536-04/06 (NTD Cohort) | 31  | Grade 1        | 0                           | 6 (19.4)                    | 0                           | 0                           | 0                           | 6 (19.4)                    |
| Luspatercept -- Supportive Studies A536-04/06 (NTD Cohort) | 31  | Grade 2        | 0                           | 0                           | 1 (3.2)                     | 0                           | 0                           | 1 (3.2)                     |
| Luspatercept -- Supportive Studies A536-04/06 (NTD Cohort) | 31  | Grade 3        | 0                           | 0                           | 0                           | 0                           | 0                           | 0                           |
| Luspatercept -- Supportive Studies A536-04/06 (NTD Cohort) | 31  | Grade 4        | 0                           | 0                           | 0                           | 0                           | 0                           | 0                           |
| Luspatercept -- Supportive Studies A536-04/06 (NTD Cohort) | 31  | Total          | 9 (29.0)                    | 20 (64.5)                   | 2 (6.5)                     | 0                           | 0                           | 31 (100.0)                  |
| Pooled Luspatercept -- NTD β- thalassemia Data Poolc       | 126 | Grade 0        | 39 (31.0)                   | 48 (38.1)                   | 2 (1.6)                     | 0                           | 0                           | 89 (70.6)                   |
| Pooled Luspatercept -- NTD β- thalassemia Data Poolc       | 126 | Grade 1        | 1 (0.8)                     | 29 (23.0)                   | 6 (4.8)                     | 0                           | 0                           | 36 (28.6)                   |
| Pooled Luspatercept -- NTD β- thalassemia Data Poolc       | 126 | Grade 2        | 0                           | 0                           | 1 (0.8)                     | 0                           | 0                           | 1 (0.8)                     |
| Pooled Luspatercept -- NTD β- thalassemia Data Poolc       | 126 | Grade 3        | 0                           | 0                           | 0                           | 0                           | 0                           | 0                           |
| Pooled Luspatercept -- NTD β- thalassemia Data Poolc       | 126 | Grade 4        | 0                           | 0                           | 0                           | 0                           | 0                           | 0                           |
| Pooled Luspatercept -- NTD β- thalassemia Data Poolc       | 126 | Total          | 40 (31.7)                   | 77 (61.1)                   | 9 (7.1)                     | 0                           | 0                           | 126 (100.0)                 |

Source: NTDISS Table 14.3.4.4.1

The proportion of subjects in the pooled luspatercept treatment group with normal (Grade 0) ACR and Grade 3 ACR at baseline (70.6% and 0%, respectively), was similar to the placebo treatment group in Study ACE-536-B-THAL-002. During study participation, the proportio n of increasing ACR (worsening of ≥ 1 grade) was higher in the pooled luspatercept treatment group than in the placebo treatment group in Study ACE-536-B-THAL-002. Most of these changes were Grade 0 to Grade 1. For 1.6% of subjects in the pooled luspatercept treatment group, the worsening was 2 grades (Grade 0 to 2).

<div style=\"page-break-after: always\"></div>

## Hypertension AESI

Hypertension has been reported in the luspatercept Phase 2 and Phase 3 studies. Therefore, hypertension was identified as an EOI and evaluated in the luspatercept clinical program.

Luspatercept has been associated with mean increases in SBP and DBP of approximately 5 mm Hg and has been infrequently associated with sustained blood pressure increases commensurate with a diagnosis of hypertension.

Table 96: Hypertension events of interest (NTD beta-thalassemia safety population)

|                             | Supportive StudiesA536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Pool\"            |
|-----------------------------|---------------------------------------------|------------------------------------|------------------------------------|-----------------------------------------|
| EO1 Category Preferred Term | Luspatercept N=33 n (%) [EAIR]              | Luspatercept N=96 n (%) [EAIR']    | Placebo N= 49 n (%) [EAIR]         | Pooled Luspatercept N = 129 n(%) [EAIR] |
| Hypertension EOIc           | 6 (18.2) [8.2]                              | 34 (35.4) [28.3]                   | 8 (16.3) [14.6]                    | 40 (31.0) [20.7]                        |
| Hypertension                | 5 (15.2) [6.5]                              | 19 (19.8) [12.9]                   | 1 (2.0) [1.6]                      | 24 (18.6) [10.7]                        |
| Prehypertension             | 0[0]                                        | 22 (22.9) [16.2]                   | 7 (14.3) [12.7]                    | 22 (17.1) [9.9]                         |
| Blood pressure increased    | 2 (6.1) [2.5]                               | [0]o                               | [0]o                               | 2 (1.6) [0.8]                           |
| Systolic hypertension       | 2 (6.1) [2.4]                               | 0[0]                               | [0]o                               | 2 (1.6) [0.8]                           |

Source:NTDISSTable14.3.1.19

The proportion of subjects in the pooled luspatercept treatment group with hypertension EOIs was 31.0% (EAIR 20.7 per 100 subject-years), which is higher than the placebo treatment group in Study ACE-536B-THAL-002 by a difference of 14.7%, with a corresponding EAIR difference of 6.1 per 100 subject-years. Of note, among the subjects who experienced a hypertension EOI, the proportion of subjects with a medical history of hypertension was higher in the pooled luspatercept treatment group (20.0%; 8 of 40 subjects) than in the placebo treatment group in Study ACE-536-B-THAL-002 (12.5%; 1 of 8 subjects). The proportion of hypertension EOIs was highest within the first 4 treatment cycles. The median time to onset of hypertension was 84.5 days (range, 1.0 to 763.0 days) in the pooled luspatercept treatment group versus 37.5 days (range, 1.0 to 275.0 days) in the placebo treatment group in Study ACE-536-BTHAL-002, with a median duration of 370.0 days (range, 1.0 to 930.0 days) and 166.0 days (range, 21.0 to 546.0 days), respectively.

At the updated data cut-off date (22 Sept 2021), hypertension events were reported for 35 subjects (36.5%, EAIR 20.9 per 100 subject-years) excluding the cross-over subjects and 39 subjects (29.1%, EAIR 20.9 per 100 subject-years) including the cross-over subjects.

14 subjects required intervention as follows:

- Dose delay without any medications: 3 subjects (1021017, 2041001, 2041005)
- Dose delay and antihypertensive medication: 4 subjects (1021005, 1021006, 1021009, 1021014)

<div style=\"page-break-after: always\"></div>

- Dose reduction and antihypertensive medication: 2 subjects (2031005, 5012003)
- Dose reduction, dose delay and antihypertensive medication: 1 subject (1022015)
- Antihypertensive medication alone: 4 subjects (2041008, 2061006, 3011001, 5011004) The majority of subjects requiring intervention (11/14) were ≥ 50 years old.

At the time of the data extraction, antihypertensive medication was still ongoing in 9 of the 11 subjects requiring antihypertensive drugs.

The remaining 25 luspatercept-exposed subjects reporting a hypertension type event did not require any intervention.

## Musculoskeletal Disorder-Bone Pain AESI

Table 97: Musculoskeletal disorder bone pain of interest (NTD-beta Thalassemia safety population)

|                                         | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Pool?             |
|-----------------------------------------|----------------------------------------------|------------------------------------|------------------------------------|------------------------------------------|
| EOI Category Preferred Term             | Luspatercept N=33 n (%) [EAIR]               | Luspatercept N=96 n (%) [EAIR]     | Placebo N=49 n (%) [EAIR]          | Pooled Luspatercept N = 129 n(%) [EAIR'] |
| Musculoskeletal disorder-bone pain EOrc | 26 (78.8) [118.5]                            | 65 (67.7) [95.2]                   | 15 (30.6) [32.8]                   | 91 (70.5) [100.9]                        |
| Bone pain                               | 16 (48.5) [35.4]                             | 35 (36.5) [31.3]                   | 3 (6.1) [5.1]                      | 51 (39.5) [32.5]                         |
| Back pain                               | 9 (27.3) [14.9]                              | 27 (28.1) [19.8]                   | 5 (10.2) [8.9]                     | 36 (27.9) [18.3]                         |
| Pain in extremity                       | 9 (27.3) [12.6]                              | 16 (16.7) [10.6]                   | 5 (10.2)[9]                        | 25 (19.4) [11.3]                         |
| Musculoskeletal pain                    | 11 (33.3) [18.7]                             | 6 (6.3) [3.6]                      | 3 (6.1)[5]                         | 17 (13.2) [7.5]                          |
| Neck pain                               | 4 (12.1) [5.4]                               | 7 (7.3) [4.3]                      | 2 (4.1) [3.4]                      | 11 (8.5) [4.6]                           |
| Spinal pain                             | 1 (3.0) [1.2]                                | 5 (5.2) [3]                        | 1 (2.0) [1.6]                      | 6 (4.7) [2.4]                            |
| Pain in jaw                             | 2 (6.1) [2.6]                                | 1 (1.0) [0.6]                      | 0[0]                               | 3 (2.3) [1.2]                            |

Source:NTDISSTable14.3.1.19

The proportion of musculoskeletal disorder-bone pain EOIs was highest within the first 4 cycles of treatment, independent of which treatment was administered (NTD ISS Table 14.3.1.20). The proportion of Grade 3 musculoskeletal disorder-bone pain EOIs was 2.3% (EAIR 1.2 per 100 subject-years) in the pooled luspatercept treatment group and 0% in the placebo treatment group in Study ACE-536-B-THAL002. No Grade 4 or higher musculoskeletal disorder-bone pain EOIs were reported.

The median time to onset of musculoskeletal disorder-bone pain EOIs was 4.0 days (range, 1.0 to 1272.0 days) in the pooled luspatercept treatment group compared with 42.0 days (range, 4.0 to 252.0 days) in the placebo treatment group in Study ACE-536-B-THAL-002, with a median duration of 16.0 days (range, 1.0 to 1396.0 days) and 9.0 days (range, 1.0 to 322.0 days), respectively.

<div style=\"page-break-after: always\"></div>

As of the 22 Sep 2021 updated data cut-off date, musculoskeletal disorder-bone pain EOIs were reported for 72 subjects (75.0%, EAIR 81.8 per 100 subject-years) in the luspatercept treatment arm excluding the cross-over subjects and 90 subjects (67.2%, EAIR 89.1 per 100 subject-years) including the crossover subjects. The most frequently reported PTs were bone pain (47 subjects, 35.1%) and back pain (43 subjects, 32.1%).

## Hypersensitivity-type reactions

## Table 98: Summary of subjects with hypersensitivity type reactions (NTD beta-thalassemia safety population)

|                                  | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Poola            |
|----------------------------------|----------------------------------------------|------------------------------------|------------------------------------|-----------------------------------------|
| Category Preferred term          | Luspatercept N=33 n (%) [EAIRb]              | Luspatercept N=96 n (%) [EAIRb]    | Placebo N=49 n (%) [EAIRb]         | Pooled Luspatercept N=129 n (%) [EAIRb] |
| Hypersensitivity type reactionsc | 3 (9.1) [3.7]                                | 11 (11.5) [7]                      | 0 [0]                              | 14 (10.9) [5.9]                         |
| Immunogenicitytypereactions      | 3 (9.1) [3.7]                                | 11 (11.5) [7]                      | 0 [0]                              | 14 (10.9) [5.9]                         |
| Injection site erythema          | 0                                            | 5 (5.2)                            | 0                                  | 5 (3.9)                                 |
| Face oedema                      | 0                                            | 3 (3.1)                            | 0                                  | 3 (2.3)                                 |
| Drug hypersensitivity            | 1 (3.0)                                      | 1 (1.0)                            | 0                                  | 2 (1.6)                                 |
| Injection site swelling          | 1 (3.0)                                      | 1 (1.0)                            | 0                                  | 2 (1.6)                                 |
| Injection site inflammation      | 0                                            | 1 (1.0)                            | 0                                  | 1 (0.8)                                 |
| Injection site pruritus          | 0                                            | 1 (1.0)                            | 0                                  | 1 (0.8)                                 |
| Injection site rash              | 0                                            | 1 (1.0)                            | 0                                  | 1 (0.8)                                 |
| Injection site reaction          | 1 (3.0)                                      | 0                                  | 0                                  | 1 (0.8)                                 |
| Swelling face                    | 0                                            | 1 (1.0)                            | 0                                  | 1 (0.8)                                 |

## Long-term Adverse Events

To investigate the potential AEs after long-term exposure to luspatercept, an analysis of all the TEAEs reported for ≥ 5% of subjects in either treatment group in Study ACE 536 -B-THAL-002 was performed by every 4 cycles up to Cycle 32. At the 22 Sep 2021 data cutoff date, 134 subjects initiated luspatercept treatment (including 38 subjects who crossed over from placebo treatment group to receive luspatercept after study unblinding), and by the start of Cycles 21 to 24, 82 subjects remained; by the start of Cycles 29 to 32, 72 subjects remained.

<div style=\"page-break-after: always\"></div>

Table 99: Treatment emergent adverse events reported in at least ≥ 5% of subjects presented by cycle -22- Sep 2021 data cut-off (ACE-536-B-THAL-002, safety population)

|                                                         | C1-C4                                        | C5-C8                                        | C9-C12                                       | C13-C16                                     | C17-C20                                     | C21-C24                                     | C25-C28                                     | C29-C32                                     |
|---------------------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| System Organ Class Preferred Term                       | Luspatercept Including Crossorer N=134 n (%) | Luspatercept Including Crossorer N=127 n (%) | Luspatercept Including Crossorer N=115 n (%) | Luspatercept Including Crossover N=92 n (%) | Luspatercept Including Crossorer N=84 n (%) | Luspatercept Including Crossover N=S2 n (%) | Luspatercept Including Crossover N=77 n (%) | Luspatercept Including Crossover N=72 n (%) |
| Subjects With At Least One TEAE In the Specified Cycles | 124 (92.5)                                   | 93 (73.2)                                    | 72 (62.6)                                    | 68 (73.9)                                   | 54 (64.3)                                   | 52 (63.4)                                   | 42 (54.5)                                   | 35 (48.6)                                   |
| Mfusculoskeletalandconnective tissue disorders          | 83 (61.9)                                    | 37 (29.1)                                    | 23 (20.0)                                    | 23 (25.0)                                   | 18 (21.4)                                   | 15 (18.3)                                   | 11 (14.3)                                   | 9 (12.5)                                    |
| Bone pain                                               | 39 (29.1)                                    | 9 (7.1)                                      | 6 (5.2)                                      | 8 (8.7)                                     | 5 (6.0)                                     | 3 (3.7)                                     | 0                                           | 1 (1.4)                                     |
| Back pain                                               | 23 (17.2)                                    | 10 (7.9)                                     | 4 (3.5)                                      | 6 (6.5)                                     | 2 (2.4)                                     | 2 (2.4)                                     | 4 (5.2)                                     | 1 (1.4)                                     |
| Arthralgia                                              | 18 (13.4)                                    | 17 (13.4)                                    | 7 (6.1)                                      | 2 (2.2)                                     | 6 (7.1)                                     | 3 (3.7)                                     | 1 (1.3)                                     | 5 (6.9)                                     |
| Myalgia                                                 | 7 (5.2)                                      | 1 (0.8)                                      | 4 (3.5)                                      | 3 (3.3)                                     | 2 (2.4)                                     | 1 (1.2)                                     | 0                                           | 1 (1.4)                                     |
| Pain in exhremity                                       | 8 (6.0)                                      | 4 (3.1)                                      | 3 (2.6)                                      | 3 (3.3)                                     | 0                                           | 5 (6.1)                                     | 1 (1.3)                                     | 1 (1.4)                                     |
| Musculoskeletal pain                                    | 4 (3.0)                                      | 1 (0.8)                                      | 1 (0.9)                                      | 0                                           | 1 (1.2)                                     | 0                                           | 1 (1.3)                                     | 0                                           |
| Neck pain                                               | 2 (1.5)                                      | 1 (0.8)                                      | 3 (2.6)                                      | 1 (1.1)                                     | 2 (2.4)                                     | 1 (1.2)                                     | 0                                           | 0                                           |
| Muscle spasm                                            | 3 (2.2)                                      | 0                                            | 1 (0.9)                                      | 0                                           | 0                                           | 0                                           | 0                                           | 0                                           |
| Muscular weakness                                       | 1 (0.7)                                      | 0                                            | 0                                            | 0                                           | 1 (1.2)                                     | 0                                           | 0                                           | 0                                           |
| Spinal pain                                             | 1 (0.7)                                      | 3 (2.4)                                      | 0                                            | 1 (1.1)                                     | 0                                           | 0                                           | 0                                           | 1 (1.4)                                     |
| Infectionsandinfestations                               | 33 (24.6)                                    | 25 (19.7)                                    | 24 (20.9)                                    | 14 (15.2)                                   | 11 (13.1)                                   | 14 (17.1)                                   | 14 (18.2)                                   | 5 (6.9)                                     |
| Upper respiratory tract infection                       | 10 (7.5)                                     | 5 (3.9)                                      | 4 (3.5)                                      | 1 (1.1)                                     | 4 (4.8)                                     | 4 (4.9)                                     | 3 (3.9)                                     | 0                                           |
| Pharyngitis                                             | 6 (4.5)                                      | 4 (3.1)                                      | 5 (4.3)                                      | 2 (2.2)                                     | 0                                           | 4 (4.9)                                     | 4 (5.2)                                     | 0                                           |
| Influenza                                               | 4 (3.0)                                      | 3 (2.4)                                      | 5 (4.3)                                      | 1 (1.1)                                     | 1 (1.2)                                     | 1 (1.2)                                     | 1 (1.3)                                     | 0                                           |
| Rhinitis                                                | 2 (1.5)                                      | 2 (1.6)                                      | 0                                            | 0                                           | 2 (2.4)                                     | 3 (3.7)                                     | 0                                           | 0                                           |
| Gastroentenitis                                         | 1 (0.7)                                      | 4 (3.1)                                      | 4 (3.5)                                      | 0                                           | 1 (1.2)                                     | 0                                           | 0                                           | 0                                           |
| COVID-19                                                | 2 (1.5)                                      | 1 (0.8)                                      | 0                                            | 0                                           | 0                                           | 0                                           | 0                                           | 1 (1.4)                                     |
| Nasopharyngitis                                         | 0                                            | 1 (0.8)                                      | 2 (1.7)                                      | 2 (2.2)                                     | 1 (1.2)                                     | 0                                           | 1 (1.3)                                     | 0                                           |
| Tooth abscess                                           | 0                                            | 1 (0.8)                                      | 0                                            | 2 (2.2)                                     | 0                                           | 1 (1.2)                                     | 0                                           | 0                                           |
| Tonsillitis                                             | 0                                            | 0                                            | 0                                            | 1 (1.1)                                     | 1 (1.2)                                     | 0                                           | 0                                           | 0                                           |
| General disordersand administration site conditions     | 35 (26.1)                                    | 25 (19.7)                                    | 17 (14.8)                                    | 11 (12.0)                                   | 10 (11.9)                                   | 7 (8.5)                                     | 7 (9.1)                                     | 8 (11.1)                                    |
| Fatigule                                                | 9 (6.7)                                      | 3 (2.4)                                      | 2 (1.7)                                      | 2 (2.2)                                     | 1 (1.2)                                     | 1 (1.2)                                     | 1 (1.3)                                     | 0                                           |
| Influenza like illness                                  | 8 (6.0)                                      | 4 (3.1)                                      | 0                                            | 2 (2.2)                                     | 3 (3.6)                                     | 2 (2.4)                                     | 1 (1.3)                                     | 2 (2.8)                                     |
| Asthenia                                                | 5 (3.7)                                      | 3 (2.4)                                      | 5 (4.3)                                      | 0                                           | 3 (3.6)                                     | 2 (2.4)                                     | 2 (2.6)                                     | 3 (4.2)                                     |
| Pyrexia                                                 | 7 (5.2)                                      | 4 (3.1)                                      | 4 (3.5)                                      | 2 (2.2)                                     | 2 (2.4)                                     | 2 (2.4)                                     | 2 (2.6)                                     | 3 (4.2)                                     |
| Injection site erythema                                 | 5 (3.7)                                      | 3 (2.4)                                      | 0                                            | 1 (1.1)                                     | 1 (1.2)                                     | 1 (1.2)                                     | 0                                           | 0                                           |
| Nervous system disorders                                | 31 (23.1)                                    | 22 (17.3)                                    | 11 (9.6)                                     | 13 (14.1)                                   | 7 (8.3)                                     | 7 (8.5)                                     | 9 (11.7)                                    | 6 (8.3)                                     |
| Headache                                                | 21 (15.7)                                    | 15 (11.8)                                    | 7 (6.1)                                      | 9 (9.8)                                     | 7 (8.3)                                     | 5 (6.1)                                     | 6 (7.8)                                     | 3 (4.2)                                     |
| Dizziness                                               | 6 (4.5)                                      | 3 (2.4)                                      | 2 (1.7)                                      | 2 (2.2)                                     | 0                                           | 1 (1.2)                                     | 1 (1.3)                                     | 0                                           |
| Migaine                                                 | 2 (1.5)                                      | 0                                            | 0                                            | 1 (1.1)                                     | 1 (1.2)                                     | 1 (1.2)                                     | 0                                           | 2 (2.8)                                     |
| Vasculardisorders                                       | 25 (18.7)                                    | 14 (11.0)                                    | 8 (7.0)                                      | 2 (2.2)                                     | 6 (7.1)                                     | 2 (2.4)                                     | 3 (3.9)                                     | 4 (5.6)                                     |
| Prehypertension                                         | 17 (12.7)                                    | 8 (6.3)                                      | 3 (2.6)                                      | 1 (1.1)                                     | 2 (2.4)                                     | 0                                           | 1 (1.3)                                     | 1 (1.4)                                     |
| Hypertension                                            | 8 (6.0)                                      | 7 (5.5)                                      | 5 (4.3)                                      | 2 (2.2)                                     | 3 (3.6)                                     | 1 (1.2)                                     | 3 (3.9)                                     | 1 (1.4)                                     |
| Gastrointestinaldisorders                               | 25 (18.7)                                    | 18 (14.2)                                    | 14 (12.2)                                    | 16 (17.4)                                   | 7 (8.3)                                     | 11 (13.4)                                   | 9 (11.7)                                    | 12 (16.7)                                   |
| Nausea                                                  | 6 (4.5)                                      | 2 (1.6)                                      | 3 (2.6)                                      | 0                                           | 2 (2.4)                                     | 1 (1.2)                                     | 1 (1.3)                                     | 0                                           |
| Dianhoea                                                | 5 (3.7)                                      | 4 (3.1)                                      | 3 (2.6)                                      | 3 (3.3)                                     | 3 (3.6)                                     | 3 (3.7)                                     | 4 (5.2)                                     | 5 (6.9)                                     |
| Dyspepsia                                               | 3 (2.2)                                      | 3 (2.4)                                      | 1 (0.9)                                      | 3 (3.3)                                     | 0                                           | 1 (1.2)                                     | 0                                           | 2 (2.8)                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Toothache                                      | 3 (2.2)   | 4 (3.1)   | 2 (1.7)   | 3 (3.3)   | 2 (2.4)   | 2 (2.4)   | 0       | 2 (2.8)   |
|------------------------------------------------|-----------|-----------|-----------|-----------|-----------|-----------|---------|-----------|
| Abdominal pain upper                           | 3 (2.2)   | 5 (3.9)   | 3 (2.6)   | 3 (3.3)   | 0         | 1 (1.2)   | 1 (1.3) | 0         |
| Vomiting                                       | 2 (1.5)   | 0         | 2 (1.7)   | 1 (1.1)   | 0         | 2 (2.4)   | 0       | 1 (1.4)   |
| Abdominal pain                                 | 3 (2.2)   | 1 (0.8)   | 1 (0.9)   | 5 (5.4)   | 0         | 2 (2.4)   | 1 (1.3) | 1 (1.4)   |
| Gastrooesophageal reflux disease               | 0         | 0         | 0         | 1 (1.1)   | 2 (2.4)   | 0         | 0       | 0         |
| Respiratory,thoracic and mediastinal disorders | 18 (13.4) | 17 (13.4) | 14 (12.2) | 11 (12.0) | 5 (6.0)   | 8 (9.8)   | 4 (5.2) | 4 (5.6)   |
| Oropharyngeal pain                             | 9 (6.7)   | 3 (2.4)   | 5 (4.3)   | 3 (3.3)   | 1 (1.2)   | 3 (3.7)   | 2 (2.6) | 0         |
| Cough                                          | 5 (3.7)   | 5 (3.9)   | 3 (2.6)   | 3 (3.3)   | 2 (2.4)   | 3 (3.7)   | 2 (2.6) | 2 (2.8)   |
| Epistaxis                                      | 1 (0.7)   | 7 (5.5)   | 2 (1.7)   | 2 (2.2)   | 2 (2.4)   | 0         | 1 (1.3) | 0         |
| Rhinitis allergic                              | 1 (0.7)   | 1 (0.8)   | 1 (0.9)   | 2 (2.2)   | 1 (1.2)   | 0         | 0       | 0         |
| Rhinonhoea                                     | 1 (0.7)   | 0         | 0         | 0         | 0         | 1 (1.2)   | 0       | 1 (1.4)   |
| Nasal congestion                               | 1 (0.7)   | 1 (0.8)   | 1 (0.9)   | 1 (1.1)   | 0         | 0         | 0       | 1 (1.4)   |
| Slinandsubcutaneous tissue disorders           | 12 (9.0)  | 8 (6.3)   | 4 (3.5)   | 2 (2.2)   | 4 (4.8)   | 3 (3.7)   | 3 (3.9) | 6 (8.3)   |
| Erythema                                       | 2 (1.5)   | 2 (1.6)   | 1 (0.9)   | 1 (1.1)   | 0         | 0         | 0       | 0         |
| Skin ulcer                                     | 2 (1.5)   | 0         | 1 (0.9)   | 1 (1.1)   | 2 (2.4)   | 1 (1.2)   | 1 (1.3) | 3 (4.2)   |
| Eye disorders                                  | 6 (4.5)   | 4 (3.1)   | 3 (2.6)   | 2 (2.2)   | 2 (2.4)   | 0         | 1 (1.3) | 1 (1.4)   |
| Psychiatric disorders                          | 7 (5.2)   | 6 (4.7)   | 3 (2.6)   | 5 (5.4)   | 2 (2.4)   | 3 (3.7)   | 3 (3.9) | 0         |
| Insomnia                                       | 3 (2.2)   | 4 (3.1)   | 2 (1.7)   | 5 (5.4)   | 2 (2.4)   | 2 (2.4)   | 1 (1.3) | 0         |
| Anxiety                                        | 1 (0.7)   | 2 (1.6)   | 0         | 1 (1.1)   | 0         | 1 (1.2)   | 2 (2.6) | 0         |
| Reproductivesystem andbreast disorders         | 6 (4.5)   | 6 (4.7)   | 6 (5.2)   | 7 (7.6)   | 8 (9.5)   | 7 (8.5)   | 3 (3.9) | 4 (5.6)   |
| Dysmenonhoea                                   | 3 (2.2)   | 3 (2.4)   | 2 (1.7)   | 1 (1.1)   | 2 (2.4)   | 2 (2.4)   | 0       | 0         |
| Menshuation iregular                           | 3 (2.2)   | 2 (1.6)   | 1 (0.9)   | 3 (3.3)   | 4 (4.8)   | 2 (2.4)   | 3 (3.9) | 2 (2.8)   |
| Ovanian cyst                                   | 0         | 1 (0.8)   | 1 (0.9)   | 1 (1.1)   | 1 (1.2)   | 0         | 0       | 0         |
| Metabolism and nutrition disorders             | 4 (3.0)   | 10 (7.9)  | 1 (0.9)   | 8 (8.7)   | 9 (10.7)  | 2 (2.4)   | 3 (3.9) | 2 (2.8)   |
| Hyperwicaemia                                  | 2 (1.5)   | 2 (1.6)   | 0         | 3 (3.3)   | 2 (2.4)   | 0         | 0       | 0         |
| Iron overload                                  | 1 (0.7)   | 4 (3.1)   | 1 (0.9)   | 3 (3.3)   | 0         | 1 (1.2)   | 0       | 2 (2.8)   |
| Vitamin D deficiency                           | 0         | 4 (3.1)   | 0         | 1 (1.1)   | 5 (6.0)   | 1 (1.2)   | 1 (1.3) | 0         |
| Folate deficiency                              | 0         | 3 (2.4)   | 0         | 0         | 0         | 0         | 2 (2.6) | 0         |
| Blood and lynphatic system disorders           | 3 (2.2)   | 6 (4.7)   | 3 (2.6)   | 2 (2.2)   | 2 (2.4)   | 0         | 2 (2.6) | 1 (1.4)   |
| Extramedullary haemopoiesis                    | 1 (0.7)   | 3 (2.4)   | 0         | 0         | 1 (1.2)   | 0         | 1 (1.3) | 1 (1.4)   |
| Injury, poisoning and procedural complications | 5 (3.7)   | 9 (7.1)   | 6 (5.2)   | 5 (5.4)   | 3 (3.6)   | 5 (6.1)   | 6 (7.8) | 2 (2.8)   |
| Traumaticfirachure                             | 1 (0.7)   | 1 (0.8)   | 1 (0.9)   | 0         | 0         | 2 (2.4)   | 3 (3.9) | 0         |
| Vaccination complication                       | 1 (0.7)   | 2 (1.6)   | 2 (1.7)   | 0         | 0         | 0         | 1 (1.3) | 0         |
| Ligament sprain                                | 0         | 1 (0.8)   | 0         | 1 (1.1)   | 1 (1.2)   | 0         | 0       | 0         |
| Muscle strain                                  | 0         | 1 (0.8)   | 1 (0.9)   | 2 (2.2)   | 0         | 0         | 1 (1.3) | 0         |
| Cardiae disorders                              | 2 (1.5)   | 3 (2.4)   | 2 (1.7)   | 3 (3.3)   | 4 (4.8)   | 2 (2.4)   | 1 (1.3) | 1 (1.4)   |
| Palpitations                                   | 1 (0.7)   | 3 (2.4)   | 2 (1.7)   | 1 (1.1)   | 1 (1.2)   | 1 (1.2)   | 0       | 0         |

## Safety data from other sources

<div style=\"page-break-after: always\"></div>

Table 100: Summary of adverse events of interest (safety population from studies ACE-536MDS-001, ACE-536-B-THAL-001 and ACE-536-B-THAL-002)

|                                       | ACE-536-MDS-001 (MDS TD Subjects)   | ACE-536-MDS-001 (MDS TD Subjects)   | ACE-536-B-THAL-001 (β-thalasseimia TD Subjects)   | ACE-536-B-THAL-001 (β-thalasseimia TD Subjects)   | ACE-536-B-THAL-002 (β-thalassemia NTD Subjects)   | ACE-536-B-THAL-002 (β-thalassemia NTD Subjects)   |
|---------------------------------------|-------------------------------------|-------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Subjects with ≥1:                     | Luspatercept N =153 n (%) [EAIR]    | Placebo N=76 n (%) [EAIR]           | Luspatercept N=223 n(%) [EAIR\"]                   | Placebo N=109 n(%) [EAIR\"]                        | Luspatercept N=96 n (%) [EAIR\"]                   | Placebo N=49 n(%) [EAIR\"]                         |
| Malignancy EO1b                       | 6 (3.9) [4.4]                       | 1 (1.3) [2.2]                       | 1 (0.4) [0.4]                                     | 0                                                 | 0                                                 | 2 (4.1) [3.2]                                     |
| Premalignant disorder EOI             | 2 (1.3) [1.5]                       | 3 (3.9) [7.0]                       | 0                                                 | 0                                                 | 1 (1.0) [0.6]                                     | 1 (2.0) [1.6]                                     |
| EMH masses EOI                        | 0                                   | 0                                   | 0                                                 | 0                                                 | 6 (6.3) [3.5]                                     | 1 (2.0) [1.7]                                     |
| Thromboembolic EOId                   | 4 (2.6) [3.0]                       | 3 (3.9) [6.8]                       | 9 (4.0) [3.5]e                                    | 1 (0.9) [0.8]                                     | 0                                                 | 0                                                 |
| Kidney injury EOI                     | 15 (9.8) [11.4]                     | 4 (5.3) [9.2]                       | 8 (3.6) [3.1]                                     | 3 (2.8) [2.5]                                     | 2 (2.1) [1.2]                                     | 0                                                 |
| Hypertension EOI                      | 13 (8.5) [10.3]                     | 7 (9.2) [17.4]                      | 18 (8.1) [7.3]                                    | 4 (3.7) [3.3]                                     | 34 (35.4) [28.3]                                  | 8 (16.3) [14.6]                                   |
| Musculoskeletaldisorder-bone pain EOI | 38 (24.8) [33.8]                    | 12 (15.8) [31.9]                    | 105 (47.1) [68.7]                                 | 45 (41.3) [52.8]                                  | 65 (67.7) [95.2]                                  | 15 (30.6) [32.8]                                  |

- α Exposure-adjusted incidence rates per 100 subject-years. EAIR per 100 subject-years is 100 times the number of subjects with the specific TEAE divided by the total exposure time (in years) to the event. Exposure time is the overall treatment exposure for subjects without the event and the time up to the first event startdateforsubjectswiththeevent.

EAIR=exposure-adjusted incidence rate;EOI=event ofinterest;EMH=extramedullaryhematopoiesis;IP=investigational product;MedDRA=Medical Dictionary for Regulatory Activities; NTD = nontransfusion dependent; PT = preferred term; SMQ = standard MedDRA Query; TD = transfusion dependent; TEAE = treatment-emergent adverse event; TEE = thromboembolic event.

- b The analysis of malignancy EOI in Study ACE-536-B-THAL-002 was the same as that in Studies ACE-536-MDS-001 and ACE-536-B-THAL-001, except the PTs of human chorionic gonadotropin positive,human chorionic gonadotropin increased, leukostasis syndrome,tumor lysis syndrome, gammopathy and monoclonal gammopathy were excluded, as these conditions do not qualify as malignant tumors.
- d The analysis of thromboembolic EOI in Study ACE-536-B-THAL-002 was the same as that in Studies ACE-536-MDS-001 and ACE-536-B-THAL-001, except thePTsof device occlusion,devicerelatedthrombosis,thrombosisindevice,andtransientischemicattackwereexcluded.
- c One subject had an event of human chorionic gonadotropin increased, which is part of the standardized MedDRA query category of *Malignancies\" (and can be used as a biomarker for some malignancies). However, it was the result of a false positive pregnancy test and not diagnostic of a malignancy.

e Includes 1 case of device occlusion; excluding this event, the incidence of thromboembolic EOI would be 8 (3.6%) subjects.

- Note: Treatment-emergent adverse events include adverse events that started on or after the date of first dose and up to 63 days after the date of the last dose of IP. If a subject experienced multiple events under the same EOI category and PT, then the subject was counted only once for that EOI and PT level. MedDRA StudyACE-536-B-THAL-002

Source: MDS/B-THALISSTable 14.3.1.3.1,MDS/B-THALISS Table 14.3.1.3.2,MDS/B-THAL ISSTable 14.3.1.19.1,MDS/B-THAL ISS Table 14.3.1.19.2, NTD ISS Table 14.3.1.19

## Laboratory findings

## Haematology

## Individual Subject Changes

Shifts from baseline to worst postbaseline NCI-CTCAE grade for hematologic parameters of leukocyte count, platelet count, and absolute neutrophil count for Studies A536-04/06 (NTD Cohort), Study ACE-536-BTHAL002, and NTD β -thalassemia Data Pool are presented in the Table below. For all 3 parameters, the worst postbaseline value represents the worst decrease from baseline. The majority of the values were Grade 0 at baseline. There were no Grade 5 results recorded for any of the parameters.

<div style=\"page-break-after: always\"></div>

Table 101: Shift (worsening) from baseline to worst (lowest) post-baseline NCI-CTCAE grade for selected haematology parameters (NTD beta-thalassemia safety population)

| Parameter(LowRelativeto                  | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Pool      |
|------------------------------------------|----------------------------------------------|------------------------------------|------------------------------------|----------------------------------|
| Normal Range) Extent of Shiftb           | Luspatercept N=33 n (%)c                     | Luspatercept N=96 n (%)c           | Placebo N =49 n (%)c               | Pooled Luspatercept N=129 n (%)c |
| Leukocyte count (Shifts to Low)          | m=33                                         | m=93                               | m=48                               | m=126                            |
| Grade 0 to 1                             | 1 (3.0)                                      | 8 (8.6)                            | 0                                  | 9 (7.1)                          |
| Grade 0 to 2                             | 0                                            | 3 (3.2)                            | 2 (4.2)                            | 3 (2.4)                          |
| Grade 0 to 3                             | 2 (6.1)                                      | 0                                  | 0                                  | 2 (1.6)                          |
| Grade 1 to 2                             | 0                                            | 0                                  | 1 (2.1)                            | 0                                |
| Grade 2 to 3                             | 0                                            | 1 (1.1)                            | 1 (2.1)                            | 1 (0.8)                          |
| Platelet count (Shifts to Low)           | m=33                                         | m=95                               | m=48                               | m=128                            |
| Grade 0 to 1                             | 3 (9.1)                                      | 13 (13.7)                          | 8 (16.7)                           | 16 (12.5)                        |
| Grade 0 to 2                             | 0                                            | 1 (1.1)                            | 0                                  | 1 (0.8)                          |
| Grade 1 to 2                             | 1 (3.0)                                      | 0                                  | 0                                  | 1 (0.8)                          |
| Absolute neutrophil count(Shifts to Low) | m=32                                         | m=93                               | m=48                               | m=125                            |
| Grade 0 to 1                             | 2 (6.3)                                      | 13 (14.0)                          | 3 (6.3)                            | 15 (12.0)                        |
| Grade 0 to 2                             | 4 (12.5)                                     | 7 (7.5)                            | 1 (2.1)                            | 11 (8.8)                         |
| Grade 0 to 3                             | 2 (6.3)                                      | 0                                  | 2 (4.2)                            | 2 (1.6)                          |
| Grade 0 to 4                             | 1 (3.1)                                      | 0                                  | 0                                  | 1 (0.8)                          |
| Grade 1 to 3                             | 0                                            | 1 (1.1)                            | 0                                  | 1 (0.8)                          |
| Grade 2 to 3                             | 0                                            | 2 (2.2)                            | 1 (2.1)                            | 2 (1.6)                          |

Note: NCI-CTCAE version 4.0 was used. Baseline was the last value measured before the first IP dose.

° Percentages are based on m (number of subjects with baseline value and at least one postbaseline value).

Note: Neutrophils segmented was used for absolute neutrophil count in Study ACE-536-B-THAL-002.

Note: nRBC-correction was implemented for leukocytes in Study ACE-536-B-THAL-002 but not in Studies A536-04/06.

Source:NTDISSTable14.3.4.1

## NTD β -thalassemia Data Pool (ACE-536-B-THAL-002 and A536-04/06 NTD Cohort)

A slightly higher proportion of subjects shifted from normal (Grade 0) or Grade 1 leukocyte count to Grade 3 leukocyte count in the pooled luspatercept treatment group compared with the placebo treatment group in Study ACE-536-B-THAL-002 (1.6% versus 0%). No subjects had Grade 4 leukocyte count postbaseline.

No subjects shifted from normal (Grade 0) or Grade 1 platelet count to Grade 3 or 4 platelet count in the pooled luspatercept treatment group, similar to the placebo treatment group in Study ACE-536-B-THAL002.

A  similar  proportion  of  subjects  shifted  from  normal  (Grade  0)  or  Grade  1  neutropenia  to  Grade  3 neutropenia in the pooled luspatercept treatment group compared with the placebo treatment group in Study ACE-536-B-THAL-002 (2.4% and 4.2%, respectively). One (0.8%) subject in the pooled luspatercept treatment group had Grade 4 neutropenia postbaseline.

<div style=\"page-break-after: always\"></div>

## Platelet counts

Shifts  in  platelet  counts  from  baseline  to  highest  postbaseline  value  for  Study  ACE-536-B-THAL-002, Studies A53604/06 (NTD Cohort), and NTD β -thalassemia Data Pool are presented below.

Table  102:  Shift  table  for  platelet  counts  from  baseline  to  highest  value  post-baseline  (3 categories) (NTD beta-thalassemia safety population)

|                                                          |     |                           | Highest Value Postbaseline, n (%)b   | Highest Value Postbaseline, n (%)b   | Highest Value Postbaseline, n (%)b   | Highest Value Postbaseline, n (%)b   | Highest Value Postbaseline, n (%)b   |
|----------------------------------------------------------|-----|---------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| Treatment Group                                          | N   | Baseline Value Category\"a | <500 x10°/L n (%)                    | 500 to <1000 x10°/L n (%)            | ≥1000 x10°/L n (%)                   | Missing n (%)                        | Total n (%)                          |
| Luspatercept- Pivotal Study ACE-536-B-THAL- 002          | 96  | <500×10%/L                | 64 (98.5)                            | 1 (1.5)                              | 0                                    | 0                                    | 65 (67.7)                            |
| Luspatercept- Pivotal Study ACE-536-B-THAL- 002          | 96  | 500 to <1000 x10°/L       | 0                                    | 24 (88.9)                            | 3 (11.1)                             | 0                                    | 27 (28.1)                            |
| Luspatercept- Pivotal Study ACE-536-B-THAL- 002          | 96  | ≥1000×10°/L               | 0                                    | 1 (33.3)                             | 2 (66.7)                             | 0                                    | 3 (3.1)                              |
| Luspatercept- Pivotal Study ACE-536-B-THAL- 002          | 96  | Missing                   | 0                                    | 0                                    | 1 (100.0)                            | 0                                    | 1 (1.0)                              |
| Luspatercept- Pivotal Study ACE-536-B-THAL- 002          | 96  | Total                     | 64 (66.7)                            | 26 (27.1)                            | 6 (6.3)                              | 0                                    | 96 (100.0)                           |
| Placebo - Pivotal Study ACE-536-B-THAL- 002              | 49  | <500×10°/L                | 23 (95.8)                            | 1 (4.2)                              | 0                                    | 0                                    | 24 (49.0)                            |
| Placebo - Pivotal Study ACE-536-B-THAL- 002              | 49  | 500to<1000 ×10°/L         | 0                                    | 19 (76.0)                            | 5 (20.0)                             | 1 (4.0)                              | 25 (51.0)                            |
| Placebo - Pivotal Study ACE-536-B-THAL- 002              | 49  | ≥1000× 10%/L              | 0                                    | 0                                    | 0                                    | 0                                    | 0                                    |
| Placebo - Pivotal Study ACE-536-B-THAL- 002              | 49  | Missing                   | 0                                    | 0                                    | 0                                    | 0                                    | 0                                    |
| Placebo - Pivotal Study ACE-536-B-THAL- 002              | 49  | Total                     | 23 (46.9)                            | 20 (40.8)                            | 5 (10.2)                             | 1 (2.0)                              | 49 (100.0)                           |
| Luspatercept- Supportive Studies A536-04/06 (NTD Cohort) | 33  | <500×10°/L                | 11 (100.0)                           | 0                                    | 0                                    | 0                                    | 11 (33.3)                            |
| Luspatercept- Supportive Studies A536-04/06 (NTD Cohort) | 33  | 500 to<1000 x10%/L        | 0                                    | 13 (65.0)                            | 7 (35.0)                             | 0                                    | 20 (60.6)                            |
| Luspatercept- Supportive Studies A536-04/06 (NTD Cohort) | 33  | ≥1000 ×10%/L              | 0                                    | 0                                    | 2 (100.0)                            | 0                                    | 2 (6.1)                              |
| Luspatercept- Supportive Studies A536-04/06 (NTD Cohort) | 33  | Missing                   | 0                                    | 0                                    | 0                                    | 0                                    | 0                                    |
| Luspatercept- Supportive Studies A536-04/06 (NTD Cohort) | 33  | Total                     | 11 (33.3)                            | 13 (39.4)                            | 9 (27.3)                             | 0                                    | 33 (100.0)                           |
| Pooled Luspatercept -NTD β-thalassemia Data Poolc        | 129 | <500× 10%/L               | 75 (98.7)                            | 1 (1.3)                              | 0                                    | 0                                    | 76 (58.9)                            |
| Pooled Luspatercept -NTD β-thalassemia Data Poolc        | 129 | 500 to<1000 x10°/L        | 0                                    | 37 (78.7)                            | 10 (21.3)                            | 0                                    | 47 (36.4)                            |
| Pooled Luspatercept -NTD β-thalassemia Data Poolc        | 129 | ≥1000×10°/L               | 0                                    | 1 (20.0)                             | 4 (80.0)                             | 0                                    | 5 (3.9)                              |
| Pooled Luspatercept -NTD β-thalassemia Data Poolc        | 129 | Missing                   | 0                                    | 0                                    | 1 (100.0)                            | 0                                    | 1 (0.8)                              |
| Pooled Luspatercept -NTD β-thalassemia Data Poolc        | 129 | Total                     | 75 (58.1)                            | 39 (30.2)                            | 15 (11.6)                            | 0                                    | 129 (100.0)                          |

Source:NTDISSTable14.3.4.3.2

## Individual Clinically Significant Abnormalities

Clinically significant abnormalities in selected hematology laboratory parameters were investigated, including platelet counts, absolute neutrophil count, WBC counts, and haemoglobin. Incidence of thrombocytosis was based on a threshold of ≥ 500 × 10 9  platelets/L.

<div style=\"page-break-after: always\"></div>

Table 103: Clinically significant abnormalities in selected heamatology parameters (NTD betathalassemia safety population)

|                                                | Supportive StudiesA536- 04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Poola           |
|------------------------------------------------|----------------------------------------------|------------------------------------|------------------------------------|----------------------------------------|
| Parameter Threshold                            | Luspatercept N=33 n (%) [EAIR]               | Luspatercept N=96 n (%) [EAIR]     | Placebo N=49 n (%) [EAIR]          | Pooled Luspatercept N=129 n (%) [EAIR] |
| Platelet count ≥1000 × 10° cells/L             | 9 (27.3) [14]                                | 6 (6.3) [3.6]                      | 5 (10.2) [6]                       | 15 (11.6) [6.5]                        |
| Platelet count ≥500 to <1000×10° cells/L       | 22 (66.7) [63.1]                             | 32 (33.3) [26.1]                   | 25 (51.0) [78.1]                   | 54 (41.9) [34.3]                       |
| White blood cell count ≥2 x baseline AND > ULN | 7 (21.2) [10.8]                              | 9 (9.4) [5.5]                      | 3 (6.1) [5.2]                      | 16 (12.4) [2]                          |
| Whiteblood cellcount ≥3 x baseline AND > ULN   | 1 (3.0) [1.2]                                | 1 (1.0) [0.6]                      | 0 [0]                              | 2 (1.6) [0.8]                          |
| Absolute neutrophil count <0.5 ×10° cells/L    | 1 (3.0) [1.2]                                | 0 [0]                              | 0 [0]                              | 1 (0.8) [0.4]                          |
| Hemoglobin > 11.5 g/dL                         | 10 (30.3) [17.1]                             | 37 (38.5) [31.9]                   | 1 (2.0) [1.6]                      | 47 (36.4) [26.9]                       |

EAIR =exposure-adjusted incidence rate; NTD =nontransfusion dependent; ULN =upper limit of normal.

b Exposure-adjusted incidence rate in events per 100 subject-years. EAIR per 100 subject-years is 100 times the number of subjects with the specific abnormality divided by the total exposure time (in years) to the event. Exposuretimeistheoveralltreatmentexposureforsubjectswithouttheeventand thetimeuptothefirstevent start datefor subjectswith the event.

α Includes subjects from Study ACE-536-B-THAL-002 and the NTD cohort from Studies A536-04/06.

Note: Neutrophils segmented was used for absolute neutrophil count in Study ACE-536-B-THAL-002.

Source:NTDISSTable14.3.4.2

## Chemistry Liver Laboratory Results

## Individual Subject Changes

Shifts from baseline to worst postbaseline NCI-CTCAE grade for liver chemistry parameters of ALP, ALT, AST, and total bilirubin for Studies A536-04/06 (NTD Cohort), Study ACE-536-BTHAL002, and NTD β -thalassemia Data Pool are presented. For all parameters the worst postbaseline value represents the worst increase from baseline. Except for total bilirubin, the majority of the values were Grade 0 at baseline. There were no Grade 5 results recorded for any of the parameters.

## NTD β -thalassemia Data Pool (ACE-536-B-THAL-002 and A536-04/06 NTD Cohort)

No subjects had Grade 4 ALP, ALT or AST at baseline or postbaseline.

The proportion of subjects in the pooled luspatercept treatment group who shifted from Grade 2 total bilirubin values to Grade 3 or 4 total bilirubin values was similar to the placebo treatment group in Study ACE-536-B-THAL-002 (13.2% and 10.4%, respectively), as was the proportion of subjects who shifted from Grade 3 to Grade 4 (2.3% and 2.1%, respectively).

<div style=\"page-break-after: always\"></div>

Table 104: Shift (worsening) from baseline to worst (highest/lowest) post-baseline NCICTCAE grade for selected liver chemistry parameters (NTD beta-thalassemia safety population)

|                                                                 | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Poola       |
|-----------------------------------------------------------------|----------------------------------------------|------------------------------------|------------------------------------|------------------------------------|
| Parameter(High orLow Relative to Normal Range) Extent of Shiftb | Luspatercept N=33 n (%)c                     | Luspatercept N=96 n (%)c           | Placebo N=49 n (%)c                | Pooled Luspatercept N = 129 n (%)c |
| ALP (Shift to High)                                             | m=33                                         | m=96                               | m = 48                             | m=129                              |
| Grade 0 to 1                                                    | 4 (12.1)                                     | 14 (14.6)                          | 5 (10.4)                           | 18 (14.0)                          |
| Grade 0 to 2                                                    | 0                                            | 1 (1.0)                            | 0                                  | 1 (0.8)                            |
| Grade 0 to 3                                                    | 0                                            | 1 (1.0)                            | 0                                  | 1 (0.8)                            |
| ALT (Shift to High)                                             | m=33                                         | m=96                               | m=48                               | m=129                              |
| Grade 0 to 1                                                    | 11 (33.3)                                    | 20 (20.8)                          | 6 (12.5)                           | 31 (24.0)                          |
| Grade 0 to 2                                                    | 0                                            | 2 (2.1)                            | 0                                  | 2 (1.6)                            |
| Grade 0 to 3                                                    | 1 (3.0)                                      | 1 (1.0)                            | 0                                  | 2 (1.6)                            |
| Grade 1 to 2                                                    | 0                                            | 2 (2.1)                            | 0                                  | 2 (1.6)                            |
| Grade 1 to 3                                                    | 0                                            | 1 (1.0)                            | 0                                  | 1 (0.8)                            |
| AST (Shift to High)                                             | m=33                                         | m=96                               | m = 48                             | m=129                              |
| Grade 0 to 1                                                    | 8 (24.2)                                     | 33 (34.4)                          | 8 (16.7)                           | 41 (31.8)                          |
| Grade 0 to 3                                                    | 0                                            | 2 (2.1)                            | 0                                  | 2 (1.6)                            |
| Grade 1 to 2                                                    | 2 (6.1)                                      | 1 (1.0)                            | 1 (2.1)                            | 3 (2.3)                            |
| Grade 1 to 3                                                    | 1 (3.0)                                      | 1 (1.0)                            | 0                                  | 2 (1.6)                            |
| Total Bilinubin (Shift to High)                                 | m=33                                         | m=96                               | m=48                               | m=129                              |
| Grade 0 to 1                                                    | 1 (3.0)                                      | 4 (4.2)                            | 3 (6.3)                            | 5 (3.9)                            |
| Grade 0 to 2                                                    | 0                                            | 2 (2.1)                            | 1 (2.1)                            | 2 (1.6)                            |
| Grade 1 to 2                                                    | 5 (15.2)                                     | 8 (8.3)                            | 4 (8.3)                            | 13 (10.1)                          |
| Grade 2 to 3                                                    | 3 (9.1)                                      | 14 (14.6)                          | 5 (10.4)                           | 17 (13.2)                          |
| Grade 3 to 4                                                    | 1 (3.0)                                      | 2 (2.1)                            | 1 (2.1)                            | 3 (2.3)                            |

## Individual Clinically Significant Abnormalities

Clinically significant abnormalities in selected chemistry laboratory parameters are presented for Studies A536-04/06 (NTD Cohort), Study ACE-536-B-THAL002, and the NTD β -thalassemia Data Pool in Table 105. With the exception of total bilirubin, the proportion and EAIR of the selected liver chemistry laboratory parameters were higher in the pooled luspatercept treatment group than in the placebo treatment group.

<div style=\"page-break-after: always\"></div>

Table 105: Clinically significant abnormalities in selected liver chemistry parameters (NTDbeta thalassemia safety population)

|                                                      | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Pool?            |
|------------------------------------------------------|----------------------------------------------|------------------------------------|------------------------------------|-----------------------------------------|
| Threshold                                            | Luspatercept N=33 n(%) [EAIR']               | Luspatercept N=96 n(%) [EAIR']     | Placebo N=49 n (%) [EAIR']         | Pooled Luspatercept N=129 (%) u [EAIR'] |
| ALT≥3xULN                                            | 1 (3.0) [1.2]                                | 6 (6.3) [3.7]                      | 0 0                                | 7 (5.4) [2.8]                           |
| AST≥3x ULN                                           | 3 (9.1) [3.8]                                | 5 (5.2) [3]                        | 1 (2.0) [1.6]                      | 8 (6.2) [3.3]                           |
| ALP≥2 xULN                                           | 1 (3.0) [1.2]                                | 3 (3.1) [1.8]                      | 0 [0]                              | 4 (3.1) [1.6]                           |
| Total bilirubin ≥2 x ULN                             | 26 (78.8) [119.2]                            | 71 (74.0) [135.6]                  | 35 (71.4) [160.5]                  | 97 (75.2) [130.8]                       |
| Direct bilirubin ≥ 2 x ULN                           | 17 (51.5) [43.6]                             | 5 (5.2) [3]                        | 0 [0]                              | 22 (17.1) [10.8]                        |
| AST and/or ALT ≥3x ULN AND total bilirubin ≥ 2 x ULN | 3 (9.1) [3.7]                                | 6 (6.3) [3.7]                      | 0 []                               | 9 (7.0) [3.7]                           |

Source:NTDISSTable14.3.4.2

## Hy's Law

The baseline total bilirubin was elevated in 75.2% of luspatercepttreated subjects in the NTD β -thalassemia Data Pool. Of the 9 subjects who potentially fit Hy's Law criteria (ALT or AST ≥ 3.0 × ULN and total bilirubin ≥ 2.0 × ULN), all subjects had increased total bilirubin at baseline or screening and 4 subjects had transaminases increased at baseline. None of the 9 subjects had confirmed drug-induced liver injury or symptomatic events and 3 subjects experienced liver enzyme elevations as a TEAE, all nonserious. The remaining 6 subjects with liver enzyme elevations were not reported as a TEAE. Treatment was not discontinued for any of these subjects in relation to the liver enzyme elevations. All 9 subjects who potentially met Hy's Law criteria recovered.

All elevations in ALT and/or AST and total bilirubin in these subjects had alternative explanations, including:

- Four subjects with a history of liver disease (hepatitis C, hepatomegaly, cholelithiasis, and Gilbert syndrome)
- Five subjects with clinically significant iron overload with liver iron concentration ≥ 7 mg/g dry weight
- One subject with a concurrent TEAE (upper respiratory tract infection) around the time of elevation
- Two subjects on concomitant medication known to potentially cause liver injury (one subject received paracetamol, and one subject received deferasirox and allopurinol)

<div style=\"page-break-after: always\"></div>

Higher mean values over time for ALT and AST were observed at most time points in luspatercept-treated subjects in Pivotal Study ACE-536-B-THAL-002. In Supportive Studies A536-04/06 mean postbaseline values of serum chemistry parameters varied slightly from baseline with no clinically significant trends observed.

<!-- image -->

## Chemistry - Renal Laboratory Results

## Individual Subject Changes

Shifts from baseline to worst postbaseline NCI-CTCAE grade for renal chemistry parameters of creatinine and eGFR for Studies A536-04/06 (NTD Cohort), Study ACE-536-B-THAL-002, and NTD β -thalassemia Data Pool are presented in Table 106. For creatinine, the worst postbaseline value represents the worst increase from baseline. For eGFR, the worst postbaseline value represents the worst decrease from baseline. The majority of the values were Grade 0 at baseline. There were no Grade 3-5 results recorded for either of the parameters.

Further discussion of renal data can be found in Section AESI Kidney injury.

Table 106: Shift (worsening) from baseline to worst (highest/lowest) post-baseline NCICTCAE grade for selected renal chemistry parameters (NTD beta-thalassemia safety population)

|                                                                   | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β-thalassemia Data Pool       |
|-------------------------------------------------------------------|----------------------------------------------|------------------------------------|------------------------------------|-----------------------------------|
| Parameter (High or Low Relative to Normal Range) Extent of Shiftb | Luspatercept N=33 n(%)c                      | Luspatercept N=96 n (%)c           | Placebo N=49 n(%)c                 | Pooled Luspatercept N =129 n (%)c |
| Creatinine (Shift to High)                                        | m=33                                         | m=96                               | m=48                               | m= 129                            |
| Grade 0 to 1                                                      | 1 (3.0)                                      | 6 (6.3)                            | 1 (2.1)                            | 7 (5.4)                           |
| Grade 0 to 2                                                      | 1 (3.0)                                      | 0                                  | 0                                  | 1 (0.8)                           |
| eGFR (Shift to Low)                                               | m=33                                         | m=96                               | m=48                               | m= 129                            |
| Grade 0 to 1                                                      | 4 (12.1)                                     | 21 (21.9)                          | 6 (12.5)                           | 25 (19.4)                         |
| Grade 0 to 2                                                      | 1 (3.0)                                      | 1 (1.0)                            | 0                                  | 2 (1.6)                           |
| Grade 1 to 2                                                      | 1 (3.0)                                      | 1 (1.0)                            | 1 (2.1)                            | 2 (1.6)                           |

Note:NCI-CTCAEversion 4.0 was used.Baseline was the last value measured before the first IPdose.

Source:NTDISSTable14.3.4.1

<div style=\"page-break-after: always\"></div>

## Individual Clinically Significant Abnormalities

Clinically significant abnormalities in eGFR for Studies A536-04/06 (NTD Cohort), Study ACE-536-B-THAL002, and the NTD β -thalassemia Data Pool are presented in Table 107. The proportion of subjects and EAIRs of eGFR &lt; 0.5 × baseline was similar between the pooled luspatercept treatment group and the placebo treatment group.

The 2 cases of eGFR &lt; 0.5 × baseline in Study ACE -536-B-THAL-002 were transient over one dose and returned to baseline at the next visit, with no recurrence after the first instance. One of the 2 subjects who experienced eGFR &lt; 0.5 × baseline in Studies A536 -04/06 (NTD Cohort) experienced additional recurrences after the first instance.

Table 107: Clinically significant abnormalities in estimated glomerular filtration rate (NTD beta-thalassemia safety population)

|                   | SupportiveStudies A536-04/06 (NTD Cohort)   | PivotalStudy ACE-536-B-THAL-002   | PivotalStudy ACE-536-B-THAL-002   | NTD β-thalassemia Data Pool              |
|-------------------|---------------------------------------------|-----------------------------------|-----------------------------------|------------------------------------------|
| Threshold         | Luspatercept N=33 n (%) [EAIR']             | Luspatercept N=96 n (%) [EAIR']   | Placebo N =49 n (%) [EAIR']       | Pooled Luspatercept N =129 n (%) [EAIR'] |
| eGFR<0.5xbaseline | 2 (6.1) [2.5]                               | 1 (1.0) [0.6]                     | 1 (2.0) [1.6]                     | 3 (2.3) [1.2]                            |

EAIR = exposure-adjusted incidence rate; eGFR = estimated glomerular filtration rate; NTD =nontransfusion dependent.

aIncludessubjectsfromStudyACE-536-B-THAL-002andtheNTDcohortfromStudiesA536-04/06

Exposure-adjusted incidence rate in events per 100 subject-years. EAIR per 100 subject-years is 100 times the number of subjects with the specific abnormality divided by the total exposure time (in years) to the event. Exposuretimeistheoveralltreatmentexposureforsubjectswithouttheeventandthetimeuptothefirstevent startdateforsubjectswiththeevent.

Source:NTDISSTable 14.3.4.2

## Vital signs

An overview of SBP and DBP change from baseline to last available assessment, hypertension TEAEs, and hypertension medical history for Studies A536-04/06 (NTD Cohort), Study ACE-536-B-THAL-002, and the NTD β -thalassemia Data Pool is provided.

Hypertension AESIs are discussed in more detail in the respective section.

## Pivotal Study ACE-536-B-THAL-002

Overall, the mean blood pressures for subjects in the luspatercept treatment group were higher than those in the placebo treatment group, but were generally within the normal range (Figures below). Variability between the 2 treatment groups for SBP and DBP changes after Dose 39 Day 1 was noted due to small sample size (ie, very few subjects reached treatment after Dose 40 as of the data cut-off date).

<div style=\"page-break-after: always\"></div>

Figure 43: mean systolic pressure values over time in study ACE-536-B-THAL-002 (NTD betathalassemia safety population)

<!-- image -->

DxDy = Dose x Day y; mmHg = mm of mercury; LUS\\_N = number of subjects in the luspatercept treatment group; NTD = nontransfusion dependent; PBO\\_N = number of subjects in the placebo treatment group; SBP = systolic blood pressure; SE = standard error.

Source:ACE-536-B-THAL-002CSRFigure22A

Figure 44: Mean diastolic blood pressure values over time in study ACE-536-B-THAL-002 (NTD beta-thalassemia safety population)

<!-- image -->

DBP = diastolic blood pressure; DxDy = Dose x Day y; mmHg = mm of mercury; LUS\\_N = number of subjects in the luspatercept treatment group; NTD = nontransfusion dependent; PBO\\_N = number of subjects in the placebo treatment group; SE = standard error.

Source:ACE-536-B-THAL-002CSRFigure 22B

<div style=\"page-break-after: always\"></div>

Table 108: Increases from baseline in systolic and diastolic blood pressure based on last available post-baseline value, hypertension TEAEs and medical history of hypertension (NTDbeta thalassemia safety population)

|                                                                          | Supportive Studies A536-04/06 (NTD Cohort)   | Pivotal Study ACE-536-B-THAL-002   | Pivotal Study ACE-536-B-THAL-002   | NTD β- thalassemia Data Pool\"   |
|--------------------------------------------------------------------------|----------------------------------------------|------------------------------------|------------------------------------|---------------------------------|
|                                                                          | Luspatercept N=33 n (%)                      | Luspatercept N=96 n (%)            | Placebo N= 49 (%) uI               | Pooled Luspatercept N=129 n (%) |
| Systolic Blood Pressure (Last Available Assessment)                      |                                              |                                    |                                    |                                 |
| No increase                                                              | 10 (30.3)                                    | 48 (50.0)                          | 28 (57.1)                          | 58 (45.0)                       |
| Increased < 20 mm Hg                                                     | 19 (57.6)                                    | 47 (49.0)                          | 20 (40.8)                          | 66 (51.2)                       |
| Increased ≥ 20 mm Hg                                                     | 4 (12.1)                                     | 1 (1.0)                            | 0                                  | 5 (3.9)                         |
| SBP ≥ 160 mm Hg with ≥ 20 mm Hg increase                                 | 0                                            | 0                                  | 0                                  | 0                               |
| DiastolicBloodPressure (Last Available Assessment)                       |                                              |                                    |                                    |                                 |
| No increase                                                              | 12 (36.4)                                    | 45 (46.9)                          | 25 (51.0)                          | 57 (44.2)                       |
| Increased < 20 mm Hg                                                     | 20 (60.6)                                    | 48 (50.0)                          | 23 (46.9)                          | 68 (52.7)                       |
| Increased ≥ 20 mm Hg                                                     | 1 (3.0)                                      | 3 (3.1)                            | 0                                  | 4 (3.1)                         |
| DBP ≥ 100 mm Hg with ≥ 20 mm Hg increase                                 | 0                                            | 0                                  | 0                                  | 0                               |
| AnyTEAEof Hypertension                                                   | 6 (18.2)                                     | 34 (35.4)                          | 8 (16.3)                           | 40 (31.0)                       |
| Subjectswith a TEAE of Hypertension and Medical History of Hypertensionb | 2/6 (33.3)c                                  | 6/34 (17.6)c                       | 1/8 (12.5)c                        | 8/40 (20.0)c                    |
| Grade3TEAEof Hypertension                                                | 1 (3.0)                                      | 3 (3.1)                            | 0                                  | 4 (3.1)                         |
| Grade4TEAEofHypertension                                                 | 0                                            | 0                                  | 0                                  | 0                               |
| SAE of Hypertension                                                      | 0                                            | 0                                  | 0                                  | 0                               |
| Hypertension TEAE Leading to TreatmentDiscontinuation                    | 0                                            | 0                                  | 0                                  | 0                               |

Note: Hypertension is based on grouped PTs from MedDRA narrow scope of SMQ hypertension (see Table 27).

Source:NTD ISS Tables 14.3.5.1,14.3.1.19,14.3.1.27,14.3.1.24,14.3.1.23,14.3.1.21, and 14.3.1.22

## NTD β -thalassemia Data Pool (ACE-536-B-THAL-002 and A536-04/06 NTD Cohort)

A total of 45.0% of subjects in the pooled luspatercept treatment group had no increase in SBP and 44.2% had no increase in DBP from baseline to last available assessment. More subjects in the pooled luspatercept  treatment group had increases from baseline of ≥ 20 mm Hg in SBP or DBP than subjects in the placebo treatment group in Study ACE-536-THAL-002 (3.9% versus 0% for SBP, and 3.1% versus 0% for DBP). At most of the visits for these subjects, blood pressure values fluctuated between those measured at baseline and those measured at the last assessment (or were slightly above). All subjects with a ≥ 20 mm Hg increase in SBP at the last assessment had an SBP ≤ 131 mm Hg at that visit. All

<div style=\"page-break-after: always\"></div>

subjects with a ≥ 20 mmHg increase in DBP at the last assessment had a DBP ≤ 90 mm Hg at that visit. No subject in the pooled luspatercept treatment group had an SBP ≥ 160 mm Hg or a DBP ≥ 100 mm Hg.

## Weight

The proportion of subjects experiencing a weight decrease of ≥ 10% was higher in the pooled luspatercept treatment group compared to the placebo treatment group in Study ACE-536-THAL-002 (5 [3.9%] and 1 [2.0%], respectively). For most of these subjects, the decrease in weight was gradual and started increasing by the last assessment prior to cut-off. Two subjects experienced a more abrupt drop in weight (#3011014 and #4011037). There were no AEs reported in these 2 subjects with regards to weight drop but there were other AEs or SAEs reported during that period that could potentially explain the drop in weight. In all cases except one (#3011014) the decrease in weight was less than 12%.

## Safety in special populations

Treatment-emergent AEs were analysed by intrinsic (age, sex, race, drug-disease interactions) and extrinsic (geographic region) factors. Analyses focus on the pooled luspatercept group due to population size and highlight differences of 10%.

No clinically relevant differences were noted between any of the subgroups investigated. In general, any trends observed in the luspatercept treatment group across subgroups were also observed in the placebo treatment group.

## Pregnancy and lactation

Pregnant and lactating women were excluded from the study population and throughout the clinical development program. Female participants of childbearing potential (defined as sexually mature women who had not undergone hysterectomy or bilateral oophorectomy or were not naturally postmenopausal for at least 24 consecutive months) and male participants in any luspatercept study were to use highly effective (Pearl index &lt; 1% per year) birth control methods.

As of the safety data cut-off date, there are no data regarding the clinical effects of luspatercept in pregnancy. There have been no pregnancies reported in female subjects or in a partner of male subjects participating in NTD β -thalassemia clinical studies.

## Hepatic and renal impairment

No analyses with regard to the safety in patients with hepatic or renal impairment have been undertaken.

## Paediatric population

The safety of Luspatercept in children and adolescents under the age of 18 has not been established.

## Immunological events

## Pivotal Study ACE-536-B-THAL-002

Method: Blood samples (approximately 3 mL) were collected from all subjects for assessment of ADAs against luspatercept in serum at the time points [Day 1 of Cycle 1 (baseline), Dose 2, 4, and 6; 8, 12, 16, and every 6 doses: at Dose 22, 28, 34, etc. up to max. 2 years from Dose 1 Day 1]. During the first year of treatment, the ADA test was conducted using the PK samples from the same visit. Additional sampling for ADAs was permitted at investigator's or sponsor's discretion (recorded as an unscheduled visit).

<div style=\"page-break-after: always\"></div>

## Anti-drug Antibody Assessment

In the safety population, all subjects (96 subjects in the luspatercept treatment group and 49 subjects in the placebo treatment group) were evaluated for ADAs. Treatment-emergent ADAs against luspatercept were observed in the luspatercept treatment group at a lower incidence: 3 (3.1%) subjects developed binding antibodies as well as neutralizing antibodies. However, not all treatment-emergent ADAs appeared to be related to luspatercept treatment, as they were also observed in 3 (6.1%) subjects in the placebo treatment group.

In the luspatercept treatment group, the maximum treatment-emergent ADA titer among subjects ranged from 11.5 to 92.0. All 3 subjects in the luspatercept treatment group with treatment-emergent ADA tested positive within 233 days of the first dose, and 2 subjects had positive samples for more than 2 consecutive visits.

Table 109: ADA measurements by parameter and positive category (safety populationsubjects with ADA sample collected)

|                                | Luspatercept (N =96)   | Luspatercept (N =96)     | Luspatercept (N =96)   | Placebo (N = 49)    | Placebo (N = 49)         | Placebo (N = 49)     |
|--------------------------------|------------------------|--------------------------|------------------------|---------------------|--------------------------|----------------------|
| ADA Test                       | Pre- existing n (%)    | Treatment Emergent n (%) | Positive Total n (%)   | Pre- existing n (%) | Treatment Emergent n (%) | Positive Total n (%) |
| Anti-ACE-536\"                  | 2 (2.1)                | 3 (3.1)                  | 5 (5.2)                | 0                   | 3 (6.1)                  | 3 (6.1)              |
| Anti-536-mECDbc                | 1 (1.0)                | 1 (1.0)                  | 2 (2.1)                | 0                   | 0                        | 0                    |
| Anti-ActRIIBb                  | 0                      | 1 (1.0)                  | 1 (1.0)                | 0                   | 0                        | 0                    |
| Neutralizing Luspaterceptb,    | 1 (1.0)                | 3 (3.1)                  | 4 (4.2)                | NA                  | NA                       | NA                   |
| Neutralizing ActRIIB-ECD-Fcb.d | 0                      | 0                        | 0                      | NA                  | NA                       | NA                   |

Note: Only subjects taking any of ADA tests in the safety population were included.

Source:Table 14.3.8.2.

## Correlation of Antidrug Antibody versus Safety

In ACE-536-B-THAL-002, all 6 subjects who tested positive for ADAs during treatment with the study drug reported at least 1 TEAE. All TEAEs reported in the 3 ADA-positive subjects during treatment in the luspatercept treatment group were reported as single incidents. Treatment-emergent AEs in the 3 ADApositive subjects during treatment in the placebo treatment group were each only reported in 1 subject, except for the event of pyrexia, which was reported in 2 of the 3 subjects.

## Hypersensitivity

No systemic hypersensitivity reactions occurred in subjects who tested positive for ADA.

<div style=\"page-break-after: always\"></div>

## ACE536-04

Method: ADAs were measured on Day 1 of Cycle 1 (baseline), Day 1 of Cycle 4, End of treatment (Day 113 ± 7d) and on End of study (Day 141 ± 7d). If the subject had a positive ADA result at their last assessment, the subject was asked to return approximately every three months for additional testing until a negative result was obtained or the result was considered stabilised.

## Anti-drug Antibody Assessment

F our subjects had a positive ADA result at baseline. Of these subjects, 1 remained positive throughout the study (subject rolled over to extension study ACE536-006 and confirmed negative on follow-up); 1 became negative until the EOS visit, where the subject had a reportable ADA result of positive; and 2 subjects had negative reportable ADA results after C1D1. No subjects who had a reportable ADA result of negative became positive during the study.

## ACE536-06

Method: ADAs were measured on Day 1 of Cycle 1, on Day 1 of Cycle 5, Day 1 of Cycle 21 and on End of treatment. If the participant had a positive ADA result at their last assessment, the participant could be asked to return approximately every 3 months for additional testing, until a negative result was obtained or the result was considered stabilised.

## Anti-drug Antibody Assessment

One participant had a reportable ADA result of positive at Cycle 1 Day1 (baseline; titer 736), which became negative at the subsequent visit and remained negative throughout the study; no participant had negative reportable results at baseline that subsequently became positive.

## Safety related to drug-drug interactions and other interactions

Given that drug-drug interactions generally do not occur with biologic agents, drug-drug interaction studies with luspatercept were not performed.

## Discontinuation due to adverse events

- Adverse Events Leading to Investigational Product Discontinuation

<div style=\"page-break-after: always\"></div>

Table 110: TEAEs (regardless of causality and treatment related) leading to study drug discontinuation by PT (safety population)

|                                                                     | AllTEAEsLeadingtoStudy DrugDiscontinuation (Regardless of Causality)   | AllTEAEsLeadingtoStudy DrugDiscontinuation (Regardless of Causality)   | Treatment-relatedTEAEs Leading to Study Drug Discontinuation   | Treatment-relatedTEAEs Leading to Study Drug Discontinuation   |
|---------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
| PT                                                                  | Luspatercept (N = 96) n (%)                                            | Placebo (N = 49) n (%)                                                 | Luspatercept (N = 96) n (%)                                    | Placebo (N = 49) n (%)                                         |
| Subjects With at Least 1 TEAE Leading to Study Drug Discontinuation | 3 (3.1)                                                                | 4 (8.2)                                                                | 2 (2.1)                                                        | 0                                                              |
| Arthralgia                                                          | 1 (1.0)                                                                | 0                                                                      | 1 (1.0)                                                        | 0                                                              |
| ExtramedullaryHaemopoiesis                                          | 1 (1.0)                                                                | 0                                                                      | 1 (1.0)                                                        | 0                                                              |
| Haemolytic Anaemia                                                  | 1 (1.0)                                                                | 0                                                                      | 1 (1.0)                                                        | 0                                                              |
| Lupus-like syndrome                                                 | 1 (1.0)                                                                | 0                                                                      | 1 (1.0)                                                        | 0                                                              |
| Pulmonary Arterial Hypertension                                     | 1 (1.0)                                                                | 0                                                                      | 0                                                              | 0                                                              |
| Spinal Cord Compression                                             | 1 (1.0)                                                                | 0                                                                      | 1 (1.0)                                                        | 0                                                              |
| Asthenia                                                            | 0                                                                      | 1 (2.0)                                                                | 0                                                              | 0                                                              |
| DiffuseLargeB-cell Lymphoma                                         | 0                                                                      | 1 (2.0)                                                                | 0                                                              | 0                                                              |
| Fatigue                                                             | 0                                                                      | 1 (2.0)                                                                | 0                                                              | 0                                                              |
| HepatocellularCarcinoma                                             | 0                                                                      | 1 (2.0)                                                                | 0                                                              | 0                                                              |
| Hypotension                                                         | 0                                                                      | 1 (2.0)                                                                | 0                                                              | 0                                                              |

## · Adverse Events Leading to Dose Reduction

## Pivotal Study ACE-536-B-THAL-002

The proportion of subjects with TEAEs leading to dose reduction was higher in the luspatercept treatment group (10.4%; EAIR 6.4 per 100 subject-years) than in the placebo treatment group (0%; EAIR 0 per 100 subject-years). The TEAEs leading to dose reduction reported in more than one subject in the luspatercept treatment group included bone pain in 4 subjects (4.2%) and hypertension in 3 subjects (3.1%). Arthralgia, dizziness, influenza-like illness, myalgia, nausea, and vision blurred occurred in 1 subject each. All TEAEs that led to dose reduction were considered by the investigator to be treatment related.

## NTD β -thalassemia Data Pool (ACE-536-B-THAL-002 and A536-04/06 NTD Cohort)

In the NTD β -thalassemia Data Pool, the proportion of subjects with TEAEs leading to dose reduction was higher in the pooled luspatercept treatment group (11.6%; EAIR 6.4 per 100 subject-years) than in the placebo treatment group in Study ACE-536-B-THAL-002 (0%; EAIR 0 per 100 subject-years). The TEAEs leading to dose reduction reported in more than one subject in the pooled luspatercept treatment group included bone pain and hypertension in 4 (3.1%) subjects each; and headache and extramedullary hemopoiesis in 2 (1.6%) subjects each.

<div style=\"page-break-after: always\"></div>

## · Adverse Events Leading to Dose Interruption

## Pivotal Study ACE-536-B-THAL-002

The proportion of subjects with TEAEs leading to dose interruption in the luspatercept treatment group was similar to the placebo treatment group regarding the EAIR (24.0%; EAIR 15.2 per 100 subject-years vs 18.4%; EAIR 16.3 per 100 subject-years, respectively).

The TEAEs leading to dose interruption reported in more than one subject in the luspatercept treatment group included hypertension in 6 (6.3%) subjects; pyrexia in 3 (3.1%) subjects; and bone pain, gastroenteritis, and traumatic fracture in 2 (2.1%) subjects each. In the placebo treatment group, pyrexia (3 [6.1%] subjects) was the only TEAE leading to dose interruption reported in more than one subject.

## NTD β -thalassemia Data Pool (ACE-536-B-THAL-002 and A536-04/06 NTD Cohort)

Also in the NTD β -thalassemia Data Pool, the proportion of subjects with TEAEs leading to dose interruption in the pooled luspatercept treatment group (23.3%; EAIR 13.6 per 100 subject-years) was similar to the placebo treatment group in Study ACE-536-B-THAL-002 (18.4%; EAIR 16.3 per 100 subject-years).

The TEAEs leading to dose interruption reported in more than one subject in the pooled luspatercept treatment group included hypertension in 6 (4.7%) subjects; pyrexia in 3 (2.3%) subjects; and bone pain, gastroenteritis, pharyngitis, pleural effusion and traumatic fracture in 2 (1.6%) subjects each.

## Post marketing experience

Luspatercept was first approved for marketing in the US on 08 Nov 2019 for the treatment of anemia in adult patients with β -thalassemia who require regular RBC transfusions. Based on PSUR (Sequence No. 0017), which covers the reporting period from 25 Jun 2020 to 24 Dec 2020, luspatercept is approved in 33 countries.

As of 24 Dec 2020, an estimated 6,886 patients were exposed to commercial luspatercept.

The postmarketing safety profile of luspatercept in the β -thalassemia setting continues to be generally consistent with the clinical development program. Important identified risks with luspatercept as per EU Risk Management Plan (RMP), Version 1.5 are thromboembolic events specific in β -thalassemia population with splenectomy and EMH masses (in the TD and nonTD β -thalassaemia population). Important potential risks include hematologic malignancies (including AML), off label use in pediatric patients (developmental toxicity of luspatercept), use during pregnancy and lactation and bone fractures (in the nonTD β -thalassaemia population). The reports of these events remain consistent with findings from the β -thalassemia clinical development program and the overall safety profile of luspatercept.

The postmarketing safety profile of luspatercept in the β -thalassemia setting continues to be consistent with the safety profile of luspatercept established in the other clinical development programs. Expected AEs are easily monitored and generally manageable. The identified and potential safety concerns can be mitigated by the relevant product information provided to health care professionals and patients as reflected in the RMP. All of these safety concerns are addressed in the planned pharmacovigilance actions. Risks are mitigated through the measures outlined in the RMP. The safety profile of luspatercept continues to be closely monitored, with particular attention to important identified and potential risks.

<div style=\"page-break-after: always\"></div>

## 2.5.1. Discussion on clinical safety

Safety data in support of this extension of indication derive from one pivotal, placebo-controlled study (ACE-536-B-THAL-002) and two supportive open-label studies (A536-04 &amp; A536-06). In the ISS, which forms the basis of the safety assessment, data are presented separately for the supportive studies and the pivotal study, respectively, and also pooled data are presented.

In all safety tables presented, an overview is given of how many patients, also expressed as a percentage (%) of subjects, experienced certain TEAEs. Additionally, treatment-related TEAEs, Grade 3 and 4 AEs, SAEs, and AESIs were reported along with calculated events/n for each AE, which is acceptable.

The pooled luspatercept group includes 129 subjects (A536-04 &amp; A536-06, n=33; ACE-536-B-THAL-002, n=96). The mean treatment duration of the subjects in the supportive phase 2 studies (A536-04/-06) was 137.5 weeks, in the pivotal study (ACE-536-B-THAL-002) 94.0 weeks for luspatercept-treated and 66.0 weeks for placebo-treated subjects. The majority of subjects treated with luspatercept (74.2%) received therapeutic doses for ≥ 18 months. Considering the rare nature of the disease as well as supportive safety data from already approved indications, the number of subjects with NTD β -thalassemia exposed to luspatercept seems adequate for the safety evaluation.

Overall, the treatment duration appears adequate for assessing safety of a chronic treatment. However, the data cut-off for ACE-536-B-THAL-002 is 14 Sept 2020 and was the date the last subject completed 48 weeks of study treatment (or had discontinued study drug before the end of the 48-week DBTP). At the initial data cut-off date, treatment with the study drug was ongoing for 84.4% of subjects in the luspatercept treatment group and 36.7% of subjects in the placebo treatment group. Updated data on SAEs and AESIs were submitted with responses (cut-off date of 22 Sep 2021). This represents approximately 12 months of additional data, which allows a more thorough assessment of the longerterm effects of luspatercept.

The mean age of the NTD β -thalassemia data pool is 39.3 years and only few subjects were ≥ 60 years old. In view of the limited number of subjects ≥ 60 years, the information that only limited data are available for β -thalassaemia patients ≥ 60 years has been included in section 4.2 of the SmPC. In the pivotal, placebo-controlled study, some differences were noted in co-morbidities at baseline between the treatment arms: Beside the splenectomy status (42.6% luspatercept arm vs 53.1% placebo arm, respectively), differences were observed in the PT of osteoporosis (23.3% vs 38.8%, respectively), thrombocytosis (15.5% vs 22.4%, respectively), and extramedullary hematopoiesis (13.2% vs 26.5%, respectively).

## Treatment -emergent adverse events

Common TEAEs reported in ≥ 15% of subjects with a &gt; 2% higher frequency for luspatercept than placebo were bone pain, arthralgia, back pain, pain in extremity, myalgia, pharyngitis, upper respiratory tract infection, influenza, pyrexia, asthenia, diarrhoea, headache, oropharyngeal pain, cough, prehypertension, and hypertension whereas the most common TEAEs in the placebo treatment group were pyrexia, fatigue, and headache. The highest imbalances can be found in the SOCs of Musculoskeletal and connective tissue disorders (81.4% luspatercept arm vs 57.1% placebo arm).

The majority of TEAEs were mild to moderate in severity (Grade 1 or 2).

## Treatment -related adverse events

In the luspatercept data pool, the subject incidence of AEs considered to be treatment-related was 77.5% [100/129 subjects] in the luspatercept group, and 36.7% [18/49 subjects] in the placebo group. The most frequently reported treatment-related AEs were bone pain (34.1% luspatercept and 2% placebo, respectively), back pain (16.3%, and 4.1%, respectively), arthralgia (17.8%, and 6.1%, respectively),

<div style=\"page-break-after: always\"></div>

prehypertension (11.6%, and 10.2%, respectively) and hypertension (11.6%, and 0%, respectively), headache (16.3%, and 8.2%, respectively), and myalgia (10.9%, and 4.1%, respectively). The majority of treatment-related TEAEs had resolved as of the 14 Sep 2020 data cut-off date. The most frequently reported treatment-related TEAEs that had not resolved were prehypertension (7.0% of subjects) and hypertension (3.1%).

## Grade 3 or 4 adverse events

The subject incidence of Grade 3 or 4 treatment-related TEAEs was 27.9% in the luspatercept group compared to 24.5% in the placebo treatment group. After adjustment for exposure, the EAIR was lower for luspatercept treated patients (EAIR 18 vs 22.2 subject per year).

The most commonly reported Grade ≥ 3 TEAE (at least 2% of patients) reported was traumatic fracture with 4 luspatercept treated subjects compared to 1 placebo treated subjects. Hereditary haemolytic disorders cause ineffective erythropoiesis and bone marrow hyperplasia. Little is known about their effect on growth and skeletal health, but chronic haemolysis may lead to impaired growth and bone health, even in young NTD patients. The degree of haemolysis determines bone health risk. As recently reported, correlations between different parameters revealed a potential role of osteocalcin, haemoglobin (Hb) and lactate dehydrogenase (LDH) as prognostic markers for bone health, in the setting of chronic haemolysis ( Doulgeraki A et al. Hemoglobin. 2021 ). In this context, the higher rate of traumatic fracture was contextualized upon request. Traumatic fractures were mostly due to falls with no further circumstances reported. The majority of the subjects had a history of fractures, or concomitant diseases such as osteoporosis, osteopenia but the imbalance between treatment with luspatercept and placebo cannot be explained therewith alone. In this context, it is worth noting that, at baseline, higher incidences of both conditions have been reported as medical history in the placebo group and overall baseline measurement of BMD seemed comparable between groups. Furthermore, it remains uncertain how many accidental falls/road accidents occurred in the placebo arm without fractures, which preclude the conclusions that fractures occurred only due to accidents, as the proportion of accidents that resulted in fractures is unknown for both study arms. Taken together, an increased risk of traumatic fractures due to treatment cannot be ruled out based on the currently available data. This is especially of concern as many betathalassaemia patients already suffer from osteoporosis or osteopenia. Since an early treatment before the onset of such co-morbidities would be envisaged, it is equally important to investigate whether there is an increased risk with treatment for the occurrence of fractures in patients not suffering from osteopenia/osteoporis at baseline. The baseline risk factors for the occurrence of fractures need to be further investigated. In addition, section 4.4 of the SmPC states that 'In non-transfusion-dependent β -thalassaemia patients, traumatic fractures were observed in 8.3% (8/96) of patients treated with luspatercept. Patients should be informed of the risk of traumatic fracture.' It is also included as ADR in section 4.8 of the SmPC, further long term data are considered necessary. The MAH agreed to add fractures (traumatic and pathological) as Event Of Interest in the ongoing LTFU study, to present the data in future reports separately for TDT and NTDT patients and to explore potential risk factors for the occurrence of fractures related to luspatercept treatment (please see RMP).

It is already known that the PTs Bone pain and Hypertension are related to luspatercept, but these TEAEs seem to be reported more frequently in NTDT patients than in TDT patients.

## Serious adverse events

One de ath was reported in the NTD β -thalassemia Data Pool. The subject from the supportive study died of cardiac arrest (asystole), which is not considered related to luspatercept.

SAEs occurred more frequently in the placebo treatment group (subject incidence 24.5%) than in the pooled luspatercept treatment group (10.1%). The difference was mainly driven by imbalances in SOC

<div style=\"page-break-after: always\"></div>

infections and infestations, which occurred more frequently in placebo-treated patients (12.2% and 1.6%, respectively).

The frequency of subjects who reported Grade ≥ 3 TEAEs and SAEs were comparable among the 0.6 to 0.8 mg/kg, 1.0 mg/kg, and 1.25 mg/kg dose level groups. In the 1.0 mg/kg dose group, slightly more TEAEs leading to dose reduction and TEAEs leading to dose interruption were observed, however a dosedependent increase in severe toxicity is not evident.

## Long -term data

In the luspatercept treatment group, generally the highest incidence of the most frequently reported TEAEs (including bone pain, back pain, arthralgia, myalgia, pain in extremity, upper respiratory tract infection, fatigue, influenza-like illness, headache, prehypertension, hypertension, and oropharyngeal pain) occurred during Cycles 1 through 4 (C1-C4) and was lower during each subsequent 4-cycle dosing interval. Long-term observations suggest that AEs did not increase significantly over time and were clinically manageable. This can be supported by the finding that only 2 subjects had to discontinue the study due to treatment-related TEAEs (in the pivotal study). Although the MAH clarified that all events reported in later intervals are newly reported cases, it is not evident whether the TEAEs reported at study beginning (C1-C4) resolved under luspatercept, were treated or were still ongoing. It is worrying that late-onset kidney injuries occurred under luspatercept administration (Cycle 21-24). Moreover, from an integrated analysis of the relationship between luspatercept serum exposure and the likelihood of hypertension, it appears that there is an increased risk of hypertension over time. Based on data provided by the MAH, this increased risk for hypertension events, however, seems to be limited to the first 8-12 months of treatment. For further discussion of hypertension events please refer to the section below.

## Adverse events of special interest

AEs of special interest included Malignancy, Premalignant disorder, EMH masses, Thromboembolic events, Kidney injury, Hypertension, and Muscoskeletal disorder-Bone Pain. The categories were selected based on non-clinical findings or clin ical findings from the phase 2 and/or phase 3 studies of luspatercept in β -thalassaemia and other indications. The choice of the AESIs is generally supported, but the AESI Hypersensitivity-type reactions was excluded, which should also be evaluated in the context of the AESIs.

Hypersensitivity-type reactions were only reported for luspatercept-treated subjects (10.9% pooled luspatercept group vs 0.0% placebo). Events occurred as isolated cases with the exception of injection site erythema (5.2%) and facial oedema (3.1%). It is reassuring that no anaphylactic reactions have been reported. Upon request Hypersensitivity-type reactions were also included in SmPC section 4.8.

The majority of AESIs occurred in the Muscoskeletal disorder-Bone pain category, in particular for events of back pain and bone pain. Events are already reflected in section 4.8 of the SmPC, however it is noticeable that compared to the initial approval for TDβ thalassaemia patients, there has been a considerable increase in the number of EOIs for bone pain in this patient population of NTDβ thalassaemia patients (47.1% vs 67.7% of subjects, respectively)

In the double-blind phase of the pivotal study, EMH masses were reported in 7 subjects in the luspatercept treatment group, including 1 subject with an EMH mass reported on Study Day 1, and 1 subject in the placebo treatment group. During the open label portion of the study, EMH masses were observed in 2 additional patients for a total of 9/134 (6.7%) of patients while receiving luspatercept. Of note, no such events have been reported in studies submitted for the initial approval in TDT patients or MDS patients. However, with the Day120 responses, EMH mass events were also reported for the TDT population (ACE-536-B-THAL-001 and ACE-536-LTFU-001). Most events in the luspatercept arm were of Grade 1 or 2 in severity, considered by the investigator to be not related to the study drug, and did not result in study drug discontinuation. However, it is noted that the EMH events did not resolve while the subjects were still receiving IP. One subject (with a previously stable EMH) developed a Grade 4 EMH

<div style=\"page-break-after: always\"></div>

causing spinal canal compression that improved to Grade 2 after study drug discontinuation. The event was considered related by the investigator. The increased incidence in luspatercept-treated patients is of concern, as extramedullary haemopoiesis was observed more frequently in the placebo group at baseline (13.2% versus 26.5% subjects), but in the pooled NTD β thalassaemia patient population (includi ng the double-blind phase of the pivotal study and NTD Cohort from supportive studies) there was an imbalance with 10 (7.8%) subjects (EAIR 4 per 100 subject-years) for luspatercept and only 1 (2%) subject (EAIR 1.7 per 100 subject-years) for placebo. The development of extramedullary haematopoiesis during luspatercept therapy with a higher frequency of EMH in study ACE-536-B-THAL-002 in luspatercept patient as compared to placebo raises concern. An underlying MoA for EMH by luspatercept was not established, but data were reported from non-clinical findings where EMH was detected in lymph nodes in cynomolgus monkeys, which were considered a common background finding in cynomolgus monkeys at this age. Since no EMH events were reported in the control group, this argument is not fully conclusive, group may be a chance finding.

In the pivotal ACE-536-B-THAL-002 study, one thromboembolic event was reported after rolling over from placebo (0.7%). Two luspatercept-treated subjects experienced thromboembolic events in the supportive studies A536-04/06 (NTD Cohort). Both subjects were splenectomized and had additional patients in section 4.4 of the SmPC was extended to NTDT patients.

but given very low numbers (n=3 per sex per group), the observed absence of EMH masses in the control In the meanwhile the MAH submitted an additional variation to update the SmPC for the existing indications to include information about EMH masses identified also in TDT and MDS patients. Consequently, and given the haematopoiesis stimulating properties of luspatercept, a causal relationship appears very likely and these EMH events are considered to be of particular concern. Further, it has been noted that 6 of the subjects who developed EMH masses while on luspatercept treatment were nonresponders with regard to the primary endpoint. The addition of EMH masses and spinal cord compression as ADRs in section 4.8 of the SmPC and the inclusion of a respective warning in section 4.4 are supported. Further, concerns were raised for patients that are not only at risk for EMH masses, but already require treatment to control the growth of EMH masses. Therefore, the requirement for treatment to control the growth of EMH masses was included as contraindication in section 4.3 of the SmPC. Nevertheless, based on the currently available data an increased risk for EMH masses with long term treatment cannot be excluded. As some aspects cannot be addressed in detail with the planned studies due to missing baseline data, further monitoring in the long term is required to address at least the potential risk increase. EMH masses are included in the RMP and will be followed up in the LTFU study. Together with the already included contraindication, warning and the stopping recommendation this is regarded as adequately addressed for the moment. In case an increased risk will be identified, this has to be re-evaluated. relevant risk factors, hence both events were likely to be attributed to splenectomy. The warning for TDT

A numerical imbalance of the AESI Kidney injury was observed in subjects treated with luspatercept. As of the initial data cut-off date, reported AESIs were classified by the MAH as Grade 1 or 2 severity, were not severe and resolved while subjects were still receiving IP. No acute kidney injury TEAEs (ie, PTs of renal failure, acute kidney injury, and renal impairment) were reported in any subject in the luspatercept or placebo treatment group. However, the AESI kidney injury increased to a total of 9 subjects (6.7%) after the initial data cut-off. Events were reported as not associated with prolonged or irreversible worsening of clinically important indicators of kidney function or injury. Upon request,  insufficient information was provided on the new cases, i.e. whether they were transient or persistent events, and the outcome of the events (resolved/not resolved) was left unanswered. As kidney events (single cases of blood creatinine increased, blood urea increased and proteinuria) were reported in later treatment cycles (21 and 24), a long-term effect cannot be excluded. Additionally, more cases of ACR shifts towards a

<div style=\"page-break-after: always\"></div>

higher Grade were found after luspatercept administration. Consequently, kidney injury, proteinuria and albuminuria were added as ADR in section 4.8 of the SmPC upon request.

Hypertension AESIs occurred more frequently in subjects treated with luspatercept (36.5%) compared with placebo (16.3%) in the pivotal study (data cut-off 22 Sept 2021). None of these events was serious or led to cardiovascular complications or IP discontinuation, and most of these events were Grade 1 or 2 in severity. All Grade 3 events of hypertension were non-serious in nature, related to IP, resulted in dose reduction, and subsequently resolved to Grade 2 or lower. Few subjects had hypertension EOIs that led to dose reduction or interruption. Mean SBP and DBP were overall higher in the luspatercept treatment group compared to placebo. Increases from baseline of ≥ 20 mm Hg in SBP or DBP were observed only in the luspatercept treatment group, but not in the placebo group. SBP increase was more pronounced after long-term treatment with luspatercept, alongside a mean increase in SBP after extended exposure. Although most cases of hypertension were of mild severity, the frequency seems to be increased in comparison to data from TDT. As commented above, the risk for hypertension also appears to increase after 6 weeks of treatment. Based on the available data this increased risk persists for the first 8-12 months of treatment. Overall, the increased risk for hypertension events is seen critical. The MAH considers these events as manageable with dose interruption/reduction and provided supporting data upon request. However, it is currently not clear whether these recommendations work in the long term. Further, several hypertension events are still ongoing or patients are on additional hypertension therapy. Also, no data is available whether long term treatment would result in further increase of blood pressure and subsequent further need for additional medication, or puts treated patients on increased CV risk in the long-term. In addition, statistically significant associations between hypertension events and age and exposure have been identified. Although age and exposure are highly confounded, a further increased risk for hypertension events with age cannot be excluded. These aspects can be addressed with the LTFU study and the MAH committed to additionally record and report whether hypertension events were addressed with dose interruptions/reductions or other treatments.

One subject in the luspatercept treatment group had a non-serious colon adenoma (Grade 2) on Day 667. No action was taken with the study drug due to the event and the event resolved on the same day. The investigator considered the event to be not related to the study drug. This decision is acknowledged. No Malignancies are currently reported in the NTD β -thalassemia data pool. Although this is reassuring at present, it could be a consequence of the small number of patients and the short follow-up period (since the pivotal study is ongoing). There is still an uncertain risk related to malignancies, which is currently under investigation in the LTFU study for TD β -thalassaemia and MDS patients, for whom luspatercept has already been approved.

## Labo ratory findings

Overall, changes in haematology parameters appear within the range that can be expected after haematopoiesis-modifying treatment. However, Hb &gt; 11.5 g/dL was observed considerably more frequently in the luspatercept group (36.4%) compared to placebo (2%), which may contribute to the overall risk of luspatercept. In addition, the incidence of Hb increase &gt; 2 g/dL/3 weeks was 10% in Study ACE-536-B-THAL-002 and an hemoglobin increase does not appear to be a negligible problem.

Moreover, all investigated parameters, except haemoglobin, were abnormal more frequently in the supportive studies A536-04/06 compared to the luspatercept group in the pivotal study ACE-536-B-THAL002 with a much shorter study duration. A shift of platelet counts 500 to &lt; 1000 × 10 9 /L at baseline to ≥ 1000 × 10 9 /L postbaseline was observed in more patients in the supportive studies (35%) compared to both treatment groups (11.1% and 20% in the luspatercept and placebo groups, respectively) in the pivotal study ACE-536-B-THAL-002. In line with this observation, EAIR of abnormal platelet counts were considerably higher in the supportive studies compared to both treatment groups in pivotal study ACE536-B-THAL-002, which might reflect the progression of the disease.

<div style=\"page-break-after: always\"></div>

Clinically relevant elevated liver parameters, i.e. patients potentially fulfilling Hy´s law were only observed in the luspatercept group (9 vs. 0). This finding was included in the SmPC upon request. Worsening by one grade in creatinine and eGFR was observed more frequently in the luspatercept group compared to placebo (creatinine: 5.4% vs 2.1%; eGFR: 21% vs 14.6%), and worsening by two grades was observed only in the luspatercept group (creatinine: 0.8%; eGFR: 1.6%). Hence, clinically significant abnormalities in eGFR were overall rare and no acute safety concerns arise from renal laboratory results. Yet, abnormalities increased after long-term treatment with luspatercept in supportive studies and a longterm effect cannot be excluded.

Overall, after long-term luspatercept treatment in supportive studies A536-04/06 elevation of liver and renal parameters became more pronounced, which may be of concern and are of unclear relevance regarding long term treatment.

## Discontinuation due to adverse events

All luspatercept treatment-related TEAEs that led to study drug discontinuation were isolated cases. The rate of study discontinuations due to AEs was generally low across the clinical development program of luspatercept (2.1% of luspatercept-treated subjects vs 0% for placebo).

## Immunogenicity

In the luspatercept treatment group, there were 3 (3.1%) subjects who were positive for treatmentemergent antibodies to luspatercept following treatment initiation and all 3 subjects were positive for neutralizing antibodies against luspatercept. The low incidence of TEADAs observed in the NTD β -thalassemia population was consistent with that previously reported for the TD β -thalassemia population (1.81%). Hypersensitivity reactions were not reported in any of the ADA-positive subjects, which is reassuring. The observed influence of either preexisting or treatment emergent anti-drug-antibodies on the safety profile of luspatercept appears limited and does not cause concern at the present time.

During the first Periodic Safety Update Single Assessment (PSUSA) for luspatercept (data lock point: 24 December 2020), the MAH reviewed the following safety concerns of thromboembolic events, malignancies, off-label use in paediatric patients/ use during pregnancy and lactation. No new significant information was identified. Regarding the missing information of long-term safety, there is an ongoing long-term follow-up study (ACE-536-LTFU-001) to evaluate the long-term safety including thromboembolic events (TEEs) (only in the β -thalassaemia subjects) and progression to AML and/or other malignancies/pre-malignancies. The second PSUSA for luspatercept had the data lock point 24 June 2021. Although no safety issues were reported by the MAH during the reporting interval, the PRAC considers that an EMH signal should be initiated and included as safety concern of the PSUR.

## 2.5.2. Conclusions on clinical safety

The safety profile of luspatercept includes a variety of adverse events of special interest of which several resulted in warnings in the SmPC. The risk for EMH masses, traumatic fractures, hypertension, worsening of liver and kidney parameter, potential kidney damage and the unknown risk for malignancies are of special concern. Although most AEs have already been identified in the initial studies in transfusion dependent beta-thalassamia (TDT) patients, additional adverse events have been observed amongst those are traumatic fractures, EMH masses and kidney injuries and others were reported more frequently like hypertension and bone pain. In addition, several uncertainties regarding the long term safety of luspatercept have been identified, that cannot be addressed with the currently available data but with data from a LTFU study (please see RMP). Several amendments to the ongoing study have been implemented by the MAH to address these issues.

<div style=\"page-break-after: always\"></div>

The safety aspects have also been discussed by experts in an AHEG meeting. The experts concurred that the described safety aspects are non-negligible, but might be manageable temporarily with additional treatment or dose interruption/reduction. Nevertheless, the expert group considered that long term data are definitively required to address the uncertainties and improve the treatment strategy for the patients.

Additional information on adverse reactions and recommendations for patient management have been introduced in the SmPC. An additional contraindication for 'patients requiring treatment to control the growth of EMH masses' has also been added.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 1.5 is acceptable.

The CHMP endorsed the Risk Management Plan version 1.5 with the following content:

<div style=\"page-break-after: always\"></div>

## Safety concerns

## Table 2.8.1-1: Summary ofSafety Concerns

| Importantidentifiedrisks   | TEEs (only in the TD and non-TD β-thalassaemia population with splenectomy) EMH masses (In the TD and non-TD β-thalassaemia population)                    |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Importantpotentialrisks    | Haematologic malignancies (including AML) Off-label use in paediatric patients (developmental toxicity of luspatercept) Use during pregnancy and lactation |
| Missinginformation         | Long-term safety                                                                                                                                           |

## Pharmacovigilance plan

Table 3.2.1-1:

Category1 to3:Qngoing andPlanned Studies/Activities in thePostauthorisationPharmacovigilance

|                                                                                                                                                                                                                    | DevelopmentPlan                                                                                                                                                                                                    | DevelopmentPlan                                                                                                                                                                                                                             | DevelopmentPlan                                                                                                                                                                                                    | DevelopmentPlan                                                                                                                                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study/Status                                                                                                                                                                                                       | Summary ofobjectives                                                                                                                                                                                               | Safety concerns addressedMilestone(s)                                                                                                                                                                                                       |                                                                                                                                                                                                                    | Due Date(s)                                                                                                                                                                                                            |
| Category1-Imposedmandatory additional pharmacovigilance activitieswhichare conditions of themarketing authorisation                                                                                                | Category1-Imposedmandatory additional pharmacovigilance activitieswhichare conditions of themarketing authorisation                                                                                                | Category1-Imposedmandatory additional pharmacovigilance activitieswhichare conditions of themarketing authorisation                                                                                                                         | Category1-Imposedmandatory additional pharmacovigilance activitieswhichare conditions of themarketing authorisation                                                                                                | Category1-Imposedmandatory additional pharmacovigilance activitieswhichare conditions of themarketing authorisation                                                                                                    |
| None                                                                                                                                                                                                               | None                                                                                                                                                                                                               | None                                                                                                                                                                                                                                        | None                                                                                                                                                                                                               | None                                                                                                                                                                                                                   |
| Category 2 -Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisationoramarketingauthorisationunderexceptionalcircumstances | Category 2 -Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisationoramarketingauthorisationunderexceptionalcircumstances | Category 2 -Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisationoramarketingauthorisationunderexceptionalcircumstances                          | Category 2 -Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisationoramarketingauthorisationunderexceptionalcircumstances | Category 2 -Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisationoramarketingauthorisationunderexceptionalcircumstances     |
| None                                                                                                                                                                                                               | None                                                                                                                                                                                                               | None                                                                                                                                                                                                                                        | None                                                                                                                                                                                                               | None                                                                                                                                                                                                                   |
| Category3-Requiredadditionalpharmacovigilanceactivities                                                                                                                                                            | Category3-Requiredadditionalpharmacovigilanceactivities                                                                                                                                                            | Category3-Requiredadditionalpharmacovigilanceactivities                                                                                                                                                                                     | Category3-Requiredadditionalpharmacovigilanceactivities                                                                                                                                                            | Category3-Requiredadditionalpharmacovigilanceactivities                                                                                                                                                                |
| Ongoing                                                                                                                                                                                                            | ACE-536-LTFU-001/Toevaluate the1ong-term safety (including progression to AML and/or other malignancies/pre-malignancies) of luspatercept in subjects who have participated in other luspatercept clinical trials. | TEEs (only in the TD and non-TD β-thalassaemia population with splenectomy) EMH masses (In the TD and non-TD β-thalassaemia population), Haematologicmalignancies (including AML). Bone fractures (in the non-TD β-thalassaemia population) | Final report Interim safety updates                                                                                                                                                                                | Q2 2029 Annually for the first 5 years.                                                                                                                                                                                |
| ACE-536-MDS-005 Study toEvaluate the Effectiveness of the Additional Risk Minimisation Measures in Europe/ Ongoing                                                                                                 | To assess HCP awareness of key messages included in the HCP Checklist for luspatercept including recommendations for counselling of WCBPandinstructionsforprovidingWCBP with the Patient Card.                     | Use during pregnancy and lactation.                                                                                                                                                                                                         | Protocol submission                                                                                                                                                                                                | European Commission approval date: 25-Jun-2020 Registration in the EU PAS Register: Prior to start of data collection Start of data collection: Ju1 2021 End of data collection:Sep2022 Final report of study results: |

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

Table 5.1.3-1:

Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

|                                                                             | Safety Concern Risk Miniwisation Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Pharmacovigilance Aetivities                                                                                                                                                                                                                                                                                                |
|-----------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks                                                  | Important Identified Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                             |
| TEEs (only in the TD and non-TD β-thalassaemia population with splenectomy) | Routine risk minimisation measures: SmPC Section 4.8 - TEEs (including DVT, portal vein thrombosis, ischaemic strokce, and pulmonary embolism) are included as undesirable effects in patients with TD β-thalassaemia. PL Section 4 - Stroke symptoms and blood clots in the veins are included as possible side effects. SmPC Section 4.4 --Incidence of TEEs, risk factors and advice to consider fhromboprophylaxis in higher risk patients. PL Section 2 - Advice regarding preventative measures and medications. SmPC Section 4.4 and PL Section 2 — Waming regarding luspatercent treatment in β-thalassaemia patients with a splenectomy and other TEE risk factors. SmPC Section 4.2 - Advice regarding intemuption and dose modification of luswatercent for persistent treatment-related Grade > 3 adverse reactions wtil the toxicity has improved or returmed to baseline. Additional risk minimisation measures: None proposed. Legal status: Luspatercent, is subject to restricted medical | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Evaluation through routine pharmmacovigilamce and aggregate analysis in the PSUR Safety signal detection activities. AE follow-up fonm for adverse reaction. Additional pharmacovigilance aetivities: Study ACE-536-LTFU-001. |
| EMH masses (In the TD and non- TD β-thalassaemia population)                | Routine risk minimisation measures: SmPC Section 4.3- Contraindication for patients requiring treatment to control the growth of EMH masses. SmPC Section 4.8 - EMH masses is included as an umdesirable effect. SmPC Section 4.4 Waming regarding the risk of EMH masses. PL Section 2 - Waming regarding luspatercent treatment in patients. Additional risk minimisation measures: None proposed. Legal status: Luspatercent, is subject to restricted medical                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Evaluation through routine phanmacovigilance and aggregate analysis in the PSUR Safety signal detection activities. AE follow-up fomm for adverse reaction Additional pharmacovigilance aetivities: Study ACE-536-LTFU-001.   |

<div style=\"page-break-after: always\"></div>

|                                                                               | Safety Concern Risk Minimiation Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                               |
|-------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risks                                                     | Important Potential Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                            |
| Haematologic malignancies (including AML)                                     | Routine risk minimisation measures: SmPC Section 5.3  Haematologic malignancies were observed in juvenile rats. SmPC Section 4.2 - Advice regarding intemuption and dose modlification of lusnatenent for persistent treatment-related Grade > 3 adverse reactions wtil the toxicity has improved or retumed to baseline. Additional risk minimisation measures: None proposed. Legal status: Luspadercent is subject to restricted medical preseription.                                                                                                                                                                                                                                                                                                                                                                                                                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Evaluation through routine pharmacovigilance and aggregate analysis in the PSUR Safety signal detection activities. AE follow-up fomm for adverse reaction. Additional pharmacovigilance activities: Study ACE-536-LTFU-001. |
| Off-label use in paediatric patients (developmental toxicity of luswatercent) | Routine risk minimisation measures: SmPC Section 4.1 —- Target population is adults. SmPC Section 4.2  Statement that there is no relevant use of luspatercent in the paediatric population for the indication of MDS, or in paediatric patients less fthan 6 years of age in β-fhalassaemia. The safety and efficacy of buspatercent in the paediatric patients aged from 6 years to less than 18 years have not yet been established in β-thalassaemia. SmPC Section 4.2  Statement that luspatercept treatment should be initiated by a physician experienced in treathment of baewatolozical, diseases. SmPC Section 5.3 — Nonclinical findings regarding pre- and post-natal development and juvenile toxicity. PL Section 2  Statement that luswatercent is not recormmended for use in children and adolescents umder 18 years. Additional risk minirwisation measures: | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Evaluation through routine pharmmacovigilance and aggregate analysis in the PSUR Safety signal detection activities. Additional pharmacovigilance aetivities: None proposed.                                                 |

<div style=\"page-break-after: always\"></div>

Table 5.1.3-1: Summary Table of Pharmacovigilance Activities and Risk MinimisationActivities by Safety Concern

| Safety Concern                     | Risk Miniwiwation Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                      |
|------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Use during pregnancy and lactation | Routine risk minimisation measures: SmPC Section 4.2  Statement that luspatercent should Jo puatunean ui paouatadxe trenots.ud e Aq papeut aq baematoloaical, diseases. SmPC Section 4.3 - Contraindication im pregnancy. SmPC Section 4.6 — Instruction not to start luepaterwent if the patient is pregnant, and to discontinue luspatercent if a patient becomes pregnant. SmPC Section 4.6 — Instructions to use effective contraception during and for at least 3 months after the last dose of lusnatercent., and to have a pregmancy test prior to therapy. SmPC Section 4.6  Advice whether to discontinue breast-feeding or lusnatewvept for 3 months after the last dose. SmPC Section 4.6 (cross-referencing to Section 5.3)  Nonclinical findings regarding reproductive toxicity , lactation, and fertility. PL Section 2 - Contraindication regarding lusnaterent treatment during pregnancy, warmings and precautions regarding lwspatercent therapy during breast-feeding, and advice regarding contraception usage. | Routine pharmacovigilance aetivities beyond adverse reactions reporting and signal detection: Evaluation through routine phanmacovigilance and aggregate analysis in the PSUR Safety signal detection activities. AE follow-up fonm for adverse reaction. Additional pharmacovigilance aetivities: Study to evaluate the effectiveness of the additional risk minimisation measures in Europe (ACE-536- MDS-005). |

## Additional risk mjujrwjsation measures:

- +Patient Card (for WCBP only).
- +HCP Checklist.

## Legal status:

Lwspatercent is subject to restricted medical prescription.

Routine risk minimisation measures:

SmPC Section 4.4 Waming regarding the risk of traumatic fracture in non-TD β-thalassaemia patients.

SmPC Section 4.8 — Traumatic fracture is included as an umdesirable effect.

Additional risk miujwjsajion measures:

None proposed.

Legal status:

Luspatercent is subject to restricted medical prescription.

## Missing Information

Safety Concern

Risk Minimiwatiou Measures

Long-tenm safety Routine risk minimisation measures:

None proposed.

Additional risk minimisation measures:

None proposed.

Legal status:

Luspaterent is subject to restricted medical prescription.

Bone fractures

(in the non-TD

β-thalassaemia population)

Routine pharmacovigilance aetivities beyond adverse

reactions reporting and signal detection:

Evaluation through routine analysis in the PSUR

phammacovigilance and aggregate

Safety signal detection activities.

Additional pharmacovigilance activities:

Study ACE-536-LTFU-001.

Pharmacovigilance Activities

Routine pharmacovigilance activities beyond adverse

reactions reporting and signal detection:

Evaluation through routine phammacovigilance and aggregate

analysis in the PSUR

Safety signal detection activities.

Additional pharmacovigilance aetivities:

Study ACE-536-LTFU-001.

<div style=\"page-break-after: always\"></div>

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

- The readability of the PL of Reblozyl (luspatercept), in English, was assessed during the assessment of the initial Marketing Authorisation Application (MAA) according to the methods outlined in the European Commission's guideline titled: A guideline on the readability of the label and package leaflet of medicinal products for human use, Revision 1, 12 January 2009. The final report was then submitted to the EMA in December 2019 (Response to the List of Questions, original Marketing Authorisation Application (MAA)) as per EMA operational procedure guidance (EMEA/277378/2005). Reblozyl (luspatercept) was approved on 25 June 2020.
- The new indication, which essentially includes the use of Reblozyl (luspatercept) for adult patients with non-transfusion-dependent beta-thalassaemia, that is hereby applied for concerns the same route of administration and has a similar safety profile as the previously approved indications (i.e., key safety messages for the existing and new applied for indication are largely the same).
- Administration of Reblozyl (luspatercept) is done by a health care professional. The instructions for dose calculation, preparation, administration, storage and disposal are currently reflected in the approved PL.
- The general design and layout of the proposed PL have not changed compared to the tested one.
- Overall, the proposed leaflet shares large text sections with the reference one. The modifications now proposed in the PL (i.e., those relevant to the new indication) do not represent major changes.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The claimed indication is an extension of the current indication ´treatment of adult patients with transfusion-dependent anaemia associated with beta-thalassaemia` to include also non-transfusion dependent β -thalassaemia patients.

The β -thalassaemias are a group of inherited disorders characterised by absent or reduced production of the β -globin chains of haemoglobin, the oxygen carrying molecule in human RBCs.

Transfu sion dependent (TD) β -thalassaemia refers to the most severe form of beta thalassemia in which there is minimal to no beta globin chain production and consequently little to no HbA and HbG, which

<div style=\"page-break-after: always\"></div>

then has to be externally substituted (by regular transfusio ns). Patients with TD β -thalassaemia (which includes conventional β -thalassaemia major and severe forms of HgbE/β -thalassaemia) commonly come to clinical attention in early childhood (before 2 years of age) with severe anaemia (&lt; 7 g/dL); they require life-long, regular blood transfusion therapy.

In contrast, patients with Nontransfusion dependent (NTD) β -thalassemia present later in childhood or adolescence with mild to moderate anaemia (Hb values of 11.9 - 8.0 g/dL for females and 11.0 - 8.0 g/dL for males; WHO/NMH/NHD/MNM/11.1) without requiring regular RBC transfusion therapy for survival. However, NTD β -thalassemia patients still need transfusion therapy intermittently when low Hb levels are anticipated (eg, significant infection, surgery, or pregnancy) or even more frequently for limited periods of time to improve underlying anemia that may be negatively impacting growth and development in children or causing clinical morbidity such as splenomegaly, EMH pseudotumours, leg ulcers or low QoL (due to fatigue, tiredness, lack of energy, dyspnea, shortness of breath, etc) in adults (Musallam, 2021a; Cappellini, 2018).

Patients with NTD β -thalassemia may also develop clinically significant iron overload irrespective of receiving transfusions. Ineffective erythropoiesis is suggested to lead to low hepcidin levels, resulting in a marked increase in intestinal iron absorption. Iron overload is a major cause of morbidity for patients with NTD β -thalassemia (Vichinsky, 2016). A rise in liver iron concentration (LI C) in NTD β -thalassemia has been proportionally associated with an increased risk of multiple complications, pulmonary hypertension, vascular disease, endocrinopathies, and osteoporosis.

## 3.1.2. Available therapies and unmet medical need

NTD β -thalassemia is a condition of unmet medical need. The main available management options for NTD β -thalassemia patients are RBC transfusions, iron chelation therapy (ICT), prophylactic anticoagulant therapy, splenectomy, and foetal haemoglobin (HbF) induction (such as hydroxyurea).

The only approved pharmacologic therapies in the US and EU for NTD β -thalassemia are iron chelating agents used for managing iron overload. Deferasirox (oral) is approved in the EU and US and deferoxamine (SC or intravenous [IV] administration) is approved in the EU.

Vitamin B9 prophylaxis (more typically referred to as folate or folic acid) is given to prevent any occurrence of vitamin deficiency anemia.

It is important to bear in mind that there is an available alternative treatment option (transfusion therapy), which is however only started if the need is sufficiently high, since risks associated with transfusion therapy (e.g., iron accumulation and subsequent liver/cardiac disease, or hypersensitivity reactions) as well as impairment on quality of life due to regular transfusions are considered to outweigh its direct effect on alleviating symptoms associated with anemia, while benefits in terms of prevention of co-morbidities in the long term are not known. The decision to use RBC transfusions would be taken based on balancing the benefits and risks considering each patient's clinical condition (age, presence of comorbidities that, if left untreated, would put patients at risk of permanent damage) (Taher, 2017; Galanello, 2010).

## 3.1.3. Main clinical studies

Study ACE-536-B-THAL-002 is a Phase 2, double-blind, randomized, placebo-controlled study to compare the efficacy and safety of luspatercept (ACE-536) versus placebo in adults with non-transfusion dependent beta ( β )-thalassemia and a Hb level ≤ 10 g/dL (dia gnosis of β -thalassemia or HbE/β -thalassemia, with or without concomitant α -globin mutation and/or duplication).

<div style=\"page-break-after: always\"></div>

Consenting subjects entered a 4-week screening period during which eligibility was assessed and 24 weeks of RBC transfusion history and ICT was collected retrospectively, if applicable. Eligible subjects were randomized to luspatercept or placebo in a 2:1 ratio, using baseline Hb level (&lt; 8.5 or ≥ 8.5 g/dL) and NTDT-PRO T/W (score ≥ 3 or &lt; 3) as stratification factors. The study included a double-blind treatment period [48 weeks], and an open label treatment period [after week 48; subjects could enter to receive luspatercept for a maximum of 15 months]. A post-treatment follow-up period for up 5 years after the first dose of study drug or 3 years after the last dose (whichever occurs later) followed for subjects who discontinued study drug in the DBTP or OLP. Patients were allowed to roll-over into the overarching long term follow-up study LTFU-001.

The primary objective of the study is to evaluate the effect of luspatercept plus best supportive care (BSC) versus placebo plus BSC on anemia. The primary endpoint was the proportion of subjects who had an increase from baseline ≥ 1.0 g/dL in mean of Hb values over a continuous 12-week interval from Week 13 to Week 24 in the absence of transfusions. The study was unblinded after completion of the doubleblind treatment period for evaluation of the primary and secondary efficacy endpoints.

Efficacy assessments included Hb evaluation over time, Hb responder analyses evaluating a threshold of 1.5 g/dL increase from baseline and analyses evaluated during weeks 37-48. Appropriate sensitivity analyses were provided for the primary and key secondary endpoints. Furthermore, QoL outcome tools (NTDT PRO T/W, NTDT PRO SoB, FACIFF, SΒ6 MCS and PCS subdomains) as well as 6MWT evaluating functional exercise capacity were included as secondary measures, also evaluated up to week 48. The luspatercept effect on morbidities associated with β -thalassaemia such as iron overload, pulmonary function, osteoporosis and EMH masses were also assessed as exploratory outcome parameters.

The ITT population of efficacy included 145 subjects (96 randomized to luspatercept plus BSC and 49 randomized to placebo plus BSC). The study population included a heterogeneous patient population with and without anemia-related symptoms.

## 3.2. Favourable effects

A consistent effect has been demonstrated on haemoglobin for the primary endpoint (increase of at least 1 g/dL in Hb during weeks 13-24) as well as all secondary endpoints addressing haemoglobin change and also seen in most subgroups.

When analysed according to baseline symptomatic score, among subjects with a baseline NTDT-PRO T/W domain score of ≥ 3 out of 10 ( ' symptomatic ' ), the LS mean difference for luspatercept versus placebo was -0.73 (95% CI: -1.48, 0.03). Results for the FACIT-F evaluation (score &lt;43) are in line with the results observed for the NTDT PRO T/W.

There is some evidence from published literature data that supports the clinical benefit of increasing Hb levels in NTDT B-Thalassaemia patients, based on cross-sectional or retrospective studies. In these studies, higher Hb levels at baseline were shown to be associated with a lower risk of co-morbidity development and mortality, while lower Hb levels at baseline were associated with more unfavourable outcomes in β -thalassaemia patients.

Further support may be derived from other secondary endpoints such as SF-36, FACIT-F or the 6MWT, where at least no detrimental (mean) effect for the overall population comparing luspatercept and placebo groups have been observed.

Longer term data suggest a durable Hb response among subjects with prolonged Luspatercept treatment.

<div style=\"page-break-after: always\"></div>

## 3.3. Uncertainties and limitations about favourable effects

Haemoglobin: Splenectomised subjects showed an overall lower Hb response compared to nonsplenectomised subjects. For the primary endpoint (mean haemoglobin increase of ≥ 1.0 mg/dL from baseline to Week 13-24), the treatment effect of luspatercept over placebo was 55.9% versus 88.7%, respectively, among splenectomised subjects compared to non-splenectomised subjects. For the secondary endpoint 'Mean Hb change from baseline' (week 13-24), mean Hb was 1.09 vs. 1.53 g/dL among splenectomised subjects and non-splenectomised subjects, respectively, compared to placebo.

QoL: With regards to Quality of Life data, the questionnaires have been adequately validated. Results in terms of NTDT PRO T/W and SoB are undermined by the fact that phase 2 data were used to confirm the validity/reliability of the PRO, limiting its interpretability as a confirmatory parameter. It should be further noted that the Fatigue FS is also not specifically validated for the NTDT population. For the mean change from baseline in NTDT-PRO T/W domain score over a continuous 12-week interval from Week 13 to Week 24; no statistically significant effect has been demonstrated (LS mean difference for luspatercept versus placebo -0.48 (95%CI: -1.03, 0.08). Discrepant results were observed comparing symptomatic and asymptomatic patients. Further inconsistent NTDT T/W PRO results have also been observed across several other subgroup analyses e.g. when subjcts are classified by their Hb baseline level, subjects with compared to without splenectomy). The results on the FACIT- Fatigue subscale do not give reassurance as to a compelling luspatercept treatment effect on symptom improvement. The meaningfulness of the observed small effects in terms of QoL/functional capacity evaluated by other secondary outcome measures (SF-36 and 6MWT) is also not clear.

Surrogacy of Hb increase of 1g/dL is not established: While the provided publications indicate an association of lower Hb levels at baseline in NTD B-thalassaemia patients with a more unfavourable outcome (in terms of co-morbidity/mortality risk) after ten years of follow-up as compared to patients with lower Hb levels at baseline, these studies were of small sample sizes and present important methodological flaws and confounding effects cannot be ruled out. Further, the impact of Hb level variations over time on the co-morbidity risk has not been investigated so far. In addition, there is no study that analysed the magnitude of effect on Hb increase (due to intervention) that would be needed to result in a certain co-morbidity risk reduction. Additional efficacy data will be provided as part of the LFTU follow-up study (please see RMP).

Patients with clinically significant iron overload: Approximately 37.0% of the study population was having a clinically significant iron overload at baseline (&gt; 800 μg/L Serum Ferritin or LIC &gt; 5 Fe/g dw), while roughly 30% of subjects received ICT at baseline as well as around 40% during the study. Results in terms of iron parameters do not indicate a significant effect of luspatercept compared to placebo. For LIC at week 48 and LIC/ICT responders at week 24 and 48, even a larger effect in the placebo group is evident, which the MAH possibly attributes to the greater proportion of placebo-treated subjects receiving concomitant deferasirox compared with the luspatercept-treated subjects (30.6% versus 24.0%, respectively).

RBC Transfusion requirements: Only a low number of patients were not transfusion-free at baseline, i.e., only approximately 14% of subjects received transfusions within 24 weeks before randomisation. Of note, it is not known how this distributes between 'symptomatic' and 'asymptomatic' patients, as reasons for transfusions were not collected and might also have been due to infection or surgery, while being otherwise asymptomatic.

Data regarding transfusion need were only documented for 24 weeks before randomisation, thus, representativeness of the baseline transfusion need and comparability between treatment groups in terms of longer term transfusion data cannot be confirmed. A rather unexpected increase from baseline in RBC transfusions during the double-blind phase in the placebo group may raise the question as to whether in

<div style=\"page-break-after: always\"></div>

the placebo group a potentially more severely affected patient population could have been included as compared to the luspatercept group (a stable transfusion count over longer time periods would have been expected during the one year double-blind treatment).

Reasons for transfusions administered before randomisation were not provided, thus it cannot be followed whether in Luspatercept patients who received transfusions at baseline but not during the studies were truly attributable to Luspatercept or rather to a lack of similar triggers (e.g. infection, surgery). It can therefore not be concluded with sufficient certainty that the observed effect was truly attributable to Luspatercept treatment.

In addition, the potential for functional unblinding needs to be highlighted, considering the robust Hb response in Luspatercept patients only and that decision criteria to transfuse were subjective. This may have differently affected the decision to transfuse between both treatment groups.

Lastly, a substantial proportion of the population remained transfusion-free throughout the study and in these patients, the benefit in terms of transfusions remains unknown, i.e., whether and to what extent transfusions would be avoidable over time with treatment.

Patients with concomitant co-morbidities such as EMH pseudotumours, leg ulcers, osteoporosis, pulmonary hypertension: No clear benefit could be observed up to 48 weeks of luspatercept compared to placebo treatment in terms of improvement of co-morbidities. For EMH masses, even a potential detrimental effect might be suggested by the data, albeit based on a small number of patients only (see also safety section). An insufficient number of patients with co-morbidities such as diabetes mellitus, liver or kidney disease was included to allow any conclusions in these patients.

## 3.4. Unfavourable effects

100% of subjects in the pooled luspatercept treatment group and 98.0% of subjects in the placebo treatment group reported at least 1 TEAE. Incidence rates of TEAEs of Grade 3 or 4, TEAEs leading to dose reduction, and treatment-related TEAEs leading to IP discontinuation, were higher in the pooled luspatercept treatment group than in the placebo treatment group.

Common TEAEs reported in ≥ 15% of subjects with a &gt; 2% higher frequency for luspatercept than placebo were bone pain, arthralgia, back pain, pain in extremity, diarrhoea, pharyngitis, oropharyngeal pain, cough, prehypertension, essential hypertension/hypertension/hypertensive crisis, headache, and influenza like illness.

The most commonly reported Grade ≥ 3 TEAE (at least 2% of patients) reported was traumatic fracture with 4 (4.2%) luspatercept treated subjects compared to 1 (2%) placebo treated subjects in the pivotal study. In the luspatercept group, 3 had reported osteoporosis (47- and 60-year old females) or osteopenia (44-year old male) at baseline while only one patient did not present baseline BMD abnormalities (47-year old female). The patient in the placebo group (55-year old female) had osteoporosis at baseline. Given the overall higher frequencies of osteoporosis and osteopenia at baseline in the placebo group (38.8% and 61.2%, respectively) compared to luspatercept (25.0% and 45.8%, respectively), the observed imbalance of traumatic fractures is of concern and occurred as newly identified safety signal of luspatercept.

The performed exposure response analysis showed a statistically significant association with increased luspatercept AUCevent and bone pain/arthralgia ≥ Grade 1 in Week 1 to 6 and hypertension ≥ Grade 1 in Week 1 to 48 with increasing incidence over time. In the analysis age was associated with both TEAE showing that older subjects are more likely to experience these TEAEs.

Adverse events of special interest (AESIs):

<div style=\"page-break-after: always\"></div>

EMH masses were more frequently reported in the luspatercept treated subjects (n=9, 6.7%) than in the placebo treatment group (n=1, 2.1%). EMH events did not resolve while the subjects were still receiving IP. One subject in the luspatercept treatment group experienced a Grade 4 SAE of spinal cord compression as the result of a pre-existing paravertebral EMH mass. Based on the observed cases in NTDT patients, an association between the use of luspatercept and EMH masses is very likely. The initially submitted data for this variation only included cases in NTDT patients, however, respective cases have also been observed in TDT and MDS patients, however with lower incidences (data submitted in a parallel variation procedure (EMEA/H/C/004444/II/0011)). The observation of EMH masses have been addressed in section 4.3, 4.4 and 4.8 of the SmPC.

Kidney injury was reported in 6.7% of luspatercept treated subjects and 0% of placebo treated subjects, and newly occurring kidney injury EOIs proteinuria (3/134 [2.2%]) and albuminuria (4/134 [3.0%]) were observed after extended treatment in the luspatercept group (vs 0 in placebo).

Regarding hepatic and renal laboratory parameters, a trend towards overall elevated liver enzymes as well as bilirubin values over time was observed in patients treated with luspatercept. Patients potentially fulfilling Hy´s law were only seen in the luspatercept group, but not in the placebo group (7% vs. 0%). Also, worsening by one grade in creatinine and eGFR was observed more frequently in the luspatercept group compared to placebo (creatinine: 5.4% vs 2.1%; eGFR: 21% vs 14.6%). Worsening by two grades was observed only in the luspatercept group (creatinine: 0.8%; eGFR: 1.6%).

Hypertension occurred more frequently in subjects treated with luspatercept (29.1%) compared with placebo (16.3%). An increased risk for hypertension events was observed within the first 12 months of treatment. The most frequently reported hypertension-related AE was the preferred term of hypertension (19.8% and 2.0% of subjects in the luspatercept and placebo treatment group, respectively). The frequency seems to be increased in comparison to data from TDT patients. Luspatercept is associated with a mean increase in SBP and DBP of about 5 mm Hg from baseline. A warning in section 4.4 together with recommendations on dose adjustment in section 4.2 of the SmPC is addressing this risk.

The proportion of subjects with musculoskeletal disorder-bone pain was higher in the luspatercept treatment group (67.2%) than in the placebo treatment group (32.7%). The main drivers were bone pain, back pain and pain in extremity.

The most frequently reported treatment-related TEAEs in NTDT patients receiving Reblozyl (at least 15% of patients) were bone pain, headache, arthralgia, back pain, myalgia, prehypertension, and hypertension.

SAEs occurred in 13.4% of patients treated with luspatercept and in 26.5% of patients treated with placebo. The most commonly reported SAEs were traumatic fractures in the luspatercept group, reported by 5 (3.9%) patients compared to one (2%) patient in the placebo control group. A treatment-related SAE was reported for one (1.0%) subject in the luspatercept treatment group (PT: spinal cord compression).

One luspatercept-treated subject from the supportive studies had Grade 5 (fatal) TEAE during the study and died of cardiac arrest (asystole). The TEAE was not considered related to luspatercept.

Overall, 2 (2.1%) luspatercept-treated patients but no placebo-treated patients experienced treatmentrelated adverse events that led to treatment discontinuation (one case each of arthralgia, extramedullary haemopoiesis, haemolytic anemia, lupus-like syndrome and spinal cord compression).

<div style=\"page-break-after: always\"></div>

## 3.5. Uncertainties and limitations about unfavourable effects

Evaluation of comparative safety against placebo from the pivotal phase 2 study is limited by a considerably shorter duration of exposure for placebo patients (48 weeks). Safety follow-up data is available for approx. 150 weeks (median) for 96 NTDT patients.

The reported incidences for EMH masses might be underestimated, since based on the study procedures, it cannot be assumed that all EMH masses that occurred during the studies were detected, as most of them remain asymptomatic. MRI scans for EMH masses were only performed at baseline (and week 48) in subjects with a history of masses. Consequently also pre-existing masses cannot be excluded.

6 of the 9 subjects who developed EMH masses while on luspatercept in the ACE-536-B-THAL-002 study were non-responders with regard to the primary endpoint.

Data submitted for a variation procedure for the approved indications, show also EMH masses in TDT and MDS patients, that were previously not detected. Consequently an increased risk for EMH masses over time cannot be ruled out.

The imbalance of traumatic fractures is considered a cause for concern, especially since the baseline medical history indicates lower incidences of osteoporosis in the treatment group. In addition, slightly lower mean T-scores (hip/spine) were measured by DXA scan at baseline in the placebo group (Luspatercept: mean hip T-score -0.77, mean spine T-score: -1.61; placebo: mean hip T-score: -1.08, mean spine T-score: -1.79). Of note, overall, a substantial proportion of subjects did not show osteoporosis or osteopenia at baseline or during the study. BMD was measured at week 48 and no notable change has been observed in T-scores within one year of treatment with Luspatercept or in the placebo group. In addition, it remains uncertain how many accidental falls/road accidents happened in the placebo arm without fractures precluding the conclusions that fractures occurred due to accidents only as the proportion of accidents resulting in fractures is unknown for both study arms.

Although an increased risk for hypertension events was only observed within the first 12 months of treatment, currently it is not clear whether the events resolved due to dose modifications (interruption or reduction), with additional anti-hypertension medication or by themselves. In addition, statistically significant associations between hypertension events and age and exposure have been identified, which are however highly confounded. However, a further increased risk for hypertension events with age cannot be excluded.

It is not known whether newly occurring events of AESI/EOI kidney injury (during the open-label phase) were transient or persistent events, whether they resolved or whether they were considered related to Luspatercept. Additional safety data will come from the LFTU study (please see RMP).

In contrast to TD β -thalassaemia and MDS patients, no malignancies are reported for luspatercept during the placebo controlled study phase, but this may be a consequence of the small number of patients and the short follow-up period. There is still an uncertain risk related to malignancies, which is currently under investigation in the LTFU study for TD β -thalassaemia and MDS patients, for whom luspatercept has already been approved.

Similarly, the risk for thrombotic events is currently unclear for NTD patients, but has been observed in TD β -thalassaemia and MDS patients. Although the risk for thrombotic events might be lower in NTD patients, it cannot be neglected given their overall hypercoagulable state. Further investigation that luspatercept (long term) treatment is not associated with a higher risk of thrombosis is also needed.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 111: Effects Table for Reblozyl in non-transfusion dependent beta-thalassemia associated anaemia (data cut-off: 14 Sep 2020)

| Effect                                                                                       | Short description                                                                                                                                                                                                                                                                      | Unit               | Treatment           | Control            | Uncertainties / Strength of evidence      | References                       |
|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------------|--------------------|-------------------------------------------|----------------------------------|
| Favourable Effects                                                                           | Favourable Effects                                                                                                                                                                                                                                                                     | Favourable Effects | Favourable Effects  | Favourable Effects | Favourable Effects                        | Favourable Effects               |
| Erythroid Response during Week 13-24                                                         | Proportion of subjects who had an increase from baseline ≥ 1.0 g/dL in mean of Hb values in the absence of transfusions (Hb values from samples collected within 21 days after a transfusion were excluded from analyses) Subjects with missing Values are classified as Nonresponders | n/N (%)            | 74/96 (77.1)        | 0                  | Lack of surrogacy of Hb increase          | pivotal Study ACE536-B-THAL- 002 |
| Erythroid Response during Week 13-24                                                         | Proportion of subjects who had an increase from baseline ≥ 1.0 g/dL in mean of Hb values in the absence of transfusions (Hb values from samples collected within 21 days after a transfusion were excluded from analyses) Subjects with missing Values are classified as Nonresponders | %(95% CI)          | 77.1 (63.4, 87.0)   | 77.1 (63.4, 87.0)  |                                           |                                  |
| Mean change from baseline in NTDT- PRO T/W domain score (Week 13 - 24)                       | NTDT-PRO was administered as a daily diary for the first 24 weeks                                                                                                                                                                                                                      | Score (0- 10)      | -0.48 (-1.03, 0.08) |                    | Lack of independent validation of the PRO | See above                        |
| Mean change from baseline in mean of Hb values in the absence of transfusions (Week 13 - 24) | Hb values from samples collected within 21 days after a transfusion were                                                                                                                                                                                                               | g/dL               | 1.42 (1.16,1.67)    |                    | Lack of surrogacy of Hb increase          | See above                        |

<div style=\"page-break-after: always\"></div>

| Effect                               | Short description                                            | Unit                 | Treatment                       | Control              | Uncertainties / Strength of evidence                                      | References                       |
|--------------------------------------|--------------------------------------------------------------|----------------------|---------------------------------|----------------------|---------------------------------------------------------------------------|----------------------------------|
|                                      | excluded from analyses.                                      |                      |                                 |                      |                                                                           |                                  |
| Erythroid Response during Week 37-48 | Subjects with missing Values are classified as Nonresponders | n/N (%) % (95%CI)    | 68/96 (70.8) 68.8% (54.3, 80.4) | 1/49 (2.0)           | Lack of surrogacy of Hb increase                                          | See above                        |
| Unfavourable Effects                 | Unfavourable Effects                                         | Unfavourable Effects | Unfavourable Effects            | Unfavourable Effects | Unfavourable Effects                                                      | Unfavourable Effects             |
| Systemic AE                          | Bone pain                                                    | %                    | 36.5                            | 2.0                  | SoE: These were the most commonly reported AEs related to IP #            | pivotal Study ACE536-B-THAL- 002 |
| Systemic AE                          | Back Pain                                                    | %                    | 19.8                            | 4.1                  | see above                                                                 | see above                        |
| Systemic AE                          | Arthralgia                                                   | %                    | 18.8                            | 6.1                  | see above                                                                 | see above                        |
| Systemic AE                          | Prehypertension                                              | %                    | 15.6                            | 10.2                 | see above                                                                 | see above                        |
| Systemic AE                          | Hypertension                                                 | %                    | 13.5                            | 0                    | see above                                                                 | see above                        |
| Systemic AE                          | Arthralgia                                                   | %                    | 18.8                            | 6.1                  | see above                                                                 | see above                        |
| Systemic AE                          | Myalgia                                                      | %                    | 9.4                             | 4.1                  | see above                                                                 | see above                        |
| Systemic AE                          | Traumatic fracture                                           | %                    | 4.2                             | 2.0                  | see above                                                                 | see above                        |
| AESI                                 | EMH mass                                                     | %                    | 6.7                             | 2.1                  | SoE: These were newly identified AEs (pivotal Study ACE536-B-THAL- 002) * | see above                        |
| Systemic AE                          | Spinal cord compression                                      | %                    | 1.0                             | 0                    | This was the only treatment-related SAE                                   | see above                        |
| Laboratory finding                   | Hb > 11.5 g/dL                                               | %                    | 38.5                            | 2.0                  | Clinically significant abnormality                                        | see above                        |

Abbreviations: AESI: Adverse event of special interest; ISS: Integrated summary of clinical safety; SoE: Strength of evidence

Notes: [%] indicated under Unfavourable Effects refer to the percentage of subjects who experienced the TEAE until data cut-off.

# The data presented is based on the initial 14 Sep 2020 data cutoff date.

* The data on EMH mass events is based on an updated 24 Dec 2021 data cutoff date.

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The unmet medical need in the NTD B-Thalassaemia patient population is recognised, as there are limited therapeutic options in this population, i.e., iron chelation, splenectomy and transfusion strategies, the latter being limited due to the risk of alloimmunization. As, based on published literature, patients with lower Hb levels seem to be more likely to develop downstream manifestations of the disease (named 'comorbidities') such as iron overload/hepatic disease, hypercoagulability, leg ulcers, pulmonary hypertension, EMH masses, splenomegaly or osteoporosis, safe and effective treatment options are needed that would be able to reduce this co-morbidity risk.

Unfortunately, such effect remains unknown for luspatercept, as no effect on co-morbidities has been observed in the BEYOND study, which was of only 48 week double blind treatment duration, and it cannot be quantified based on available data, as patient-level surrogacy has not been established for Hemoglobin (Hb) increase.

A consistent treatment effect on Hb levels compared to placebo and best standard of care (BSC) has been shown (primary and key secondary Hb-related endpoints). However, mean increase in Hb of around 1 to 1.5 g/dL is no established surrogate for the prediction of long term outcome in NTD β -thalassaemia. The meaningfulness of the observed Hb effects is therefore difficult to interpret, in particular on a patient group level and this is further complicated by the large heterogeneity in the population studied in terms of clinical phenotype/disease severity, e.g. reflected by different baseline Hb levels or anemia-related symptoms.

An expert panel that was asked during the procedure whether they would consider the efficacy results from the BEYOND study of clinical benefit to the investigated patient population took the view that the observed Hb increase from baseline of 1-1.5g/dL in (symptomatic) NTDT patients can be considered a clinical benefit to the patient based on the following assumptions:

- a) Expected improvement of quality of life symptoms
- b) Expected improvement of in morbidity or mortality

Although there is evidence from published literature that low Hb levels at baseline were associated with co-morbidities in a cohort of ß-thalassaemia patients followed over ten years, this needs yet to be confirmed as the available data carry important limitations due to small sample sizes and retrospective study design, Hb variations over time were not evaluated and there is no available interventional study that could confirm and quantify the reduced risk for co-morbidities by increasing Hb levels with intervention. It also remains open whether even a certain Hb threshold would need to be exceeded to be able to reduce the co-morbidity risk to a relevant extent.

Nevertheless, it may be reasonable to assume that an increase of Hb levels will have a positive impact on the course of disease based on the available evidence.

Based on the lack of surrogacy of mean Hb increase and the PRO results and the issues raised during the evaluation; the MAH had proposed to restrict the target population to patients with presence of anemiarelated symptoms, as in these, improvement of symptoms may be more plausibly expected and an increased trend of an improvement would be evident in this patient group in the study. According to MAH, this patient population would be adequately represented by classification of their NTDT PRO T/W baseline score of ≥3 (out of 10 possible points).

<div style=\"page-break-after: always\"></div>

Regarding the clinical meaningfulness of the Hb effect and the failure of the study to show interpretable QoL results, the consulted ad hoc expert group (AHEG) commented that it may overall be difficult to capture a significant improvement in symptoms in a study in this patient population, as patients are often well adapted to their anemia-related symptoms and it may be difficult to show relevant changes in the study due to treatment. It should however be noted that, when focusing on the symptomatic only patients in whom an improvement in symptoms may be more readily expected, the observed effects in symptom improvement also remains largely non interpretable (validity issues of the PROs taken aside). Focusing on a subgroup rather than on the broader patient population was found to introduce additional uncertainties related to e.g. the data driven look at the data, the small sample size, the identified imbalances between treatment groups at baseline with unclear impact on the results and, lastly, the lack of validation of the PRO based on which the relevance of symptom improvement has been justified by the MAH. There is no concrete definition that concisely defines a 'symptomatic' patient population (i.e. that presents with anemia-related symptoms), as was agreed with by the AHEG. Furthermore, considering that increasing Hb levels is indeed considered a relevant target based on the experts' view, who also expect a Hb increase to have positive impact on morbidity and mortality in the long-term, a restriction to symptomatic patients was ultimately not considered justified by the CHMP. Even if there is no observed immediate benefit such as improvement of anemia-related symptoms, an improvement in terms of risk for co-morbidity development may be presumed in the overall population (NTD betathalassaemia patients with Hb≤10 g/dL) based on plausibility considerations, albeit not quantified in the present study, and as such, the observed Hb increase compared to placebo may be considered a clinical benefit per se to the patient. With regard to transfusion-related endpoints, results are associated with considerable uncertainty and, although the transfusion-related endpoints show a favourable effect for luspatercept-treated patients, it seems impossible to conclude with certainty whether this effect is truly attributable to treatment or due to other reasons unrelated to treatment. In addition, it needs to be kept in mind that a substantial proportion of the population remained transfusion-free throughout the study and in these patients, it remains unknown whether and to what extent transfusions would be avoidable with treatment and for how long three-weekly applications would be needed to achieve an effect that outweighs the risks associated with the product. Results can therefore not be easily transferred to the entire study population. It should also be noted that most patients receiving a transfusion during the study had Hb levels below 8.5 g/dL and, again, it remains open how results are transferrable to less severely affected patients. The safety profile of luspatercept includes a variety of adverse events of special interest of which several resulted in warnings in the SmPC. Some are of special concern and are discussed in more detail below. Although most AEs have already been identified in the initial studies in transfusion dependent betathalassamia (TDT) patients, additional adverse events have been observed, amongst those are traumatic fractures, EMH masses and kidney injuries. Others were reported more frequently, like hypertension and bone pain. In addition, several uncertainties regarding the long term safety of luspatercept have been identified that require further follow up in the post marketing. (LFTU study, please see RMP). Details are discussed below. The safety aspects addressed below have also been discussed by experts in an AHEG meeting. The experts concurred that the described safety profile is non-negligible, but might be manageable at least temporarily with additional treatment or dose interruption/reduction. Nevertheless, the expert group considered that long term data are definitively required to address the uncertainties and improve the treatment strategy for the patients. EMH masses are known to occur in beta-thalassemia patients due to their ineffective erythropoiesis. Since luspatercept is supposed to improve erythropoiesis, the observed increase in EMH masses is concerning. Further, it has been noted that 6 of the 9 subjects who developed EMH masses while on

<div style=\"page-break-after: always\"></div>

luspatercept treatment were non-responders with regard to the primary endpoint. While pre-existing masses cannot be excluded due to missing baseline screening, the increased incidence rate in the luspatercept group in NTDT patients and reports of further cases after longer treatment in TDT or MDS also after long term treatment. These findings raise the question how this risk will evolve over time not only for patients without EMH masses at baseline, but also in patients with pre-existing EMH masses, as they may increase in volume over time.

patients may hint at a causal relation between luspatercept treatment and the occurrence of EMH masses Consequenty, recommendations for baseline screening and regular monitoring for EMH masses were included in section 4.4. of the SmPC, which was strongly supported by the AHEG. In addition, section 4.4 of the SmPC includes an adequate warning that treatment with luspatercept must be discontinued in case of serious complications due to EMH masses. Further, concerns are raised for patients that are not only at risk for EMH masses, but already require treatment to control the growth of EMH masses. A respective contraindication has been added to the SmPC. Based on the currently available data an increased risk for EMH masses with long term treatment cannot be excluded. As some aspects cannot be addressed in detail with the planned studies due to missing baseline data, further monitoring in the long term is required. EMH masses are included in the RMP and will be followed up in the LTFU study. Together with the contraindication, warning and the stopping recommendation, this is regarded as adequately addressed for the moment. The increased risk for hypertension events is also seen critical. Although the MAH claims that these events can be managed with dose interruption/reduction and respective recommendations have been implemented, it is currently not clear whether i) these recommendations work (in the long term) and ii) whether they were applied to the reported events or whether additional medication was used. Further, several hypertension events are still ongoing and it is not clear whether attempts were made to treat those patients accordingly. Also, no data is available whether long term treatment would result in further increase of blood pressure and subsequent further need for additional medication, or puts treated patients on increased CV risk in the long-term. In addition, statistically significant associations between hypertension events and age and exposure have been identified, which are however highly confounded. Nevertheless, a further increased risk for hypertension events with age cannot be excluded. These aspects can be addressed with the LTFU study. In order to provide useful data the MAH will additionally record whether hypertension events will be addressed with dose interruptions/reductions or other treatments. In the SmPC, there is an adequate warning in section 4.4 together with recommendations on dose adjustment, addressing this risk. In addition to the previously known adverse events, an increased incidence of traumatic fractures has been observed. The occurrence of traumatic fractures may have been partially favoured by pre-existing osteoporosis/osteopenia, but the imbalance between treatment with luspatercept and placebo cannot be explained therewith alone. It is worth noting that, at baseline, higher incidences of both conditions have been reported as medical history in the placebo group and overall baseline measurement of bone mineral density seem largely comparable between groups. Taken together, an increased risk of traumatic fractures due to treatment cannot be ruled out based on the currently available data. This is especially of concern as many beta-thalassaemia patients already suffer from osteoporosis or osteopenia. Since an early treatment before the onset of such co-morbidities would be envisaged, it is equally important to investigate whether there is an increased risk with treatment for the occurrence of fractures in patients not suffering from osteopenia/osteoporosis at baseline. The baseline risk factors for the occurrence of fractures need to be further investigated. Although the risk for fractures is considered acceptable at this stage, considering the overall low number of events observed and the inclusion as ADR in section 4.8 of the SmPC, further long term data are needed. In case an increased risk is observed over time, this may impact on the benefit risk balance. Fractures (traumatic and pathological) are added as Event Of Interest in the ongoing LTFU study. The data should be presented in future reports for TDT and NTDT patients

<div style=\"page-break-after: always\"></div>

separately. If possible, risk factors for the occurrence of fractures related to luspatercept treatment should be explored.

During the long term open-label phase, events of kidney injury and related laboratory values were observed, which have not been reported previously in Luspatercept-treated patients or in the placebo group. Kidney injury is included in section 4.8 of the SmPC and in the RMP as identified risk and is consequently further investigated post marketing.

It is of note that a trend towards overall elevated hepatic and renal laboratory parameters over time was observed in patients treated with luspatercept. The implications for patients with pre-existing more severe hepatic and renal impairment are unknown, since those patients were not included in the submitted studies. It would for example be worrisome if hepatically impaired patients showed a further deterioration of their liver disease due to Luspatercept treatment. This is especially important with a view on the risk of iron overload in this patient population, which will lead to hepatic impairment. These aspects could however be addressed in the post marketing setting also with regular monitoring in the LTFU study.

In contrast to TD β -thalassaemia and MDS patients, no malignancies are reported for luspatercept during the placebo controlled study phase, but this may be a consequence of the small number of patients and the short follow-up period. There is still an uncertain risk related to malignancies, which is currently under investigation in the LTFU study for TD β -thalassaemia and MDS patients, for whom luspatercept has already been approved. This will also need further follow-up in the long term in NTD patients.

In summary, several adverse events have been identified that are of concern. While most might be manageable at least in the short term by additional treatments or dose adjustments, they will require additional regular monitoring and it is not known whether the recommended dose adjustments indeed resolve those events and/or might reduce the treatment effect, since no data has been provided in that respect. This will be addressed within the ongoing LTFU study. In their response to the major objection, the MAH has acknowledged the limitations associated with the single arm design of the ACE-536-LTFU001 study. To circumvent this limitation, and in order to establish a benchmark for the key clinical and safety endpoints for luspatercept subjects in the long term follow up study, literature data focusing on the natural disease progression will be systematically reviewed in thalassemia patient population. Parameters of interest will include disease progression including complications, RBC transfusion requirements, morbidity-free survival, quality of life assessments and iron parameters. Historical data sources such as electronic health records, claims or registries will also be considered to put the long-term follow up data in context. The respective analysis has to be thoroughly documented a priori to ensure unbiased results.

The lack of long term data has also been highlighted as a limitation by the expert group as outlined in their responses. Consequently, the collection of additional data, in particular, appropriate long term data and regular monitoring is required to further investigate the risk of fractures or EMH masses.

Furthermore, it needs to be investigated whether observed AEs such as hypertension, renal or hepatic impairment would increase or worsen in severity with long term treatment. The risk for thrombotic events or malignancies with long term treatment should also be investigated. The MAH has already amended the ongoing LTFU to address these issues. The LTFU is included as category 3 study in the RMP.

## 3.7.2. Balance of benefits and risks

A clear effect on Hb levels was demonstrated, although there are remaining uncertainties as regards its impact on long term outcome in terms of co-morbidity risk reduction. Also, a direct and immediate patient benefit has not been observed in the study beyond Hb increase, as QoL data are not considered sufficiently interpretable and also may not be anticipated for all treated patients considering the large

<div style=\"page-break-after: always\"></div>

heterogeneity of the NTDT patient population in whom not all are (relevantly) affected by anemia-related symptoms.

However, based on plausibility considerations and the available evidence that shows a correlation between lower Hb levels and higher co-morbidity risk, and under the premise of a manageable safety profile, this may ultimately not preclude approval.

As regards safety, overall, there is residual uncertainty as to the (long term) risk profile of luspatercept. Taking into account the expert group's view on the manageability of the safety profile (and additional amendments to the SmPC wording), the observed non-negligible safety profile may ultimately be judged acceptable for the time being, bearing in mind the unmet medical need.

Residual uncertainty can be addressed within the ongoing LTFU study, which was requested as a category 3 PASS.

The indication was requested to be amended as follows:

' Reblozyl is indicated in adults for the treatment of anemia associated with transfusion dependent and non-transfusion dependent beta-thalassaemia (see section 5.1) ' .

## 3.7.3. Additional considerations on the benefit-risk balance

## 3.8. Conclusions

The overall B/R of Reblozyl for this extension of indication is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

## C.I.6 (Extension of indication)

Extension of indication in β -thalassaemia to include adult patients with nontransfusion dependent β -thalassaemia (NTDT) for Reblozyl; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.5 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

<div style=\"page-break-after: always\"></div>

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I, IID and IIIB and to the Risk Management Plan are recommended.

## Similarity with authorised orphan medicinal products

The marketing authorisation for the medicinal product Zynteglo was withdrawn by virtue of the 'Commission Implementing Decision of 24.3.2022 withdrawing, at the holder's request, the conditional marketing authorisation granted by Decision C(2019) 4181(final) for \"Zynteglo - betibeglogene autotemcel\", an orphan medicinal product for human use'. Further to the withdrawal of the marketing authorisation, the market exclusivity of Zynteglo expired.

The CHMP maintains it previous opinion, as applicable, that Reblozyl is not similar to Zynteglo within the meaning of Article 3 of Commission Regulation (EC) No 847/2000. (The previous opinion of the CHMP was adopted on 30 April 2020 in the context of the assessment of the marketing authorisation application for Reblozyl. In this respect, see: CHMP assessment report for Reblozyl of 30 April 2020 (EMA/270924/2020), pages 11 and 193.)

## Additional market protection

Furthermore, the CHMP reviewed the data submitted by the MAH, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies (see appendix 1).